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 Summary 
Cell signaling networks are regulated by reversible protein post-translational modifications (PTMs). 
Acetylation of the ε-amino group on lysines was first discovered on histones, and it is now widely 
accepted as an important modulator for diverse cellular processes. Acetylation is catalyzed by two 
types of enzymes: lysine acetyltransferases acetylate lysine residues on proteins by transferring an 
acetyl group from acetyl-coenzyme A, while histone deacetylases (HDACs) remove acetyl groups. 
Among HDAC family proteins, HDAC6 is a unique cytoplasmic deacetylase with tandem deacetylase 
domains and a ubiquitin binding zinc-finger domain. HDAC6 has been implicated in several biological 
processes, such as stress response and regulation of the cytoskeleton. However, there is still little 
information about how HDAC6 regulates these processes. Moreover, the mechanism how HDAC6 
deacetylate its substrates also remains unexplored. 
 
The first, and main part of the thesis is the identification of novel substrates of HDAC6 to clarify how 
HDAC6 functions in stress response pathway. Previous work from our laboratory had demonstrated 
that HDAC6 is important for the formation of stress granules (SGs). SGs are membrane-less organelles 
forming in response to stress, and liquid-liquid phase separation (LLPS) of proteins containing 
intrinsically disordered regions (IDRs) has been proposed as a mechanism underlying the formation 
of membrane-less organelles including SGs. We systematically identified HDAC6 substrates using 
acetylome analysis, and found that the very large majority of the high-confidence HDAC6 target sites 
map to IDRs. We confirmed that DDX3X, an RNA helicase component of SGs, is a novel substrate of 
HDAC6. We also revealed that specific stresses elicit activation of the lysine acetyltransferase CBP in 
vivo, leading to acetylation of multiple proteins, including DDX3X. Acetylation of DDX3X-IDR was 
associated with its inefficient LLPS in vitro and the decreased total volume of SGs in vivo. 
Deacetylation of DDX3X by HDAC6 was required for assembly of large, mature SGs. In sum, we 
define HDAC6 as a global regulator of IDRs, and demonstrated a framework to understand how 
acetylation/deacetylation of IDRs regulates LLPS spatiotemporally for membrane-less organelle 
formation in vivo. 
 
The second part addresses the mechanistic insights of HDAC6-mediated deacetylation. This work was 
done in collaboration with Y. Miyake and L. Wang. We solved the crystal structure of both HDAC6 
catalytic domains. We proposed a new insight into deacetylation mechanism of its substrate α-tubulin. 
Furthermore, we provided reasonable explanation for the efficacy of HDAC inhibitors on HDAC6, 
which form the fundamental basis to develop more potent HDAC6-specific inhibitors in the future. 
 
Therefore, in this thesis, I demonstrate the novel insights about HDAC6-mediated deacetylation and 
its substrates, and propose a new role of protein acetylation as a regulator of intracellular phase 
transitions, in particular, in the context of SG formation controlled by HDAC6. 
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Introduction 
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 1.1 Lysine acetylation/acylation 
1.1.1 Brief history of lysine acetylation/acylation 
Cell signaling networks control almost all cellular functions and are regulated by reversible 
protein post-translational modifications (PTMs). Dozens of different PTMs have been identified so far, 
including phosphorylation (Pawson and Scott, 2005), acetylation (Choudhary et al., 2014; Verdin and 
Ott, 2015), methylation (Biggar and Li, 2015; Greer and Shi, 2012), glycosylation (Moremen et al., 
2012), and modification by ubiquitin and ubiquitin-like modifiers (Dikic et al., 2009; Swatek and 
Komander, 2016). Acetylation of the ε-amino group on lysines was discovered on histones by Vincent 
Allfrey and colleagues in 1964, and they proposed that histone acetylation regulates gene expression 
(Allfrey et al., 1964). This daring proposal about histone acetylation is now widely confirmed and 
accepted in the field (Verdin and Ott, 2015). Histone acetylation sites are located primarily in the N-
terminal tail, which protrudes from the nucleosome core and provides a signaling platform used to 
remodel chromatin and regulate transcription. Changes in the charge of the histone tails by acetylation 
weaken the interaction of histone and DNA. Acetylation also alters histone-histone interactions and 
their interactions with other regulatory proteins, and provides binding site for specific domains. These 
changes affect the structure of individual nucleosomes and their folding, leading to permissive 
chromatin structure for transcription. 
It took more than 30 years from the discovery of histone acetylation until the identification of 
the first acetylation-modifying enzyme (Brownell and Allis, 1995). Numerous studies have 
subsequently identified three classes of regulatory proteins for acetylation: lysine acetyltransferases 
(KATs) as ‘writers’, which add acetyl groups to proteins; lysine deacetylases (KDACs) as ‘erasers’, 
which remove acetyl groups from proteins; and proteins harboring acetyllysine binding domains 
(including bromodomain (BRD), YEATS domain and double plant homeodomain finger (DPF) 
domain) as ‘readers’, which interact with acetylated lysines (Kac). 
During the past decade, developments in high-sensitivity mass spectrometry analysis have 
facilitated lysine acetylation research (Choudhary et al., 2014). The advancements can be summarized 
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 in the following three points. First, a large number of acetylation sites in non-histone proteins have 
been identified. The number is similar to other major PTMs, and indicates the regulatory potential of 
acetylation at proteomic scale. Second, acetylation has been found in organisms ranging from bacteria 
to humans, suggesting that some regulatory functions of acetylation are well conserved. Third, this 
proteomics approach also has recently identified other types of lysine modifications by short fatty acids 
collectively called acylations: these include crotonylation (Kcr), succinylation (Ksuc), glutarylation 
(Kglu) among others (Sabari et al., 2017) (Fig. 1). 
 
 
Figure 1.   Structures of short-chain acylations on the ε-amine group of Lys, clustered into three groups based 
on their chemical properties. Adapted from (Sabari et al., 2017). 
 
These findings have broadened the paradigm about lysine acetylation to the acylations, and further 
nominated these writer, eraser and reader proteins for regulators of protein “acyl”ations. Thus, lysine 
acetylation and acylation are now widely recognized as general regulators in various cellular functions 
beyond the initial expected effect on transcriptional regulation. 
 
1.1.2 Writers, Erasers and Readers for lysine acetylation/acylation 
Lysine acetyltransferases (KATs) 
Lysine acetyltransferases/histone acetyltransferases (KATs/HATs) are enzymes that acetylate 
lysine residues on proteins by transferring an acetyl group from acetyl-coenzyme A (acetyl-CoA) to 
form ε-N-acetyllysine. There are three major families of HATs: GNAT (Gcn5-related N-
acetyltransferase), MYST (named for the founding members: Moz, Ybf2, Sas2 and Tip60) and the 
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 p300/CREB-binding protein (p300/CBP) families (Table 1). Most HATs form multisubunit complexes, 
and the combinations of their subunits contribute to the specific characters of each KAT complex. As 
the major target of these complexes are histones, some subunits have chromatin-binding domains (such 
as bromodomain, chromodomain and Tudor domain) to recruit the KAT to the appropriate location in 
the genome. Some KATs can also acetylate non-histone substrates; for example, the tumor suppressor 
p53 is acetylated by p300/CBP, and this acetylation stimulates its DNA-binding ability (Gu and Roeder, 
1997). Besides the function as lysine “acetyl”transferase, KATs belonging to all three major families 
can also use different acyl-CoAs, which structurally fit their catalytic pockets, as substrates for lysine 
“acyl”ations. For example, structural studies of p300 suggest that its active site contains a deep 
aliphatic pocket, which is not seen in other KATs (Kaczmarska et al., 2017). This pocket can 
accommodate relatively longer acyl-chains, and explains well that p300 is able to catalyze diverse 
acylations. 
  
 
Table 1.   Characteristics of KAT families. Each KAT has unique specificity for each histone variant. 
Modified figure from (Furdas, 2012; Parthun, 2007). 
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 It is important to note that KATs are not absolutely required for lysine acylation reaction; under specific 
conditions, some acylation may also occur non-enzymatically. In particular, the higher acyl-CoA 
concentration and the elevated pH in mitochondria, compared to in the cytoplasm and nucleus, cause 
the deprotonation of the amino groups and favor non-enzymatic lysine acylation (Wagner and Payne, 
2013), and recent proteomics approach for lysine acylation have demonstrated that a large part of the 
mitochondrial proteins are acylated (discussed in 1.1.3). 
 
Lysine deacetylases (KDACs) 
The mammalian genomes encode 18 enzymes with deacetylase activity (lysine 
deacetylases/histone deacetylases; KDACs/HDACs), which can be divided into 2 groups: classical 
HDACs (Fig. 2), whose enzymatic activity requires Zn2+, and sirtuins (Fig. 3), which are NAD+-
dependent.  
 
       
Figure 2.   Classical HDAC classification. The domain structures of classical HDACs are shown (numbers 
refer to amino acid residues in the human proteins). Blue rectangles depict the deacetylase domain, and red 
rectangles indicate phosphorylation sites. Zinc finger (ZnF) and leucine rich motifs are also indicated. Adapted 
from (Reichert et al., 2012). 
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 The classical HDAC family harbors 11 members classified into four classes. Class I contains HDAC1, 
2, 3, and 8, class IIa comprises HDAC4, 5, 7, and 9, class IIb includes HDAC6 and 10, and class IV 
comprises HDAC11. The sirtuins are classified as class III HDACs. This family contains seven 
members (SIRT1-7) which are organized into four classes. SIRT1-SIRT3 belong to class I, SIRT4 to 
class II, SIRT5 to class III, and SIRT6 and SIRT7 to class IV. The class I HDAC family proteins 
(HDAC1, 2, 3 and 8) show homology to Rpd3, a founding member from budding yeast, and are 
ubiquitously expressed. They harbor a conserved deacetylase domain with short N- and C-terminal 
regions, and they are localized mainly to the nucleus to deacetylate histones. HDAC1 and HDAC2 are 
generally found together in co-repressor complexes such as the Sin3, NuRD and CoREST complexes. 
HDAC3 is engaged in a distinct N-CoR complex, and no complexes have been reported for HDAC8. 
These class I HDACs are localized predominantly to the nucleus to deacetylate histones as their major 
substrates. 
The class IIa HDACs (HDAC4, 5, 7 and 9) have long N-terminal regions where a few serine 
phosphorylation sites reside. Some kinases, such as calcium/calmodulin-dependent protein kinase 
(CaMK) and protein kinase D (PKD), phosphorylate these N-terminal regions, allowing 14-3-3 
proteins binding and cytoplasmic retention (McKinsey et al., 2000; Vega et al., 2004a; Wang et al., 
2000). These regulated phosphorylations of class IIa HDACs provide a mechanism for coupling 
extracellular signals to transcription and have key roles during development. Unlike other ubiquitously 
expressed HDACs, class IIa shows restricted expression patterns; HDAC5 and HDAC9 are highly 
expressed in muscles, heart and brain (Chang et al., 2004; Zhang et al., 2002), HDAC4 is found in the 
brain and skeleton (Vega et al., 2004b), and HDAC7 is expressed in endothelial cells and thymocytes 
(Chang et al., 2006b). Class IIa HDACs possess much lower in vitro HDAC activity compared to other 
HDACs, and they have been shown to recruit class I HDACs through their HDAC domains (Fischle 
et al., 2002); this may contribute to their transcription repression function. 
The class IIb HDACs are composed of HDAC6 and HDAC10. HDAC6 is distinct from all 
other HDACs, as it harbors two deacetylase domains and a C-terminal ubiquitin binding zinc finger 
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 domain. It mainly localizes in the cytosol and contributes to various biological processes such as 
cytoskeleton control, protein homeostasis and stress response (Matthias et al., 2008) (discussed in 1.2). 
HDAC10 has recently been reported as a “PDAC” deacetylating polyamines that are polycations 
binding to other cellular anionic molecules to stabilize their structure and regulate their functions (Hai 
et al., 2017); its biological role is still unexplored.  
HDAC11, alone class IV member, has small N- and C-terminal regions in addition to its 
deacetylase domain. Initial study showed that HDAC11 was mainly expressed in brain, heart, muscle, 
kidney and testis (Gao et al., 2002). However, HDAC11 expression was reported later in hematopoietic 
cells as well; HDAC11 is bound on the IL10 promoter, and represses its activity in antigen-presenting 
cells (APCs) (Villagra et al., 2009), suggesting a role in immune functions. 
 
 
Figure 3.   Sirtuin classification. The seven human sirtuins (SIRT1-7) are aligned. Numbers refer to amino 
acid residues in the human proteins. The conserved core domain that all sirtuins have in common is in yellow. 
Nuclear localization sequences (NLSs) and mitochondrial targeting sequences (MTSs) are also indicated. 
Modified figure from (Guarente, 2013). 
 
Class III HDACs, Sirtuins, are NAD+-dependent deacetylases, which show an individual 
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 pattern of subcellular localization (Fig. 3). Sirtuins deacetylate histones and transcription factors (such 
as PGC1α and FOXO) in the nucleus, on the other hand, they also deacetylate metabolic enzymes in 
cytosol and mitochondria (such as PEPCK and IDH2) (Houtkooper et al., 2012). As a result, Sirtuins 
regulate glucose and lipid metabolism in response to cellular energy levels through deacetylation. 
Apart from their deacetylase function, some of the members can also work as ADP-ribosyltransferases 
(SIRT4 and 6), and deacylases (for depropionylation, debutyrylation, decrotonylation, demalonylation, 
desuccinylation and deglutarylation; SIRT1-5 and 7) (Table 2). Deacylation is likely to be mediated 
mainly by class III HDACs, although a few studies reported deacylase function of class I HDACs (Wei 
et al., 2017). 
  
 
Table 2.   The enzymatic specificities of the different classes of KATs and KDACs with respect to acetylation 
and acylation. Kbhb, lysine β-hydroxybutyrylation; Kbu, lysine butyrylation; Kcr, lysine crotonylation; Kglu, 
lysine glutarylation; Khib, lysine 2-hydroxyisobutyrylation; Kma, lysine malonylation; Kpr, lysine 
propionylation; Ksucc, lysine succinylation; NA, not available. Adapted from (Sabari et al., 2017). 
 
Acetyl-lysine binding proteins 
Three domains have been reported to recognize lysine acetylation (Kac). Bromodomains 
(BRDs) form a conserved structural fold of four α-helices and two inter-helical loops that constitute a 
hydrophobic pocket. The human proteome encodes 42 BRD-containing proteins, which mainly 
recognize histone acetylations and regulate gene expression mainly through three mechanisms. First, 
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 some work as scaffolds for other larger protein complexes (e.g. Bromodomain and Extra-Terminal 
(BET) family proteins). Second, some act as transcription factors or co-regulators (e.g. speckled 
proteins (SPs)). Third, they have various catalytic functions, including ATP-dependent chromatin 
remodeling complexes (e.g. SMARCA2/4), methyltransferases (e.g. MLL) and KATs (e.g. PCAF, 
p300/CBP). Their major targets are histone acetylations, but a few examples demonstrate that some 
acetyl-lysine binding proteins can recognize non-histone acetylated proteins (Mujtaba et al., 2004; Shi 
et al., 2014). 
Double PHD fingers (DPF) domain is another domain to recognize Kac. Although a large 
number of PHD-finger containing proteins recognize histone methylation 
(H3K4me3/H3K9me3/H3K36me3) or unmodified histone tails (H3K4), DPF is highly specific for 
histone acetylations. So far, DPF domains from five human proteins have been characterized as 
acetylated lysine readers, including two KATs from the MYST family (MOZ, MORF) and DPF1, DPF2 
and DPF3, which are subunits of the BRG1/BRM-associated factor (BAF) chromatin remodeling 
complex. These proteins use two PHDs to recognize Kac; for example, a PHD of DPF3 binds to the 
first four N-terminal residues of H3 tail, while another PHD uniquely binds to H3K14Ac in the binding 
pocket composed of hydrophobic and charged residues (Zeng et al., 2010). This hydrophobic ‘dead-
end’ pocket of PHD1 favors to accommodate lysine crotonylation (Kcr), due to intimate encapsulation 
and an amide-sensing hydrogen bonding network. (Xiong et al., 2016) (Fig. 4). 
The recently identified YEATS (named for Yaf9, ENL, AF9, Taf14 and Sas5) domains also 
recognize Kac. This domain is also related to transcription regulation (Li et al., 2014). The binding 
pocket contains an open end where the acetyl group is positioned, suggesting that an extended acyl 
chain could also be accommodated – recent studies with AF9 have shown that the Kcr is indeed fitting 
better than Kac in the pocket (Li et al., 2016b). This preferential binding to Kcr is due to the interactions 
of the crotonylamide group with two sandwiching aromatic residues in the binding pocket, in addition 
to hydrophobic interactions caused by hydrocarbon extension. In sum, BRDs prefer to bind Kac, while 
DPF and YEATS domains prefer non-acetyl lysine acylations (Fig. 4). 
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Figure 4.   Comparison of the acyl-lysine binding pockets among YEATS (left, PDB: 5HJB), Bromodomain 
(middle, PDB: 5HJC), and DPF (right, PDB: 5B76). The histone peptide is shown in yellow, with the side chain 
of acyl-lysine, and the green color in side chain highlights two extended hydrocarbon crotonyl group. Adapted 
from (Zhao et al., 2017). 
 
1.1.3 Proteomics approach for lysine acetylation/acylation 
Recent progress in high-sensitivity mass spectrometry has enabled the identification of 
acetylation/acylation sites at proteomic scale (acetylome/acylome), which provides important 
resources to clarify their novel regulatory functions. Although different methodological approaches 
can be used in the acetylome/acylome analysis, the bottom-up proteomics approach, which involves 
enzymatic digestion of all proteins in the samples followed by liquid chromatography and tandem MS 
(LC-MS/MS), is the gold standard in the field (Fig.5). Proteins are extracted from cells, and digested 
with a protease such as trypsin and Lys-C. The acetylated peptides in the samples are enriched with 
acetyllysine-specific antibodies. This process is often coupled to sample fractionation in order to 
reduce complexity and obtain broader dynamic range. The resulting peptides are separated by LC and 
ionized before entering the mass spectrometer, where mass spectra and fragmentation spectra are 
measured. The first acetylome analysis identified 388 acetylation sites in 195 proteins among proteins 
from HeLa cells and mouse liver mitochondria (Kim et al., 2006). In addition to regulators of chromatin, 
which were well-known targets of acetylation at that time, non-nuclear acetylated proteins with diverse 
functions were identified. Most strikingly, more than 20% of mitochondrial proteins including many  
-12-
  
Figure 5.   Standard procedure for acetylome analysis. Proteins are extracted from cells or tissues and 
digested into peptides using proteases. To reduce the sample complexity, acetylated peptides are enriched by 
immunoaffinity purification with pan-acetyllysine antibodies. The complexity can be further reduced by peptide 
fractionation methods, such as microscale strong cation exchange chromatography (Micro-SCX) or isoelectric 
focusing (IEF). After separation by liquid chromatography (LC), peptides undergo electrospray ionization, and 
peptide ions are transferred into the mass spectrometer. MS and MS/MS spectra are then computationally 
processed to deduce peptide sequences, including the presence and location of PTMs, and to quantify the 
abundance of peptides and proteins. Adapted from (Choudhary et al., 2014). 
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 metabolic enzymes were found to be acetylated. Quantitative analyses can identify acetylation sites 
that are regulated under specific conditions. The most commonly used methods enable the 
identification by comparing the intensities of acetylated peptides among samples, including metabolic 
labelling (e.g. Stable Isotope Labelling by Amino acids in Cell culture (SILAC)), chemical labelling 
(e.g. Tandem Mass Tags (TMT) and isobaric Tags for Relative and Absolute Quantitation (iTRAQ)) 
and label-free quantification. SILAC has been successfully used to uncover relative changes in 
acetylome depending on cell types, chemical or genetic perturbations. For example, Choudhary et al. 
identified 3600 lysine acetylation sites on 1750 proteins from human cell lines, and quantified 
acetylation changes in response to two deacetylase inhibitors SAHA (suberoylanilide hydroxamic acid) 
and MS-275 using SILAC (Choudhary et al., 2009). This study revealed that lysine acetylation 
preferentially targets large protein complexes involved in diverse cellular processes, such as DNA 
damage repair, RNA splicing, nuclear transport, and cytoskeleton remodeling. The large coverage of 
the study enabled the authors to analyze structural properties of acetylation; acetylation frequently 
localizes in structured regions, such as α-helices and β-sheets. This shows stark contrast between 
acetylation and another PTM, phosphorylation; many phosphorylation sites are found in unstructured 
regions. At the same time, no clear acetylation motifs have been found, maybe due to the diversity of 
the KATs/KDACs targeting these sites and also due to the non-enzymatic acetylations. Their 
experiments were successfully followed by another survey to connect acetylated substrates to the 
regulator enzymes, using 19 different inhibitors for all 18 human lysine deacetylases (Scholz et al., 
2015). Lysine deacetylases inhibitors (KDACis) are used in basic research and also in clinical trials 
for treatment of cancer and other diseases. However, their specificities in cells still remained to be 
solved at that time. Over 8,100 acetylation sites in HeLa cells were quantified under KDACis, and the 
data sets were compared with that of KDAC knockout cells. Another recent study analyzed the 
CBP/p300-acetylome in time-resolved manner under two catalytic inhibitors and a BRD inhibitor 
(Weinert et al., 2018). They combined the acetylomes with the transcriptomes which CBP/p300 
regulates through acetylation of histones and other transcription regulators, and suggested that the 
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 subset of rapidly regulated CBP/p300-catalyzed acetylation sites is a critical driver of gene 
transcription. 
In parallel with acetylome analysis, proteome analysis for other acylations has also been 
reported. A study described succinylome from the liver and embryonic fibroblasts of SIRT5 KO mice, 
where lysine succinylation was increased due to lack of SIRT5 activity (Park et al., 2013). Among the 
identified 2,565 succinylation sites on 779 proteins, most of the sites (75%) do not overlap with 
acetylation sites, indicating differential regulation of succinylation and acetylation. These 
succinylation sites were enriched with enzymes involved in metabolism, including amino acid 
degradation and TCA cycle. Detailed biochemical analysis revealed that SIRT5 especially repressed 
two protein complexes, pyruvate dehydrogenase and succinate dehydrogenase. Thus, this work 
demonstrated widespread roles of lysine succinylation in metabolism. The glutarylome from the liver 
of SIRT5 KO mice subsequently identified 683 glutarylation sites in 191 proteins (Tan et al., 2014). 
Glutarylation was also highly enriched in metabolic enzymes, and validated carbamoyl phosphate 
synthase 1 (CPS1), an enzyme in the urea cycle, as a novel substrate of SIRT5; glutarylation suppressed 
CPS1 enzymatic activity. These two studies expand the landscape of lysine acylations at proteome 
scale and increase our understanding of the deacylase SIRT5. 
In sum, acetylome/acylome analysis is now widely used in various organisms, leading to the 
identification of thousands of novel acetylation sites. Such analyses have demonstrated that acetylation 
sites are frequently conserved across diverse organisms. The most striking observation from 
acetylome/acylome analysis is that the majority of modified sites are on non-nuclear proteins, 
including mitochondrial proteome, suggesting an important role for acetylation/acylation in diverse 
biological functions beyond the control of gene expression.  
 
1.1.4 Functional roles of acetylation/acylation 
The best established role of acetylation/acylation is transcriptional regulation. However, it 
also alters a variety of protein functions by eliminating the positive charge from the ε-amino group of 
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 lysine or introducing steric hindrance, resulting in the modulation of protein interactions with other 
molecules, changes in enzymatic activity or subcellular localization. Furthermore, it has become clear 
that acetylation/acylation connects metabolism to cell signaling and gene expression. 
 
Regulation of nucleic acid binding and protein-protein interactions 
As discussed above, the first function of acetylation/acylation is regulation of nucleic acid 
binding ability of proteins. Lysine acetylations on the N-terminal tails of the histones neutralize the 
positive charge of the tails and decrease their affinity for negatively charged DNA (Hong et al., 1993). 
This was confirmed well with in vitro biochemical experiments, and proposed as a driving force for 
other epigenetic regulators to access the nucleosome. The second function of acetylation/acylation is 
regulation of protein-protein interactions. Acetylated lysines can function as docking sites for reader 
proteins containing BRD, DPF and YEATS domains. Acetylation can also work as a molecular switch 
to change interaction partner from RNA to proteins. For example, nonacetylated HIV Tat protein 
preferentially binds to HIV RNA stem-loop structure TAR (transactivating response element) (Mujtaba 
et al., 2002). Once acetylated by p300, Tat shows increased binding to PCAF, which promotes the 
association of Tat with RNA polymerase II and HIV gene transcription elongation (Dorr et al., 2002).  
 
Regulation of enzymatic activity 
Lysine residues are often present in the active sites of enzymes, and their acetylation/acylation 
has been implicated in regulating the catalytic activity of various types of enzymes. Activities of KATs 
themselves are regulated by acetylation; as the autophosphorylation of kinases reflects their activation 
state, several KATs, including p300/CBP (Thompson et al., 2004) and MYST1 (Yuan et al., 2012), are 
known to be autoacetylated. Hypoacetylated p300/CBP has a low basal rate of catalytic activity due to 
autoinhibition by its activation loop, where autoacetylation of several lysines (K1499, K1549, K1554, 
K1558 and K1560) occurs to enhance its catalytic activity. p300/CBP is autoacetylated as a dimer, 
suggesting that dimerization triggers autoacetylation and following activation of the enzyme. A large 
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 part of mitochondrial proteins are acylated due to the high concentration of acyl-CoA in the 
mitochondrial matrix (discussed in 1.1.3), and their catalytic activities are regulated by these acylations. 
Acetyl-CoA synthetase 2 (ACECS2) is a mitochondrial matrix enzyme which ligates acetate with CoA 
to produce acetyl-CoA. ACECS2 is reversibly acetylated at K642 in the active site of the enzyme, and 
this acetylation inactivates the protein enzymatically. The mitochondrial SIRT3 deacetylates K642 and 
rescues catalytic activity of ACECS2 (Schwer et al., 2006). Other diverse acylations in mitochondria 
also tune the function of metabolic enzymes there (Nishida et al., 2015; Park et al., 2013; Tan et al., 
2014). Carbamoyl phosphate synthase 1 (CPS1), the rate-limiting enzyme in urea cycle, provides 
another example (discussed in 1.1.3) (Tan et al., 2014). There are eight glutarylation sites on CPS1; 
structure prediction by homology modeling revealed that these sites may be important for binding to 
either its interaction partner, or CPS1 itself for dimerization, or metabolite as allosteric activator for 
this enzyme. The mitochondrial SIRT5 removes glutarylation to rescue CPS1 function by these 
possible mechanisms. In sum, acylation globally regulates catalytic activities of enzymes. 
 
Crosstalk with other PTMs 
Acetylation/acylation can compete with other PTMs, such as methylation and ubiquitination, 
because all these modifications occur on lysine residues. Ubiquitination is a major PTM which 
regulates protein degradation by proteasome. About one-third of acetylation sites in human cells also 
undergo ubiquitination (Wagner et al., 2011). Transforming growth factor-β (TGFβ) family members 
regulate gene expression by receptor-mediated activation of receptor-regulated SMADs (R-SMADs) 
transcription factors. One of the inhibitory SMADs called SMAD7 forms a complex with a ubiquitin 
ligase, SMURF1, and inhibits TGFβ signaling by blocking the interaction between the receptor and R-
SMADs. In addition, SMURF1 ubiquitinates both the receptors and SMAD7, thereby inducing their 
degradation. Two ubiquitination sites of SMAD7 by SMURF1 are acetylated by p300, which prevents 
SMAD7 from degradation (Gronroos et al., 2002). By contrast, the deacetylation of SMAD7 by 
HDAC1 enhances ubiquitination and degradation (Simonsson et al., 2005). This kind of competitive 
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 crosstalk between acetylation and ubiquitination regulating protein stability is widely observed. In 
addition to competitive crosstalk, other PTMs can affect acetylation at nearby sites (non-competitive 
crosstalk). It is well-known that p53 is modified by diverse PTMs, including acetylation, methylation, 
as well as ubiquitination. In response to DNA damage, the lysine methyltransferase SETD7 methylates 
p53 at K372 (Ivanov et al., 2007). This methylation stabilizes binding of p53 to chromatin, so that 
p300/CBP effectively acetylates it at K373 (Dornan et al., 2003). This acetylation also competes with 
ubiquitination, and stabilized p53 induces subsequent transcription of p21 which promotes cell cycle 
arrest. This exemplifies that the regulatory mechanism of acetylation also depends on other PTMs. 
 
Regulation of protein localization 
Acetylation can regulate the subcellular localization of proteins. The ubiquitin ligase S-phase 
kinase-associated protein 2 (SKP2) has an important role in tumorigenesis by promoting the 
destruction of tumor suppressor proteins such as p21 and p27. SKP2 is acetylated by p300 and 
deacetylated by SIRT3 at K68 and K71, which are located in its nuclear localization sequence (Inuzuka 
et al., 2012). This acetylation promotes SKP2 nuclear export and, at the same time, inhibits its 
degradation by a ubiquitin ligase complex APC/Cdh1, resulting in tumor growth. In the same way, 
subcellular localization of transcription factor FOXO is regulated by crosstalk of phosphorylation and 
acetylation. In response to insulin, AKT phosphorylates FOXO and induces its nuclear exclusion and 
subsequent degradation (Brunet et al., 1999). The positive charge of lysines in FOXO1 contributes to 
its DNA-binding, and acetylation at these residues attenuates its ability to bind target DNA sequence 
(Matsuzaki et al., 2005). This acetylation is regulated by the counteracting activities of CBP and 
SIRT1/2 (Frescas et al., 2005; Jing et al., 2007). Phosphorylation of FOXO at S253 by AKT is 
enhanced by this acetylation, leading to its association with 14-3-3 proteins and its sequestration in the 
cytoplasm. Thus, acetylation regulates the localization and shuttling between cytoplasm and nucleus 
of target proteins. 
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 Coupling metabolism with cell signaling and gene expression 
Cell signaling and gene expression have been widely known to regulate metabolic processes 
in response to available nutrients and growth factors with appropriate amounts of metabolic enzymes. 
In recent years, it has become increasingly clear that cellular metabolites including acyl-CoAs 
reciprocally regulate signaling networks and gene expression. Acetyl-CoA and other acyl-CoAs, key 
factors for acetylation/acylation, are also key metabolic intermediates in major carbon catabolic 
pathways, such as glycolysis and pyruvate oxidation, as well as in β-oxidation of fatty acids. Global 
histone acetylation levels directly correlate with nuclear acetyl-CoA produced by ATP citrate lyase 
(ACL) (Wellen et al., 2009). In yeast cells, when cell growth is arrested in the presence of glucose, 
acetylation is increased specifically in mitochondrial proteins, but not in other compartments, 
indicating that acetylation in mitochondria is driven by the generation of acetyl-CoA there (Weinert et 
al., 2014). These two examples clearly demonstrate that the concentration of acetyl-CoA defines the 
global acetylation level of each cellular compartment. There, acetylation tunes the expression of 
metabolic enzymes through histone modification and modulate activities of mitochondrial enzymes to 
adapt cells to specific nutrient conditions. Similar regulatory mechanisms are also likely to take place 
with other non-acetyl acylations; thus, the concentration of each acyl-CoA species in the compartment 
may define the global landscape of acylation there (Sabari et al., 2017). This model provides a rationale 
for some observations. For example, it has been observed that Kcr can be easily detected by mass 
spectrometry in some tissue-derived cells (Tweedie-Cullen et al., 2012), while enrichment is required 
to detect it from cells grown in culture media. Cultured cells are usually exposed to higher glucose 
concentration in cell culture media such as DMEM, than in tissues. Glucose is converted into citrate 
in mitochondria, and catalyzed by ACL to produce acetyl-CoA. Hence, this artificially enhanced 
acetyl-CoA may overcome non-acetyl acylations including Kcr in cultured cells. Another example 
demonstrates that gene expression can be modulated by incorporation of acyl-CoAs into cells. 
Activation of Toll-like receptor 4 (TLR4) signaling pathway by lipopolysaccharide (LPS) leads to an 
increase in both Kac and Kcr at loci of p300 target genes. When cells are cultured with crotonyl-CoA 
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 before stimulation by LPS, Kcr level at p300 target genes is increased (Sabari et al., 2015). As positive 
regulator of transcription AF9 prefers to bind Kcr than Kac (Li et al., 2016b) (discussed in 1.1.2); this 
enhanced Kcr efficiently recruits AF9 at p300 target genes, and their transcripiton is also promoted. 
This kind of acyl-CoA metabolism-mediated transcription plays important role in physiological 
condition such as ketogenesis. Ketogenesis is a physiological response to low blood glucose and liver 
glycogen levels; acetyl-CoA is converted to ketone bodies such as β-hydroxybutyrate in the 
mitochondria of liver cells. The major role of β-hydroxybutyrate is as an energy source, but at the same 
time, histone Kbhb modification by resulting β-hydroxybutyryl-CoA is subsequently increased. In 
particular, the expression of genes related to starvation response are upregulated by Kbhb (Xie et al., 
2016). Further studies will be required to know how histones are modified by different sets of acyl-
CoA depending on their genomic locus and when these mechanisms are essential in physiological 
conditions other than ketogenesis. Nevertheless, the observations mentioned above clearly 
demonstrate the importance of acyl-CoA metabolism in cell signaling and gene expression. 
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 1.2 Histone deacetylase 6 (HDAC6) 
1.2.1 Domain structure and catalytic activities of HDAC6 
Histone deacetylase 6 (HDAC6), which was originally cloned by its homology to the S. 
cerevisiae histone deacetylase HDA1, is one of the class II histone deacetylase (Grozinger et al., 1999; 
Verdel and Khochbin, 1999). HDAC6 locates mainly in the cytoplasm and has unique structural 
features (Fig. 6); it contains tandem catalytic domains (CD1 and CD2) and a C-terminal ubiquitin 
binding zinc finger domain (ZnF-UBP). In addition to these domains, HDAC6 has two nuclear export 
signals (NESs) and the region called SE14 (only observed in human protein), which ensures to keep 
HDAC6 in the cytoplasm.  
 
 
Figure 6.   Functional domain organization of human HDAC6 (numbers refer to amino acid residues in the 
human proteins). NLS: nuclear localization signal. NES1 and 2: nuclear export signal 1 and 2, respectively. CD1 
and 2: catalytic domains 1 and 2, respectively. DMB: dynein motor binding domain. SE14 (only in human): 
anchoring the protein in the cytoplasm. ZnF-UBP: a high affinity ubiquitin-binding motif. 
 
The biological roles of HDAC6 are dependent on these two domains – catalytic domains and 
ZnF-UBP. HDAC6 primarily functions through altering biochemical properties of its substrates by 
deacetylation. In addition to its established targets such as α-tubulin, cortactin and heat shock protein 
90 (Hsp90) (Hubbert et al., 2002; Kovacs et al., 2005; Zhang et al., 2007; Zhang et al., 2003), several 
other cytoplasmic proteins have recently been reported as novel substrates. The roles of each substrate 
will be discussed in the next section (1.2.2). HDAC6 ZnF-UBP binds to aggregated proteins and the 
importance of this function on protein homeostasis will be discussed separately (discussed in 1.2.3). 
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 1.2.2 HDAC6 substrates 
Early work demonstrated that HDAC6 mainly localizes in cytoplasm and functions as tubulin 
deacetylase. Recent discoveries confirmed the unique functions of HDAC6 among HDAC family 
proteins, and identified it as a versatile deacetylase involved in wide range of biological processes: 
HDAC6 regulates cytoskeletal networks, protein folding, stress and viral response, signaling pathways 
for cell growth, transcription as well as organelle formation through its deacetylase activity. These 
substrates are listed (Table 3) and summarized schematically (Fig. 7) below, and discussed in more 
detail in the following section.  
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 Name HDAC6 
species 
HDAC6 target 
sites 
Methods to identify / 
confirm as substrate 
Biological meaning of 
acetylation 
Reference 
1. α-tubulin Mouse 
Human 
K40 HD6 KD in NIH3T3 cells. 
 
Mechanical resilience of 
microtubules 
(Hubbert et al., 2002) 
2. β-tubulin Mouse K58 MS analysis of brain from HD6 
KO mice. 
Unknown (Liu et al., 2015) 
3. Tau Human N.A. Tubastatin A treatment in 
OLN-93 cells expressing 
human Tau. 
Protein stability (Noack et al., 2014) 
4. Cortactin Mouse 
Human 
 
K124, 161, 235, 
309 (Human) 
HD6 KD and overexpression in 
A549 and HeLa cells. MS 
analysis of 293T. 
ACY-1215 and Tubastatin A 
treatment in megakaryocytes. 
Localization (Messaoudi et al., 2017; 
Zhang et al., 2007) 
5. MHC9 Mouse N.A. Acetylome analysis of liver 
from HD6 KO mice. 
Binding ability to actin (Zhang et al., 2015b) 
6. Hsp90 Mouse 
Human 
N.A. HD6 KD in human A431 and 
A549 cells. 
Binding ability to its 
cochaperone 
(Kovacs et al., 2005) 
 
7. Hsp70 Rat N.A. HPOB treatment in PC12 cell. Chaperone activity (Li et al., 2016c) 
8. Hsc70 Mouse N.A. Acetylome analysis of liver 
from HD6 KO mice. 
Dimerization ability (Zhang et al., 2015b) 
9. DNAJA1 Mouse N.A. Acetylome analysis of liver 
from HD6 KO mice. 
Dimerization ability (Zhang et al., 2015b) 
10. GRP78 Human N.A. Panobinostat treatment in 
MCF7 and MDA-MB-231 
cells. 
Binding ability (Rao et al., 2010) 
11. Peroxiredoxins Human K197 HD6 KD and overexpression in 
LNCaP and LAPC4 cells, 
respectively. 
Reducing ability (Parmigiani et al., 2008) 
12. TDP-43 Human K145, 192 HD6 KD with overexpressed 
TDP-43 in Neuro2A cell. 
Aggregates formation (Cohen et al., 2015) 
13. TRIM50 Human K372 HD6 overexpression in 
HEK293T cell. 
Localization (Fusco et al., 2014) 
14. RIG-I     
(DDX58) 
Mouse 
Human 
K909 HD6 KO MEF cells. 
HD6 overexpression in 
HEK293T cells. 
Binding ability to RNA (Choi et al., 2016) 
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 15. Tat HIV K28 HD6 KD, overexpression and 
Tubacin treatment in HEK293T 
cells. 
Transactivator function (Huo et al., 2011) 
 
16. K-RAS Human K104 HD6 KD in SW480 cell. Binding ability to GEFs (Yang et al., 2013) 
17. ERK1 Human K72 ACY-1215 treatment, HD6 
overexpression in MEFs and 
HEK293T, A549 cells. 
Kinase activity (Wu et al., 2018) 
18. AKT Human K163,377 ACY-1215 treatment in human 
neural progenitor cells. 
Kinase activity (Iaconelli et al., 2017) 
19. PTEN Human K163 TSA treatment in HEK293T 
cells. 
Localization (Meng et al., 2016) 
20. MST1 Not 
mentioned 
K35 HD6 overexpression of 
HDAC6 and MST1 in 
HEK293T cells. 
Protein stability (Li et al., 2016a) 
21. Pin1 Human K46 HD6 overexpression in MCF7 
and MDA-MB-231 cells. 
Catalytic activity (Nogues et al., 2016) 
22. 14-3-3ζ Human K49, 120 Identified by acetylome. 
Confirmed by Tubacin 
treatment in MDA-MB-231 
cells. 
Binding ability to its client 
proteins 
(Mortenson et al., 2015) 
23. β-catenin Human K49 HD6 KD in HCT116 cells. Localization (Li et al., 2008) 
24. p53 Human K120 
 
K381,382 
K120: ACY-1215 treatment in 
TOV-21G cells. 
K381, 382: HD6 KD in 
HCT116 and HT29 cells. 
Binding ability to a pro-
apoptotic protein (K120) 
Transcription activity (K381 
and 382) 
(Bitler et al., 2017) 
 
(Ryu et al., 2017a) 
25. RelA/p65 Human N.A. Tubastatin A treatment in NU-
DUL-1 cells. 
Localization and transcription 
activity 
(Jia et al., 2017) 
26. HIF1 α Mouse N.A. HD6 KO MEF cells. 
 
Protein stability (Ryu et al., 2017b) 
27. HMGN2 Human K2 Bufexamac treatment in MCF7 
cells. 
Co-activator function (Medler et al., 2016) 
28. Ku70 Human K539, 542 Tubacin treatment in SH-SY5Y 
cells. 
Binding ability to a pro-
apoptotic protein 
(Subramanian et al., 2011) 
29. Survivin Not 
mentioned 
K129 Overexpression of HDAC6 and 
MST1 in MCF7 cells. 
Dimerization ability (Riolo et al., 2012) 
30. MSH2 Mouse 
Human 
K845, 847, 871, 
892 (Human) 
HD6 KO MEF cells. 
MS analysis of overexpressed 
MSH2 in 293T under TSA. 
Protein stability (Zhang et al., 2014) 
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 31. Mfn1 Mouse K222 HD6 KO MEF cells. Mitochondrial fusion (Lee et al., 2014a) 
32. CIDEC Mouse K56 Acetylome analysis of 
HD6 KO mice. 
Protein stability (Qian et al., 2017) 
33. hERG Human N.A. Overexpression of HDAC6 and 
hERG in HEK293T cells. 
Protein stability (Li et al., 2018) 
00. DDX3X Mouse K118 Acetylome analysis of MEFs 
and HeLa cells.  
Phase separation and 
stress granule formation 
(Saito et al., 2019) 
Table 3.   Summary of HDAC6 substrates. It is important to note that 00. DDX3X was identified by the work for this thesis, and it is separately 
discussed in detail (2.1). 
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Figure 7.   Diverse functions of HDAC6 substrates. Reported 33 HDAC6 substrates are divided into eight groups: cytoskeleton, stress and viral 
responses, protein folding, organelle control, growth and apoptosis, ion transport, transcription and stress granule formation. It is important to note that 
stress granule formation through DDX3X deacetylation was revealed by the work for this thesis, and it is separately discussed in detail (2.1).
-26-
 Regulation of cytoskeleton: α/β-tubulins, Tau, cortactin, and MHC9 
The major biological function of HDAC6 is regulation of cytoskeletal networks. HDAC6 
regulates microtubules through deacetylation of its components, tubulins with associated protein Tau, 
and it also regulates actin filaments through deacetylation of cortactin and Myosin heavy chain 9 
(MHC9) as actin associated proteins. 
The first reported in vivo HDAC6 substrate is α-tubulin at K40 (Hubbert et al., 2002; Zhang 
et al., 2003). α-tubulin acetyltransferase (α-TAT) prefers to acetylate K40 of α-tubulin on microtubules 
over α/β-tubulin dimers (Maruta et al., 1986) and this preference was also confirmed for HDAC6 
initially (Hubbert et al., 2002). However, recent studies including ours challenge this; HDAC6 can 
deacetylate α-tubulin K40 in the lumen of microtubules, but its preferred substrate is unpolymerized 
tubulin (Miyake et al., 2016; Skultetyova et al., 2017). Although the biological meaning of K40 
acetylation has been a long-standing question, recent studies suggested that acetylation increases 
mechanical resilience to protect long-lived microtubules from mechanical breakage (Portran et al., 
2017; Xu et al., 2017). Another microtubule component, β-tubulin has also been reported as a potential 
HDAC6 substrate by quantitative proteomic analyses (Choudhary et al., 2009; Liu et al., 2015). 
Importantly, these proteomic analyses also detected additional acetylation sites on α-tubulin other than 
K40. However, it is still unexplored how these acetylations affect the function of microtubules. 
HDAC6 also deacetylates the microtubule-associated protein Tau which has an important role in 
microtubule assembly and stabilization. Acetylation of Tau at several lysine residues tunes its stability, 
and these acetylations are removed by HDAC6 (Min et al., 2010; Noack et al., 2014).  
The formation of actin filaments is also regulated through HDAC6-mediated deacetylation of 
several effector proteins including cortactin and MHC9. An actin binding protein, cortactin interacts 
with actin filaments to increase cell motility (Bryce et al., 2005). The positive charge of lysine residues 
in its repeat region promotes the actin binding ability of cortactin, which is attenuated by acetylations 
in the region. HDAC6 leads to actin filament remodeling through cortactin deacetylation (Zhang et al., 
2007), which is important for angiogenesis in developmental process (Kaluza et al., 2011), platelet 
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 production (Messaoudi et al., 2017) and quality-control autophagy (Lee et al., 2010) (discussed in 
1.2.3). On the other hand, actin binding ability of MHC9 is increased by its acetylation (Zhang et al., 
2015b). Thus, inhibition of HDAC6 induces distribution of MYH9 to the actin filaments at cell-cell 
junctions, which also may explain the effect of HDAC6 inhibition on cell movement. 
 
Protein folding: Hsp90, Hsp70, Hsc70, DNAJA1 and GRP78 
HDAC6 is involved in protein quality control by modifying the activity of some chaperone 
proteins. Heat shock protein 90 (Hsp90) becomes acetylated, and this acetylation prevents it from 
binding to its cochaperone p23 and impairs the chaperone activity, which is rescued by HDAC6 
(Kovacs et al., 2005). Glucocorticoid receptor (GR), a Hsp90 clients, becomes defective in ligand 
binding, nuclear translocation and gene activation in the absence of HDAC6. Another chaperone 
protein Hsp70 is also involved in regulation of GR by HDAC6. (Li et al., 2016c). Heat shock factor 1 
(HSF1) in Foxp3+ T-regulatory cells (Tregs) represents another example in HDAC6-Hsp90 regulatory 
axis (de Zoeten et al., 2011). The chaperone proteins Hsc70 and DNAJA1 have recently been identified 
also as HDAC6 substrates (Zhang et al., 2015b). Deacetylation of these chaperone proteins by HDAC6 
helps their dimerization, although the biological importance is still unclear. Glucose-regulated protein 
78 (GRP78, also called BiP, HSPA5) is an endoplasmic reticulum (ER) specific homolog of Hsp70 
(Ron and Walter, 2007). In stressed condition, accumulated misfolded proteins in ER bind to GRP78 
and induce its dissociation from the receptor, leading to activation of Protein kinase RNA-like ER 
kinase (PERK) for the following stress response. HDAC6 also localizes in the ER and deacetylate 
GRP78 (Rao et al., 2010), which promotes GRP78 binding to PERK. Thus, HDAC6 regulates a variety 
of chaperone proteins by changing the binding ability to their interaction partners, including client 
proteins, through deacetylation. In each case, however, it is still unknown how large the population of 
client proteins affected by HDAC6-mediated deacetylation is. Apart from tuning chaperone activity 
by deacetylation, HDAC6 directly interacts with another chaperone protein, VCP/p97, and controls 
the fate of ubiquitinated misfolded proteins (Boyault et al., 2007). However, VCP/p97 itself has not 
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 been reported as a substrate (discussed in 1.2.3). 
 
Stress and viral response: Peroxiredoxins, TDP-43, TRIM50, RIG-I and Tat 
Cellular responses to stresses, including oxidative stress, protein misfolding, and even viral 
infection, is also mediated by HDAC6. HDAC6 regulates antioxidant proteins to cope with oxidative 
stress, and also prevents protein aggregations in oxidative stress. Peroxiredoxins (Prx) family proteins 
function as antioxidants; they reduce elevated H2O2 level through oxidization of their cysteine residue. 
Acetylation increases this reducing activity, which is counteracted by HDAC6 (Parmigiani et al., 2008). 
As antioxidant activity of Prx is linked to resistance to chemotherapy and radiation therapy for cancer 
(Chen et al., 2002), inactivating Prx would be beneficial in HDAC6-targeted cancer therapy. An RNA-
binding protein, TDP-43 is another HDAC6 substrate associated with oxidative stress response. TDP-
43 is recurrently mutated in inherited form of the neurodegenerative disease such as amyotrophic 
lateral sclerosis (ALS) and frontotemporal lobar degeneration with ubiquitin-positive inclusions 
(FTLD-U) (Lagier-Tourenne and Cleveland, 2009), and its aggregates are observed in the cytoplasm 
and nucleus of neurons in the patients (Neumann et al., 2006). This aggregation is likely to be enhanced 
by acetylation; immunohistochemistry with cortical brain and spinal cord sections of the patients 
shows that TDP-43 in pathological aggregates is acetylated. Acetylations occur in RNA-binding motif 
of TDP-43 (K145 and K192), and weaken its RNA-binding function. Oxidative stress promotes TDP-
43 acetylation, and HDAC6 is required to deacetylate TDP-43 and prevent its aggregation (Cohen et 
al., 2015). 
Apart from TDP-43, HDAC6 is generally important for aggregate formation, which are often 
associated with neurodegenerative diseases (discussed in 1.2.3). Aggregated proteins, which are not 
efficiently degraded by ubiquitin-proteasome system (UPS), often accumulate into microscopically 
visible structures called as aggresomes (Kopito, 2000). HDAC6 binds to ubiquitinated and aggregated 
proteins through its ZnF-UBP domain, and directly brings them into an aggresome using dynein motor 
system (Kawaguchi et al., 2003). Moreover, HDAC6 also deacetylates K372 of TRIM50, which is 
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 important for aggresome clearance, to enhance its localization into aggresome (Fusco et al., 2012). As 
mentioned below (in 1.2.3), influenza virus A (IAV) hijacks this HDAC6-mediated aggresome 
formation pathway to be efficiently uncoated in host cells (Banerjee et al., 2014), indicating the role 
of HDAC6 in viral infection. In parallel, HDAC6 also regulates infectivity of other RNA viruses 
through deacetylation of RIG-I (Retinoic-acid-inducible gene-I, also known as DDX58). RIG-I 
functions as a sensor of viral infection; viral RNAs induce conformational change of RIG-I so that it 
can interact with mitochondrial antiviral signaling proteins to induce innate immunity responses such 
as the production of type I interferons (Leung and Amarasinghe, 2012). Acetylations of RIG-I at K858 
and K909 impair its binding to dsRNA. In response to RNA viral infection, HDAC6 interacts with and 
deacetylates RIG-I, thereby increasing its viral RNA sensing ability (Choi et al., 2016). Accordingly, 
HDAC6 KO mice are more susceptible to an RNA virus (vesicular stomatitis virus) (Choi et al., 2016). 
Furthermore, HDAC6 also deacetylates viral protein itself; K28 of HIV-1 Tat is acetylated by 
p300/PCAF, while it is deacetylated by HDAC6 (Huo et al., 2011). This deacetylation impairs 
transactivation activity of Tat toward HIV-1 transcription. These findings indicate the multifaceted 
roles of HDAC6 in RNA virus infection. 
 
Growth and apoptosis signaling pathways: K-RAS, ERK1, AKT, PTEN, MST1, Pin1 and 14-3-
3ζ 
Several components of phosphorylation signaling, including the MAPK, PI3K-AKT and 
Hippo pathways, have been reported as HDAC6 substrates. Upon stimulation of growth factors, RAS 
GTPase protein becomes its active form to activate downstream signaling proteins. RAS proteins cycle 
between ‘active’ and ‘inactive’ states that are conferred by the binding of GTP and GDP (Pylayeva-
Gupta et al., 2011), and the GTP-bound form activates several downstream signaling pathways. One 
of RAS isoforms, K-RAS, becomes acetylated at K104 (Yang et al., 2012), and this acetylated form is 
resistant to guanine nucleotide exchange factors (GEFs)-mediated activation; thus acetylated K-RAS 
cannot maintain a constitutively activated state. This K104 acetylation of K-RAS is removed by 
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 HDAC6 and SIRT2, resulting in cancer cell survival (Yang et al., 2013). Two representative 
downstream kinases are also targeted by HDAC6; ERK1 (Wu et al., 2018) and AKT (Iaconelli et al., 
2017) are activated by HDAC6-mediated deacetylation. The acetylation site of ERK1 (K72) regulated 
by HDAC6 is located near the ATP binding site, and stabilizes one wall of the ATP binding site via 
intramolecular contacts. Acetylation reduces enzymatic activity of ERK1 through the conformation 
change of the ATP binding site, which is recovered by HDAC6. Two acetylation sites in the kinase 
domain of AKT, K163 and K377, are deacetylated by HDAC6 (Iaconelli et al., 2017). As is the case 
of ERK1, K163 of AKT is located in the ATP binding site, and this acetylation decreases kinase activity 
of AKT. As AKT activity is important during neural progenitor cells (NPCs) differentiation (Zhang et 
al., 2010), HDAC6 inhibition in NPCs impedes their differentiation into neurons, and promotes the 
glial lineage. A negative regulator of PI3K-AKT pathway, the tumor suppressor PTEN is impaired by 
HDAC6-mediated deacetylation. PTEN dephosphorylate PIP3, thereby attenuating PI3K-AKT 
signaling (Song et al., 2012). Acetylation of PTEN at K163 inhibits the intramolecular interaction 
between C-terminal tail of PTEN and its remaining region, which brings PTEN to the cell membrane 
for its catalytic function. K163 deacetylation is mediated by HDAC6; inhibition of HDAC6 induces 
PTEN acetylation and subsequent membrane translocation to enhance its tumor suppressor activity 
(Meng et al., 2016). Another tumor suppressor, MST1, is also negatively regulated by HDAC6. MST1 
inhibits the activation of YAP/TAZ, key transcription co-activators in Hippo pathway to prevent the 
expression of pro-survival target genes. HBXIP, which is upregulated in breast cancer (Liu et al., 2014), 
induces expression of HDAC6, which deacetylates K35 of MST1. This deacetylation of MST1 
promotes its interaction with Hsc70, resulting in lysosome-dependent degradation through chaperone-
mediated autophagy (Li et al., 2016a). 
Regulatory proteins for serine/threonine kinase signaling pathways mentioned so far have also 
been reported as HDAC6 substrates. Pin1 is a peptidyl-prolyl isomerase (PPIase); it specifically 
recognizes phosphorylated Pro-directed Ser/Thr (pSer/Thr-Pro) sequence, which is often catalyzed by 
MAPKs, and adopts its cis and trans conformations (Lu and Zhou, 2007). Pin1 plays a central role in 
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 tumor progression by activating oncoproteins, and inactivating tumor suppressor proteins by its PPIase 
function (Zhou and Lu, 2016). In breast cancer cell lines, HDAC6 becomes phosphorylated by G-
protein-coupled receptor kinase 2 (GRK2) and induces deacetylation of Pin1 (Nogues et al., 2016). 
GRK2/HDAC6-mediated deacetylation enhances Pin1 stability, and also increases its binding to 
mitotic cellular substrates. In addition, regulatory 14-3-3 proteins, which are phospho-serine/threonine 
binding proteins, are also HDAC6 substrates (Morrison, 2009). An isoform 14-3-3ζ suppresses 
apoptosis via interaction with pro-apoptotic Bad (Datta et al., 2000). Acetylations at two lysine residues 
located in the binding pocket (K49 and K120) impair the interaction between 14-3-3ζ and its 
interaction partners including Bad, which is counteracted by HDAC6 to protect cells from apoptosis 
(Mortenson et al., 2015). 
 
Nuclear proteins: β-catenin, p53, RelA/p65, HIF1α, HMGN2, Ku70, survivin and MSH2 
Some nuclear proteins are deacetylated by HDAC6 when they localize in the cytosol. 
Furthermore, some reports suggest that HDAC6 can localize in the nucleus and interact with its 
substrates there. β-catenin, a key transcription factor in Wnt signaling pathway (Clevers and Nusse, 
2012), is also regulated by EGF signaling; it releases β-catenin from E-cadherin complex and enhances 
nuclear localization of β-catenin (Lu et al., 2003). Upon EGF stimulation, HDAC6 is recruited to 
caveolae and deacetylates β-catenin at K49, leading to inhibition of β-catenin S45 phosphorylation and 
its nuclear localization (Li et al., 2008). p53 is another transcription factor targeted by HDAC6. 
Mitochondrial p53 acetylated at K120 promotes apoptosis through decreasing mitochondrial 
membrane potential (Chen et al., 2011). Cancer cells with ARID1A mutation exhibit higher HDAC6 
expression, and HDAC6 inactivates the apoptosis-promoting function of p53 through deacetylation of 
K120 (Bitler et al., 2017). Apart from mitochondrial function, acetylation of p53 is generally known 
to be important for its transcriptional activator functions (Gu and Roeder, 1997) due to its effect on 
DNA binding. In agreement with this, K381/382 of p53 are deacetylated by HDAC6, resulting in 
impaired transcriptional activation by p53 (Ryu et al., 2017a; Ryu et al., 2018). Two other transcription 
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 factors are also reported as HDAC6 substrates: RelA/p65 (Jia et al., 2017) and HIF1α (Ryu et al., 
2017b). RelA/p65 is a negative regulator of miR-27b expression in diffuse large B-cell lymphoma 
(DLBCL) cells. Acetylation caused by HDAC6 inhibition impairs nuclear localization of RelA/p65, 
leading to elevated miR-27b expression. As miR-27b represses the expression of the c-Met receptor 
tyrosine kinase, which is important for lymphoma cell survival, HDAC6 inhibition may be an attractive 
therapeutic strategy in DLBCL (Jia et al., 2017). HIF1α, an essential transcription factor for cellular 
response to hypoxia, becomes acetylated by HDAC6 inhibition, and this acetylation promotes HIF1α 
degradation under hypoxia (Ryu et al., 2017b), suggesting that a role of HDAC6 in the hypoxia 
response pathway is to regulate the level of HIF1α. In addition to transcription factors, HDAC6 also 
deacetylates the chromatin remodeling protein HMGN2 to regulate activity of a transcription factor 
Stat5a (Medler et al., 2016). 
HDAC6 regulates apoptosis through deacetylation of nuclear proteins. Ku70 is a nuclear 
protein which binds to Bax, a pro-apoptotic Bcl2 family protein, to prevent localization of Bax on 
mitochondria. HDAC6 deacetylates Ku70 to keep the Ku70-Bax complex in the cytosol; in agreement 
with this, HDAC6-specific inhibition triggers Ku70 acetylation and cell death (Subramanian et al., 
2011). Survivin is another anti-apoptotic protein regulated by HDAC6. K129 of survivin is acetylated 
by CBP, which promotes homodimerization of survivin and maintains its nuclear localization. HDAC6 
localizes to nucleus to deacetylate survivin in the estrogen-receptor-positive breast cancer cell line 
MCF7, and induces survivin to localize in cytosol for its anti-apoptotic activity (Riolo et al., 2012).  
HDAC6 is also involved in DNA repair through deacetylation of MutS protein homolog 2 
(MSH2). MSH2 is a component of the DNA mismatch repair (MMR) system and works as a 
heterodimer with MSH6 (called as MutSα) or MSH3 (MutSβ) (Li, 2008). As acetylation sites (K845, 
847, 871, and 892) are also targeted by ubiquitination, HDAC6 leads to ubiquitination-dependent 
degradation of MSH2. Instability of MSH2 induced by HDAC6 decreases the amount of MutSα 
complex, but not MutSβ, and causes DNA mismatch repair activity (Zhang et al., 2014). 
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 Other biological functions: Mfn1, CIDEC, and hERG 
Formation of some organelles such as mitochondria and lipid-droplets (LDs) are impacted by 
HDAC6. Mitochondrial fusion is a two-step process, where outer membrane fusion is regulated by 
Mfn1 and Mfn2, while inner membrane fusion is regulated by Opa1. Deacetylation of Mfn1 by 
HDAC6 is required for mitochondrial fusion (Lee et al., 2014a); mitochondria in HDAC6 KO MEFs 
do not undergo fusion and are fragmented in glucose-starvation. The location of the acetylation site 
K222 in the dynamin-related GTPase domain of Mfn1 suggests that acetylation may inhibit its GTPase 
activity for mitochondrial fusion although this has not been confirmed yet. LDs are tissue-specific 
organelles, which regulate the storage and hydrolysis of neutral lipids, and are found largely in the 
adipose tissue. LD formation is regulated negatively by HDAC6 through deacetylation of CIDEC 
(Qian et al., 2017). It is one of the LD-associated proteins that promote LD fusion in adipocytes (Gong 
et al., 2009). Acetylation of CIDEC at K56 by PCAF is caused by fatty acids, and leads to a 
conformational change which prevents ubiquitination and degradation. Therefore, deacetylation of 
CIDEC by HDAC6 results in its decreased stability, which impairs LD fusion and growth. 
In addition to organelle formation, regulation of ion channel is likely to be regulated by 
HDAC6. The human ether-a-go-go-related (hERG) gene encodes the α subunit of a rapidly activating 
delayed-rectifier potassium (IKr) channel, whose mutations cause long QT syndrome type 2 (LQT2). 
HDAC6 directly interacts and deacetylates hERG, resulting in its increased ubiquitination and 
degradation (Li et al., 2018). Thus, the repertoire of HDAC6 substrate is still expanding, and more 
comprehensive studies will be required. 
 
1.2.3 HDAC6 as a unique regulator of protein homeostasis 
The functional uniqueness of HDAC6 among HDAC family proteins is mainly due to its 
involvement in protein homeostasis. Misfolded proteins are often polyubiquitinated and degraded by 
proteasome, a process called ubiquitin-proteasome system (UPS). However, the UPS does not work 
efficiently for degradation of aggregated proteins and it is known that polymerization of aggregated 
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 proteins can form microscopically visible structures such as inclusion bodies and aggresomes (Kopito, 
2000). Inclusion bodies are multiple intracellular foci where misfolded proteins are sequestered, while 
the aggresome is a special type of inclusion bodies that is usually found at the microtubule organizing 
center (MTOC). The aggresome was first identified in the study of a mutant of the cystic fibrosis 
transmembrane conducting regulator CFTR-ΔF508, which tends to be misfolded (Jensen et al., 1995). 
Under normal conditions, misfolded CFTR-ΔF508 is degraded by the proteasome. However, upon 
proteasome inhibition, CFTR-ΔF508 forms aggregates and concentrates into a juxtanuclear inclusion 
body that was named aggresome (Johnston et al., 1998). Further studies revealed that other misfolded 
proteins also form an aggresome which is cleared by subsequent autophagy. In addition to aggresome, 
more transient and dynamic condensates with proteins and RNAs, called cellular granules (also known 
as membrane-less organelles or biomolecular condensates) (discussed in 1.3) are also observed in cells. 
Stress granules (SGs) are an example of cellular granules composed of ribonucleoproteins (RNPs) 
which form when translation initiation is impaired; they are thought to represent a pool of mRNAs 
stalled in translation (discussed in 1.3.3). SGs are also cleared by autophagy (Buchan et al., 2013) as 
well as aggresome mentioned above. As mentioned below, aggresome and SGs seem to be functionally 
interconnected to each other although the molecular mechanisms which explain the transition of these 
two states are still missing. HDAC6 impacts several steps of these protein homeostasis processes: UPS, 
aggresome formation, SGs formation and their clearance by autophagy through six mechanisms 
discussed below and schematized in Fig. 8. 
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Figure 8.   HDAC6 in protein homeostasis. (1) Unfolded/misfolded proteins are usually cleared by ubiquitin-
proteasome system (UPS). VCP/p97 removes ubiquitinated proteins from HDAC6 complex to enhance their 
processing by proteasome. (2) If unfolded/misfolded proteins are not degraded by the proteasome appropriately, 
they may form aggregates. These aggregates are processed by ataxin-3 and transported by HDAC6/dynein 
complex to aggresome. (3) Another complex, HDAC6 with TRIM50 and an autophagy receptor p62 also brings 
aggregated proteins into the aggresome. (4) HDAC6 regulates quality-control autophagy by actin filament 
remodeling through deacetylation of cortactin to clear aggresomes and stress granules (SGs). (5) Poh1, a 
proteasomal deubiquitinase produces C-terminal free unanchored K63 ubiquitin chains in aggresome, resulting 
in HDAC6 activation there and subsequent quality-control autophagy. (6) HDAC6 regulates SG formation, 
although the molecular mechanism is not well explored when this thesis was started. 
 
(1) HDAC6 uniquely has a ZnF-UBP domain and binds to C-terminal diglycine motif of 
unanchored ubiquitin (Boyault et al., 2007; Ouyang et al., 2012). This makes HDAC6 an essential 
factor to coordinate the responses to cytotoxic ubiquitinated misfolded proteins. It binds ubiquitinated 
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 proteins with high-affinity to be hindered from the recognition by ubiquitin specific proteases (USPs) 
and proteasomes while an HDAC6 interaction partner, VCP/p97 chaperone protein removes them from 
HDAC6 to enhance their processing by USPs or proteasome (Boyault et al., 2006). This suggests that 
HDAC6 inhibits misfolded protein degradation by UPS, and that cellular concentrations of these two 
proteins strongly affect the fate of ubiquitinated proteins. HDAC6 thus prevents ubiquitinated proteins 
from being delivered to the proteasome. 
(2) HDAC6 also works as an adaptor for the dynein motor protein system (Kawaguchi et al., 
2003). Upon proteasome inhibition, HDAC6-enriched inclusion body appears and this is indeed 
aggresome based on its localization and protein components. HDAC6 binds dynein through its binding 
motif sequence between two catalytic domains, and proteasome inhibition stimulates HDAC6-dynein-
ubiquitinated protein complex formation. HDAC6 directly brings ubiquitinated misfolded proteins into 
an aggresome using the dynein motor system. It is important to note that, from a structural point of 
view, HDAC6 cannot recognize polyubiquitin chains anchored to misfolded proteins because the C-
terminal diglycine motif is not exposed. A reasonable molecular model to explain the physical 
interaction between HDAC6 and aggregated proteins has been proposed (Ouyang et al., 2012); the 
deubiquitinase ataxin-3 is first recruited to aggregated proteins and partially cleaves them through its 
deubiquitination activity, this then allows HDAC6 to recognize aggregated proteins through those 
exposed and unanchored ubiquitin C-termini. The contribution of HDAC6 to aggresome formation 
may be linked to pathogenesis of human diseases; for example, it is concentrated in Lewy bodies, 
aggresome-related structure observed in neurodegenerative disorders such as Parkinson’s disease. 
(3) In addition to dynein, HDAC6 interacts with other proteins and forms a complex to bring 
aggregated proteins into aggresome. Autophagy receptors including p62/SQSTM1 link aggregated 
proteins to autophagy. These proteins interact with both ubiquitin and LC3/GABARAP on the 
autophagosome, thereby promoting autophagy of ubiquitinated aggregated proteins (Kirkin et al., 
2009). An E3 ubiquitin ligase, TRIM50 interacts with an autophagy receptor p62/SQSTM1 and also 
with HDAC6 to promote the sequestration of aggregated proteins into the aggresome (Fusco et al., 
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 2012). As mentioned above (in 1.2.2), HDAC6 deacetylates TRIM50 at K372, resulting in its 
ubiquitination and localization on aggresome (Fusco et al., 2014). It is important to note that the 
relationship between HDAC6/dynein complex and HDAC6/p62/TRIM50 complex for bringing 
aggregated proteins into aggresome is still unknown. 
(4) HDAC6 does not only contribute to aggresome formation, but also plays important roles 
for its clearance process. Autophagy had been predominantly defined as a non-selective degradation 
caused by nutrient starvation. However, it has now become clear that autophagy is also dedicated to 
cellular quality control by selective disposal of aggregated proteins, aggresomes and damaged 
organelles (Mizushima and Komatsu, 2011). HDAC6 regulates this quality-control autophagy by actin 
filament remodeling through deacetylation of cortactin (Lee et al., 2010) (discussed in 1.2.2). Cortactin 
is recruited to protein aggregates where it enhances F-actin polymerization to clear aggregates by 
autophagy. Deacetylation by HDAC6 is required for cortactin to stimulate F-actin polymerization in 
the process. Thus, HDAC6 KO MEFs are defective in aggregated protein clearance, which is due to 
inefficient autophagosome-lysosome fusion process, but are normally equipped with starvation-
induced autophagy. 
(5) Autophagy acts as a compensatory degradation system through aggresome clearance in 
case that UPS is inhibited, as discussed so far. However, proteasomes are also localized in aggresomes 
and Lewy bodies although they cannot process protein aggregates. Poh1, a proteasomal deubiquitinase 
produces C-terminal free unanchored ubiquitin chains in aggresome, resulting in HDAC6 activation 
there and subsequent quality-control autophagy of aggresome (Hao et al., 2013). Poh1 specifically 
cleaves K63 linkages (Cooper et al., 2009) and K63-linked, but not K48-linked, ubiquitin chains 
interact with HDAC6. The K63-linked ubiquitin chains produced by Poh1 bind to HDAC6 ZnF-UBP 
and activate its catalytic activity, leading to deacetylation of the substrate cortactin. Cortactin-mediated 
autophagy process does not depend only on F-actin, but also depends on MHC10, as knockdown of 
MHC10 impairs autophagy of aggresome. 
This regulation of aggresome-autophagy pathway by HDAC6, dynein motor and 
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 actinomyosin system is “hijacked” and utilized by influenza virus A (IAV) for its uncoating. This 
identified HDAC6 as a host factor important for IAV infection (Banerjee et al., 2014). Our group 
together with the lab of Ari Helenius showed that IAV capsid uncoating process is severely impaired 
in HDAC6 deficient cells. Analysis of the stepwise IAV entry in HDAC6 deficient cells revealed no 
significant differences in other processes such as endocytic uptake, acid-induced HA conversion, and 
fusion. Impairment of capsid uncoating in the absence of HDAC6 is rescued by catalytic-dead mutant 
of HDAC6, but not by non-ubiquitin-binding mutant, suggesting that ZnF-UBP function is essential 
for this process. Virions were found to be loaded with C-terminal free ubiquitin chains inside, thus 
potentially explaining the requirement for the ZnF domain (Banerjee et al., 2014). Inhibition of 
microtubule/actin filament assembly and dynein/myosin motor system, which are important for 
aggresome formation by HDAC6, also impairs capsid uncoating. These observations allowed to 
conclude that HDAC6 works as a linker molecule between ubiquitin chains in IAV and motor proteins, 
which allows to generate physical forces to break apart the capsid. It still remains unknown which 
other types of viruses besides IAV have polyubiquitin chains inside and how this process is regulated. 
(6) As discussed so far, the action of HDAC6 is required for normal resolution of the protein 
aggregates. Our previous work (Kwon et al., 2007) highlighted HDAC6 as an important factor for SG 
formation. HDAC6 was found to bind to a SG component, G3BP and to localize to SGs under several 
stress conditions, including oxidative stress and UV (Kwon et al., 2007). Moreover, HDAC6 KO MEFs 
exhibit impaired SG assembly and this phenotype is rescued by re-expression of WT HDAC6, but not 
by catalytic-dead or non-ubiquitin-binding mutants of HDAC6. SG assembly is impaired by 
microtubule-disrupting drugs, suggesting that the assembly process is dependent on the microtubule 
network. These observations encouraged us to propose a model that HDAC6 brings translationally 
stalled mRNAs binding with G3BP to SGs using dynein motor system on microtubule network, similar 
to the contribution of HDAC6 to aggresome formation. It is important to mention, however, that there 
has been no rationale to explain the importance of HDAC6 catalytic activity for SG assembly.  
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 In sum, HDAC6 collects ubiquitinated aggregated proteins by bringing them to aggresome 
using motor proteins, where the interaction between HDAC6 and ubiquitinated proteins are tuned by 
chaperones. Ubiquitin chains derived from aggresome processing enhance catalytic activity of HDAC6 
to promote re-constitution of actinomysin network surrounding aggresome and supports subsequent 
quality-control autophagy. The formation of another type of protein condensates, SG is also regulated 
by catalytic activity of HDAC6 although the molecular mechanism is not clarified yet.  
Thus, HDAC6 was known to be important for the formation of different kinds of cellular 
granules, such as aggresomes or SGs, in response to environmental cues including stress but there was 
no unifying mechanistic rationale. This therefore remained a long-standing unanswered question until 
recently, – when the general concept from physics “phase transitions” was introduced into molecular 
biology by biophysicists (Brangwynne et al., 2009). 
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 1.3 Phase transitions and cellular granules 
1.3.1 Liquid-liquid phase separation in biology 
Cellular granules (also known as membrane-less organelles or biomolecular condensates) are 
involved in diverse biological processes, including protein homeostasis, RNA metabolism, ribosome 
biogenesis, and signal transduction (Fig. 9). 
 
 
Figure 9.   Cellular granules. Schematic of the numerous condensates in the nucleus, cytoplasm and 
membranes of eukaryotic cells. Some compartments are observed only in specific cell types. For example, 
Balbiani bodies and germ granules are specific to germ cells (green hues), and RNA transport granules and 
synaptic densities are specific to neuronal cell types (pink hues). Adapted from (Banani et al., 2017). 
 
Classic cellular organelles, such as mitochondria and the endoplasmic reticulum, are defined 
as compartments surrounded by lipid membranes. Those membranes physically separate the interior 
and exterior of the organelles, and transport machineries tightly regulate organelle compositions. In 
contrast, granules, including aggresomes and stress granules (SGs) in the cytoplasm, as well as nucleoli, 
and promyelocytic leukemia (PML) bodies in the nucleus, lack a physical barrier to separate their 
internal components from the surrounding milieu. Fundamental questions – how they form and how 
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 they maintain their structures and compositions – remained elusive for many years due to their complex 
composition, consisting of dozens of different molecules and the lack of genetics. 
The recent discovery, that germ (P) granules in C. elegans are liquid-like, brought an 
important clue to understand the process of granule formation, and it is now recognized that phase 
transition, especially liquid-liquid phase separation (LLPS, also called coacervation) driven by 
multivalent macromolecular interactions is contributing critically to the formation of these organelles 
(Banani et al., 2017; Brangwynne et al., 2015; Hyman et al., 2014; Shin and Brangwynne, 2017). Phase 
transitions are commonly used to describe transitions between solid, liquid and gaseous states, with 
each phase having unique physical characteristics (Weber and Brangwynne, 2012). For example, 
gaseous molecules in water vapor move freely and rarely interact with each other. In liquids, water 
molecules transiently form hydrogen bonds for interaction, but constantly shuffle their neighborhood. 
The water molecules in solid phase are ordered in a lattice with stable hydrogen bonds holding 
neighboring molecules. Macromolecules such as proteins and RNAs in vivo also undergo phase 
transitions. The clearest example is cytoskeletal proteins; actin and tubulin can change their states 
between a soluble gas-like state where monomers freely diffuse in cytosol and a solid state as the 
component of filaments. Recent careful biophysical observations of P granules in C. elegans gave 
convincing demonstration that a liquid-like state is appropriate to describe the dynamics of the granule, 
and maybe those of other cellular granules (Brangwynne et al., 2009). This idea was supported by the 
following observations (Fig. 10): 
(1) P granules deform in shear flows. 
(2) The photobleached region of a P granule will recover through internal rearrangement. 
(3) Two spherical P granules fuse together, and form a new spherical shape. 
Thus, P granule formation appeared to be governed by LLPS, which is often seen in the daily life; for 
example, water and oil (two immiscible liquids) always phase separate. A decade of studies 
subsequently have put emphasis on the general importance of LLPS for formation of biomolecular 
condensates where components for biochemical reactions such as protein and RNA spatiotemporally 
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 localize to achieve a certain biological output. This concept is well exemplified in the formation of 
various types of cell signaling hubs, including centrosome and heterochromatin (Banani et al., 2017).  
 
 
Figure 10.   P granules exhibit liquid-like properties. (A) P granules (green) in the cytoplasm of a one cell-
stage C. elegans embryo. (B) Two P granules fuse and relax their shape within about one minute. (C) FRAP of 
P granule (left). Kymograph of linear intensity profiles along the anterior-posterior axes (right). Red color 
indicates high intensity and blue corresponds to background intensity. (D) P granule (red outline) deformed by 
sheared flow with a direction indicated by the white arrows. Modified figure based on (Hyman et al., 2014). 
 
The contribution of LLPS to biological processes in living cells is only emerging. Beyond classical 
membrane-less organelles, biological condensates are increasingly observed in diverse cellular 
processes: signaling to the cytoskeleton (Li et al., 2012), T cell activation (Su et al., 2016), 
neurodegenerative disease (Molliex et al., 2015; Patel et al., 2015), innate immune signaling (Du and 
Chen, 2018), synaptic vesicle transport and plasticity (Milovanovic et al., 2018; Zeng et al., 2018; 
Zeng et al., 2016), cell division (Woodruff et al., 2017), heterochromatin formation (Larson et al., 
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 2017; Strom et al., 2017), transcription (Cho et al., 2018; Chong et al., 2018; Lu et al., 2018; Sabari et 
al., 2018), RNA splicing (Gueroussov et al., 2017; Ying et al., 2017), miRNA-induced silencing (Sheu-
Gruttadauria and MacRae, 2018), RNAi inheritance (Wan et al., 2018), nutrient response (Delarue et 
al., 2018), autophagy (Sun et al., 2018) and even photosynthesis (Freeman Rosenzweig et al., 2017). 
At phase transitions, a system tends to go to the lowest energy state, which is determined by entropic 
and enthalpic factors. Entropy generally tends to keep a system at well mixed state, and thus, the system 
is usually required to counteract this by some attractive interactions between molecules for phase 
separation. Studies about phase transitions in nonliving materials have suggested that polymers are 
prone to undergo phase separation because of connectivity of individual subunits. This implicates the 
importance of biopolymers, such as protein, RNA, and DNA in intracellular phase separation. It is now 
widely acknowledged that distinct proteins and RNAs with certain propensities contribute to the 
process. The three representative molecular determinants – multivalent proteins with modular 
interaction domains, intrinsically disordered proteins (Fig. 11), and repeat-containing RNAs – are well 
known; they usually form phase-separated liquid droplets at certain external conditions (e.g. 
temperature, salt concentration and pH) in vitro, and this activity is well correlated with membrane-
less organelle formation in vivo. These biomolecules with phase separation propensity are listed (Table 
4) below, and discussed in more detail in the following section. 
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Figure 11.   Protein features driving intracellular phase separation. (A) Weak interactions between 
multivalent proteins drive LLPS. Proteins composed of signaling pathways often contain a set of binding 
domains, such as SH3 and proline-rich motif (PRM). Disordered proteins are also key for driving LLPS. Many 
RNA-binding proteins have IDRs in addition to the domain for RNA recognition such as RNA recognition motif 
(RRM). (B) (Top) A mixture of two synthetic proteins, repeats of SH3 and PRM, undergoes LLPS. (Bottom) 
The purified hnRNPA1, an IDR-containing RNA-binding protein, also forms liquid droplets. Adapted from 
(Shin and Brangwynne, 2017).
A B 
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 Proteins/RNAs tested for its 
phase separation propensity 
Molecular determinants Relevant biomolecular condensates/ biological 
outcomes 
Reference 
1. Nuclear pore proteins 
(e.g. Nsp1) 
FG-rich IDR Nuclear pore complex (Frey et al., 2006; 
Labokha et al., 2013) 
2. N-WASP signaling 
components 
SH2 domain + pY, 
SH3 domain + PRM 
Remodeling of actin cytoskeleton networks (Li et al., 2012) 
3. RPB1 
(subunit of RNA pol II) 
Heptapeptide (YSPTSPS) repeat 
in its C-terminal domain 
Transcription (Kwon et al., 2013) 
4. C9orf72 
(pathogenic mutants) 
Dipeptide repeat 
(GRn, PRn) 
Stress granules, nuclear speckles and Cajal 
bodies 
ALS/FTD 
(Boeynaems et al., 
2017; Kwon et al., 
2014; Lee et al., 2016) 
5. DDX4 FG, RG-rich IDR P granules (Nott et al., 2015) 
6. LAF-1 RG-rich IDR P granules (Elbaum-Garfinkle et 
al., 2015) 
7. FUS 
(and its family proteins) 
G/S-Y-rich (Prion-like) LCS, 
RGG/RG domain, and RRM 
Stress granules 
ALS/FTD 
(Murakami et al., 
2015; Patel et al., 
2015) 
8. hnRNPA1/A2 G/S-Y, RG-rich (Prion-like) 
LCS and RRM 
Stress granules 
ALS/FTD and MSP 
(Molliex et al., 2015; 
Xiang et al., 2015) 
9. RNA binding proteins 
(Pub1, Lsm4 and eIF4GII) 
IDR and RNA binding Stress granules and P bodies (Lin et al., 2015) 
10. Whi3 QN-rich IDR and 
RNA binding to its RRM 
Spatial patterning of transcripts in the fungus 
Ashbya gossypii 
(Langdon et al., 2018; 
Zhang et al., 2015a) 
11. LAT signaling components SH2 domain + pY, 
SH3 domain + PRM 
T cell receptor signaling pathways (Su et al., 2016) 
12. SPOP + DAXX Oligomerization domain (SPOP) 
+ SPOP-binding motifs in IDR 
(DAXX) 
Nuclear speckles, PML bodies and DNA-
damage loci 
Prostate cancer 
(Bouchard et al., 2018; 
Marzahn et al., 2016) 
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 13. NPM1 RNA binding to its RRM Nucleoli (Feric et al., 2016) 
14. Xvelo Prion-like domain Balbiani body (Boke et al., 2016) 
15. PML body components SIM + SUMO PML bodies (Banani et al., 2016) 
16. PSD95 Coiled-coil domain Postsynaptic densitiy (Zeng et al., 2016) 
17. TDP-43 α-helix Stress granules, cellular aggregates 
ALS/FTD 
(Conicella et al., 2016) 
18. PGL-1 and PGL-3 RGG/RG domain P granules (Saha et al., 2016; 
Zhang et al., 2018a) 
19. Dhh1 RNA binding P bodies (Mugler et al., 2016) 
20. Pab1 RRM and P-rich LCS Stress granules (Riback et al., 2017) 
21. SPD-5 Coiled-coil domain Centrosome (Woodruff et al., 2017) 
22. Repeat-containing RNAs 
(Triplet repeat: CAG, CUG 
and G4C2 repeat) 
RNA-RNA base-pairing Nuclear speckles 
Neurodegenerative diseases (Huntington’s 
disease, ALS/FTD and SCA) and myotonic 
dystrophy 
(Jain and Vale, 2017) 
23. HP1α IDR Heterochromatin (Larson et al., 2017; 
Strom et al., 2017) 
24. Rbfox G/S-Y-rich LCS RNA splicing (Ying et al., 2017) 
25. TIA1 Q-rich (Prion-like) LCS Stress granules 
ALS/FTD and myopathy 
(Mackenzie et al., 
2017) 
26. Tau IDR Neurodegenerative diseases (Alzheimer’s 
disease and Parkinson’s disease) 
(Hernandez-Vega et 
al., 2017) 
27. Sup35 Prion domain pH sensor to drive phase separation of 
translation termination factor in yeast 
(Franzmann et al., 
2018) 
28. UBQLN2 IDR and ubiquitin binding to its 
UBA 
Stress granules (Dao et al., 2018) 
29. Ago2 + TNRC6B PIWI domain + 
GW-rich IDR 
Assembly of miRNA-induced silencing complex (Sheu-Gruttadauria 
and MacRae, 2018) 
30. p62/SQSTM1 Ubiquitin binding to its UBA Autophagy (Sun et al., 2018) 
31. Htt PolyQ tract Cellular aggregates (Peskett et al., 2018) 
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 (pathogenic mutants) Huntington’s disease 
32. CYCT1 H-rich IDR Transcription (Lu et al., 2018) 
33. DYRK1A H-rich IDR Transcription (Lu et al., 2018) 
34. BRD4 IDR Transcription, component of super-enhancers (Sabari et al., 2018) 
35. MED1 S-rich IDR Transcription, component of super-enhancers (Sabari et al., 2018) 
36. cGAS DNA binding Innate immunity (Du and Chen, 2018) 
37. Synapsin1 IDR with PRM Presynaptic site (Milovanovic et al., 
2018) 
00. DDX3X RG-rich IDR Stress granules (Saito et al., 2019) 
 
Table 4.   Summary of proteins having phase separation propensity. Proteins/RNAs whose phase separation propensity were confirmed by in vitro droplet 
formation and/or hydrogel formation are listed in chronological order. It is important to note that there is no consensus on the definition of intrinsically disordered 
region, low complexity sequence and prion-like domain, because this is dependent on the prediction algorithms. It is important to note that LLPS of 00. DDX3X 
is confirmed by the work for this thesis, and it is separately discussed in detail (2.1). IDR, intrinsically disordered region; PRM, proline rich motif; LCS, low 
complexity sequence; ALS/FTD, amyotrophic lateral sclerosis/frontotemporal dementia; RRM, RNA recognition motif; MSP, multisystem proteinopathy; SIM, 
SUMO-interacting motif; SCA, spinocerebellar ataxia UBA, ubiquitin-associated domain. 
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 1.3.2 Molecular determinants in cellular phase transitions 
Modular interaction domains for multivalency 
Multivalent protein-protein interactions by modular interaction domains are the first key 
molecular determinant for phase transitions. Actin-regulatory signaling pathway consisting of three 
proteins: nephrin, Nck and neural Wiskott-Aldrich syndrome protein (N-WASP) demonstrated the 
contribution of LLPS driven multivalent proteins to cell signaling (Li et al., 2012). These proteins form 
oligomers through two types of interactions: Src homology 2 (SH2) domains in Nck and phospho-
tyrosine residues (ligands of SH2) in nephrin, and SH3 domains in Nck and proline-rich motifs (PRMs, 
ligands of SH3) in N-WASP. The resulting assembly shows both in vitro phase-separated liquid 
droplets and clusters on lipid bilayers in cells. A similar mechanism is observed in T cell receptor 
signaling pathways (Su et al., 2016). In this case, five proteins: linker for activation of T cells (LAT), 
growth factor receptor-bound protein 2 (GRB2), GRB2-related adaptor protein 2 (GADS), son of 
sevenless (SOS) and SH2 domain-containing leukocyte protein of 76 kDa (SLP76), which form 
multivalent interactions with each other through their SH2, SH3 domains and ligands, assemble into 
membrane puncta in cells in response to stimulation of the T cell receptor. 
Various synthetic proteins with repeated domains have been utilized to delineate the 
fundamental principles governing intracellular LLPS. Due to the complex nature of the diversity of 
proteins within granules, it is still challenging to elucidate the key molecular parameters during granule 
formation in cells. Simplified model systems composed of a few types of proteins, which harbor a 
variable number of modules (binding domain and its ligand), have been developed so far to establish 
generalizable concepts. One example is the system with repeats of a single SH3 domain ((SH3)m, m: 
number of SH3), and repeats of proline-rich motif ligand ((PRM)n, n: number of PRM) (Li et al., 2012). 
These two protein species have identified valency (that is, the number of interaction modules) and 
affinity between two modules. In this system, if repeats of four or more SH3 domains (n ≥ 4) are mixed 
with similarly repeating PRM domains, liquid droplets form. Moreover, the concentration of protein 
species at which droplets are observed decreases with higher valency; this clearly shows that the 
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 concentrations needed for LLPS are directly related to the valency of each protein species. Another 
system with small ubiquitin-like modifier (SUMO) ligand and the SUMO interacting motif (SIM) 
provided important insights in the principles of compositional control of granules (Banani et al., 2016). 
As observed in the SH3/PRM system, when higher valency species ((SUMO)n and (SIM)m) are mixed, 
they undergo LLPS, forming liquid droplets. If there are more unbound free SUMO ligands within 
droplets (when n > m), SIM species are preferentially recruited. On the other hand, when n < m, SUMO 
ligands are strongly recruited. Taking into account that SUMO-SIM interactions appear to be critical 
for the recruitment of many PML body components, this simple model system may help to understand 
the complexity of actual cellular granules. 
Molecular assembly and phase separation of multivalent proteins are distinct phenomena, but 
some proteins with coiled-coil domain undergo LLPS through their oligomerization. Postsynaptic 
densities (PSDs) are protein enriched compartments under postsynaptic membranes, whose formation 
and activity-dependent modulation is considered as the most basic mechanisms regulating synaptic 
plasticity in the nervous system. The PSD protein SynGAP, a Ras GTPase activating protein binds to 
another postsynaptic density protein, PSD95, resulting in LLPS of the complex, forming liquid-like 
droplets reminiscent of the PSDs. (Zeng et al., 2016). There, SynGAP forms a parallel coiled-coil 
oligomer and binds to PSD95 molecules in a 3:2 stoichiometry. This LLPS is important for SynGAP 
stabilization in PSDs and for preventing neurons from hyperexcitation. This finding provides important 
insight that oligomerization of one protein species further leads to interactions with other proteins for 
LLPS, and explains its role in formation of PSDs. Centrosome formation appears to be triggered by 
LLPS of another coiled-coil protein, SPD-5 (Woodruff et al., 2017). Centrosomes, membrane-less 
organelles for nucleating microtubule arrays, consist of centrioles surrounded by a dynamic assembly 
of protein called the pericentriolar material (PCM). SPD-5 harbors nine predicted coiled-coil domains, 
which make up ~40% of the protein. It forms spherical condensates in vitro with other PCM 
components, the microtubule polymerase ZYG-9 and the microtubule-stabilizing protein TPXL-1. 
This condensate recruits tubulin, and reconstitutes nucleation of microtubule asters; it exactly 
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 resembles PCM in vivo. Remarkably, ZYG-9 itself is sufficient for microtubule nucleation in the 
system, but the formation of asters requires three proteins together in condensates, indicating the 
importance of LLPS in centrosome formation. 
 
Intrinsically disordered proteins 
Intrinsically disordered regions (IDRs) and proteins that harbor these regions (intrinsically 
disordered proteins, IDPs) represent the second key molecular determinant that can phase separate 
under physiological conditions. IDRs do not have a defined 3D structure but often contain sequence 
elements for multivalent weak intermolecular interactions. IDPs are enriched in various granules, 
especially in ribonucleoprotein (RNP) granules, including P granules, P bodies, and SGs. Many such 
proteins can phase separate on their own in vitro under various solution conditions. The sequences of 
IDRs generally lack hydrophobic residues for folding, and they are typically enriched in particular 
amino acids, including polar (G, Q, N, S), positively charged (R, K), negatively charged (D, E), or 
aromatic (F, Y). IDRs can be divided into substructures based on their size and function (Calabretta 
and Richard, 2015); short linear motifs (SLiMs, 1-10 amino acids), which act as ligands for protein 
domains or serve as consensus sequences for enzymes, molecular recognition features (MoRFs, 10-70 
amino acids), which become structured after protein binding, and low complexity sequences (LCSs, 
hundreds of amino acids), which undergo phase transitions under physiological condition. The lack of 
sequence diversity in LCS yields multiple repetitive motifs such as -G/S-Y-, -QN-, -FG-, -RGG- in 
these molecules, which enable polypeptide backbone to interplay through 
intramolecular/intermolecular electrostatic interactions (Fig. 12). Neurodegenerative diseases (e.g. 
ALS/FTD)-related RNA binding proteins often have pathogenic mutations in their IDRs. FUS, 
hnRNPA1 and hnRNPA2, for example, harbor LCSs and their phase transitions have been intensively 
studied so far (Kato et al., 2012; Molliex et al., 2015; Murakami et al., 2015; Xiang et al., 2015). 
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Figure 12.   Molecular interactions underlying phase transitions. The three panels at the right show the 
domain architectures for FUS, DDX4 and LAF-1. The amino acid biases within LCSs of each protein are 
highlighted in square boxes that show the partial amino acid sequence and annotation of the sequence stretch 
using symbols to denote dipoles (triangles), charges (+ or -), aromatic groups (circles) and aliphatic groups 
(squares). The panel at the left shows schematics of the hierarchical modes of interactions that may contribute 
to phase separation. This is annotated to depict the types of interactions, their ranges, and their expected salt 
dependencies. Adapted from (Brangwynne et al., 2015). 
 
Their LCSs are commonly characterized by repetitive -G/S-Y- motifs, and also often recognized as a 
type of prion-like domains (PrLDs): a class of LCS particularly enriched with uncharged polar amino 
acids (Y, N, and Q) and also resembling the amino acid frequency in yeast prion domains (Aguzzi and 
Altmeyer, 2016). PrLDs are prone to aggregation and form amyloid-like fibers, and this is 
experimentally well-confirmed. Phase-separated droplets of FUS, hnRNPA1 and hnRNPA2 proteins 
rapidly exchange molecules with the soluble phase, but these proteins can form hydrogels comprised 
of amyloid-like fibers. Several recent studies have commonly revealed that they form liquid droplets 
at moderate concentrations, but these droplets can nucleate amyloid-like fibers and become hydrogel 
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 over time under high concentrations and low-temperature conditions. This process is accelerated when 
these proteins harbor disease-associated mutations. This liquid-“solid” phase transition in context of 
physiology and pathology will be discussed later (discussed in 3.3.1). 
ALS/FTD caused by C9orf72 is the most drastic example to demonstrate that pathogenic 
mutations can alter the propensity of LLPS and granule formation. Expansion of a hexanucleotide 
repeat GGGGCC (G4C2) in C9orf72 is the most common cause of C9orf72-ALS/FTD (C9-ALS/FTD). 
Unaffected individuals typically harbor between 2 and 23 G4C2 repeats, while people with C9-
ALS/FTD harbor hundreds to thousands of repeats. This mutation appears to affect disease progression 
through two types of toxic gain of function mechanism; one is from abnormality of the transcripts 
itself, and the other is from dipeptide repeat (DPR) proteins produced by repeat-associated non-ATG 
translation, which occurs without an initiating AUG codon and produces peptides from all reading 
frames. Five DPR proteins are produced from pathogenic C9orf72: GAn, GRn, PRn, PAn and GPn (n: 
number of DPR, n ≥ 20 are usually utilized as representative protein species). All of these DPRs are 
produced in C9-ALS/FTD patients and account for cytoplasmic and nuclear inclusions observed in the 
brain and spinal cord. Some DPR species, those containing arginine (GRn and PRn) are especially 
toxic, and the role of DPRs in LLPS and granule formation has recently become clear. PRn itself form 
liquid droplets and it also enhances LLPS of other IDPs (Boeynaems et al., 2017). Remarkably, GRn 
or PRn expression affects intracellular phase separation; they bind to LCSs of the proteins, and impair 
the dynamics of several types of granules, including SGs, nucleoli, nuclear speckles and Cajal bodies 
(Kwon et al., 2014; Lee et al., 2016; Lin et al., 2016). 
Apart from pathogenesis of neurodegenerative diseases, LCSs comprised of repetitive -G/S-
Y- motifs also contribute to a fundamental process for mRNA maturation: alternative splicing. 
Alternative protein isoforms and their structures from the database suggest that alternatively spliced 
exons, including those subject to tissue-, species- and lineage- specific regulation, are significantly 
enriched in IDRs. It is therefore assumed that the evolution of alternative splicing of IDRs has affected 
biological complexity by remodeling protein interaction through IDRs. Studies about evolution of 
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 alternative exons within vertebrates have revealed that important insights for regulation of hnRNPs 
and other RNA binding proteins (RBPs) (Gueroussov et al., 2017); mammalian-specific exons are 
concentrated in the -G/S-Y- rich LCSs of hnRNPs and other RBPs. Differential inclusion of the 
alternative exons, which affects the number of -G/S-Y- motifs in LCSs, regulates formation of hnRNP 
complexes through changes in their LLPS propensity. Formation of these hnRNP complexes on pre-
mRNA, in turn, is critical for the global regulation of alternative splicing events. This regulatory 
mechanism is also observed in other RBPs, Rbfox proteins; higher-order assembly of Rbfox with large 
assembly of splicing regulators (LASR) proteins is required for their large-scale exon activation during 
splicing, and this interaction is mediated by LLPS through the Rbfox -G/S-Y- rich LCS (Ying et al., 
2017). 
As exemplified above, IDPs related to ribostasis often undergo LLPS. ATP-dependent DEAD-
box RNA helicase families, for example, harbor their conserved central helicase domain, and IDRs at 
their N- and C-terminus. One of the family members, DDX4 is a major component of 
nuage/chromatoid body, which hosts machineries of an RNAi pathway, protecting spermatocytes and 
spermatids from transposable elements. The N-terminal IDR of DDX4 alone is sufficient for LLPS, 
and DDX4YFP, where the helicase domain is substituted by YFP, forms droplets within the cell nucleus 
(Nott et al., 2015). Another family members, LAF-1 (C. elegans homolog of DDX3) forms similar 
droplets in vitro and contributes to P granule assembly (Elbaum-Garfinkle et al., 2015). The IDRs 
within DDX4 and LAF-1 are polyampholytic; they contain roughly equivalent fractions of positively 
and negatively charged amino acids (Das et al., 2015). Although, the mechanism underlying charge 
pattern-driven LLPS is still poorly understood, -FG- and -RGG- motifs appear to be important in case 
of DDX4 and LAF-1, respectively. 
Recent studies demonstrated that heterochromatin formation is also regulated through LLPS 
(Larson et al., 2017; Strom et al., 2017). A heterochromatin protein 1 (HP1) family proteins, HP1α, 
can form liquid droplets, which is unique to this protein among HP1 family members. It appears that 
two types of IDRs of HP1α, hinge region between chromo and chromoshadow domains and HP1α-
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 specific N-terminal extension (NTE), contribute to LLPS. This LLPS is induced only by 
phosphorylation of NTE or presence of DNA, which allow the protein to change its conformation and 
bind other HP1 proteins. Heterochromatin domains, indeed, exhibit dynamics that are characteristic of 
LLPS; HP1 initially diffuse, then forms spherical foci that grow, fuse together, and dissolve when it is 
removed from chromatin. These findings suggest that heterochromatin-mediated gene silencing may 
occur through sequestration of compacted chromatin in HP1 liquid droplets. In addition to 
heterochromatin formation, LLPS may be related to transcriptional hub formation; thus, it is emerging 
as a general mechanism for transcriptional regulation (discussed in 3.3.2). 
Some proteins have both modular interaction domain and IDR to promote phase separation 
cooperatively. LLPS also plays a role in synaptic vesicle (SV) clusters in proximity to presynaptic sites, 
as well as PSDs mentioned above. These clusters act as a reservoir from which SVs are drawn for 
exocytosis during prolonged synaptic activity. Synapsin1, a component of the matrix for crosslinking 
SVs, interacts with SH3-containing proteins through its IDR harboring PRMs, and undergoes LLPS. 
In this case, the IDR itself is sufficient for LLPS, but it is enhanced by co-existence of SH3 domains. 
The synapsin1 droplets could capture small lipid vesicles (50-150 nm diameter), and they are dispersed 
upon phosphorylation by calcium/calmodulin-dependent protein kinase II (CaMKII) (Milovanovic et 
al., 2018). Thus, these in vitro re-constitution experiments mimic well the release of SVs occurring at 
presynaptic sites upon stimulation, suggesting that LLPS plays a role in the process (Milovanovic and 
De Camilli, 2017). This concept – vesicle clustering into a phase-separated liquid phase – may apply 
to other membrane-bound vesicles involved in traffic among ER, Golgi and endosome, and will help 
to understand their dynamic organization in future. 
Multivalent protein-protein interactions mentioned above are often modulated by 
posttranslational modifications (PTMs) to alter the phase separation threshold, as observed in the case 
of synapsin1. PTMs can either change the confirmation, directly generate binding motifs (e.g. tyrosine 
phosphorylation as a ligand of SH2 domains), or increase or decrease the net charge of the IDRs above 
or below the threshold. So far, it has been reported that methylation, phosphorylation, sumoylation and 
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 non-covalent interactions between polyubiquitin/poly(ADP-ribose) and their target proteins regulate 
phase separation (discussed in 3.2.4). 
 
RNAs as a scaffold for multivalent interactions 
RNAs form the third key molecular determinants contributing to phase separation under 
physiological conditions, whose major role appear to promote phase separation of multivalent RNA-
binding proteins and IDPs. Polypyrimidine tract binding protein (PTB), for example, is a multivalent 
RNA-binding protein with four RNA recognition motif (RRM) domains (Li et al., 2012). The nucleolar 
protein nucleophosmin (NPM1) has a RRM domain, and requires binding with ribosomal RNA 
(rRNA) to form multivalent interactions that drive phase separation (Feric et al., 2016). These proteins 
undergo LLPS in the presence of RNA, independent of any IDRs. In parallel, however, multivalent 
and weak interactions between IDRs and RNAs additionally contribute to LLPS. The LLPS of N-
terminal IDR of LAF-1, which is enriched with RGG- motifs, is affected by RNA; RNA increases 
fluidity and dynamics within LAF-1 droplets (Elbaum-Garfinkle et al., 2015). In many cases, RNA-
binding proteins contain both RNA-binding motifs and IDRs, and thus it is assumed that interactions 
with RNA promote LLPS synergistically with IDR-IDR interactions. This is well described by the 
observation that the saturation concentration for LLPS of chimeric PTB proteins, where PTB is fused 
with each IDR from different RNA-binding proteins (Pub1, Lsm4, eIF4GII, Tia1, hnRNPA1 and FUS), 
is significantly lowered in the presence of RNA (Lin et al., 2015). 
The different chemical/structural features which are yielded from genetic code information of 
mRNAs impact phase transitions. A pioneer work with Whi3 protein, which accommodates an IDR 
with polyQ and a RRM domain, indicates that different RNAs may induce a variety of granules (Zhang 
et al., 2015a). Whi3 assembly is required for organizing both CLN3 mRNA at sites of nuclear division 
and BNI1 mRNA at polarity sites of the filamentous fungus Ashbya gossypii. Interestingly, these two 
different mRNAs individually let Whi3 phase separate with different thresholds, and form droplets 
with different physical properties. The subsequent work clarified that secondary structures of CLN3 
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 and BNI1 mRNAs define the valency of Whi3 binding to these mRNAs, resulting in discrete properties 
of two droplets; perinuclear droplets are less dynamic with low protein/RNA ratio while polarity 
droplets are more dynamic with high protein/RNA ratio (Langdon et al., 2018). 
PolyQ Whi3 droplet with two types of mRNAs clearly demonstrates that the interaction 
between protein and RNA, and more specifically that the ratio of protein to RNA in the complex 
governs phase separation in vivo. This principle may be applied to other RNA binding proteins more 
generally; high protein/RNA ratios promote phase separation, whereas low ratios prevent it (Maharana 
et al., 2018). According to this rule, the nucleus can be considered as a buffered system where high 
RNA concentrations keep RNA-binding proteins soluble and prevent their aggregation. Altered 
concentration of RNA or RNA-binding proteins induces aberrant phase transitions. This concept 
explains well why disease-related RNA-binding proteins such as TDP-43 and FUS are largely soluble 
in the nucleus, but form solid pathological aggregates in the cytoplasm. The contribution of RNAs to 
phase separation discussed so far depends on the interaction with proteins. Recent work, however, 
proposes the idea that the RNA itself can phase separate and could play a role in neurodegenerative 
diseases associated with RNA repeats (Jain and Vale, 2017). As mentioned pathogenic G4C2 repeat in 
ALS/FTD above, expansions of short nucleotide repeats cause several neurological and neuromuscular 
disorders; other examples are nucleotide triplets, including CAG in Huntington disease, and CTG in 
myotonic dystrophy. These transcripts initially undergo LLPS through their multivalent base-pairing, 
and rapidly become cross-linked into gels (Fig. 13). They co-localize in nuclear speckles in cells, and 
can be dissolved by reagents that disrupt RNA gelation, suggesting that the transcripts form granules 
in the same way as in vitro gelation. It is assumed that the aberrant granules sequester various RNA-
binding proteins, and cause a disruption of cellular homeostasis. Therefore, these findings may open 
up new avenues for treating repeat expansion diseases. As discussed further in 1.3.3, the nature of 
intracellular phase separation – it is caused by interactions among dozens of proteins and RNAs – has 
important biological implications, for example in SGs formation. 
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Figure 13.   Repeat-containing RNAs form RNA gels. Consistent with the valency dependence, the 
formation of CAG/CUG RNA clusters occurred only with more than 30 triplet repeats. Adapted from (Jain and 
Vale, 2017). 
 
Molecular crowding as a general regulator for phase separation 
The three molecular determinants mentioned above define the molecular properties that yield 
weak transient interactions among molecules for phase separation. A crucial determinant for phase 
separation in another dimension in the system is molecular crowding. For example, it is well known 
that phase-separated droplet formation in vitro is strongly enhanced by adding molecular crowder such 
as polyethylene glycol (Lin et al., 2015; Molliex et al., 2015). Given that overexpression of some SG 
component spontaneously formed SGs (Tourriere et al., 2003), increased local concentration of the 
proteins or RNAs by macromolecular crowding may also play a key role in cellular phase separation. 
However, the physiological mechanisms that control crowding within the cell and the effects of 
crowding on phase separation in vivo had remained obscure. A recent ingenious work provided the 
way to measure macromolecular crowding in cells using tracer particles, and obtain insight for cellular 
phase separation; genetically encoded multimeric nanoparticles (GEMs) were developed to address 
this question (Delarue et al., 2018). These GEMs are GFP-tagged tracer particles of a defined shape 
and size (20nm in diameter), which serve as a standard microrheological tool in cells. Using this tool 
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 in combination with in situ cryo-electron tomography, the authors found that the mTORC1 pathway 
controls the diffusion of particles > 20 nm in size nearly 2-fold by regulating ribosome concentration. 
Moreover, they examined the behavior of the established SUMO/SIM model (Banani et al., 2016) 
(discussed above), which forms phase-separated droplets at appropriate conditions. Indeed, mTORC1 
inhibition by rapamycin attenuated ribosomal crowding and inhibited droplets formation. Thus, 
ribosomes can act as a crowding agent to induce phase separation, highlighting the general importance 
of molecular crowder also for cellular phase separation. 
 
1.3.3 Stress granules in physiology and diseases 
Various membrane-less organelles have been discovered so far, and some of them are now 
known as RNP granules due to their composition of RNA and protein, including cytoplasmic granules 
such as processing bodies (P bodies) and stress granules (SGs) (Fig. 14).  
P-bodies are composed of the pool of nontranslating mRNA and the conserved core of 
proteins involved in mRNA decay and translation repression. They include decapping enzyme complex 
(e.g. Dcp1/Dcp2), decapping activators (Lsm1-7 complex), translation repressors (Dhh1/RCK/p54, 
Pat1 and Scd6/RAP55), the 5’ to 3’ exonuclease (Xrn1), and deadenylase complex (e.g. 
Ccr4/Pop2/Not). mRNAs within P bodies can be targeted for decapping and degradation by these 
factors. Translation initiation factors and ribosomal proteins are normally excluded from P bodies. 
Although they are already present in unstressed cells, P-bodies are induced in response to stresses 
which inhibit translation initiation. 
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Figure 14.   SGs and P-bodies in ribostasis. SGs form from untranslating messenger ribonucleoproteins 
(mRNPs). SGs can interact with P-bodies, exchange components with the cytoplasm, and undergo autophagy. 
Adapted from (Protter and Parker, 2016). 
 
SGs are a second type of cytoplasmic RNP granule that can be overlapped with P-bodies. P 
bodies and SGs can dock to each other, suggesting a dynamic cycle where the components can be 
transferred and remodeled between these two granules. Similar to P bodies, assembly of SGs is 
dependent on the pool of nontranslating mRNAs. Although they share some components, SGs 
especially contain translation initiation factors such as components of eIF2, eIF3 and eIF4 complexes, 
poly-A binding protein (PABP), and the 40S ribosomal subunit. Assumed from that SGs harbors 
translation initiation factors, there is a clear link between SGs and the process of translation initiation. 
SGs indeed form when translation initiation is inhibited either by drugs or by stresses. SGs don’t have 
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 a uniform structure, but contain internal substructures identified by super-resolution microscopy. These 
substructures are referred to as “SG cores” and can be purified biochemically, whereas the remaining 
portion of the SG is called “SG shell” (Jain et al., 2016). Thus, SGs have two distinct layers: a core 
structure surrounded by a less concentrated and potentially more dynamic shell. In the prevalent model, 
SG formation has been considered as a two-step process. The initial step is formation of a dense stable 
SG core. Some core components harbor IDRs (as mentioned below), and thus, the core could induce 
accumulation of proteins containing IDRs at high concentration, which then trigger LLPS with other 
IDR-containing proteins there to form the peripheral shell structure. Proteomic analysis of SG cores 
revealed that they contain PTM enzymes, metabolic enzymes, chaperone proteins as well as translation 
initiation factors and RNA-binding proteins, which often contain both RNA recognition motifs and 
IDRs. A recent study added karyopherins for nuclear transport to this list of SG components (Zhang et 
al., 2018b). These proteomic surveys also revealed that the composition of SGs can vary under 
different conditions, such as cell and stress types (Markmiller et al., 2018). In any case, SGs are not 
mere static aggregates, but rather function as dynamic signaling hubs communicating a ‘state of 
emergency’ to other signaling pathways, which regulate metabolism and growth to survive in stress 
conditions. 
Similar to other membrane-less organelles, SGs are dynamic structures and show liquid-like 
properties; they undergo fusion, fission, and flow in the cytosol. Fluorescence Recovery After 
Photobleaching (FRAP) experiments demonstrate that SG components exchange rapidly, normally 
with half-time for recovery of less than 30 seconds. At the same time, these FRAP experiments have 
also revealed an immobile fraction of proteins in SGs, suggesting that a fraction of the molecules 
within SG components exchange slowly. A fascinating possibility is that a shell fraction exchanges 
rapidly while a core fraction does slowly. Although most SG components reside in SGs transiently (a 
few seconds), SGs themselves persist for minutes to hours. Notably, it was recently suggested that 
there is substantial crosstalk between quality control of the transcriptome (ribostasis) and of the 
proteome (proteostasis), which are related to SG and aggresome formation, respectively. For example, 
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 various ATP-dependent remodeling complexes (e.g. chaperones) support both protein folding and also 
RNP granule disassembly. As mentioned above (in 1.2.3), both aggresome and SGs are cleared by 
autophagy from cells. This crosstalk may explain the similar clinical outcome in the spectrum of 
degenerative diseases with perturbation of these homeostatic systems. The process of SG/aggresome 
formation and clearance is important for human physiology such as antiviral responses and 
neurodegenerative diseases (Ramaswami et al., 2013). Mutations that increase SG formation or restrict 
SG clearance link to some neurodegenerative diseases, which is supported by genetic evidence. As 
mentioned above, neurodegenerative diseases (e.g. ALS/FTD)-related RNA binding proteins often 
have pathogenic mutations in their IDRs. For example, TIA1 harbors a LCS, where mutations are 
frequently observed in ALS/FTD, and these mutations alter the phase separation properties (Mackenzie 
et al., 2017). In cells, this perturbation of TIA1 results in more viscous SGs that fail to appropriately 
disassemble and persist long after the removal of stress. On the other hand, mutations of VCP/p97 
chaperone protein, which is important for SG clearance, are observed in several neurodegenerative 
diseases including ALS and FTLD (Johnson et al., 2010). The disease-related mutants showed the 
constitutive accumulation in SGs, which could not be disassembled (Buchan et al., 2013). Thus, SGs 
are of interest for following two reasons. First, they are the representative RNP granules, suggesting 
that they reveal fundamental mechanism of RNA and protein compartmentalization through LLPS. 
Second, they would possibly reveal how to prevent pathogenic aggregation observed in 
neurodegenerative diseases. 
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 1.4 Aim of this thesis 
The laboratory of Prof. Dr. Patrick Matthias has focused on the physiological and pathological 
roles of HDACs. The aim of my Ph.D. thesis is to better understand the role of HDAC6. I aimed to 
specifically address and clarify the three questions below. 
 
1. How does HDAC6 deacetylate its substrate? 
As I mentioned in 1.2.1, the existence of tandem catalytic HDAC domains is unique to HDAC6 
among HDAC family proteins. In parallel, HDAC6 has a specific preference for its substrates; 
it uniquely deacetylates α-tubulin. It thus has been assumed that this organization of two 
domains may confer the unique activity as α-tubulin deacetylase on HDAC6. Several studies 
tried to clarify how HDAC6 recognizes and deacetylates α-tubulin and other HDAC6-specific 
substrates, but there were not yet reasonable explanations mainly due to the lack of knowledge 
about structure of the catalytic domains. Although the crystal structure of the ZnF-UBP domain 
was originally reported six years ago (Ouyang et al., 2012), there was no available structure of 
the HDAC6 catalytic domains. Considering that HDAC6 plays important roles in various 
diseases, the structural information of its catalytic domains would be useful to accelerate drug 
development. Dr. Yasuyuki Miyake, a previous postdoc in the lab, tried to address this 
important question, and solved the structure of HDAC6 catalytic domains. I was also engaged 
in this project, and the outcomes are presented both in 2.2 (published work) and in 2.3 
(appendix). 
 
2. How large population of proteins are targeted by HDAC6? 
Besides lack of structural information and of the mechanism how HDAC6 deacetylate its 
substrates mentioned above, the repertoire of HDAC6 substrates itself was not enough to 
explain the versatile role of this enzyme in cellular processes. Even though there were several 
reported HDAC6 substrates, these were all identified individually in a specific setting (specific 
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 cell types, experimental conditions etc.) and no studies provided us with a comprehensive view 
at proteome scale. In collaboration with the laboratory of Dr. Chunaram Choudhary (University 
of Copenhagen), we obtained HDAC6-dependent acetylome (presented in 2.1 and 2.3). This 
analysis was effectively utilized to solve the next question 3, which was the central aim of my 
thesis. 
 
3. How does HDAC6 control granule formation in vivo? 
Previous work by Dr. SoHee Kwon, a former Ph.D. student in the lab revealed that HDAC6 is 
a critical component of stress granules (SGs). The authors demonstrated that the catalytic 
activity of HDAC6 is important for SG formation (Kwon et al., 2007), although there were no 
detailed molecular mechanisms reported. Considering that many proteins harboring IDR 
contributes to SG formation through LLPS, and also that PTMs can alter their LLPS 
propensities (discussed in 1.3.2), we considered that HDAC6 may participate in this process 
by regulating cellular phase (liquid-liquid or liquid-solid) separation directly through 
deacetylation of IDR-containing substrates. The challenging point to tackle this question was 
the limited number of HDAC6 substrate; although there were some reports about HDAC6 
substrates, none of the reported substrates had acetylation sites in their IDRs with LLPS 
propensity. Here, we utilized an HDAC6-dependent acetylome dataset mentioned above, 
identified novel substrates and discovered that HDAC6 preferentially targets acetylated lysines 
in IDRs. Among the newly identified HDAC6 substrates harboring acetylation sites in IDRs, 
we focused on the stress granule component “DEAD box RNA helicase 3, X-linked” (DDX3X), 
and demonstrated how HDAC6 contributes to SG formation with its catalytic activity. The 
outcomes related to this part are presented both in 2.1 (published work) and in 2.3 (appendix). 
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 2.1 Acetylation of intrinsically disordered regions regulates phase separation 
(Published, Nature Chemical Biology) 
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Cells contain a variety of membrane-less organelles that control diverse biological processes. It has recently been proposed that liquid–liquid phase separation (LLPS) driven by multi-
valent macromolecular interactions is a common mechanism con-
tributing to the formation of membrane-less organelles1,2. Although 
the molecular determinants underlying LLPS in cells still remain 
unclear, several proteins harboring intrinsically disordered regions 
(IDRs) have been shown to phase separate under various solution 
conditions3. IDRs are determined by structural prediction analysis: 
they do not have defined 3D structure and often exhibit low com-
plexity domains (LCDs) of repeated sequence elements that provide 
the basis for intermolecular interactions. A central question is that 
of mechanisms regulating the properties of IDRs in vivo to ensure 
that LLPS takes place when required.
Stress granules (SGs) and aggresomes are membrane-less organ-
elles that arise when cells are under specific environmental stresses. 
SGs are composed of ribonucleoproteins (RNPs) and form when 
translation initiation is impaired; they represent a pool of mRNAs 
stalled in translation4. Aggresomes contain misfolded protein aggre-
gates that are concentrated by microtubule-dependent motors to a 
perinuclear inclusion body and subsequently processed by autoph-
agy5. Genetic evidence suggests that these granules are related to the 
inclusions seen in the pathogenesis of neurodegenerative diseases. 
Amyotrophic lateral sclerosis (ALS)-related proteins, such as FUS 
and hnRNPA1, undergo LLPS. Mutations within their IDRs are fre-
quently associated with ALS, and these mutations alter their phase 
separation properties, including droplet and pathogenic fibrils for-
mation in vitro and SG formation in vivo6,7.
Post-translational modifications (PTMs) can alter the phase 
separation threshold of IDRs, and thus are recognized as important 
regulators for granule formation. They can change both the intrinsic 
solubility and valency8. For example, phase separation of the nuage 
protein DDX4 is hindered by arginine methylation in RGG motifs9. 
FUS harbors an N-terminal LCD and C-terminal domain (CTD) 
enriched in RGG/RG motifs, and both phosphorylation of the LCD 
and methylation in CTD inhibit its phase separation10,11. These find-
ings confirm the effect of PTMs on phase separation, but their regu-
lation and roles in a biological context are not clear.
The lysine deacetylase HDAC6 critically participates in the 
formation of SGs and aggresomes12,13. It localizes mainly to the 
cytoplasm, where α -tubulin is its most prominent substrate14,15. It 
has been implicated in various biological processes, including the 
stress response16,17. Under various stresses, HDAC6 co-localizes to 
SGs with the Ras-GTPase-activating protein SH3 domain-binding 
protein 1 (G3BP-1), an established component of SGs18. HDAC6 is 
important for the formation of SGs13,19 as well as of the aggresome12, 
although the contribution of HDAC6 catalytic activity to the pro-
cess of granule formation is not understood. We hypothesized 
that HDAC6 may participate in this process by regulating cellular 
phase (liquid-liquid or liquid-solid) separation directly through 
substrate deacetylation.
Here, we used an HDAC6-dependent acetylome data set, and 
discovered that HDAC6 preferentially targets acetylated lysines 
in IDRs. Among these, we focused on the SG component “DEAD 
box RNA helicase 3, X-linked” (DDX3X). We found that oxida-
tive and osmotic stress as well as translation inhibition elicit acti-
vation of the lysine acetyltransferase CBP, leading to acetylation of 
multiple proteins, including DDX3X, whereby several lysines in its 
N-terminal IDR (IDR1) are acetylated. Notably, purified DDX3X-
IDR1 was sufficient to mediate droplet formation by LLPS in vitro, 
and this process was inhibited by acetylation. Impaired droplet for-
mation in vitro was associated with the decreased total volume of 
SGs in vivo, indicating that acetylation of IDRs affects their LLPS 
and granule formation in a biological context. Deacetylation of 
DDX3X-IDR1 by HDAC6 is required for assembly of large, mature 
SGs. Mathematical modeling derived from live-cell imaging experi-
ments demonstrates that acetylation does not impact the initial gen-
eration of SGs, but their maturation. These observations reveal that 
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Liquid–liquid phase separation (LLPS) of proteins containing intrinsically disordered regions (IDRs) has been proposed as a 
mechanism underlying the formation of membrane-less organelles. Tight regulation of IDR behavior is essential to ensure 
that LLPS only takes place when necessary. Here, we report that IDR acetylation/deacetylation regulates LLPS and assem-
bly of stress granules (SGs), membrane-less organelles forming in response to stress. Acetylome analysis revealed that the 
RNA helicase DDX3X, an important component of SGs, is a novel substrate of the deacetylase HDAC6. The N-terminal IDR of 
DDX3X (IDR1) can undergo LLPS in vitro, and its acetylation at multiple lysine residues impairs the formation of liquid droplets. 
We also demonstrated that enhanced LLPS propensity through deacetylation of DDX3X-IDR1 by HDAC6 is necessary for SG 
maturation, but not initiation. Our analysis provides a mechanistic framework to understand how acetylation and deacetylation 
of IDRs regulate LLPS spatiotemporally, and impact membrane-less organelle formation in vivo.
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counteracting “writer” and “eraser” enzymes for PTMs modulate 
the LLPS propensity of IDR-containing proteins spatiotemporally 
in vivo, and that IDR lysine acetylation levels regulate membrane-
less organelle formation more broadly.
results
HDAC6 preferentially targets acetylated lysines in IDRs. To 
determine whether acetylation and its regulation by HDAC6 may 
regulate LLPS, we re-analyzed acetylome data sets20, comparing 
data obtained with two HDAC6-specific inhibitors (Tubacin or 
Bufexamac) to those obtained with HDAC6 knockout (KO) cells. 
About 4% of the quantified acetylated sites (87 out of 2029) dis-
played a more than two-fold increase in acetylation in at least one 
condition (Supplementary Fig. 1a) and are related to various cellular 
functions (Supplementary Fig. 1b). Moreover, about 1% of the sites 
(18 out of 2029) showed a more than two-fold increase in acety-
lation in all three conditions (Fig. 1a). These 18 high-confidence 
HDAC6 target sites are enriched with a GG motif immediately 
before the acetylated lysine GGK(Ac), which is targeted by CBP and 
p300 (ref. 21; Supplementary Fig. 1c), and three sites are within the 
well-known HDAC6 substrate cortactin (Cttn), demonstrating the 
validity of the method22 (Fig. 1a).
We next determined what fraction of the acetylated sites map to 
an IDR using two different structural prediction programs, VSL2 and 
VL3-BA; only 43–55% of the 2029 acetylated peptides fall within an 
IDR. In striking contrast, 83–94% of the high-confidence HDAC6 
target sites map to an IDR (Fig. 1b and Supplementary Fig. 2), sug-
gesting that HDAC6 may broadly regulate IDRs. Notably, previous 
work reported that acetylated lysines are significantly enriched in 
structured regions and depleted in unstructured regions23. Thus, the 
HDAC6 acetylome defines a skewed subset of the acetylated lysines, 
which may play a role in LLPS.
DDX3X is a substrate of both HDAC6 catalytic domains. Among 
the high-confidence HDAC6 target sites, DDX3X-K118 acetyla-
tion (SGFGK(Ac)FER) caught our interest because it showed one 
of the highest SILAC ratios in our data sets. DDX3X harbors two 
IDRs, one at the N terminus, where K118 is localized, and one at 
the C terminus (Fig. 1c). DDX3X was also independently reported 
to be acetylated in mouse liver24 (Supplementary Fig. 3), indicat-
ing that the regulation of DDX3X by acetylation is also observed 
in the whole organism. Furthermore, HDAC6 and DDX3X were 
both independently reported to be localized to SGs under oxidative 
stress13,25, offering a possible link between HDAC6 and DDX3X in 
the process of granule formation (Supplementary Fig. 4). We first 
evaluated the acetylation status of DDX3X in cells to confirm the 
data from the acetylome analysis.
To test which histone acetyltransferases (HATs) can act on 
DDX3X, we expressed four different HATs in HEK293T (hereafter 
293T) cells and detected acetylation of DDX3X. Both CBP and p300, 
but not PCAF or Tip60, led to acetylation of endogenous or overex-
pressed DDX3X (CBP: 3.8 ± 0.5, p300: 2.0 ± 0.4, PCAF: 1.1 ± 0.1, and 
Tip60: 1.2 ± 0.2 fold; Fig. 1d; Supplementary Figs. 5a and 6a). HDAC6 
inhibition and acetylation by CBP showed a cooperative effect on 
the acetylation level of overexpressed DDX3X (Supplementary 
Fig. 5b) as well as of endogenous DDX3X (Tubacin: 1.2 ± 0.03 fold, 
CBP: 2.0 ± 0.2 fold, and CBP + Tubacin: 4.0 ± 0.9 fold; Fig. 1e and 
Supplementary Fig. 6b). To confirm that DDX3X-K118 is acety-
lated by CBP, we co-expressed CBP together with a DDX3X-K118R 
mutant, which cannot be acetylated, in 293T cells. DDX3X-K118R 
displayed a weaker signal compared to DDX3X-WT, indicating that 
K118 is a major acetylation site but that there are also other acety-
lation sites (Supplementary Fig. 5c); indeed, four additional acety-
lation sites were detected in the IDR1 (K50, K64, K66, and K81; 
Supplementary Fig. 5d,e). This result is consistent with another 
acetylome data set, which revealed that several lysines in IDR1 
(K50, K55, K64, K66, K118 and K130) are acetylated20. As K118 
exhibited the highest SILAC ratio among identified sites, we gener-
ated a DDX3X-K118Ac-specific antibody (Supplementary Fig. 7); 
in the following experiments this antibody was used to monitor 
K118Ac as an indicator of IDR1 acetylation.
Different deacetylases often redundantly target the same lysine 
acetylation site on a target protein14,22,26. To test whether deacety-
lation of DDX3X-K118Ac is specific for HDAC6, we transiently 
expressed CBP in 293T cells treated with several HDAC inhibitors 
and assessed DDX3X-K118Ac. DDX3X-K118Ac increased upon 
treatment with the HDAC6-specific inhibitors, Bufexamac (3.5 ± 0.7 
fold) and Tubacin (4.4 ± 0.9 fold) (Fig. 1f and Supplementary 
Fig. 6c). Moreover, Tubastatin A, another HDAC6 specific inhibi-
tor, also increased DDX3X-K118Ac (2.6 ± 0.5 fold), further support-
ing the notion that this DDX3X residue is an HDAC6 target site. In 
contrast, neither nicotinamide, a sirtuin deacetylase inhibitor, nor 
sodium butyrate, a class I HDAC inhibitor, increased the acetylation 
status of DDX3X-K118 (Nicotinamide: 0.7 ± 0.05, Sodium butyrate: 
0.3 ± 0.1 fold). To define the domains of HDAC6 required for DDX3X 
deacetylation, we established HDAC6 KO 293T cells (Supplementary 
Fig. 8) and used them to express various HDAC6 functional mutants 
(H216A, CD1 catalytic dead; H611A, CD2 catalytic dead; H216A/
H611A double mutant, and W1182A, ubiquitin-binding-defi-
cient)27,28. We monitored the acetylation level of DDX3X-K118, α 
-tubulin-K40, and cortactin. Each single catalytic domain HDAC6 
mutant could robustly deacetylate DDX3X (Ac-DDX3X signal; WT: 
0.1 ± 0.02, H216A: 0.1 ± 0.04, H611A: 0.3 ± 0.05, H216A/H611A: 
0.9 ± 0.1, and W1182A: 0.3 ± 0.03 fold), and also to a lesser extent 
cortactin, but not α -tubulin (Ac-α -tubulin signal; WT: 0.5 ± 0.1, 
H216A: 0.5 ± 0.04, H611A: 1.0 ± 0.1, H216A/H611A: 1.1 ± 0.1, and 
W1182A: 0.7 ± 0.1 fold; Supplementary Fig. 9). This indicates that 
either HDAC6 domain, CD1 or CD2, can deacetylate DDX3X or 
cortactin, two proteins containing an acetylated IDR. This reactivity 
is different from the reactivity for α -tubulin, where the acetylated 
residue is in a structured region: deacetylation of α -tubulin requires 
the catalytic activity from CD2 (refs 29,30; Supplementary Fig. 9). 
Together, these results indicate that DDX3X-K118Ac within IDR1 is 
a specific target of HDAC6 and also suggest that CD1 may be gener-
ally active on acetylated lysines in IDRs, which has implications for 
the generation of novel inhibitors.
DDX3X is acetylated under specific stress conditions. We hypoth-
esized that deacetylation of DDX3X-IDR1 may be regulated by 
HDAC6 during the stress response process; we performed a time-
course of arsenite treatment and compared 293T and HDAC6 KO 
293T cells lysates by immunoblotting (Fig. 2a). Phosphorylation 
of eIF2α , which identifies stress-induced translational arrest, was 
observed from 10 min onward after arsenite treatment. We found 
that in 293T cells acetylation of DDX3X-IDR1 is biphasic: it gradu-
ally increased in the early phase (0 to 45 min), and decreased later 
(from 45 to 60 min; Fig. 2a, lanes –5). In contrast, in HDAC6 KO 
293T cells acetylation of DDX3X continued to increase between 
45 min and 60 min (Fig. 2a, lanes 6–10; Fig. 2b). This result is consis-
tent with the fact that DDX3X and HDAC6 localize to SGs, whereas 
CBP, which is mostly nuclear, shows a weak cytoplasmic staining 
outside of SGs during the whole process (Supplementary Fig. 10a), 
and suggests that HDAC6 effectively deacetylates DDX3X in SGs.
To define the physiological stresses where acetylation of DDX3X 
is enhanced, we systematically treated 293T cells with inducers for 
various types of stress: oxidative stress (sodium arsenite, H2O2 and 
diethyl maleate), energy depletion (CCCP and clotrimazole), trans-
lation inhibition (puromycin), ER stress (thapsigargin), proteasome 
inhibition (MG132), heat shock and osmotic stress (sorbitol), and 
confirmed SG formation under each condition (Supplementary 
Fig. 10b); phosphorylation of eIF2α was used to determine the 
best time points for each inducer. The same experiment was then 
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Fig. 1 | DDX3X-iDr1 is specifically deacetylated by HDAC6. a, The heatmap shows the quantified 18 high-confidence peptides upregulated two-fold 
or more in all three conditions (based on the data set from ref. 20). b, Almost all of the 18 high-confidence HDAC6 target sites map to IDRs. Structural 
prediction analysis was performed with the 18 high-confidence HDAC6 target sites as well as with all (2,029) acetylated sites examined here, as a control. 
The VSL2 and VL3-BA programs of the PONDR suite (Prediction Of Naturally Disordered Regions) were used, as indicated. P values were determined 
by chi-squared test; ***P <  0.001. c, Analysis of the DDX3X protein sequence for intrinsically disordered regions, using the program VL3-BA. The amino 
acid position in the linear sequence is plotted on the x axis, and the disorder tendency is displayed on the y axis. Both the N-terminal and the C-terminal 
regions of DDX3X show a strong disorder potential. Notably, residue K118 is found in the region with the maximum disorder potential. d, Acetylation of 
endogenous DDX3X by CBP and p300. Tagged versions of PCAF, CBP, Tip60 and p300 were transiently transfected into 293T cells. The acetylation status 
of endogenous DDX3X under Tubacin was analyzed by immunoblotting with a pan-acetyllysine antibody (AcK) following DDX3X immunoprecipitation 
(IP). Representative results are shown (n =  3 biologically independent samples). Uncropped gel images can be found in Supplementary Fig. 27a.  
e, Enhanced acetylation of endogenous DDX3X following Tubacin treatment. 293T cells expressing CBP were treated with 10 μ M Tubacin for 12 h.  
The acetylation status of DDX3X was analyzed with a pan-acetyllysine antibody following immunoprecipitation. Representative results are shown  
(n =  3 biologically independent samples). Uncropped gel images can be found in Supplementary Fig. 27b. f, Effects of HDAC inhibitors on DDX3X-K118Ac 
in 293T cells. CBP was transiently expressed in 293T cells treated overnight with different HDAC inhibitors, as indicated. The acetylation status of 
endogenous DDX3X was tested with the DDX3X-K118Ac-specific antibody. Representative results are shown (n =  3 biologically independent samples). 
Uncropped gel images can be found in Supplementary Fig. 27c.
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Fig. 2 | Stress induces acetylation of DDX3X and other proteins. a, DDX3X-K118 acetylation in 293T and HDAC6 KO 293T cells under arsenite treatment. 
The acetylation status of DDX3X was analyzed in both 293T and HDAC6 KO 293T cells after CBP expression and 1 mM arsenite treatment for the 
indicated times. Representative results are shown (n =  3 biologically independent samples). Uncropped gel images can be found in Supplementary Fig. 
27d. b, Quantification of Ac-DDX3X signals as in a. Intensity of the band at each time point was quantified using ImageJ, and normalized by the signal at 
0 min. (mean ±  s.d., n =  3 biologically independent samples). c, DDX3X-IDR1 acetylation increases under various types of stress. HDAC6 KO 293T cells 
expressing CBP were treated with different stress inducers (1 mM sodium arsenite for 1 h, 2 mM H2O2 for 1 h, 3 mM diethyl maleate for 1 h, 20 μ M CCCP in 
glucose-free culture medium for 1 h, 40 μ M clotrimazole in glucose-free culture medium for 3 h, 20 μ g/ml puromycin for 3 h, 10 μ M thapsigargin for 1 h, 
10 μ M MG132 for 3 h, heat shock at 43 °C for 1 h and 0.5 M sorbitol for 1 h). Cell cytosolic extracts were analyzed by immunoblotting with the indicated 
antibodies. eIF2α phosphorylation was used as a marker of cellular stress. Representative results are shown (n =  3 biologically independent samples). 
Uncropped gel images can be found in Supplementary Fig. 27e. d, Quantification of Ac-DDX3X signals and AcK signals in c (mean ±  s.d.; n =  3 biologically 
independent samples). e, CBP acetylation is induced by various types of stress. WT MEF cells were treated with different stress inducers and analyzed 
as in d above. Representative results are shown (n =  3 biologically independent samples). Uncropped gel images can be found in Supplementary Fig. 27f. 
f, Quantification of Ac-CBP signals in e (mean ±  s.d.; n =  3 biologically independent samples). P values were determined by Student’s two-tailed t-test; 
*P <  0.05, **P <  0.01, ***P <  0.001 and ****P <  0.0001.
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repeated with HDAC6 KO 293T cells, and acetylation of DDX3X-
IDR1 was monitored (Fig. 2c). As DDX3X is an HDAC6 specific sub-
strate, its acetylation is expected to be stable in cells lacking HDAC6. 
Oxidative stress inducers including arsenite, puromycin and sorbi-
tol all significantly increased acetylation of DDX3X-K118 (arsenite: 
3.7 ± 0.9, H2O2: 2.4 ± 0.6, diethyl maleate: 2.5 ± 0.5, puromycin: 
2.1 ± 0.5, sorbitol: 3.0 ± 0.8 fold; Fig. 2d). In contrast, acetylation 
of DDX3X was not significantly altered under any other condi-
tion, although phosphorylation of eIF2α was observed (Fig. 2c). 
Global protein acetylation was observed with the same induc-
ers (arsenite: 1.5 ± 0.05, H2O2: 1.4 ± 0.1, diethyl maleate: 1.3 ± 0.1, 
puromycin: 1.2 ± 0.1, sorbitol: 2.0 ± 0.03 fold; Fig. 2d) as for DDX3X 
acetylation (Fig. 2c,d). We next tested whether stress induction 
might lead to elevated CBP activity. CBP autoacetylates and its level 
of acetylation can be taken as a measure of its activity31. We treated 
mouse embryonic fibroblasts (MEFs) with different stress inducers 
and examined the level of endogenous CBP acetylation (Fig. 2e). 
As seen in Fig. 2f, oxidative stress, puromycin and sorbitol lead 
to a robust increase in CBP acetylation (arsenite: 1.7 ± 0.1, H2O2: 
1.6 ± 0.1, diethyl maleate: 1.6 ± 0.2, puromycin: 1.6 ± 0.3, sorbitol: 
3.9 ± 0.6 fold), thus establishing a direct link between the stress 
response and protein acetylation.
Acetylation of DDX3X-IDR1 impairs its LLPS. We next inves-
tigated the role of DDX3X-IDR1 acetylation in LLPS; for this, we 
expressed and purified the IDR1 (Supplementary Fig. 11a). When 
polyethylene glycol (PEG) was added to the sample, it became 
turbid, and micron-sized droplets were observed by differential 
interference contrast (DIC) microscopy (Supplementary Fig. 11b). 
Droplets of IDR1 fused to each other (Supplementary Video 1) and 
were also sensitive to salt concentration (Supplementary Fig. 11c) 
and temperature (Supplementary Video 2 and Supplementary Fig. 
11d), indicating that IDR1 undergoes LLPS.
To monitor the effect of DDX3X-IDR1 acetylation on LLPS, 
the turbidity (OD600) of unacetylated and acetylated IDR1 during 
LLPS was quantified. Incubation of purified IDR1 with CBP and 
acetyl-CoA led to acetylation of all of its ten lysine residues, includ-
ing K118 (Supplementary Fig. 11e). Notably, the turbidity of this 
acetylated IDR1 solution was much lower compared to the solution 
of unacetylated IDR1 (Fig. 3a). Moreover, the turbidity was restored 
upon co-incubation of acetylated IDR1 with the purified catalytic 
domains of HDAC6 (ref. 30; Fig. 3b), indicating that lysine acetyla-
tion affects LLPS. We hypothesized that this effect is due to the loss 
of intermolecular interactions between cationic lysine and anion or 
aromatic π , caused by the neutralization of positively charged lysine 
by acetylation. Therefore, we further confirmed this effect using 
acetyllysine mimic (K to Q) mutants. We expressed and purified 
K118Q, K118R and allQ (all IDR1 lysines mutated to glutamine) 
mutants (Supplementary Fig. 11f) and measured their turbidity 
during LLPS. The allQ mutant showed the lowest turbidity among 
the samples, and this effect was clearly visible with its transparent 
solution under conditions wherein the WT solution was opalescent 
(Fig. 3c). The K118Q mutant also showed lower turbidity compared 
to WT; in contrast, this effect was not observed with the K118R 
mutant, which maintains the positive charge (Fig. 3c). These results 
demonstrate that DDX3X-IDR1 plays a role in LLPS, and reveal that 
a single acetylation on K118 is already sufficient to robustly alter the 
dynamics of droplet formation in vitro.
Although our data about the acetyl-mimic K118Q mutant indi-
cate that acetylation on a single lysine residue is sufficient to affect 
LLPS, acetylation on multiple lysine residues (mimicked by allQ 
mutant) shows a stronger effect. This indicates the possibility that 
each lysine within the IDR1 may contribute to efficient LLPS. To test 
this, we compared the LLPS efficiency of individual K to Q mutants 
(Supplementary Fig. 12a) to that of WT and allQ mutant. Seven 
mutants (K35, 50, 55, 64, 66, 81 and 118) showed significantly lower 
turbidity compared to WT, but none of them showed the severe 
impairment as the allQ mutant did (Fig. 3d and Supplementary 
Fig. 12b). In contrast, three mutants (K130, 138 and 162) formed 
droplets to the same extent as the WT. One study may explain these 
positional effects on LLPS: the DDX3X region (a.a. 1-167) that is 
predicted to be an IDR by several established algorithms has a con-
served region (a.a. 132-167 in human and mouse) which harbors a 
predicted short α -helix32. Although secondary structures such as α 
-helix were also reported to trigger LLPS33, our observations indi-
cate that in the case of DDX3X, lysine acetylation in a ‘genuine’ IDR 
impairs LLPS more effectively than acetylation in an α -helix.
Next, we investigated LLPS of purified full-length DDX3X 
(Supplementary Fig. 13a). The concentration of cytosolic DDX3X 
was estimated to be around 0.8 μ M (Supplementary Fig. 13b), and 
we confirmed that acetyllysine mimic mutants (K118Q and allQ) at 
this physiological concentration still exhibit less turbidity compared 
to WT in droplet-formation assays (Supplementary Fig. 13c). This 
effect was also observed with WT DDX3X acetylated by CBP, and 
counteracted by the catalytic domains of HDAC6, as initially shown 
with the IDR1 (Supplementary Fig. 13d). Similarly, we also observed 
that the IDR of another HDAC6 substrate, cortactin34, undergoes 
LLPS. In this case as well, acetyl-mimic mutation impairs LLPS 
(Supplementary Fig. 14). Thus, our observations with DDX3X hint 
to a general mechanism for LLPS regulation by acetylation.
To further examine the role of acetylation on the capacity of 
DDX3X-IDR1 to assemble in granules, we performed in vitro 
experiments with the chemical biotinylated isoxazole (b-isox), that 
can selectively precipitate proteins with LCDs from cellular lysates35. 
We found that b-isox precipitated DDX3X and another LCD-
containing protein, TIAR (Fig. 3e, lanes 3 and 4), but not acetylated 
DDX3X (lane 4, compare with lane 2), demonstrating that the IDR1 
acetylation status is critical for DDX3X to form crystals with b-isox. 
Taken together, these experiments revealed that DDX3X undergoes 
LLPS, which is impaired by acetylation-mediated neutralization of 
cationic lysines in the IDR1.
DDX3X-IDR1 is important for SG formation. The above find-
ings about LLPS of DDX3X regulated by acetylation support our 
hypothesis that DDX3X is one of the effector substrates regulated 
by HDAC6 during SG formation. To confirm liquid-like proper-
ties of DDX3X-positive SGs, an mCherry-DDX3X fusion protein 
was expressed in MEFs, and the dynamics of SG formation were 
monitored over time. We observed that granules fusion is accompa-
nied by first a transient change of overall shape, which is followed 
by gradual recovery of the initial round shape; this behavior has the 
properties expected from LLPS (see examples in Supplementary 
Video 3 and Supplementary Fig. 15). Although the role of DDX3X 
in SGs had already been examined25, its stress dependence was 
unclear. To address this question, we generated DDX3X KO MEFs 
(Supplementary Fig. 16), and SG formation was monitored in 
DDX3X KO and parental MEFs under various types of stresses 
(Supplementary Fig. 17a). We quantified the total area of G3BP foci, 
as done by ref. 36, and observed clear defects in G3BP granule forma-
tion under oxidative stress, energy depletion and translation inhibi-
tion (Supplementary Fig. 17b), indicating that DDX3X is important 
for SG assembly under these specific stress conditions. The observed 
impairment was not due to changes in expression level of G3BP or 
phosphorylation level of eIF2α (Supplementary Fig. 17c,d).
We anticipated that the DDX3X-IDR1 would contribute to LLPS 
in cells and thus might impact SG formation; to test this directly, we 
expressed DDX3X mutants lacking different domains in HeLa cells 
and monitored their behavior in SG localization (Supplementary 
Fig. 18). Although the DDX3X helicase core itself does not localize 
to SGs under arsenite treatment, the construct including the IDR1 
(del-IDR2) does (Supplementary Fig. 18c). It is important to note 
that the IDR1 is necessary but not sufficient for SG localization; 
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independent experiments). P values were determined by Student’s two-tailed t-test; *P <  0.05, **P <  0.01, ***P <  0.001 and ****P <  0.0001. e, Acetylation 
of the DDX3X IDR regulates its ability to precipitate with biotinylated isoxazole (b-isox) in vitro. Left, lysates from 293T cells expressing GFP (control) 
or CBP were subjected to b-isox-mediated precipitation and analyzed by immunoblotting. The presence of endogenous DDX3X-K118Ac was assessed in 
the precipitate fraction (b-isox ppt) and in the lysate fraction (input) and compared to the level of total precipitated DDX3X. TIAR was used as a control 
protein harboring an IDR, whereas ubiquitin and α -tubulin were used as control proteins lacking an IDR. Proteins were detected with specific antibodies, 
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thus, both the IDR1 and the helicase core interacting with RNAs 
contribute to SG localization, which is consistent with a molecular 
feature increasingly observed in RNPs. Furthermore, the reduced 
total area of G3BP foci in cells lacking DDX3X is restored to WT 
levels by re-expression of WT or del-IDR2 DDX3X (Supplementary 
Fig. 18d). This observation identifies the critical role of the IDR1 
for SG formation and encouraged us to investigate the role of its 
acetylation in this process.
Deacetylation of DDX3X-IDR1 is required for SG formation. To 
investigate acetylation of DDX3X-IDR1 in SG formation, we first 
used fluorescence recovery after photobleaching (FRAP) to mea-
sure the mobility of mCherry-DDX3X. For this we used DDX3X 
KO MEFs and transiently re-expressed mCherry-DDX3X WT or 
mutants thereof: two acetyl-mimic mutants (K118Q, allQ) and two 
acetyl-dead mutants (K118R, allR). The expression level of each 
protein was comparable to that of endogenous DDX3X (Fig. 4a). 
Furthermore, the allR mutant (which is fully unacetylated, but pre-
serves positive charges) served as a control to monitor the acetyla-
tion status of other constructs under physiological conditions. All 
DDX3X constructs formed SGs under arsenite, and we found that 
acetyl-mimic or dead mutations significantly altered the dynamic 
exchange of DDX3X inside and outside SGs (Fig. 4b). Compared to 
WT, acetyl-mimic mutants exhibited decreased half-recovery times 
and a larger mobile fraction (Fig. 4c and Supplementary Fig. 19), 
suggesting that their granules are less viscous than those made by 
WT. In contrast, granules of acetyl-dead mutants were more viscous 
(Fig. 4c and Supplementary Fig. 19). Importantly, these effects reflect 
the degree of K to Q or K to R mutations; allQ and allR mutants have 
the most significant effects, whereas K118Q and K118R mutants 
are mildly affected (Fig. 4c and Supplementary Fig. 19). The clear 
phenotypic difference between WT and allR DDX3X provides evi-
dence for DDX3X acetylation under physiological conditions. To 
confirm this, we established rescue lines stably expressing either 
DDX3X WT or each mutant and visualized Ac-DDX3X by immu-
nofluorescence microscopy. The expression level of each construct 
was comparable with that of endogenous DDX3X (Supplementary 
Fig. 20a), and broadly distributed signals of Ac-DDX3X in cytosol 
including SGs were observed with WT, but not with allR rescuant 
(Supplementary Fig. 20b).
To test whether the impaired LLPS propensity of acetyl-mimic 
mutants has an impact on SG formation, we quantified the volume 
of SGs under arsenite: we found that the total volume of SGs per 
cell decreased in both acetyl-mimic mutants, but increased in the 
acetyl-dead allR mutant (Fig. 5a,b and Supplementary Dataset 1). 
In agreement with this, acetylation of endogenous DDX3X induced 
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by ectopic expression of CBP also decreased the total volume of 
SGs in WT MEF cells (Supplementary Fig. 21 and Supplementary 
Dataset 1). Given these results, we next investigated whether endog-
enous CBP and HDAC6 counteract each other to regulate the acety-
lation status of DDX3X-IDR1 and SG formation. After pretreatment 
with an inhibitor of p300/CBP (A-485) or HDAC6 (Tubacin), we 
treated DDX3X WT rescuant cells with five stress inducers, which 
lead to increased CBP autoacetylation and DDX3X acetylation 
(Supplementary Fig. 22). As expected, inhibition of CBP increased 
the total volume of SGs, and inhibition of HDAC6 decreased it 
under four stress inducers (arsenite, H2O2, diethyl maleate, puro-
mycin) in which DDX3X is important for SG formation (Fig. 5c 
and Supplementary Dataset 1). This effect was not observed under 
sorbitol, as DDX3X does not contribute to SG formation there 
(Fig. 5c and Supplementary Dataset 1). We also tested the SG 
volume of each mutant under arsenite in combination with A-485 
or Tubacin and noticed that the effects of these inhibitors are miti-
gated (Fig. 5d and Supplementary Dataset 1), suggesting that CBP 
and HDAC6 regulate SG formation by modulating IDR1 acetyla-
tion. Consistent with this pharmacological inhibition, knockdown 
of CBP also led to a similar result (Supplementary Fig. 23 and 
Supplementary Dataset 1). We also monitored the disappearance 
of SGs over time. After 1 h recovery, about 77% of the cells express-
ing WT still had detectable SGs, but only 26% of the cells express-
ing allQ mutant or 54% of the cells expressing K118Q mutant did 
(Fig. 5e). Together, these experiments indicate that acetylation of 
IDR1 impairs the formation and stability of DDX3X SGs and that 
this is regulated by CBP and HDAC6 under physiological conditions. 
Our earlier work had demonstrated that loss of HDAC6 reduces 
the number of large SGs under arsenite treatment13, which is likely 
related to the acetylation of DDX3X shown here (Supplementary 
Fig. 24). Consistent with this hypothesis, inhibition of CBP or HDAC6 
does not affect SG volume when the DDX3X-IDR1 is mutated.
SG maturation is promoted by deacetylation of DDX3X. SG for-
mation has recently been proposed as a two-step process, with initial 
nucleation of a stable’core’ followed by maturation with accumula-
tion of proteins harboring IDRs into a peripheral ‘shell’ through 
LLPS6,37–39. Many components of SGs can undergo LLPS, and hetero-
typic interactions among these proteins contribute to SG maturation. 
Given this model and our observation that HDAC6 deacetylates 
DDX3X to recover its LLPS propensity in later stage of SG formation 
(Fig. 2a,b), we hypothesized that LLPS of DDX3X is important for 
inducing LLPS of other SG components as well as resulting SG matu-
ration. To examine this hypothesis, we immunoprecipitated DDX3X 
WT and allQ/R mutants from arsenite-treated cells, and their inter-
actomes were defined (Supplementary Fig. 25a and Supplementary 
Dataset 2). The DDX3X interactomes are consistent with SG com-
ponents reported in recent studies37,40. Strikingly, the comparison 
between WT and allQ/R mutants revealed that several SG proteins 
are not enriched with the allQ mutant, while they interact with the 
WT and allR mutant: HNRNPA2/B1 and DHX9, which are harbor-
ing GY-rich IDRs, and PABPC1, whose homolog in S. cerevisiae 
(Pab1) undergoes LLPS41 (Supplementary Fig. 25b). This result indi-
cates that interactions between cationic lysines in the DDX3X IDR 
and aromatic π in IDRs are impaired in the allQ mutant. Moreover, 
this suggests that the LLPS propensity of DDX3X is important for 
recruitment of additional proteins which themselves can undergo 
LLPS and contribute to the formation of the SG shell.
In addition, we also analyzed the growth of SGs formed by differ-
ent DDX3X mutants (Supplementary Video 4), followed by mathe-
matical modeling. Remarkably, the data (Supplementary Dataset 3) 
is well described by the Avrami equation for nucleated particle 
growth or film growth42.
= − − −A t A e( ) (1 )F k t T( )
This simple model depends only on three parameters: the total 
area of the SGs, AF, at steady state, their growth rate, k, and the 
initiation time of SGs T (measured with respect to the start time 
of arsenite treatment, set to t = 0). Because T can be determined 
directly from the time-course experiment, only AF and k need to 
be fitted. This model has recently been used to model the growth 
of nuclear DDX4 organelles in cells9. For each DDX3X protein 
SG growth was observed at roughly the same time after arsenite 
addition (WT: 13.2 ± 2.3 min, K118Q: 13.5 ± 3.9 min, and allQ: 
16.4 ± 3.1 min; Supplementary Fig. 26a). The result from five cells 
expressing each mutant is plotted (Supplementary Fig. 26b). After 
normalization of AF by A0 (cell area at t = 0, see Supplementary Fig. 
26c), the parameters for fitting of WT and mutants (each n = 5) 
were compared (Supplementary Fig. 26a). Fitting the growth of WT 
DDX3X-positive SGs over time to this model resulted in a charac-
teristic growth rate of k = 0.11 ± 0.014 min−1 with a scaling ratio r 
( = AF / A0) of 10.1 ± 3.3 (× 10−3). The kinetics of the acetyl-mimic 
K118Q DDX3X-positive SGs also fit with the equation above, and 
k (0.12 ± 0.061 min−1) is similar to that of WT. However, the ratio 
r is significantly different (K118Q: 4.0 ± 1.6 (× 10−3)), indicating a 
reduced steady-state level. The allQ mutant also shows significant 
difference in the ratio r with an even much lower steady-state level 
(1.4 ± 0.6 (× 10−3); Fig. 6a and Supplementary Fig. 26a). Together, 
these results suggest that granule growth of the acetyl-mimic 
mutants starts as for the WT protein, but becomes impaired during 
the process due to low LLPS efficiency; deacetylation by HDAC6 is 
then required for SG maturation (Fig. 6b).
Discussion
The central concept revealed by our study is that lysine acetylation 
in IDRs regulates LLPS, and impacts SG maturation via DDX3X, 
a novel HDAC6 substrate. Cancer-associated mutations in DDX3X 
map to its helicase domain and correlate with an altered tendency to 
form SGs43. LAF-1, a related C. elegans protein, had been shown to 
undergo LLPS44, but the contribution of the DDX3X-IDR1 to LLPS 
had not been examined.
A few studies have suggested a role for lysine acetylation on 
granule formation under stress, although without mechanistic 
insight. An RNAi screen identified the HAT p300 as an impor-
tant factor for SG formation45, while another study described the 
deacetylase SIRT6 as a critical factor46; these two findings, indicat-
ing that both HATs and HDACs are implicated, underscore the role 
of lysine acetylation for SG formation. We now demonstrate that 
spatiotemporal acetylation of DDX3X-IDR1, regulated by CBP and 
HDAC6, is important for controlling SG formation. Specific stresses 
induce autoacetylation and activation of CBP, and lead to global 
protein acetylation, including DDX3X. Deacetylation of DDX3X by 
HDAC6 is then necessary for robust LLPS and SG formation. Our 
results show that this process is critical not for the initiation of the 
SGs, but for their maturation, which is consistent with the recent 
“Cores First” model4. Another RNP component, TDP-43, also 
becomes acetylated in its RNA-binding domain by CBP under oxi-
dative stress. In this case, acetylation impairs its RNA binding ability 
and aberrant aggregate formation is observed, which is counter-
acted by HDAC647. Thus, acetylation impacts granules formation in 
different ways, by modulating the LLPS propensity (DDX3X) or by 
affecting the ability to bind RNA (TDP-43); in each case, the action 
of HDAC6 is required for normal resolution of the stress response. 
It is currently unknown how specific stresses lead to activation of 
CBP with concomitant acetylation of multiple cellular targets, how 
the LLPS propensity of different acetylated proteins is altered, and 
whether or not this global acetylation provides any benefits to cel-
lular fitness. However, active deacetylation by HDAC6 of some RNP 
components (DDX3X, TDP-43, others?) is essential for their nor-
mal dynamics and function in the stress response. Thus, our results 
demonstrate a physiological role for acetylation/deacetylation in 
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of the box represent the 25th and 75th percentile of the data, with the median value represented by a horizontal bold line. On each side of the thin line is a 
kernel density estimation showing the distribution shape of the data points from minima to maxima. P values were determined by Student’s two-tailed  
t-test; *P <  0.05, **P <  0.01, ***P <  0.001 and ****P <  0.0001. e, Percentage of cells still having SGs after 30 min or 60 min post-stress recovery  
(mean ±  s.d.; n =  3 biologically independent samples). P values were determined by Student’s two-tailed t-test; *P <  0.05 and **P <  0.01.
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LLPS during SG maturation, and may help to further refine the 
models for SG assembly. Our observations also offer a novel thera-
peutic rationale for targeting HDACs or HATs in diverse neurode-
generative diseases.
The contribution of LLPS to biological processes in living cells is 
only little explored. We close by pointing out the emerging concept 
that transcription may also be regulated by LLPS48–50. Transcriptional 
hubs are composed of multiple components, many of which carry 
PTMs, and interactions between them may provide the valency nec-
essary for LLPS. Given that HDAC6 regulates SG formation by pro-
moting LLPS, it is tempting to speculate that other HDACs in the 
nucleus may also regulate the formation of transcriptional hubs by 
modulating LLPS. It is important to consider that acetylated lysines 
also provide a binding platform for acetyllysine binding “reader” 
domains, which are often part of transcription regulatory proteins, 
and may themselves promote LLPS. This could therefore be another 
mechanism for acetylation-mediated LLPS, distinct from our find-
ings that acetylation impairs LLPS through neutralization of IDRs. 
Collectively, we provide evidence that histone deacetylases regulate 
LLPS in membrane-less organelle formation, and anticipate that 
additional biological processes regulated by acetylation-modulated 
LLPS will be identified in the future.
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Methods
DNA constructs and antibodies. DDX3X cDNA was cloned from WT MEF cells 
into expression vectors (pcDNA3.1 for transient expression or pMSCV for stable 
expression). Expression vectors for HATs (FLAG-PCAF, HA-CBP, Myc-Tip60 and 
HA-p300) were kindly supplied from R. Voit (German Cancer Research Center, 
Heidelberg). To construct expression vectors for functional mutants of HDAC6 
and DDX3X, a plasmid of interest was amplified with appropriate sets of primers, 
then the PCR product was self-ligated to obtain a mutated plasmid. Primary 
antibodies were as follows: anti-α -tubulin (DM1A; Sigma, T9026), anti-acetylated 
tubulin (6-11B-1) (Sigma, T7451), anti-FLAG (M2) (Sigma, F1804), anti-HDAC6 
(ab56926), anti-HA (16B12) (ab130275), anti-c-Myc (9E10) (ab32), anti-phopho-
eIF2α (Ser51) (D9G8) (Cell Signaling Technology (CST) #3398), anti-histone H3 
(D1H2) (CST#4499), anti-acetyl-CBP (Lys1535)/p300 (Lys1499) (CST#4771), anti-
eIF2α (D7D3) (CST#5324), anti-CBP (D6C5) (CST#7389), anti-HDAC6 (D21B10) 
(CST#7612), anti-DDX3 (D19B4) (CST#8192), anti-TIAR (D32D3) (CST#8509), 
anti-acetylated-lysine (CST#9441), anti-PABP1 (clone 10E10) (Millipore#04-1467), 
anti-acetyl-histone H3 (Millipore#06-599), anti-DDX3X (Millipore#09-860), 
anti-cortactin (p80/85) (4F11) (Millipore#05-180), anti-DDX3X (clone 15D1B11) 
(BioLegend#658602), anti-Ub (P4D1) (Santa Cruz, sc-8017), anti-[K(Ac)40]-α 
-tubulin (Enzo, BML-SA452-0100) and anti-G3BP (Aviva Systems Biology, 
ARP37713_T100). Anti-mouse-HDAC6 was developed in the Matthias laboratory 
in the Friedrich Miescher Institute (FMI)51. Secondary antibodies were as follows: 
Amersham ECL Mouse IgG, HRP-linked whole Ab from sheep (GE Healthcare, 
NA931V), Amersham ECL Rabbit IgG, HRP-linked whole Ab from donkey (GE 
Healthcare, NA934V), Alexa Fluor 488 goat anti-mouse IgG (H + L) secondary 
antibody (Invitrogen, A11001), alexa fluor 568 goat anti-mouse IgG (H + L) 
secondary antibody (Invitrogen, A11004), alexa fluor 488 goat anti-rabbit IgG 
(H + L) secondary antibody (Invitrogen, A11034) and alexa fluor 568 goat anti-
rabbit IgG (H + L) secondary antibody (Invitrogen, A11036).
Establishment and characterization of DDX3X-K118Ac-specific antibody. The 
DDX3X-K118 acetylated peptide, CDRSGFGK(Ac)FERG (PSL Peptide Specialty 
Laboratories) was conjugated with mcKLH by Imject Maleimide Activated Carrier 
Protein Spin Kits (Thermo scientific) and the KLH conjugated peptide was used 
to immunize two rabbits (Pocono Rabbit Farm & Laboratory). Collected serum 
was passed over K118 acetylated peptide CDRSGFGK(Ac)FERG-conjugated 
agarose column prepared by SulfoLink Immobilization Kit for Peptides (Thermo 
scientific) and eluted with 0.2 M glycine-HCl, pH 2.0 and neutralized. Then, the 
elution was passed over K118 unacetylated peptide CDRSGFGKFERG-conjugated 
agarose column, and the flow through was used as a DDX3X-K118Ac-specific 
antibody. The specificity for K118Ac was assessed by ELISA using K118 acetylated 
and unacetylated peptide-coated plates (TaKaRa) and 1-Step Slow TMB-ELISA 
(Thermo scientific).
Cell culture. MEF cells, HEK293T cells, HeLa cells and Plat-E packaging cells were 
cultured in DMEM supplemented with 10% heat-inactivated FBS, penicillin and 
streptomycin at 37 °C and 5% CO2.
Transfection. HEK293T cells, HeLa cells and Plat-E packaging cells were 
transfected with Lipofectamine 2000 (Life Technologies) or FuGENE HD 
(Promega), and MEF cells were transfected with 4D-Nucleofector System (Lonza), 
following the manufacturer’s protocol.
Immunoblotting and immunoprecipitation. Cells were washed by ice-cold 
PBS and lysed in Triton lysis buffer (50 mM Tris, pH 8.0, 150 mM NaCl, 1 mM 
EDTA, 0.1% TritonX-100 and Complete EDTA-free protease inhibitors (Roche)) 
for analysis. To detect protein acetylation, 0.2 μ M trichostatin A and 5 mM 
nicotinamide were added to PBS for wash, and 10 μ M trichostatin A, 10 mM 
nicotinamide and 50 mM sodium butyrate were added to Triton lysis buffer. To 
detect protein phosphorylation, Pierce Protease and Phosphatase Inhibitor Mini 
Tablets (Thermo Scientific) were added to Triton lysis buffer instead of Complete 
EDTA-free protease inhibitors. 500 μ g protein lysates were incubated with the 
specific antibody overnight at 4 °C, and immunoprecipitated with Dynabeads 
Protein G (Invitrogen) for 1 h at 4 °C. Samples were boiled for 10 min in SDS–
PAGE sample buffer, and separated with 4–12% NuPAGE gels (Invitrogen). 
Proteins were transferred onto PVDF membranes (Immobilon-P, Millipore), 
probed with specific primary antibody overnight and secondary antibody for 1 h 
under 5% non-fat dry milk in TBS or 5% BSA, 0.1% Tween20 in TBS blocking 
conditions and detected with Amersham ECL western blotting reagent (GE 
Healthcare). For inhibition of HDACs in cells, the concentration of each HDAC 
inhibitor was as described in ref. 20.
Identification of the DDX3X acetylation sites. The protein pellets were reduced 
with 10 mM TCEP, alkylated with 20 mM iodoacetamide and cleaved first with 
0.1 µ g Lys-C (Wako) for 6 h and then with 0.1 µ g porcine sequencing grade trypsin 
(Promega) overnight. The extracted peptides were analyzed by capillary liquid 
chromatography tandem mass spectrometry with an EASY-nLC 1000 using the 
two-column set up (Thermo Scientific). The peptides were loaded in 0.1% formic 
acid, 2% acetonitrile in H2O onto a peptide trap (Acclaim PepMap 100,  
75 µ m × 2 cm, C18, 3 µ m, 100 Å) at a constant pressure of 600 bar. Then they were 
separated, at a flow rate of 150 nl/min with a linear gradient of 2–6% buffer B in 
buffer A in 3 min followed by a linear increase from 6 to 22% in 40 min, 22–28% 
in 9 min, 28–36% in 8 min, 36–80% in 1 min and 12 min at 80% buffer B in buffer 
A (buffer A: 0.1% formic acid, buffer B: 0.1% formic acid in acetonitrile) on a 
50 µ m × 15 cm ES801 C18, 2 µ m, 100 Å column mounted on a DPV ion source 
(New Objective) connected to a Orbitrap Fusion (Thermo Scientific). The data 
were acquired using 120,000 resolution for the peptide measurements in the 
Orbitrap and a top T (3 s) method with HCD fragmentation for each precursor 
and fragment measurement in the linear ion trap. MASCOT 2.5 was used in the 
Decoy mode to search the Swiss-Prot mouse version 2015_01 including common 
contaminants. The enzyme specificity was set to trypsin, allowing for up to three 
incomplete cleavage sites. Carbamidomethylation of cysteine ( + 57.0245 Da) was 
set as a fixed modification, oxidation of methionine ( + 15.9949 Da) and acetylation 
of lysines ( + 42.0106 Da) were set as variable modifications. Parent ion mass 
tolerance was set to 10 p.p.m. and fragment ion mass tolerance to 0.6 Da. The 
results were validated with the program Scaffold (version: 4.4) and Scaffold PTM 
(version: 2.2) (Proteome Software, Portland, USA). Peptide identifications were 
accepted if they could be established at greater than 0.1% probability as calculated 
in Scaffold and acetylation sites were accepted if they had a greater than 80% site 
probability as calculated with Scaffold PTM.
Interaction proteomics. FLAG-DDX3X was immunoprecipitated with Anti-FLAG 
M2 Magnetic Beads (Sigma) from cellular lysate of each 293T sample expressing 
either DDX3X WT or mutants. Cellular lysate of parental 293T cells was used 
as a negative control. Precipitants were digested on beads by Lys-C (Wako) in 
digestion buffer (3 M GuHCl, 20 mM EPPS, pH 8.5, 10 mM CAA and 5 mM 
TCEP), further digested by trypsin (Promega), and analyzed by LC–MS/MS, 
essentially as described52. In short, the peptides were separated with an EASY-nLC 
1000 on a 50 μ m × 15 cm ES801 C18, 2 μ m, 100 Å column (Thermo Scientific) 
mounted on a DPV ion source (New Objective). They were measured with a 
Orbitrap Fusion (Thermo Scientific) using a top T (3 s) method as recommended 
by the manufacturer (Thermo Scientific). Andromeda implemented in MaxQuant 
(version: 1.5.3.8)53 was used to search the mouse subset of the UniProt (version: 
2017_04) combined with the contaminant database from MaxQuant and label-free 
quantification (LFQ54) was used with a protein and peptide FDR of 0.01. Statistical 
analysis was done in Perseus (version: 1.5.2.6)55,56. Results were filtered to remove 
reverse hits, contaminants and peptides found in only one sample. Missing values 
were imputed and potential interactors were determined using Student’s two-tailed 
t-test and visualized by a volcano plot. Significance lines corresponding to a FDR of 
0.03 and a S0 of 1.5 are shown in the corresponding figures. Results were exported 
from Perseus and visualized using statistical computing language R.
Biotinylated isoxazole (b-isox)-mediated precipitation. Cells were washed by 
ice-cold PBS and lysed in EE buffer (50 mM HEPES, pH 7.5, 150 mM NaCl, 1 mM 
EDTA, 2.5 mM EGTA, 0.1% NP-40, 10% Glycerol, 1 μ M DTT and Complete 
EDTA-free protease inhibitors (Roche)) To detect DDX3X acetylation, 10 μ M  
Tubacin was added to EE buffer. Biotinylated isoxazole (Sigma) in DMSO was 
added to cell lysates at 100 μ M final concentration. The reaction solutions 
were incubated for 4 h at 4 °C and then centrifuged at 13,200 r.p.m. for 10 min. 
Precipitates were washed five times in EE buffer before SDS solubilization, 
following analyzed by immunoblotting as mentioned above.
Immunofluorescence microscopy and live-cell imaging. Stress granules were 
induced by the following conditions: 1 mM sodium arsenite (Millipore) for 15 
min–1 h, 2 mM H2O2 (Sigma) for 1 h, 3 mM diethyl maleate (Sigma) for 1 h, 20 μ 
M CCCP (Sigma) in glucose-free DMEM (Gibco) with 10% FBS for 1 h, 40 μ 
M clotrimazole (Sigma) in glucose-free DMEM with 10% FBS for 3 h, 20 μ g/
ml puromycin (Sigma) for 3 h, 10 μ M thapsigargin (Invitrogen) for 1 h, 10 μ M 
MG132 (Sigma) for 3 h, heat shock at 43 °C for 1 h and 0.5 M sorbitol (Sigma) 
for 1 h. Catalytic activities of HDAC6 or CBP were inhibited by treatment of 
10 μ M Tubacin (Sigma) or 10 μ M A-485 (Lucerna-Chem) for 3 h, respectively. 
For knockdown of CBP, ON-TARGETplus SMARTpool siRNA mouse CBP 
(Dharmacon) were delivered via nucleofection (2 μ M). Cells on a coverglass 
were washed with ice-cold PBS, then fixed with ice-cold methanol or 4% 
paraformaldehyde. After permeabilization with 0.5% TritonX-100 or 0.005% 
digitonin in PBS for 10 min, the cells were incubated with specific primary and 
secondary antibodies in 10% goat serum (Sigma) blocking buffer, then mounted 
with ProLong Gold Antifade Reagent with DAPI (Cell Signaling Technology 
#8961). Images were captured by Axioimager Z1 microscope (Zeiss). SGs in 
images were defined by a plugin of Fiji (SG counter). Volume of SG V = 4πR3/3, 
where R is SG radius, was calculated for each SG, and total volume of SGs in a cell 
was determined. In each violin plot, the thin line at the center represents the 95% 
confidence interval, and the bottom and top of the box represent the 25th and 75th 
percentile of the data, with the median value represented by a horizontal bold line. 
On each side of the thin line is a kernel density estimation showing the distribution 
shape of the data points from minima to maxima. For live-cell imaging, WT 
or DDX3X KO MEF cells were transfected with expression vectors encoding 
mCherry-DDX3X WT or mutants, cultured for 1 d on a glass-bottom dish 35 mm 
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(Ibidi), and images were captured with a spinning-disk confocal microscope 
(Olympus IX81 + Yokogawa CSU-X1 scan head) with a 561 nm laser for  
mCherry signals.
Mathematical modeling of SG growth. Live-cell image stacks, captured as 
mentioned above, were subjected to maximum intensity projection, and SGs  
were defined by SG counter. The time point when cells are treated with arsenite 
was set as t = 0, and the initiation time of SGs (T) was defined as the time point 
when SG is observed for the first time. The obtained total SG area is regressed on 
Avrami equation:
= − − −A t A e( ) (1 )F k t T( )
Two parameters, AF and k, were estimated from this fit. To simulate kinetics of 
each DDX3X construct, the effect of size scaling was adjusted: the initial area A0 
was measured at t = 0 for each cell, and the scaling ratio r (= AF/A0) was obtained. 
The best estimate and associated error (s.d.) for k and r were calculated from the 
fit (n = 5 for each construct). To visualize the data, the mean value of r for WT is 
arbitrarily set as 100, and the curves obtained with the best estimates of T, k and r 
were shown. The areas where each curve exists with three parameters: T, k and r in 
the range of mean ± s.d. were also shown.
Establishment of KO cell lines using CRISPR–Cas9 genome editing. HDAC6 
KO HEK293T cells were established by CRISPR–Cas9 genome editing. The guide 
sequence targeting human HDAC6 was designed by the CRISPR design tool at 
http://www.genome-engineering.org/crispr/ and cloned into pX330-Cas9-T2A-
mCherry vector (Addgene). The following 20 nucleotides were inserted:
5′ -GGTGGAATCCTGGCCGGTTG-3′ 
The pX330 vector was transfected into HEK293T cells as mentioned above. 
Two days after transfection, the mCherry positive cells were collected by FACS. 
Then, single cell clones were sorted again week after and expanded. Screening for 
HDAC6 knockout was done by immunoblotting. Genomic DNA was purified from 
the HDAC6 KO clone and the region surrounding PAM of the sgRNA was cloned 
into pGEM-T Easy vector (Promega) for sequencing after amplification with a pair 
of primers:
5′ -GGCAGAGAGGTGGGGTCCTC-3′ 
5′ -CTCATCAGGGCGGGTCTAGG-3′ 
To determine the indels of individual alleles, the amplicons from 20 bacterial 
colonies were sequenced.
Establishment of DDX3X KO MEFs followed the same procedure. The inserted 
nucleotides and a pair of primers for genotyping are followings:
5′ -tggcagtggaaaatgcgct -3′ (for guide RNA)
5′ -GAGGAGGGCACACGTCTTAC-3′ (for genotyping)
5′ -AACTTAAAGAGCTGCGCCAC-3′ (for genotyping)
Protein expression and purification. The DNA fragments of mouse DDX3X-
IDR1 (a.a. 2–167) and DDX3X-full-length (a.a. 2–662) were inserted into the 
BamHI sites of the pET28 vector. All proteins were expressed in E. coli BL21 (DE3) 
cells with 1.0 mM IPTG at 16 °C for overnight. Cells were lysed with a lysis buffer 
containing 20 mM Tris, pH 7.5, 500 mM NaCl, 2 mM DTT, Complete EDTA-free 
protease inhibitors (Roche) for 30 min on ice, followed by sonication. The lysate 
was centrifuged at 15.000 r.p.m. for 30 min. The supernatant was incubated with 
Ni-NTA resin (QIAGEN) for 1 h at 4 °C. The Ni-NTA resin was packed in a 
column and washed with a buffer containing 20 mM Tris, pH 7.5, 500 mM NaCl, 
20 mM imidazole, 2 mM DTT. The bound proteins were eluted with a buffer 
containing 20 mM Tris, pH 7.5, 500 mM NaCl, 500 mM imidazole, 2 mM DTT. 
The purified His-SUMO-tagged proteins were concentrated with Amicon Ultra 
centrifugal filters (Millipore), and digested by SUMO protease for overnight at 
4 °C. Then, the digested samples were passed over Ni-NTA resin and the flow 
through was collected and concentrated. They were subjected to size exclusion 
chromatography on a Superdex 200 Increase 10/300 GL column (GE Healthcare) 
equilibrated in the Gel Filtration buffer, 20 mM Tris, pH 7.5, 250 mM NaCl, and 
2 mM DTT. The fractions were concentrated to 20 mg/ml and stored at − 80 °C. 
For full-length protein, 1 M NaCl buffers were used through the whole purification 
process. The purities of the purified proteins were tested on SDS–PAGE gels, and 
the concentrations were determined by absorbance at UV at 280 nm.
In vitro droplet formation assay. For the phase separation of purified DDX3X, 
experiment was performed in 20 mM Tris, pH 7.5, 2 mM DTT. The concentrations 
of DDX3X and NaCl are 0 – 200 μ M and 0 – 250 mM, respectively as indicated 
in the figure legends. As a molecular crowder, PEG4000 (Sigma) was added to 
samples at 10% (w/v). For acetylation of DDX3X-IDR1 in vitro, 40 μ g of the IDR1 
was incubated with 2.5 μ g of human recombinant CBP catalytic domain (Enzo) 
and 10 mM acetyl-CoA (Sigma) for 3 h at 37 °C. For deacetylation of DDX3X-IDR1 
in vitro, D. rerio HDAC6 CD1-CD2 (a.a. 40-831) was expressed in Sf9 insect cells, 
purified based on the method previously described30 (buffer and salt were adjusted 
to the droplet formation assay), and added into DDX3X-IDR1 acetylation reaction 
mixture. Alexa Fluor 488 Protein Labeling Kit (Molecular Probes) was used for 
fluorescent labeling of the IDRs, followed by dialysis against Gel Filtration buffer 
using Slide-A-Lyzer MINI Dialysis Devices (Thermo scientific). The droplets 
were observed using an Axioimager Z1 microscope (Zeiss) and Spinning-Disk 
Confocal microscope, and turbidity of the samples (OD600) is quantified with 
NanoDrop (Thermo scientific). For temperature-dependent droplet dissolution 
and condensation experiments, samples were mounted inside small compartments 
sealed with a pegylated coverslip on a custom-built temperature-controlled stage57. 
For imaging, the heating/cooling system was mounted on a Nikon TiE stand 
equipped with a Perfect Focus System. Image stacks were captured every 10 s using 
a 40x air objective (0.95NA) combined with a spinning-disk confocal unit CSU-X1 
(Yokogawa) and an EMCCD camera IXON + (Andor). Image data was analyzed 
with MATLAB. In brief, image stacks were subjected to maximum intensity 
projection, the background was subtracted, and they were binarized after further 
filtering. In the binarized image-series, particle number was analyzed.
Computational prediction of disordered regions. Computational prediction of 
disordered regions was done with the PONDR VSL2 and VL3-BA programs. As 
queries for the prediction, protein sequences from the UniProt database released in 
March 2017 were used. Missing protein entries in this version were cited from the 
one released in February 2012.
Reporting Summary. Further information on research design is available in the 
Nature Research Reporting Summary linked to this article.
Data availability
Published research reagents from the FMI are shared with the academic 
community under a Material Transfer Agreement (MTA) having terms and 
conditions corresponding to those of the UBMTA (Uniform Biological Material 
Transfer Agreement).
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Sample size Experiments were done with independent biological samples (usually n≥3) and highly comparable results were obtained. This sample size is 
widely accepted as sufficient when using independent biological samples. 
Data exclusions No data was excluded.
Replication All attempts at replication were successful in ≥3 experiments with independent biological samples. The methods and reagents used are 
described in detail, so that replication of the experiments by other scientists should be facilitated.
Randomization Samples were organized by experimental variable, measurements were done in an automated manner (e.g. by the microscope) and the 
results are reported in completion. 
Blinding Not applicable. The setup was the same for all samples tested in the experiment, and the analysis of obtained data was performed in parallel 
in an automated manner (e.g. by the microscope), with identical parameters for all measurements. 
Reporting for specific materials, systems and methods
Materials & experimental systems
n/a Involved in the study
Unique biological materials
Antibodies
Eukaryotic cell lines
Palaeontology
Animals and other organisms
Human research participants
Methods
n/a Involved in the study
ChIP-seq
Flow cytometry
MRI-based neuroimaging
Antibodies
Antibodies used Primary antibodies were as follows: Anti-α-tubulin (DM1A) (Sigma, T9026, lot:049K4767), Anti-Acetylated Tubulin (6-11B-1) 
(Sigma, T7451, lot: 103M4772V), Anti-FLAG (M2) (Sigma, F1804, lot: SLBV9325), Anti-HDAC6 (ab56926, lot: GR211012-2), Anti-
HA (16B12) (ab130275, lot: GR250145-3), Anti-c-Myc (9E10) (ab32, lot:931293), Anti-Phopho-eIF2α (Ser51) (D9G8) (Cell 
Signaling Technology (CST) #3398, lot:6), Anti-Histone H3 (D1H2) (CST#4499, lot:1), Anti-Acetyl-CBP (Lys1535)/p300 (Lys1499) 
(CST#4771, lot:5), Anti-eIF2α (D7D3) (CST#5324, lot:3), Anti-CBP (D6C5) (CST#7389, lot:3), Anti-HDAC6 (D21B10) (CST#7612, 
lot:2), Anti-DDX3 (D19B4) (CST#8192, lot:1), Anti-TIAR (D32D3) (CST#8509, lot:1), Anti-Acetylated-Lysine (CST#9441, lot:11), 
Anti-PABP1 (clone 10E10) (Millipore#04-1467, lot:2349625), Anti-acetyl-Histone H3 (Millipore#06-599, lot:2370129), Anti-DDX3X 
(Millipore#09-860, lot:2714517), Anti-Cortactin(p80/85) (4F11) (Millipore#05-180, lot:2210407), Anti-DDX3X (clone 15D1B11) 
(BioLegend#658602, lot:B177028), Anti-Ub (P4D1) (Santa Cruz, sc-8017, lot:G2303), Anti-[K(Ac)40]-α-tubulin (Enzo, BML-
SA452-0100, lot:01051550) and Anti-G3BP (Aviva Systems Biology, ARP37713_T100, lot:QC6154-42482). Anti-mouse-HDAC6 was 
developed in Matthias laboratory, FMI (Rabbit polyclonal, Banerjee I. et al., Science, 346, 2014). Anti-Acetylated-DDX3X (K118) 
was also developed in Matthias laboratory. DDX3X-K118 acetylated peptide (PSL Peptide Speciality Laboratories) conjugated with 
mcKLH was used to immunize two rabbits (Pocono Rabbit Farm & Laboratory), and the fraction of interest was affinity purified 
from the collected serum. The specificity of the antibody for K118Ac was assessed by ELISA. Secondary antibodies were as 
follows: Amersham ECL Mouse IgG, HRP-linked whole Ab from sheep (GE Healthcare, NA931V, lot:12227046), Amersham ECL 
Rabbit IgG, HRP-linked whole Ab from donkey (GE Healthcare, NA934V, lot:13601187), Alexa Fluor 488 Goat anti-Mouse IgG (H
+L) Secondary Antibody (invitrogen, A11001, lot:1858182), Alexa Fluor 568 Goat anti-Mouse IgG (H+L) Secondary Antibody 
(invitrogen, A11004, lot:1419715), Alexa Fluor 488 Goat anti-Rabbit IgG (H+L) Secondary Antibody (invitrogen, A11034, 
lot:1910795D) and Alexa Fluor 568 Goat anti-Rabbit IgG (H+L) Secondary Antibody (invitrogen, A11036, lot:1704462).
Validation The data are provided in the manuscript. Anti-α-tubulin (DM1A) (Sigma, T9026; WB for human and mouse proteins (Dilution 
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1:5000)), Anti-Acetylated Tubulin (6-11B-1) (Sigma, T7451; WB for human (1:5000)), Anti-FLAG (M2) (Sigma, F1804; WB (1:2000), 
IP (1:100)), Anti-HDAC6 (ab56926; IF for human (1:20)), Anti-HA (16B12) (ab130275; WB (1:5000)), Anti-c-Myc (9E10) (ab32; WB 
(1:1000)), Anti-Phopho-eIF2α (Ser51) (D9G8) (Cell Signaling Technology (CST) #3398; WB for human and mouse (1:1000)), Anti-
Histone H3 (D1H2) (CST#4499; WB for human (1:1000)), Anti-Acetyl-CBP (Lys1535)/p300 (Lys1499) (CST#4771; WB for mouse 
(1:1000)), Anti-eIF2α (D7D3) (CST#5324; WB for human and mouse (1:5000)), Anti-CBP (D6C5) (CST#7389; WB for mouse 
(1:1000), IP for mouse (1:100)), Anti-HDAC6 (D21B10) (CST#7612; WB for human (1:1000)), Anti-DDX3 (D19B4) (CST#8192; WB 
for human and mouse (1:2000), IP for human (1:100)), Anti-TIAR (D32D3) (CST#8509; WB for human (1:1000)), Anti-Acetylated-
Lysine (CST#9441; WB for human and mouse (1:1000)), Anti-PABP1 (clone 10E10) (Millipore#04-1467; IF for human (1:100)), 
Anti-acetyl-Histone H3 (Millipore#06-599; WB for human (1:1000)), Anti-DDX3X (Millipore#09-860; IF for human (1:100)), Anti-
Cortactin(p80/85) (4F11) (Millipore#05-180; WB for human (1:1000), IP for human (1:100)), Anti-DDX3X (clone 15D1B11) 
(BioLegend#658602; IF for mouse (1:100)), Anti-Ub (P4D1) (Santa Cruz, sc-8017; WB for human (1:500)), Anti-[K(Ac)40]-α-tubulin 
(Enzo, BML-SA452-0100; WB for human (1:5000)), Anti-G3BP (Aviva Systems Biology, ARP37713_T100; WB for mouse (1:1000), 
IF for human and mouse (1:100)), Anti-mouse-HDAC6 (Matthias laboratory; WB for mouse (1:1000)) and Anti-Acetylated-DDX3X 
(K118) (Matthias laboratory; WB for human and mouse (1:1000), IF for mouse (1:20), ELISA for synthesized peptide (1:1000)). 
Amersham ECL Mouse IgG, HRP-linked whole Ab from sheep (GE Healthcare, NA931V; WB (1:2000)), Amersham ECL Rabbit IgG, 
HRP-linked whole Ab from donkey (GE Healthcare, NA934V; WB (1:2000)), Alexa Fluor 488 Goat anti-Mouse IgG (H+L) Secondary 
Antibody (invitrogen, A11001; IF (1:500)), Alexa Fluor 568 Goat anti-Mouse IgG (H+L) Secondary Antibody (invitrogen, A11004; IF 
(1:500)), Alexa Fluor 488 Goat anti-Rabbit IgG (H+L) Secondary Antibody (invitrogen, A11034; IF (1:500)) and Alexa Fluor 568 
Goat anti-Rabbit IgG (H+L) Secondary Antibody (invitrogen, A11036; IF (1:500)). 
Eukaryotic cell lines
Policy information about cell lines
Cell line source(s) MEFs were generated in the Matthias laboratory. HEK293T and HeLa cells were from Matthias lab aliquots (originally 
obtained from ATCC). Plat-E cells, originally from the University of Tokyo, were obtained from the lab of S. Gaubatz 
(University of Würzburg). Sf9 cells were obtained from the lab of N. Thomä (FMI).
Authentication Cells initially obtained from ATCC had been authenticated by the supplier (morphology, karyotyping, PCR). 
Mycoplasma contamination No mycoplasma contamination was confirmed by the authors.
Commonly misidentified lines
(See ICLAC register)
No commonly misidentified cell lines were used.
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Supplementary Figure 1. Characterization of the HDAC6-dependent acetylome 
(related to Figure 1).  
(a) HDAC6-dependent acetylome. The scatter plots show the correlation between 
acetylated sites quantified in HDAC6-specific inhibitor-treated MEFs vs acetylated sites 
quantified in HDAC6 KO MEFs. X-axis: SILAC ratio of Tubacin-treated MEFs vs control-
treated MEFs (left panel) or SILAC ratio of Bufexamac-treated MEFs vs control-treated 
MEFs (right panel). Y-axis, both panels: SILAC ratio of HDAC6 KO MEFs vs WT MEFs. 
In each plot, the red dotted line shows the 2-fold increase threshold. Correlation was 
determined with Pearson correlation coefficient. (b) Proteins were assigned to cellular 
function based on gene ontology annotations using the STRING database 58. The 
presented analysis was performed with the 87 peptides that showed a more than 2-fold 
increase in acetylation upon chemical inhibition or genetic ablation of HDAC6. The protein 
interaction network obtained under medium confidence (interaction score >= 0.400) is 
shown. (c) Left: Venn diagram showing the overlap between the different conditions 
tested: Tubacin, Bufexamac, or HDAC6 KO. The region of overlap between all 3 
conditions contains 18 peptides and corresponds to the high-confidence sites. Right: 
Definition of an HDAC6 target motif based on analysis of the 18 high-confidence sites. 
The analysis was done with the iceLogo software 59. K represents the acetylated lysine 
site at position 0; it has been inserted in the figure for visualization only (there is no score 
on the Y-axis at position 0, because all analysed peptides have K).   
-86-
Cttn Cav1
Enah Serbp1
Ddx3x Ahsa1
Pex5
0 40 80 120 180 240 300 360 420 480 540
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
0 20 40 60 80 100 120 140 160 180
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
0 60 120 200 280 360 440 520 600 680 760
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
0 40 80 120 160 200 240 280 320 360 400
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
0 40 100 160 220 280 340 400 460 520 580 640
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
0 20 60 100 140 180 220 260 300 340
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
0 40 80 140 200 260 320 380 440 500 560 620
0.1
0.2
0.3
0.4
0.5
0.6
0.7
Usp47
Tsmb10
Eif4b
Exoc4
Hn1
Cnn3
0 80 180 300 420 540 660 780 900 1040 1180 1320
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
0 20 40
0.95
0.96
0.97
0.98
0.99
0 20 60 100 140 180 220 260 300 340
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
0 60 140 220 300 380 460 540 620 700 780 860 940
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
0 200 460 720 980 1260 1560 1860 2160 2460 2760 3060
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
Ranbp2
0 20 40 60 80 120 160 200 240 280 320
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
Nat6
0 40 80 140 200 260 320 380 440 500 560 620
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
0 20 40 60 80 100 120 140 160
0.84
0.86
0.88
0.90
0.92
0.94
0.96
0.98
0 80 180 300 420 540 660 780 900 1020 1160 1300
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
Synrg
87
198
309
5
695 122
118
3
28 122
15
156
11
1814
303 586
148
509
Supplementary Fig. 2
-87-
Supplementary Figure 2. High-confidence HDAC6 target sites in IDRs (related to 
Figure 1). 
Sequence of proteins harbouring high-confidence HDAC6 target sites were subjected to 
analysis for intrinsically disordered regions, using the program VSL2. The amino acid 
position in the linear sequence is plotted on the X-axis and the disorder tendency is 
displayed on the Y-axis. The position of each high-confidence HDAC6 target site in IDR 
is indicated and labelled in red, while it is labelled in black if it is in a structured region. 
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Supplementary Fig. 3
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Supplementary Figure 3. Comparison of the HDAC6-dependent acetylome in two 
studies (related to Figure 1). 
Venn diagram comparing the HDAC6-dependent acetylome in our study (based on the 
original acetylome of 20) and the mouse liver HDAC6-dependent acetylome described in 
24. The number of proteins is indicated. 
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Supplementary Figure 4. Co-localization between DDX3X and HDAC6 (related to 
Figure 1).  
(a) Co-localization of DDX3X with PABP1 (stress granule (SG) marker) under oxidative 
stress. 293T cells were treated with 1 mM arsenite for 30 min, and localization of 
endogenous DDX3X and PABP1 was assessed by immunofluorescence microscopy. 
Representative results are shown (n = 3 biologically independent experiments). Scale 
bar, 10 μm. (b) Localization of HDAC6 on SGs under oxidative stress. 293T cells were 
treated with 1 mM arsenite for 30 min, and localization of endogenous HDAC6 was 
assessed by immunofluorescence microscopy. Red arrows indicate granules containing 
HDAC6. Representative results are shown (n = 3 biologically independent experiments). 
Scale bar, 10 μm. (c) Localization of DDX3X and HDAC6 on SGs under oxidative stress. 
293T cells were treated with 1 mM arsenite for 30 min, and localization of endogenous 
DDX3X and HDAC6 was assessed by immunofluorescence microscopy. Representative 
results are shown (n = 3 biologically independent experiments). Scale bar, 10 μm. 
-90-
Supplementary Fig. 5
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Supplementary Figure 5. Multiple acetylation sites are present in DDX3X-IDR1 
(related to Figure 1). 
(a) Acetylation of overexpressed DDX3X by CBP and p300. Tagged versions of DDX3X, 
CBP and p300 were transiently expressed in 293T cells. The acetylation status of FLAG-
DDX3X was analyzed with a pan-acetyl-lysine antibody after immunoprecipitation. 
Representative results are shown (n = 3 biologically independent samples). Uncropped 
gel images can be found in Supplementary Fig. 27i. (b) Acetylation of exogenous 
DDX3X is increased by Tubacin treatment. 293T cells were transiently transfected with 
FLAG-DDX3X together with CBP or p300 and were treated overnight with 10 μM Tubacin, 
as indicated. Cell lysates were used to examine the acetylation status of FLAG-DDX3X 
by immunoblotting with a pan-acetyl-lysine antibody after immunoprecipitation. 
Representative results are shown (n = 3 biologically independent samples). Uncropped 
gel images can be found in Supplementary Fig. 27j. (c) Confirmation of the DDX3X 
acetylation site by immunoblotting. FLAG-DDX3X WT or K118R was expressed in 293T 
cells together with CBP. The acetylation status of FLAG-DDX3X was analyzed with a pan-
acetyl-lysine antibody after immunoprecipitation. Representative results are shown (n = 
3 biologically independent samples). Uncropped gel images can be found in 
Supplementary Fig. 27k. (d) Structural prediction analysis of DDX3X showing the 
positions of acetylated lysines. FLAG-DDX3X was immunoprecipitated with a FLAG (M2) 
antibody from lysates of 293T cells transfected with FLAG-DDX3X and CBP. The protein 
pellets were cleaved with Lys-C and trypsin, and the extracted peptides were analyzed 
by mass spectrometry. All identified acetylation sites were in IDR1. (e) MS/MS spectrum 
of the DDX3X acetylated peptides identified in d. The results were validated with the 
program Scaffold (version: 4.4) and Scaffold PTM (version: 2.2). Representative results 
are shown (n = 3 biologically independent samples). 
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Supplementary Figure 6. Quantification of immunoblots to show DDX3X as a novel 
HDAC6 substrate (related to Figure 1).  
Quantification of Ac-DDX3X signals as in Fig.1. Intensity of the band under each condition 
was quantified using ImageJ, and normalized by that of control condition. Mean and SD 
values are presented (n = 3 biologically independent samples). P values were determined 
by Student’s two-tailed t-test; (*) P < 0.05, (**) P < 0.01, (***) P < 0.001 and (****) P < 
0.0001. (a) Quantification of AcK signal in DDX3X-IP product in Fig.1d. (b) Quantification 
of AcK signal in DDX3X-IP product in Fig.1e. (c) Quantification of Ac-DDX3X (K118) 
signal in Fig.1f. 
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Supplementary Figure 7. Establishment of a DDX3X-K118Ac-specific antibody 
(related to Figure 1).  
(a) Rabbit serum was collected 18 weeks after injection with the DDX3X-K118Ac peptide 
(see Methods). As a control for the analysis, 293T cells were transiently transfected with 
FLAG-DDX3X together with GFP (control DDX3X, lane 1) or CBP (Ac-DDX3X, lane 2) 
and DDX3X was immunoprecipitated from cell lysates. Each protein sample was then 
analyzed by immunoblotting, using pre-immune serum, immune serum or a commercial 
pan-acetyl-lysine antibody as indicated. Representative results are shown (n = 3 
biologically independent samples). An uncropped gel image can be found in 
Supplementary Fig. 27l. (b) Scheme of the sequential affinity purification procedure for 
a DDX3X-K118Ac-specific antibody, with two columns. The serum was first subjected to 
affinity purification with K118Ac peptide (CSGFGK(Ac)FER) column; the bound fraction 
was eluted and subsequently passed over an unacetylated K118 peptide (CSGFGKFER) 
column, in order to remove antibodies that would also bind to the non-modified peptide. 
The flow through of the second column fraction contains the DDX3X-K118Ac-specific 
antibody and has been used in all subsequent experiments. (c) Specificity of DDX3X-
K118Ac antibody tested by enzyme-linked immunosorbent assay (ELISA). DDX3X-K118 
acetylated or unacetylated peptide-coated plates were prepared for ELISA and 
subsequently reacted with increasing concentration of the affinity purified antibody. 
Absorbance (450 nm) of ELISA substrates after the reaction was measured at each 
antibody concentration (mean ± SE, n = 3 independent experiments). 
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Supplementary Figure 8. Establishment of HDAC6 KO 293T (related to Figure 1).  
(a) The top sequence (WT) shows the genomic sequence of the human HDAC6 locus 
around the ATG translation initiation site (black and bold) as well as the PAM site that 
was selected (red) for the CRISPR/Cas9 targeting. Immediately below the nucleotide 
sequence, the HDAC6 protein coding sequence is indicated. The two sequences below 
(MT1, MT2) depict the nucleotide sequence of the alleles identified in the KO cells. (b) 
Absence of HDAC6 protein and enhanced acetylation of α-tubulin in HDAC6 KO 293T 
cells. Expression level of HDAC6 and acetylation status of its established substrate α-
tubulin were analyzed by immunoblotting in 293T and HDAC6 KO 293T cell lysates. A 
non-specific (n.s.) band reacting with the HDAC6 antibody is indicated by an arrowhead. 
Representative results are shown (n = 3 biologically independent samples). Uncropped 
gel images can be found in Supplementary Fig. 27m. (c) Saturated acetylation of α-
tubulin in HDAC6 KO 293T cells. The acetylation status of α-tubulin was analyzed in 293T 
and HDAC6 KO 293T cells following treatment with HDAC6 specific inhibitors, as 
indicated. Representative results are shown (n = 3 biologically independent samples). 
Uncropped gel images can be found in Supplementary Fig. 27n. (d) Enhanced DDX3X 
acetylation in HDAC6 KO 293T cells. The acetylation status of endogenous DDX3X was 
analyzed by immunoblotting lysates from 293T and HDAC6 KO 293T cells transiently 
expressing CBP, as indicated; the DDX3X-K118Ac-specific antibody was used. 
Representative results are shown (n = 3 biologically independent samples). Uncropped 
gel images can be found in Supplementary Fig. 27o. 
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Supplementary Figure 9. DDX3X-IDR1 is a substrate of both HDAC6 CD1 and CD2 
domains (related to Figure 1). 
(a) DDX3X and cortactin can be deacetylated by either HDAC6 catalytic domain. Left, 
top: schematic drawing of HDAC6 structure highlighting the tandem catalytic domains 
(CD1, CD2) as well as the ubiquitin-binding zinc finger domain (ZnF-UBP). The positions 
of the different mutations are indicated. To determine which catalytic domain(s) is 
responsible for DDX3X-K118Ac deacetylation, different HDAC6 functional mutants 
(H216A, CD1 catalytic dead; H611A, CD2 catalytic dead; H216A/H611A double mutant, 
and W1182A, ubiquitin-binding-deficient) 27,28 were expressed in HDAC6 KO 293T cells 
together with CBP. Left, bottom: deacetylation of DDX3X, cortactin and α-tubulin by 
HDAC6 and its functional mutants. Lysates from HDAC6 KO 293T cells expressing CBP 
(lanes 1-6) and the different HDAC6 constructs (WT, H216A, H611A, H216A/H611A, or 
W1182A, lanes 2 to 6) were used to detect the acetylation status of the different proteins 
by immunoblotting. For DDX3X and α-tubulin, antibodies specific for the respective 
acetylated site were used; for cortactin a pan-acetyl-lysine antibody was used. 
Representative results are shown (n = 3 biologically independent samples). Uncropped 
gel images can be found in Supplementary Fig. 27p. Right: structural prediction analysis 
of DDX3X, cortactin and α-tubulin illustrating the position of the acetylated sites with 
respect to IDRs or ordered regions. The VL3-BA program was used. (b) Quantification of 
the immunoblot in a. Left: Ac-DDX3X (K118) signal, Right: Ac-α-tubulin signal. (mean ± 
SD, n = 3 biologically independent samples). P values were determined by Student’s two-
tailed t-test; (*) P < 0.05, (**) P < 0.01, (***) P < 0.001 and (****) P < 0.0001. 
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Supplementary Figure 10. Time course of SG formation in 293T under various types 
of stress (related to Figure 2). 
(a) Representative microscopy images to show the localization of DDX3X, CBP and 
HDAC6 in 293T at each time point after arsenite treatment. Red arrows indicate granules 
containing HDAC6. Representative results are shown (n = 3 biologically independent 
experiments). Scale bar, 10 μm. (b) Representative microscopy images to show the co-
localization of DDX3X with G3BP (SG marker) in 293T under various types of stress. SGs 
were induced by the following conditions: 1 mM sodium arsenite for 1 h, 2 mM H2O2 for 1 
h, 3 mM diethyl maleate for 1 h, 20 μM CCCP in glucose-free culture medium for 1 h, 40 
μM clotrimazole in glucose-free culture medium for 3 h, 20 μg/ml puromycin for 3 h, 10 
μM thapsigargin for 1 h, 10 μM MG132 for 3 h, heat shock at 43°C for 1 h and 0.5 M 
sorbitol for 1 h. Representative results are shown (n = 3 biologically independent 
experiments). Scale bar, 10 μm. 
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Supplementary Figure 11. Molecular determinants of DDX3X-IDR1 phase 
separation (related to Figure 3). 
(a) A Coomassie Brilliant Blue stained SDS-PAGE gel to show the process of DDX3X-
IDR1 purification. The E. coli lysate was incubated with Ni-NTA resin, and bound proteins 
were eluted from the resin (lanes 1 to 3: input, flow through and elution). After digestion 
by SUMO protease, the samples were passed over Ni-NTA resin and the flow through 
was collected (lanes 4 and 5: digestion and product). Representative result is shown (n = 
3 biologically independent samples). (b) Phase separation of DDX3X-IDR1. Droplet 
formation of 100 μM protein (BSA or DDX3X-IDR1) in 20 mM Tris, pH 7.5, 100 mM NaCl, 
2 mM DTT and 10% PEG was tested. Images of formed liquid droplets at the surface of 
coverslip and in chamber were captured by DIC microscopy. Representative results are 
shown (n = 3 independent experiments). Scale bar, 10 μm. (c) Salt and molecular crowder 
effect on LLPS of DDX3X-IDR1. Turbidity (OD600) of DDX3X-IDR1 in 20 mM Tris, pH 
7.5, 2 mM DTT (mean ± SD, n = 3 independent experiments) at indicated NaCl and PEG 
concentrations was measured (top). Images of liquid droplets in each condition were 
captured by DIC microscopy (bottom; Scale bar, 10 μm). (d) Temperature-dependent 
dissolution and condensation of DDX3X-IDR1 droplets. DDX3X-IDR1 (150 μM, spiked 
with Alexa Fluor 488 - labelled IDR1 at a molar ratio of 100:1) was dissolved in 20 mM 
Tris, pH 7.5, 150 mM NaCl, 2 mM DTT. The sample temperature was increased from 5°C 
to 30°C and decreased to 5°C, leading to dissolution and condensation of droplets. 
Quantification of average number of droplets formed in the images is shown (mean ± SE, 
n = 6 independent experiments). See also Supplementary Movie 2. (e) Multiple 
acetylation sites in DDX3X-IDR1 following in vitro reaction with CBP. DDX3X-IDR1 was 
incubated with CBP and acetyl-CoA for overnight at 37 °C. After protein precipitation with 
TCA/Acetone, samples were cleaved with Asp-N, trypsin and chymotrypsin, and the 
extracted peptides were analyzed by HPLC. The results were validated with the program 
Scaffold and Scaffold PTM. (f) A Coomassie Brilliant Blue stained SDS-PAGE gel 
showing the purified WT and mutants of DDX3X-IDR1. Representative result is shown (n 
= 3 biologically independent samples). 
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Supplementary Figure 12. Positional effects of lysine acetylation in DDX3X-IDR1 on 
LLPS (related to Figure 3). 
(a) A Coomassie Brilliant Blue stained SDS-PAGE gel showing the purified WT and 
mutants of DDX3X-IDR1 (red arrowhead). Representative result is shown (n = 3 
biologically independent samples). (b) Liquid droplets of WT, a series of individual K to 
Q, and allQ mutants of IDR1 captured by DIC microscopy. Each protein was in 20 mM 
Tris, pH 7.5, 200 mM NaCl, 2 mM DTT and 10% PEG. Representative results are shown 
(n = 3 independent experiments). Scale bar, 10 μm. 
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Supplementary Figure 13. Acetylation of IDR1 impairs LLPS of full-length DDX3X 
(related to Figure 3). 
(a) A Coomassie Brilliant Blue stained SDS-PAGE gel showing the purified WT and 
mutants of DDX3X. Representative result is shown (n = 3 biologically independent 
samples). (b) Quantification of cytosolic DDX3X concentration. DDX3X in cytosolic 
fraction of WT MEF cells was quantified by immunoblotting, using purified full-length 
DDX3X as a standard. Cytosolic fraction and purified protein were equally diluted, and 
identical volume of samples were loaded: representative immunoblot image (top) and 
standard curve (bottom). DDX3X signal in immunoblot was quantified and plotted (mean 
± SD, n = 3 biologically independent samples), and standard curve was obtained by linear 
regression. An uncropped gel image can be found in Supplementary Fig. 27q. (c) Lysine 
to glutamine (acetyl-lysine mimic) substitution impairs LLPS of full-length DDX3X. 
Turbidity (OD600) of WT, K118Q, K118R and allQ mutants of full-length DDX3X in 20 
mM Tris, pH 7.5, 200 mM NaCl, 2 mM DTT and 10% PEG (mean ± SD, n = 3 independent 
experiments) was measured. (d) Recovery of LLPS by HDAC6-mediated deacetylation. 
Turbidity (OD600) of full-length DDX3X was measured after the reaction with CBP or CBP 
+ HDAC6 (mean ± SD, n = 3 independent experiments).  
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Supplementary Figure 14. LLPS of cortactin IDR repeat is impaired by acetylation 
(related to Figure 3). 
(a) Sequence of the cortactin repeat IDR (a.a. 84-330, mouse). Seven HDAC6 target 
GGK motifs are written in Italic and lysines within those motifs are in red. These lysines 
were replaced with glutamines to generate the acetyl-lysine mimic protein (7KQ). (b) A 
Coomassie Brilliant Blue stained SDS-PAGE gel showing the purified cortactin repeat 
(WT and 7KQ mutants, red arrowhead). Representative result is shown (n = 3 biologically 
independent samples). (c) Left: lysine to glutamine substitution impairs LLPS of cortactin 
repeat. Turbidity (OD600) of WT and 7KQ mutants of cortactin repeat in 20 mM Tris, pH 
7.5, 125 mM NaCl, 2 mM DTT and 10% PEG (mean ± SD, n = 3 independent 
experiments) was measured. Right: phase separation of 25 μM cortactin repeat solutions 
(top) and liquid droplets captured by DIC microscopy (bottom; Scale bar, 10 μm); samples 
from b. 
-106-
Supplementary Fig. 15
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Supplementary Figure 15. Dynamic behavior of mCherry-DDX3X SGs during fusion 
events is consistent with LLPS (related to Figure 4). 
Shape of mCherry-DDX3X SGs before and after fusion process. Roundness, (4*(area)) / 
(π*(major axis)2), of three granules was measured from 36.5 min to 40.5 min (time after 
0.5 mM arsenite treatment, selected continuous 9 frames in Supplementary Movie 3). 
Two granules indicated by yellow and blue arrows started to fuse at 37.5 min, resulting in 
a new granule indicated by a green arrow. Representative result is shown (n = 3 
biologically independent experiments). Scale bar, 10 μm for cell images and 4.0 μm for 
granule images. 
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Supplementary Fig. 16
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Supplementary Figure 16. Establishment of DDX3X KO MEFs (related to Figure 4).  
(a) The top sequence (WT) shows the genomic sequence of the mouse DDX3X locus 
around the ATG translation initiation site (black and bold) as well as the PAM site that 
was selected (red) for the CRISPR/Cas9 targeting. Immediately below the nucleotide 
sequence, the DDX3X protein coding sequence is indicated. The two sequences below 
(MT1, MT2) depict the nucleotide sequence of the alleles identified in the KO cells.  (b) 
Absence of DDX3X protein in DDX3X KO MEFs. The expression level of DDX3X was 
analyzed by immunoblotting in WT and DDX3X KO MEF lysates. Representative results 
are shown (n = 3 biologically independent samples). Uncropped gel images can be found 
in Supplementary Fig. 27r. (c) Immunofluorescence microscopy analysis for the 
localization of endogenous DDX3X protein in WT or DDX3X KO MEFs. Representative 
results are shown (n = 3 biologically independent experiments). Scale bar, 10 μm. 
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Supplementary Figure 17. DDX3X KO leads to decreased SG size under specific 
stress conditions (related to Figure 4).  
(a) Representative microscopy images of SGs under various types of stresses. SGs were 
induced by the following conditions: 1 mM sodium arsenite for 1 h, 2 mM H2O2 for 1 h, 3 
mM diethyl maleate for 1h, 20 μM CCCP in glucose-free culture medium for 1 h, 40 μM 
clotrimazole in glucose-free culture medium for 3 h, 20 μg/ml puromycin for 3 h, 10 μM 
thapsigargin for 1 h, 10 μM MG132 for 3 h, heat shock at 43°C for 1 h and 0.5 M sorbitol 
for 1 h. Localization of endogenous DDX3X and G3BP in WT and DDX3X KO MEFs was 
assessed by immunofluorescence microscopy. Representative results are shown (n = 3 
biologically independent experiments). Scale bar, 10 μm. (b) Quantification of total G3BP 
foci area per cell (n = 50 cells in total, from biologically independent experiments) from a, 
and displayed in violin plot; the thin line at the center represents the 95% confidence 
interval, and the bottom and top of the box represent the 25th and 75th percentile of the 
data, with the median value represented by a horizontal bold line. On each side of the 
thin line is a kernel density estimation showing the distribution shape of the data points 
from minima to maxima. P values were determined by Student’s two-tailed t-test; (*) P < 
0.05, (**) P < 0.01, (***) P < 0.001 and (****) P < 0.0001. (c) G3BP expression and 
phosphorylation of eIF2α in DDX3X KO MEFs. Cell extracts from WT (W) and DDX3X 
KO (K) MEFs under each stress were analyzed by immunoblotting with each indicated 
antibody. Representative results are shown (n = 3 biologically independent samples). 
Uncropped gel images can be found in Supplementary Fig. 27s. (d) Quantification of 
G3BP signal and P-eIF2α signal in c. Mean and SD values are presented (n = 3 
biologically independent samples). P values were determined by Student’s two-tailed t-
test; P > 0.05.  
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Supplementary Figure 18. Contribution of DDX3X-IDR1 to SG formation (related to 
Figure 4) 
(a) Schematic representation of the DDX3X deletion mutants analyzed. (b) Transient 
expression of DDX3X WT and its different deletion mutants in HeLa cells. The expression 
level of exogenous FLAG-DDX3X was analyzed by immunoblotting. Representative 
results are shown (n = 3 biologically independent samples). An uncropped gel image can 
be found in Supplementary Fig. 27t. (c) Localization of DDX3X WT and its domains 
deletion mutants transiently expressed in HeLa cells. Cells were treated with 1 mM 
arsenite for 30 min, localization of FLAG-DDX3X and endogenous G3BP was assessed 
by immunofluorescence microscopy. Representative results are shown (n = 3 biologically 
independent experiments). Scale bar, 10 μm. (d) Effect of DDX3X re-expression on G3BP 
foci area. DDX3X full-length or del-IDR2 mutant were transiently expressed in DDX3X 
KO MEFs. Cells were treated with 1 mM arsenite for 1 h, and total G3BP foci area per 
cell (n = 50 cells in total, from biologically independent experiments) was quantified and 
displayed in violin plot; the thin line at the center represents the 95% confidence interval, 
and the bottom and top of the box represent the 25th and 75th percentile of the data, with 
the median value represented by a horizontal bold line. On each side of the thin line is a 
kernel density estimation showing the distribution shape of the data points from minima 
to maxima. P values were determined by Student’s two-tailed t-test; (*) P < 0.05, (**) P < 
0.01 and (***) P < 0.001. 
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Supplementary Fig. 19
 P value (vs WT) Halftime (s) Mobile Fraction 
allQ 3.47X10-36 (****) 3.087 0.8290 
K118Q 0.007 (**) 5.258 0.7740 
WT - 7.324 0.7596 
K118R 0.043 (*) 8.682 0.7487 
allR 0.00001 (****) 10.61 0.7329 
 
Supplementary Figure 19. Halftime and mobile fraction of mCherry-DDX3X 
measured by FRAP (related to Figure 4). 
Quantification of fluorescence recovery after photobleaching (FRAP) of mCherry-DDX3X 
SGs. Halftime (seconds) and mobile fraction in Fig. 4c; P values were determined by one-
way ANOVA; (*) P < 0.05, (**) P < 0.01, (***) P < 0.001 and (****) P < 0.0001. 
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Supplementary Fig. 20
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Supplementary Figure 20. Establishment of DDX3X rescuant cell lines and 
localization of Ac-DDX3X (related to Figure 5). 
(a) Stable expression of DDX3X WT, K118Q/R mutants and allQ/R mutants (all lysines in 
IDR1 mutated to glutamine or arginine) in DDX3X KO MEFs. The expression level of 
endogenous DDX3X and exogenous FLAG-DDX3X was analyzed by immunoblotting with 
DDX3X antibody; black arrowhead indicates endogenous DDX3X while red one indicates 
FLAG-DDX3X. Representative results are shown (n = 3 biologically independent 
samples). Uncropped gel images can be found in Supplementary Fig. 27u. (b) 
Localization of Ac-DDX3X in DDX3X WT and allR rescuants. Cells were treated with 1 
mM arsenite for 30 min, localization of FLAG-DDX3X and its K118-acetylated form were 
assessed by immunofluorescence microscopy. Red arrows indicate granules containing 
Ac-DDX3X. Representative results are shown (n = 3 biologically independent 
experiments). Scale bar, 10 μm. 
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Supplementary Fig. 21
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Supplementary Figure 21. Decreased total volume of SGs upon CBP 
overexpression (related to Figure 5).  
Left: immunofluorescence microscopy of SGs in WT MEF cells that had been transiently 
transfected with empty vector (control) or CBP in order to enhance DDX3X-IDR1 
acetylation. Scale bar, 10 μm. Right panel: quantification of the number of SGs per cell 
(n = 50 cells in total, from biologically independent experiments) displayed in violin plot; 
the thin line at the center represents the 95% confidence interval, and the bottom and top 
of the box represent the 25th and 75th percentile of the data, with the median value 
represented by a horizontal bold line. On each side of the thin line is a kernel density 
estimation showing the distribution shape of the data points from minima to maxima. P 
values were determined by Student’s two-tailed t-test; (**) P < 0.01.  
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Supplementary Fig. 22
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Supplementary Figure 22. Summary of DDX3X-dependence of SG formation and 
acetylation status of DDX3X under tested stresses (related to Figure 5). 
DDX3X-dependence of SG formation is shown in Supplementary Fig. 17, while DDX3X-
IDR1 acetylation by stress is shown in Fig. 2c and d. 
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Supplementary Figure 23. Effects of CBP knockdown on DDX3X SG formation 
(related to Figure 5). 
(a) Knockdown of CBP with siRNA. Left: Each DDX3X rescuant cell line (DDX3X KO 
MEFs stably expressing FLAG-DDX3X WT or mutants) was transfected with siRNA 
targeting CBP (or non-targeting “siNT” as a control) by nucleofection. CBP depletion was 
confirmed after 24 h of siRNA treatment as shown by immunoblotting analysis with 
specific antibodies. Right: Quantification of CBP signal. Each signal of siCBP-treated 
sample was normalized by that of siNT-treated sample (mean ± SD, n = 3 biologically 
independent samples). Uncropped gel images can be found in Supplementary Fig. 27v. 
(b) DDX3X SG volume after CBP knockdown. After 24 h of siRNA treatment, each DDX3X 
rescuant cell lines were treated with 1 mM arsenite for 1 h, and localization of DDX3X 
was assessed by immunofluorescence microscopy. Total volume of DDX3X SG per cell 
(n = 50 cells in total, from biologically independent experiments) was quantified and 
displayed in violin plot; the thin line at the center represents the 95% confidence interval, 
and the bottom and top of the box represent the 25th and 75th percentile of the data, with 
the median value represented by a horizontal bold line. On each side of the thin line is a 
kernel density estimation showing the distribution shape of the data points from minima 
to maxima. P values were determined by Student’s two-tailed t-test; (*) P < 0.05. 
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Supplementary Fig. 24 
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Supplementary Figure 24. Schematic representation of the observations in this 
study (related to Figure 5). 
DDX3X N-terminal IDR (IDR1) forms liquid droplets through LLPS, and is efficiently 
precipitated in vitro by b-isox, which selectively promotes the aggregation of IDR-
containing proteins. Acetylation of the IDR1 impairs its liquid droplet formation and 
changes the b-isox aggregation propensity in vitro. In cells, elevated acetylation of 
DDX3X due to HDAC6 inhibition or CBP overexpression leads to small total volume of 
SGs, while unacetylated DDX3X forms large volume of SGs. 
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Supplementary Fig. 25_1
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Supplementary Fig. 25_2
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Supplementary Figure 25. Interactome analysis of DDX3X WT and acetyl-
mimic/dead mutants (related to Figure 6). 
(a) Interactomes of each DDX3X WT and acetyl-mimic/dead mutant. Each FLAG-DDX3X 
construct was expressed in 293T cells, immunoprecipitated with FLAG (M2) antibody, 
and their interactors were analyzed by LC-MS/MS. 293T without expression of FLAG-
DDX3X was used as control. Statistical analysis was done in Perseus (version: 1.5.2.6) 
based on biologically independent samples (n = 3), and potential interactors were 
determined using Student’s two-tailed t-test and visualized by a volcano plot. Red 
dashed-lines correspond to a given FDR and S0 (FDR = 0.03, S0 = 1.5). Defined 
interactors were annotated with published SG proteome data 37,40. The interactors with 
low number of unique peptides (= 1) or score (< 10) were not annotated in this process. 
See also Supplementary Datasheet 2. (b) Comparison of the DDX3X WT interactome 
with those of acetyl-mimic/dead mutants (n = 3 biologically independent samples). 
Different interactors were determined using Student’s two-tailed t-test and visualized by 
a volcano plot. Red dashed-lines correspond to a given FDR and S0 (FDR = 0.03, S0 = 
1.5). 
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Supplementary Fig. 26
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Supplementary Figure 26. Time-dependent growth of mCherry-DDX3X SGs (related 
to Figure 6). 
(a) The time point at which cells were treated with arsenite was set as t = 0, and the 
initiation time of SGs (T) was defined as the time point at which SGs were observed for 
the first time. The obtained total SG area was regressed on Avrami equation and two 
parameters AF and k were estimated from this fit. The initial area A0 was measured at t = 
0 for each cell, and the scaling ratio r (= AF / A0) was obtained. The best estimate (mean) 
and associated error (SD) for k and r were calculated from the fit (n = 5 cells for each 
construct). P values were determined by Student’s two-tailed t-test; (*) P < 0.05, (**) P < 
0.01 and (***) P < 0.001. (b) WT MEFs transiently expressing mCherry-DDX3X WT, 
K118Q or allQ mutant were treated with 0.5 mM arsenite, and time-lapse images were 
captured. Total area of SGs within a single cell was measured with ImageJ software, and 
plotted (n = 5 cells for each construct) after the time point at which cells were treated with 
arsenite (t = 0). (c) Quantification of initial cell area A0, showing that there is no significant 
difference between the samples. Mean and SD values are presented (n = 5 cells for each 
construct). P values were determined by Student’s two-tailed t-test; P > 0.05. 
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Supplementary Fig. 27_1
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Supplementary Fig. 27_3
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Supplementary Fig. 27_4
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Supplementary Fig. 27_5
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Supplementary Figure 27. Original full images of immunoblots. 
Boxes indicate cropped images used in the figures. It is important to note that reprobing 
was avoided for these experiments in order to accurately detect and quantify the 
acetylation status of DDX3X (a, b, i, j and k) and CBP (f); immunoprecipitated materials 
were carefully divided and separately loaded on two gels, followed by immunoblotting 
with the antibodies for target proteins and their acetylated forms (AcK or Ac-CBP 
(K1535)). Membranes with transferred proteins were cut into several pieces based on the 
position of molecular-weight size markers, so that several target proteins including 
loading control could be probed simultaneously (i.e. without exposing the membrane to 
different antibodies several times). Immunoblotting was repeated with biologically 
independent samples (n = 3), and representative results are shown for each experiment. 
(a) Fig. 1d. (b) Fig. 1e. (c) Fig. 1f. (d) Fig. 2a. (e) Fig. 2c. (f) Fig. 2e. (g) Fig. 3e. (h) Fig. 
4a. (i) Supplementary Fig. 5a. (j) Supplementary Fig. 5b. (k) Supplementary Fig. 5c. 
(l) Supplementary Fig. 7a. (m) Supplementary Fig. 8b. (n) Supplementary Fig. 8c. 
(o) Supplementary Fig. 8d. (p) Supplementary Fig. 9a. (q) Supplementary Fig. 13b. 
(r) Supplementary Fig. 16b. (s) Supplementary Fig. 17c. (t) Supplementary Fig. 18b. 
(u) Supplementary Fig. 20a. (v) Supplementary Fig. 23a. 
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Supplementary Notes 
 
Supplementary Datasheet 1: Total DDX3X SG volume (related to Figure 5). 
Summary of total DDX3X SG volume under different conditions tested in this study (n = 
50 cells in total, from biologically independent experiments). 
 
Supplementary Datasheet 2: DDX3X-interactome (related to Figure 6). 
Interactomes of each DDX3X WT and acetyl-mimic/dead mutant. Statistical analysis was 
done in Perseus (version: 1.5.2.6) based on biologically independent samples (n = 3), 
and potential interactors were determined using Student’s two-tailed t-test (FDR = 0.03, 
S0 = 1.5). Defined interactors were annotated with published SG proteome data 37,40. The 
interactors with low number of unique peptides (= 1) or score (< 10) were not annotated 
in this process. See also Supplementary Fig. 25. 
 
Supplementary Datasheet 3: Raw data used for mathematical modelling of SG 
growth (related to Figure 6). 
WT MEFs transiently expressing mCherry-DDX3X WT, K118Q or allQ mutant were 
treated with 0.5 mM arsenite, and time-lapse images were captured. Total area of SGs 
within a single cell was measured with ImageJ software (arsenite addition was at t = 0). 
The initiation time of SGs (T) was defined as the time point at which SGs where observed 
for the first time. The obtained total SG area was regressed on Avrami equation and two 
parameters AF and k were estimated from this fit. The initial area A0 was measured at t = 
0 for each cell, and the scaling ratio r (= AF / A0) was obtained. The best estimate (mean) 
and associated error (SD) for k and r were calculated from the fit (n = 5 cells for each 
construct). See also Fig. 6a and Supplementary Fig. 26. 
 
Supplementary Movie 1. Fusion behavior of DDX3X-IDR1 droplet (related to Figure 
3). 
DDX3X-IDR1 (250 μM, spiked with Alexa Fluor 488 - labelled IDR1 at a molar ratio of 
100:1) in 20 mM Tris, pH 7.5, 62.5 mM NaCl, 2 mM DTT forms droplets at R.T. Time-
lapse images at the bottom of sample chamber were captured by spinning-disk confocal 
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microscopy (Frame interval: 1 sec) over 300 frames and edited as a movie (30 fps). 
Representative result is shown (n = 5 independent experiments). Scale bar, 10 μm. 
 
Supplementary Movie 2. DDX3X-IDR1 droplet disappearance by LLPS following a 
temperature increase (related to Figure 3). 
DDX3X-IDR1 (150 μM, spiked with Alexa Fluor 488 - labelled IDR1 at a molar ratio of 
100:1) was dissolved in 20 mM Tris, pH 7.5, 150 mM NaCl, 2 mM DTT. The sample 
temperature was increased from 5°C to 30°C and decreased to 5°C, leading to dissolution 
and condensation of droplets. During this, time-lapse images were captured by spinning-
disk confocal microscopy (Frame interval: 10 sec) over 41 frames and edited as a movie 
(5 fps). Representative result is shown (n = 6 independent experiments). Scale bar, 10 
μm. Quantification of droplet number related to this movie is in Supplementary Fig. 11d. 
 
Supplementary Movie 3. Liquid-like properties of mCherry-DDX3X SGs (related to 
Figure 4). 
WT MEFs transiently expressing mCherry-DDX3X were treated with 0.5 mM arsenite, 
and time-lapse images were captured by spinning-disk confocal microscopy (13 z-stack 
for each frame, frame interval: 30 sec) over 120 frames and edited as a movie (10 fps). 
Representative result is shown (n = 5 biologically independent experiments). Scale bar, 
10 μm. 
 
Supplementary Movie 4. SG formation of WT DDX3X and its mutants (related to 
Figure 6). 
WT MEFs transiently expressing each mCherry-DDX3X WT, K118Q and allQ mutant 
were treated with 0.5 mM arsenite, and time-lapse images were captured by spinning-
disk confocal microscopy (13 z-stack for each frame, frame interval: 30 sec) over 120 
frames and edited as a movie (10 fps). Representative results are shown (n = 5 cells for 
each construct). Left: WT, middle: K118Q and right: allQ. Scale bar: 10 μm. 
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58 Szklarczyk, D. et al. The STRING database in 2017: quality-controlled protein-protein 
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 2.2 Structural insights into HDAC6 tubulin deacetylation and its selective 
inhibition 
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Acetylation on lysine residues of histone and other proteins has been recognized as a major post-translational modifica-tion that affects multiple aspects of protein function. Protein 
acetylation levels are regulated by the balance of enzymes with 
opposing activities: histone acetyltransferases (HATs) and HDACs1. 
HDAC6 is the major deacetylase for tubulin, and it also deacetylates 
proteins such as HSP90 and cortactin, among others2–4. It is mostly 
cytoplasmic with unique characteristics that set it apart from other 
deacetylases: tandem catalytic domains with the capacity to deacety-
late tubulin and the presence of a zinc finger domain with homology 
to ubiquitin-specific proteases (ZnF-UBP), which binds unanchored 
ubiquitin. HDAC6 is a central modulator of stress responses and 
autophagic clearance, essential for the formation of aggresomes 
or stress granules5–7. It also has an important role for regulatory 
T cells8, influenza virus infection9 and in pathological conditions 
such as cancer, inflammation and neurodegeneration10,11.
Microtubules (MTs) are assembled from α- and β-tubulin het-
erodimers to form dynamic cytoplasmic filaments, involved in 
multiple cellular functions comprising cell cycle, cell shape, cellu-
lar motility and intracellular transport of cargos such as vesicles or 
viruses12. MTs are heavily decorated by post-translational modifi-
cations including acetylation, glutamylation, tyrosination or phos-
phorylation, which have been proposed to regulate their properties, 
stability and functions13,14. α-TAT is the only acetyltransferase tar-
geting Lys40, a residue located in a flexible loop of α-tubulin in 
the luminal side of MTs15,16. α-TAT prefers MTs over α/β-tubulin 
heterodimers for the efficient acetylation of α-tubulin Lys40 
(refs. 17,18), and stochastic acetylation of MTs by α-TAT had been 
recently demonstrated19. Deacetylation of tubulin is promoted by 
HDAC6 (refs. 2,20) and by the NAD-dependent class III deacety-
lase SIRT2 (ref. 21). HDAC6 and SIRT2 interact and may function 
together21,22. However, alteration of HDAC6 levels is sufficient to 
increase tubulin acetylation, and fibroblasts lacking HDAC6 have 
fully acetylated tubulin23. HDAC6 also interacts with plus-end 
tip-binding proteins such as EB1 or Arp1 (ref. 24), indicating 
that it might deacetylate the end of microtubules. It is not firmly 
established which is the preferred substrate of HDAC6, α/β-tubulin 
dimers or polymeric MTs2,25. It has recently been reported that inter-
action between HDAC6 and tubulin is direct26 but also that septins 
facilitate interaction between HDAC6 and acetylated α-tubulin27.
HDACs comprise 11 family members and are considered prom-
ising targets in a number of pathologies, with cancer being the most 
advanced indication28. In most cases however, the critical HDAC(s) 
have not been conclusively identified, and the four inhibitors (vor-
inostat, romidepsin, belinostat and panobinostat) approved for 
cancer treatment until now all target multiple HDACs29. HDAC6 
is currently evaluated as a potential therapeutic target in particu-
lar in multiple myeloma. HDAC6-selective inhibitors have been 
developed and clinical trials are underway with a recent HDAC6-
selective inhibitor, ricolinostat (ACY-1215)30.
We solved the crystal structure of both catalytic domains of 
HDAC6, which together with the inter-domain linker form an ellip-
soid-shaped complex with pseudo-twofold symmetry. We structur-
ally and functionally defined features that are critical for HDAC6 
to deacetylate its physiologic substrate tubulin, and we showed that 
HDAC6 prefers tubulin dimers as substrate but that it can stochasti-
cally deacetylate MTs. We also determined the crystal structures of 
individual catalytic domains bound to either enantiomer of TSA or 
to the HDAC6-specific inhibitor nexturastat A (NextA), and found 
that (S)-TSA had moderate selectivity for HDAC6.
RESULTS
Organization of the HDAC6 tandem catalytic domains
To understand how HDAC6 deacetylates tubulin and other substrates 
we characterized this multidomain protein by X-ray crystallogra-
phy. As we did not obtain crystals with the mouse protein, we used 
the zebrafish ortholog, which efficiently deacetylates tubulin from 
various sources (Supplementary Results, Supplementary Fig. 1). 
To facilitate the comparison between zebrafish and other species, 
we aligned sequences of HDAC6 proteins (Supplementary Fig. 2). 
We first used proteins containing the tandem catalytic domains to 
characterize their activity in an HDAC assay using Fluor de Lys as 
1Friedrich miescher Institute for biomedical research (FmI), basel, Switzerland. 2Department of Chemistry & biochemistry, University of Notre Dame, 
Notre Dame, Indiana, USA. 3Faculty of Sciences, University of basel, basel, Switzerland. 4these authors contributed equally to this work.  
*e-mail: patrick.matthias@fmi.ch
structural insights into hdac6 tubulin 
deacetylation and its selective inhibition
yasuyuki miyake1,4, Jeremy J Keusch1,4, longlong Wang1, makoto saito1, daniel hess1,  
Xiaoning Wang2, bruce J melancon2, paul helquist2, heinz gut1 & patrick matthias1,3*
We report crystal structures of zebrafish histone deacetylase 6 (HDAC6) catalytic domains in tandem or as single domains in 
complex with the (R) and (S) enantiomers of trichostatin A (TSA) or with the HDAC6-specific inhibitor nexturastat A. The tan-
dem domains formed, together with the inter-domain linker, an ellipsoid-shaped complex with pseudo-twofold symmetry. We 
identified important active site differences between both catalytic domains and revealed the binding mode of HDAC6 selective 
inhibitors. HDAC inhibition assays with (R)- and (S)-TSA showed that (R)-TSA was a broad-range inhibitor, whereas (S)-TSA 
had moderate selectivity for HDAC6. We identified a uniquely positioned a-helix and a flexible tryptophan residue in the loop 
joining a-helices H20 to H21 as critical for deacetylation of the physiologic substrate tubulin. Using single-molecule measure-
ments and biochemical assays we demonstrated that HDAC6 catalytic domain 2 deacetylated a-tubulin lysine 40 in the lumen 
of microtubules, but that its preferred substrate was unpolymerized tubulin. 
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substrate. We compared wild-type catalytic 
domains 1 and 2 (CD1-CD2) to proteins with 
an inactivating substitution in either catalytic 
domain (CD1H193A-CD2 or CD1-CD2H574A) or 
in both domains (CD1H193A-CD2H574A)20,31,32. 
SDS-PAGE and size-exclusion chromatogra-
phy with multi-angle light scattering analysis 
showed that the proteins used were highly 
pure and homogeneous (Supplementary 
Fig. 3a,b). Whereas the wild-type CD1-CD2 
fusion was highly active, substitution of the 
first catalytic site (CD1H193A-CD2) had almost 
no impact. In contrast, substitution of the sec-
ond site (CD1-CD2H574A) strongly impaired 
the protein but without fully inactivating it, 
and the doubly substituted variant (CD1H193A-
CD2H574A) was fully inactive (Supplementary 
Fig. 3c). This indicates that the first catalytic 
domain of zebrafish HDAC6 has a weak but 
measurable enzymatic activity (see below). 
When tested in our assay, the full-length 
human HDAC6 protein showed weaker activ-
ity (Supplementary Fig. 3c).
We then determined structures of the 
tandem catalytic domains in complex with 
NextA (CD1-CD2, residues 25−831, 2.9 Å, 
interdomain linker present; and residues 
40−831, 2.0 Å, interdomain linker cleaved), 
CD1 in complex with TSA (CD1-TSA, residues 
40−418, 1.5 Å), CD2-TSA (residues 441−831, 
1.6 Å), as well as of the ZnF-UBP domain (res-
idues 974−1081, 1.9 Å; highly similar to the 
human ortholog33; Fig. 1a and Supplementary 
Fig. 4). Data collection and refinement 
statistics are summarized in Supplementary 
Table 1. In the CD1-CD2 crystal struc-
ture both CD1 and CD2 adopted a classical 
arginase-deacetylase fold34,35 and had a con-
served deacetylase active site ~50 Å apart. 
The two domains were closely attached to each other (Fig. 1b and 
Supplementary Fig. 5). The large domain-domain interface was 
formed by helices H13, H14, H15 and H18 of CD1, and H32, H33 
and H34 of CD2; by loops connecting helices H17 and H18 of CD1, 
and H36 and H37 of CD2; as well as by the linker (418−442) connect-
ing the two domains and by the C-terminal part of CD2 (794−806). 
This resulted in a large buried surface area of ~2,100 Å2 on each 
domain upon formation of the complex. CD1 and CD2 were struc-
turally very similar (r.m.s. deviation = 1.0 Å, 354 Cα atoms, 45% 
sequence identity), and the same structural elements were engaged 
in the domain-domain interface, resulting in a pseudo-twofold axis 
running along the interface perpendicular to the α-helices on both 
sides (Fig. 1b and Supplementary Fig. 5).
We next determined structures of individual CD1 and CD2 
domains in complex with the pan-HDAC inhibitor TSA. The isolated 
CD1 domain contained (R)-TSA in its catalytic center (Fig. 1c), and 
we obtained the structure of CD2-TSA as we were trying to crystal-
lize the tandem domains with TSA: during crystallization, prote-
olysis repeatedly took place and liberated the individual domains, 
yielding crystals of CD2 with (S)-TSA bound (Fig. 1d). Backbones 
of CD1 and CD2 were highly similar also in single domain struc-
tures (r.m.s. deviation = 0.77 Å). Superposition of other HDAC 
structures revealed variations in the N-terminal and C-terminal 
part of the HDAC6 catalytic domains (Supplementary Fig. 6). A 
notable feature is the presence of a uniquely positioned 10-residue 
α-helix, referred to as H6 in CD1 and H25 in CD2, found in each 
catalytic domain near the active sites, as well as a unique loop at 
the N terminal part of each catalytic domain: H1-H2 in CD1 and 
H20-H21 in CD2, containing Trp78 and Asp79 (CD1) and Trp459 
and Asp460 (CD2) (Fig. 1c,d and Supplementary Fig. 2).
CD1 and CD2 catalytic pockets, and TSA binding
Both HDAC6 CD1 and CD2 active sites were highly conserved 
and featured the typical narrow hydrophobic channel formed by 
residues Pro83, Gly201, Phe202 and Trp261 in CD1, and Pro464, 
Gly582, Phe583, Phe643 and Leu712 in CD2 (Fig. 1c,d). The 
Zn2+ ion was coordinated by Asp230, His232 and Asp323 in CD1, 
and Asp612, His614 and Asp705 in CD2. In CD1, the two charge 
relay systems consisted of the His192-Asp228 and His193-Gln235 
dyads, with the latter normally being a His-Asn pair. In contrast, 
CD2 had the classical dyad arrangement with His573-Asp610 
and His574-Asn617. Lastly, Tyr residues located next to the cata-
lytic zinc ion and thought to stabilize the reaction intermediate, 
as in class I enzymes35, were conserved in CD1 (Tyr363) and CD2 
(Tyr745). A noteworthy difference present in all HDAC6 sequences 
when comparing CD1 and CD2 is the use of the bulkier Trp261 
in CD1, instead of the usual phenylalanine (Phe643 in CD2), to 
form one wall of the hydrophobic acetylated lysine binding channel 
(Supplementary Figs. 2 and 7).
(R)- and (S)-TSA binding to CD1 and CD2 were highly similar 
for the hydroxamate moiety that complexes the corresponding Zn2+ 
ion in a bidentate fashion using its carbonyl and hydroxyl oxygens 
(Fig. 1c,d). The unsaturated aliphatic TSA linkers were nearly pla-
nar and sandwiched between the aromatic side chains of Phe202 
H13/14
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H37
H36CD1 CD2 ZnF-UBP
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1,0811
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a b
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dc
Figure 1 | Overall structure of HDAC6 catalytic domains. (a) HDAC6 domain architecture and 
constructs used for structural studies. this color scheme is used throughout all figures. Amino 
acid boundaries of all constructs are indicated; for CD1-CD2, two alternative proteins were made 
starting at position 25 or at position 40. (b) Cartoon representation of the CD1-CD2 crystal 
structure, with CD1 and CD2 in cyan and dark red, respectively, and the interdomain linker in 
green. metal ions are shown as gray spheres and red arrows point to the substrate binding 
clefts. Helices engaged in the CD1-CD2 interface are labeled. (c,d) magnified view into inhibitor 
binding sites of CD1-(R)-tSA (c) and CD2-(S)-tSA (d) structures. residues interacting with tSA 
or involved in catalysis are drawn as sticks in cyan (CD1) and dark red (CD2); catalytic domain 
backbones are shown as light gray cartoons with helices H6 and H25 in light red and pink. (R)- and 
(S)-tSA are shown as orange (CD1) and green (CD2) sticks with sigma-A-weighted 2mFo − DFc 
composite omit electron density maps displayed as blue mesh (1 σ). Zinc ions are shown as gray 
spheres, and polar interactions involved in Zn2+ binding are represented as green dashed lines.
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and Trp261 in CD1, and Phe583 and Phe643 in CD2. Whereas 
the carbonyl group of the hydroxamate was almost coplanar with 
the unsaturated aliphatic chain, the best fit to the electron den-
sity was achieved by kinking the hydroxylamine toward the zinc 
ion by ~30°, somewhat resembling the TSA conformation in the 
HDAC7-TSA complex structure36 (Protein Data Bank: 3C10). 
The TSA dimethylamino-phenyl CAP group used the first part 
of a CD1 groove formed by H6 and loop H1-H2 for hydropho-
bic interaction with Trp78 and Phe202 side 
chains. Owing to crystallization of the (S) 
enantiomer in CD2, we did not see such an 
orientation of the CAP group, and it instead 
interacted with the Phe643 side chain. The 
side chains of Trp78 in CD1 and of the cor-
responding Trp459 in CD2 assumed differ-
ent conformations in their respective grooves 
when engaged in ligand binding (CD1) or 
it was free (CD2), thus pointing to a role in 
substrate recognition (see below). We present 
additional differences between CD1 and CD2 
and their possible role in substrate recogni-
tion in Supplementary Figure 7.
(S)-TSA vs. (R)-TSA inhibition of 
HDAC6 and other HDACs
It had previously been reported that the unnat-
ural (S) enantiomer of TSA is biologically 
inactive37 and does not inhibit partially puri-
fied HDACs from mouse cells38; subsequently 
most studies have used the natural form, 
(R)-TSA. Our observation that HDAC6 CD2 
was bound by (S)-TSA in our crystal struc-
ture was intriguing, and we set out to charac-
terize the activity of (S)-TSA vs. (R)-TSA on 
zebrafish and human HDAC6, as well as on all 
other human HDACs. With pure preparations 
of the two enantiomers39 (Supplementary 
Fig. 8), we found that (R)-TSA and (S)-TSA 
inhibited zebrafish and human HDAC6 simi-
larly (half-maximal inhibitory concentration 
(IC50) for zebrafish was 5.45 nM (R-TSA) and 
9.88 nM (S-TSA), and for human, 4.67 nM (R-TSA) and 11.1 nM 
(S-TSA)). In contrast, when we tested other human HDACs, we 
observed differences between (R)-TSA and (S)-TSA: class I HDACs 
HDAC1−3 and class II HDAC10 were all strongly inhibited by (R)-
TSA but only weakly by (S)-TSA, whereas other HDACs, including 
HDAC6, were inhibited about equally or with only small differ-
ences (Table 1). Thus, although (R)-TSA is a pan-HDAC inhibitor, 
(S)-TSA, the unnatural enantiomer, had in vitro moderate selectiv-
ity for HDAC6 (~20-fold lower IC50 compared to the next closest 
isoform, HDAC1).
To test whether (S)-TSA also has activity in vivo, we treated 
mouse embryonic fibroblasts (MEFs) with (R)-TSA or (S)-TSA, 
or with the HDAC6-specific inhibitor NextA. After treatment 
with inhibitor, we prepared protein lysates and monitored acetyla-
tion of tubulin or histone H3 by immunoblotting (Supplementary 
Fig. 9). (S)-TSA was active in vivo, although weaker than the (R) 
enantiomer. However, acetylation of tubulin increased slightly more 
rapidly than that of histone H3, indicating a moderate selectiv-
ity for HDAC6. As expected, NextA, which in vitro has very high 
selectivity for HDAC6 (600-fold over HDAC1 and >1,000-fold over 
HDAC2; ref. 40), affected acetylation of tubulin without appreciably 
impacting histone H3 acetylation.
Conservation of active site and surrounding residues
We wondered whether active site differences between CD1 and 
CD2 are conserved through evolution, and used ConSurf41 to build 
a multiple-sequence alignment to map site-specific conservation 
scores onto the CD1-CD2 surface (Supplementary Fig. 10a,b and 
Supplementary Dataset 1). This analysis indicated that the CD2 
active site and substrate recognition region were under more evolu-
tionary pressure for conservation than the CD1 site and may point 
to different functions for the two domains, with a more important 
role for CD2 (see below).
Table 1 | inhibitory profile of (R)-TSA and (S)-TSA against 
zebrafish and human HDAC6 as well as against human HDAC1−11
isoform (R)-tsa ic50 (nm) (S)-tsa ic50 (nm)
Zebrafish HDAC6 (CD1-CD2) 5.45 ± 0.62 9.88 ± 1.01
Human HDAC6 4.67 ± 0.06 11.1 ± 0.62
Human HDAC1 5.76 ± 1.05 206.30 ± 15.84
Human HDAC2 17.81 ± 1.08 612.65 ± 116.60
Human HDAC3 8.09 ± 0.28 320.80 ± 27.01
Human HDAC4 9,613 ± 2,329.21 6,341 ± 627.91
Human HDAC5 4,385 ± 1,248.75 6,325 ± 117.38
Human HDAC7 3,499.50 ± 123.74 1,823.50 ± 6.36
Human HDAC8 410.50 ± 43.27 312.20 ± 3.96
Human HDAC9 8,861 ± 60.10 4,824 ± 228.40
Human HDAC10 29.19 ± 0.06 403.35 ± 10.25
Human HDAC11 3,642.50 ± 683.77 2,684.00 ± 398.81
IC50 is the mean of two experiments ± s.d. obtained from curve fitting of 10-point enzyme assays 
with threefold serial dilution. HDAC6 assays started at 2 μm inhibitor; HDAC4, HDAC5 and 
HDAC9 assays started at 450 μm inhibitor; HDAC1, HDAC2, HDAC3, HDAC7, HDAC8, HDAC10 
and HDAC11 assays started at 50 μm inhibitor. values were extracted from fitting dose-response 
curves to the data points using Graphpad software.
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Conservation of domain-domain interface
We used the above information to examine in more detail the CD1-
CD2 interface (Fig. 2a). Several patches of conserved residues took 
part in the interface, and a large area was composed of less con-
served residues. Important hydrophobic binding energy was pro-
vided by CD1 residues Pro306, Pro383, Leu305 and Ile405, and on 
the CD2 side Pro688, Ile783 and the Arg691 guanidinium group 
contributed the most. A key interaction was formed by the side 
chain stacking of His345 and His727, located at the same structural 
position in CD1 and CD2, with the pseudo-twofold axis running 
through the imidazole stacking pair. Neither the linker connect-
ing CD1 and CD2 (418−442), nor loops H17-H18 in CD1 and 
H36-H37 in CD2, all of which contribute to the interface, are highly 
conserved (Supplementary Fig. 2). Nevertheless, a closer look at 
the linker and its interaction with CD1 and CD2 revealed that it 
interacted with conserved residues on both domains (for example, 
Pro383 on CD1; Arg605, Glu692 and Trp794 on CD2) and provided 
a seal between them (Fig. 2b).
Structural features critical for tubulin deacetylation
Because HDAC6 is a major tubulin deacetylase, it is important to 
understand which features endow it with the capacity to deacety-
late this substrate. Calculation of the electrostatic surface potentials 
around each catalytic pocket highlights the mixed hydrophobic 
and polar character and the differences between CD1 and CD2 
(Fig. 2c). This observation suggests the potential for differential 
substrate recognition by these two domains (Fig. 3). We hypoth-
esized that the H1-H2 and H20-H21 loops that contain Trp78 and 
Asp79 in CD1, or Trp459 and Asp460 in CD2, are flexible and con-
tribute to substrate recognition. In addition, we focused on several 
highly conserved amino acids, which are also around, but not in, 
the catalytic pocket, in particular Ser150 in CD1 and Ser531 in 
CD2, which correspond to Asp101 in the H6-H7 loop of HDAC8. 
This residue is critical for substrate or inhibitor binding by HDAC8 
(ref. 42). We analyzed activities of alanine substitutions (loss of 
function) or conserved amino acid substitutions (gain of function) 
variants in vitro (Fig. 3a,b). To determine the activity of the mutants 
against the physiologic substrate α-tubulin, we incubated purified 
HDAC6 proteins with extracts from Hdac6 knockout MEFs, in which 
α-tubulin is fully acetylated23, and measured the resulting level of 
α-tubulin K40 acetylation by immunoblotting. We also assayed the 
enzymatic potential of the variants on the small substrate Fluor de 
Lys. The different point mutations in the sequence encoding CD1 
did not result in compromised deacetylation activity on α-tubulin. 
In contrast, several point mutants in sequences encoding CD2 (the 
W459A,D460A double-substitution variant, or variants with single 
substitutions N530A, N530D or S531A) were all strongly impaired 
for α-tubulin deacetylation (Fig. 3b and Supplementary Figs. 11 
and 12). However, when we tested these variants on the Fluor de Lys 
substrate, their activity was almost intact (Supplementary Fig. 13), 
suggesting that these residues are involved in substrate recognition, 
but not in the catalytic process.
importance of H6 and H25 and of tandem catalytic domains
We considered that the unique H6 and H25 α-helices 
(Supplementary Fig. 6) might be critical for substrate specificity. 
Hence, we substituted them in CD1 or CD2 with the H6-H7 loop 
from HDAC8 (Supplementary Fig. 14). Replacement of CD2 H25 
by loop H6-H7 of HDAC8 (CD1-CD2H25 → 8L) dramatically impaired 
the activity on α-tubulin (Fig. 3c), whereas substitution of CD1 
H6 had almost no detrimental effect (CD1H6 → 8L-CD2). These pro-
teins were similarly active when tested on Fluor de Lys substrate 
(Fig. 3d), indicating that the catalytic potential of HDAC6 was not 
impaired, but rather the capacity to use tubulin as a substrate was 
impaired. This was further demonstrated by in vivo experiments in 
which we stably reintroduced the same variant zebrafish proteins 
into Hdac6 knockout MEFs and monitored tubulin acetylation by 
immunoblotting. The results of these experiments were identical 
to the in vitro results, and confirmed the critical role of CD2 H25 
(Supplementary Fig. 15).
We next interrogated the overall contribution of each catalytic 
domain for tubulin deacetylation, using the same assay as above. 
Inactivating CD1 (CD1H193A-CD2) had no impact, whereas inac-
tivating CD2 (CD1-CD2H574A) abolished tubulin deacetylation 
(Supplementary Fig. 16a). Furthermore, isolated CD2 deacetylated 
α-tubulin, but isolated CD1 did not; however, the isolated CD2 was 
about tenfold less active than CD1-CD2, as for human31. Moreover, 
adding increasing amounts of CD1 to a reaction containing a 
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fixed amount of CD2 did not influence tubu-
lin deacetylation (Supplementary Fig. 16b), 
suggesting that under these conditions CD1 
cannot enhance, or inhibit, CD2 activity. 
When tested on a Fluor de Lys substrate, iso-
lated CD1 showed weak but measurable activ-
ity and also enhanced the activity of CD2 when 
the two domains were linked (Supplementary 
Fig. 17a,b). The activity of zebrafish CD1 
largely depends on F202, which in other spe-
cies is a tyrosine (Supplementary Fig. 2); 
conversion of F202 into a tyrosine (CD1F202Y) 
strongly impaired activity (Supplementary 
Fig. 17c). The fact that zebrafish CD1 had 
no activity on α-tubulin but was catalytically 
active on Fluor de Lys suggested that it may 
recognize other substrates.
Stochastic deacetylation of 
microtubules by HDAC6
We next examined how HDAC6 deacety-
lates tubulin or MTs (for their preparation, 
see Online Methods and Supplementary 
Fig. 18a−c). We first tested whether HDAC6 
can act on MTs from the ends, or whether 
like α-TAT it diffuses in MTs and deacety-
lates them stochastically. We reacted MTs 
with the HDAC6 tandem catalytic domains 
using varying enzyme amounts or for various 
durations; then we fixed them and analyzed 
by fluorescence microscopy. Addition of the 
HDAC6 catalytic domains led to deacetylation 
of the MTs over their entire length, in a dose- 
dependent and stochastic manner (Fig. 4a,b). 
We observed no preferential reaction toward 
the ends of MTs, even at the shortest incubation 
duration (Fig. 4c). Thus, in vitro, the α-tubulin 
Lys40 in the lumen of MTs was accessible 
for deacetylation by HDAC6. Next, we compared the capacity of 
HDAC6 to deacetylate tubulin dimers or taxol-stabilized MTs; for 
this, we incubated HDAC6 tandem catalytic domains with radio-
labeled acetylated tubulin or MTs and used the TCA-precipitable 
radioactivity to determine HDAC6 activity. Deacetylation 
was ~2.5× more effective on tubulin heterodimers than on MTs 
(Fig. 4d), and we obtained the same results with a different experi-
mental setup (Supplementary Fig. 19).
Structure of CD1-CD2 in complex with NextA
Although no crystal structure of HDAC6 was available, several 
HDAC6 selective inhibitors have been developed in recent 
years40,43,44. To gain structural insight into HDAC6 selective inhibi-
tion, we determined the structure of the HDAC6 tandem catalytic 
domains in complex with NextA, an inhibitor with high selectiv-
ity for HDAC6 (ref. 40). NextA features a classical hydroxamate 
zinc-binding group (ZBG) with a benzylic linker connected to 
a urea-based cap group consisting of a second benzyl and an 
n-butyl moiety (Supplementary Fig. 20a). NextA bound to CD1 
and CD2 active sites with distinct characteristics when compared to 
our TSA structures, giving insight into selective inhibition (Fig. 5a 
and Supplementary Fig. 20b−d).
Human HDAC6 homology model and NextA selectivity
Using our zebrafish HDAC6 structures we computed CD1 and 
CD2 homology models of the human ortholog to understand selec-
tivity of NextA for human HDAC6. Zebrafish CD1 has two critical 
positions His82 and Phe202, which are Phe105 and Tyr225 in the 
human protein (Supplementary Fig. 21a). As mentioned above, 
mutation of zebrafish Phe202 into tyrosine resulted in a strong 
reduction in activity (Supplementary Fig. 17c). Human CD2 in 
contrast had only two amino acid changes located at the periphery 
of the pharmacophore: zebrafish residues Asn530 and Asn645 are 
Asp567 and Met682 in the human protein, and all residues found to 
interact with (S)-TSA or NextA are fully conserved (Supplementary 
Fig. 21b). This indicates that the structure of zebrafish CD2 and the 
corresponding homology model of the human protein may be valid 
to understand selective NextA inhibition of HDAC6 over other 
HDAC isoforms.
Superposition of all HDAC isoform structures with zebrafish 
HDAC6 CD2 and the corresponding human homology model 
revealed important differences between isoform-specific phar-
macophores influencing inhibitor selectivity (Fig. 5a–c and 
Supplementary Fig. 21c). Owing to the unique position of helix 
H25 and the conformation of the following loop, only HDAC6 had 
a large open basin ~14 Å wide. NextA selectivity for HDAC6 thus 
seems to come from (i) the isoform-specific shape and height of 
the rim between the wide HDAC6 basin and the acetylated lysine 
binding channel where the NextA benzyl cap group docked, and 
(ii) the bulkiness of residues occupying the basin in other isoforms. 
Owing to the rigid nature of NextA and the 90° angle between the 
linker and the urea-benzyl cap, these isoform-specific steric con-
straints will determine how far the short NextA benzylic linker can 
reach into the cavity and whether the ZBG can complex the Zn2+ 
ion favorably. Given these structural features, only HDAC6 pro-
vided sufficient space in this region to allow tight NextA binding, 
a
AcK40 β-tubulin
HDAC6:MT = 20:1HDAC6:MT = 10:1mTAT-treated MTs
dcb
Microtubules
Free tubulin
Relative deacetylase activity
α β
P 
= 
0.
00
01
0 0.2 1.00.4 0.6 0.8
Fully acetylated MTs (–HDAC6) 
HDAC6:AcMTs = 20:1
HDAC6:AcMTs = 10:1
Distance from the end (µm)
Si
gn
al
 in
te
ns
ity
 (A
cK
40
)
(a
rb
itr
ar
y 
un
its
)
0 2 4 6 8 10 12
Si
gn
al
 in
te
ns
ity
 (A
cK
40
)
(a
rb
itr
ar
y 
un
its
)
Distance from the end (µm)
0
5
10
30
60 (min)
Tim
e
0 2 4 6 8 10 12
Figure 4 | HDAC6 prefered tubulin dimers, but deacetylated mTs stochastically. (a) microscopy 
analysis of fully acetylated mts (mtAt-treated; left) and with HDAC6 added at indicated ratios to 
monitor deacetylation (middle and right). Scale bars, 10 μm. magenta staining identifies β-tubulin 
(mts), and green staining corresponds to AcK40 of α-tubulin. (b) Quantification of fluorescence 
relative to that of fully acetylated mts in a for an average of 20 line scans of microtubule ends; 
all scanned mts were longer than 10 μm and initial mts had been fully acetylated by α-tAt. 
Fluorescence intensity of fully acetylated mts is shown by the black line. Fluorescence intensity 
of mts deacetylated by HDAC6 treatment is shown by red (HDAC6:Acmts = 10:1) and blue 
(HDAC6:Acmts = 20:1) lines, respectively. Horizontal lines show respective average fluorescence 
intensity. (c) time course deacetylation experiment on mts, with scans indicating AcK40 signal 
intensity along the mts at indicated time points after HDAC6 addition. Dashed lines indicate 
x axis for each time point. line scans from each time point are staggered vertically for clarity. 
(d) Deacetylation activity on mts vs. free tubulin dimers. Shown are mean values of three 
independent experiments with s.d.; P value is based on a two-tailed Student’s t-test. Deacetylation 
activity on free tubulin dimers was set to 1. 
np
g
© 
20
16
 N
at
ur
e A
m
er
ic
a,
 In
c.
 A
ll 
rig
ht
s 
re
se
rv
ed
.
-147-
nature chemical biology | vol 12 | September 2016 | www.nature.com/naturechemicalbiology 753
articleNATURE CHEmiCAL biOLOgy doi: 10.1038/nchembio.2140
whereas other isoforms restricted binding either with bulky side 
chains occupying the basin or with an elevated rim hindering the 
ZBG from reaching the Zn2+ ion. Similarly, only HDAC6 provided 
the unique position of H25 and conformation of the following loop, 
which, together with residues located in loop H29-H30, seemed to 
provide superior binding energy for (S)-TSA, explaining selectivity 
over other HDAC isoforms (Supplementary Fig. 21d).
DiSCUSSiON
The crystal structure of the HDAC6 tandem catalytic domains 
revealed that the two domains interact over a large surface area, 
and that both catalytic sites point outside and are accessible to 
substrates. The interdomain linker, which varies in length between 
species, was at the outside of the complex and sealed the two catalytic 
domains. Previous mutagenesis studies had shown an important 
role of the linker for optimal activity of HDAC6 (ref. 32). Moreover 
the linker region is essential for interaction between human or 
mouse HDAC6 and dynein motor proteins6,9. Given the position of 
the linker observed in our structure, it is conceivable that it forms 
part of an interface interacting with dynein, possibly together with 
additional residues in the catalytic domains.
The structure of each domain in complex with inhibitors 
revealed features of the catalytic pockets. The binding of (R)-TSA 
and (S)-TSA to CD1 and CD2 was highly similar for the hydrox-
amate moiety, but crystal lattice constraints favored a packing of 
CD2 in complex with (S)-TSA where the CAP group orientation 
differed compared with (R)-TSA binding to CD1. Our observations 
did not indicate a preferential binding of (S)-TSA to CD2, but were 
intriguing, as early reports had suggested that this enantiomer is 
inactive37,38. We found that in vitro both pure (S)-TSA and (R)-TSA 
inhibited similarly HDAC6. In contrast, when tested on all human 
HDACs, the two forms showed distinct inhibitory profiles, and 
(S)-TSA appeared to be a HDAC6-selective inhibitor, with ~20-fold 
selectivity for that isoform. This observation may open up avenues 
for the generation of new HDAC6-specific inhibitors. Furthermore, 
in MEF cells (S)-TSA was active, albeit less than (R)-TSA, and also 
showed moderate selectivity. The reduced activity of (S)-TSA on the 
main class I HDACs may explain why it had 
initially been considered to be biologically 
inactive37,38.
Mutational analysis revealed that helix H25 
and the loop H20-H21 in CD2 were critical for 
deacetylation of Lys40 on α-tubulin, but not 
for the small substrate Fluor de Lys; together 
with Asn530 and Ser531 they form the recog-
nition platform for the α-tubulin loop encom-
passing Lys40.
Early studies showed that deacetylation of 
MTs correlates with their depolymerization 
in vivo45 and in C. elegans mutation of the 
acetyltransferase MEC-17 (the homolog of 
α-TAT) affects MTs integrity46,47. In cultured 
cells and mouse organs tubulin acetylation is 
usually low due to the action of HDAC6 and 
possibly SIRT2 (refs. 20,21,23). Ablation of 
HDAC6 in mice or cells leads to an almost 
complete acetylation of α-tubulin, indicating 
that the balance between HDAC6 and α-TAT 
is critical to maintain physiological levels of 
this modification. Recently molecular and 
structural studies described how α-TAT 
acetylates MTs, in preference over tubulin; 
thereby, the α-TAT enzyme enters the lumen 
of MTs and acetylates them stochastically19. 
When HDAC6 is tested in similar assays it 
can also deacetylate Lys40 in the lumen of MTs, but the preferred 
substrate is unpolymerized tubulin, as also observed in ref. 26.
Although zebrafish HDAC6 showed some differences compared 
to the human enzyme (for example, the activity of CD1 on Fluor de 
Lys substrate) our overall analysis indicated that it is a valid model to 
describe the human enzyme. Our structure of CD1-CD2 in complex 
with the HDAC6-specific inhibitor NextA and homology model-
ing of the human CD2 domain help to understand selective inhibi-
tion of HDAC6. The unique position of H25 and the conformation 
of the following loop provided selectivity for NextA, (S)-TSA and 
likely also other HDAC6-specific inhibitors. The results presented 
here will be useful to better understand the biology of HDAC6 and 
to accelerate drug development. 
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mETHODS
Methods and any associated references are available in the online 
version of the paper.
Accession codes. Atomic coordinates and structure factors have 
been deposited in the Protein Data Bank under accession codes 
5G0G (CD1-TSA), 5G0H (CD2-TSA), 5G0I (CD1-CD2 NextA, 
cleaved linker), 5G0J (CD1-CD2 NextA, linker intact) and 5G0F 
(ZnF-UBP).
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ONLiNE mETHODS
Cloning of HDAC6 constructs. A full-length Danio rerio HDAC6 cDNA clone 
was made by synthesizing the first 495 base pairs (bp) of the coding region 
(GeneArt) and fusing it to the partial cDNA IMAGE clone 7051100 (Source 
BioScience) via In-Fusion cloning (ClonTech). The translated sequence cor-
responds to Uniprot F8W4B7. PCR products were cloned into pOPINF, which 
introduces sequence encoding an N-terminal 6×His tag and a 3C protease 
cleavage site before the sequence encoding HDAC6; in some cases, pOPINM 
vectors containing sequence encoding an N-terminal 6×His tag and a maltose 
binding protein (MBP) tag before the 3C protease cleavage site were used.
Expression and purification of HDAC6 proteins. HDAC6 CD1-CD2 (encom-
passing amino acid residues 25−831, or 40−831) and HDAC6 CD1 (40−418) 
were expressed in Sf9 insect cells using the FlashBAC baculovirus system. 
HDAC6 CD1-CD2 protein was extracted from a baculovirus-infected Sf9 
cell pellet by thoroughly resuspending the cells in ice-cold nickel lysis buffer 
(50 mM Tris, pH 7.5, 200 mM NaCl, 20 mM imidazole, 5% glycerol, 2 mM 
TCEP, 0.2% Tween-20), freshly supplemented with Complete EDTA-free pro-
tease inhibitors (Roche) and Benzonase (Sigma). After 20 min on ice the lysate 
was centrifuged at 30,000g for 30 min at 4 °C. The clarified soluble lysate was 
incubated in batch mode with Ni-NTA IMAC agarose (Qiagen), and then 
transferred into a 10 ml Econo-Pac column (Bio-Rad) for washing with nickel 
wash buffer (50 mM Tris, pH 7.5, 200 mM NaCl, 20 mM imidazole, 5% glyc-
erol, 2 mM TCEP). The target protein was eluted in nickel wash buffer contain-
ing 125 mM imidazole. The imidazole concentration in the eluate was adjusted 
to 20 mM. After an overnight digestion at 4 °C with His-tagged 3C protease, 
the cleaved HDAC6 was further purified over Ni-NTA agarose resin. The 
flow-through and wash fractions containing untagged HDAC6 were pooled, 
concentrated and separated using an AKTA Pure system (GE healthcare) with 
a HiLoad 16/600 Superdex 200 (GE Healthcare) gel filtration column equili-
brated in 20 mM Tris, pH 7.5, 200 mM NaCl, 2 mM TCEP, 0.02% NaN3. In some 
cases, a Sephacryl S-300 16/60 gelfiltration column (GE Healthcare) run on a 
DUO FLOW system (Bio-Rad) was used. Protein fractions were analyzed on a 
4–12% Bis-Tris NuPAGE gel and pure fractions containing HDAC6 CD1-CD2 
were pooled and concentrated to 11 mg/ml. Gels were stained with InstantBlue. 
HDAC6 CD1 protein was purified as described above for the HDAC6 CD1-
CD2 protein, with the following modifications. Two gel-filtration steps were 
performed on S200 in 20 mM Tris, pH 7.5, 200 mM NaCl, 2 mM TCEP, 0.02% 
NaN3. The first gel filtration run was after the initial Ni-NTA affinity step and 
the second gel filtration run was as a final polishing step. HDAC6 CD1 protein 
was concentrated to 10 mg/ml.
HDAC6 ZnF-UBP (974−1081) was expressed in E. coli BL21 (DE3) cells and 
induced with 0.5 mM IPTG at 20 °C for 20 h. E. coli BL21 (DE3) cells express-
ing HDAC6 ZnF-UBP were pelleted, resuspended in lysis buffer (50 mM Tris, 
pH7.5, 500 mM NaCl, 20 mM imidazole, 1 mM TCEP, 0.2% Tween-20) then 
rapidly frozen on dry-ice and stored at −80 °C. The frozen cell suspension was 
thawed at room temperature and supplemented with Complete EDTA-free 
protease inhibitors (Roche) and 3 U/ml Benzonase (Sigma), before passing 
through an Avestin EmulsiFlex-C3 cell disruptor. The clarified soluble lysate 
was incubated with Ni-NTA superflow resin (Qiagen) in batch mode and the 
bound protein was eluted in 50 mM Tris, pH 7.5, 500 mM NaCl, 500 mM 
imidazole. The protein was digested overnight with His-tagged 3C protease 
while dialyzing against 20 mM Tris, pH 7.5, 200 mM NaCl, 20 mM imidazole, 
1 mM TCEP, 0.02% NaN3 at 4 °C. The dialyzed protein was filtered through a 
0.22 μm filter and then purified over Ni-NTA superflow resin. Untagged 
HDAC6 ZnF-UBP protein was collected in the flow-through fraction and con-
centrated before separating on a Superdex 75 HiLoad 16/60 (GE Healthcare) 
gel filtration column equilibrated in 20 mM Tris, pH 7.5, 200 mM NaCl, 2 mM 
TCEP and 0.02% NaN3. Fractions corresponding to the pure HDAC6 ZnF-UBP 
protein were pooled and concentrated to 14 mg/ml.
Crystallization of HDAC6 proteins. Nanoliter crystallization experiments 
were performed with a Phoenix dispensing robot (Art Robbins) using the 
sitting-drop vapor diffusion method at 20 °C. Drops with HDAC6 CD1-CD2 
(40-831) protein at 14 mg/ml and 1.3 mM Nexturastat A (NextA, BioVision), 
an HDAC6-specific inhibitor, crystallized after 5 d in 3.3 M sodium formate. 
The single crystals were harvested after 15 d and cryoprotected in 3.3 M 
sodium formate, 0.1 M Tris, pH 7.5, 17% glycerol, 2 mM NextA and 4% 
DMSO. These crystals contained CD1 joined to CD2 via its internal intact 
linker. Crystallization experiments using HDAC6 CD1-CD2 (25−831) protein 
at 11 mg/ml and 0.66 mM NextA, yielded thick plate crystals after 40 days 
in 23.2% PEG3350, 0.1 M KCl. These crystals contained CD1 associated with 
CD2 although the linker region was proteolytically cleaved. The crystals were 
cryoprotected in mother liquid containing 17% ethylene glycol, 0.6 mM NextA 
and 1.3% DMSO. HDAC6 CD1 at 10 mg/ml was incubated with 1 mM TSA 
(R form, Sigma), a pan-HDAC inhibitor. Crystals did not appear in the absence 
of HDAC inhibitor. Long thick plate crystals appeared after 2 d in 23.2% 
PEG 3350, 0.2 M MgCl2, 0.1 M HEPES, pH 7.0 and Silver Bullet additive A7 
(Hampton Research). The crystals were harvested after 3 weeks and cryopro-
tected in mother liquor containing 20% ethylene glycol, 4 mM TSA (R form, 
Sigma) and 4% DMSO. Crystals containing HDAC6 CD2 were formed from 
crystallization experiments set up with HDAC6 CD1-CD2 at 9 mg/ml with 
0.5 mM TSA (racemic mixture, MBL) in 15% PEG 3350, 0.1 M KCl. Long thick 
plate crystals appeared after 13 days and were harvested two days later and cry-
oprotected in mother liquor containing 25% ethylene glycol and 0.5 mM TSA 
(racemic mixture, MBL) and 1.7% DMSO. Two crystals used for data collection 
were dissolved in H2O and analyzed by SDS-PAGE and mass-spectrometry. 
Crystals contained only the CD2 domain likely resulting from slow proteolysis 
of the CD1-CD2 protein during crystallization. Crystallization experiments 
with HDAC6 ZnF-UBP at 14.4 mg/ml yielded many poor quality crystals soon 
after the trays were dispensed. By slowing down the nucleation process, the 
best crystals appeared after several months in 1 M Li2SO4, 5 mM NiCl2, 0.1 M 
Tris, pH 8.5. Crystals were harvested and cryoprotected in 2 M Li2SO4.
Size-exclusion chromatography with multi-angle light scattering. Purified 
zebrafish HDAC6 proteins were concentrated to 1–5 mg/ml and filtered 
through a 0.1 μM Amicon filter before injection. In all, 38 μl of each pro-
tein was separated on a Superdex 200 10/300 GL gel-filtration column 
(GE Healthcare) equilibrated in 20 mM Tris, pH 7.5, 200 mM NaCl, 1 mM 
TCEP, 0.02% NaN3 at a flow rate of 0.65 ml/min. Light scattering was recorded 
on an in-line miniDAWN TREOS three-angle light scattering detector (Wyatt 
Technology) and protein concentration detected with an in-line Optilab Trex 
refractive index detector. The weight-averaged molecular mass of material 
contained in chromatographic peaks was determined using ASTRA 6 software 
(Wyatt Technology).
Data collection and structure solution. X-ray data collection was carried out at 
the SLS PX-II/III beamlines in Villigen, Switzerland. CD1-TSA and CD2-TSA 
crystals belonged to space group C2221 and P21, respectively, (one chain per 
a.u. in both cases) and diffracted to 1.50 (λ = 0.978 Å) and 1.60 Å (λ = 1.000 Å). 
CD1-CD2 (cleaved linker) in complex with NextA crystallized in space group 
C2 (two chains per a.u.) and crystals diffracted to 2.00 Å (λ = 1.000). CD1-
CD2 crystals with intact interdomain linker and NextA diffracted to 2.88 Å 
(λ = 1.000) and belonged to space group P3221 with one molecule per a.u. 
and a solvent content of ~79%. The ZnF-UBP domain crystallized in space 
group I23 with one molecule per a.u. and crystals diffracted to 1.9 Å resolution 
(λ = 1.000). Diffraction data for all projects was integrated and scaled using the 
XDS program package48, except for the anisotropic P3221 CD1-CD2 (NextA, 
intact linker) diffraction data which was processed with AutoPROC49.
CD1-TSA and CD2-TSA structures were solved by the molecular replace-
ment method with PHASER50 using homology models of respective zebrafish 
(Dr)HDAC6 domains. Phases from molecular replacement solutions were 
calculated and used for automatic model building with BUCCANEER51. 
Structures were then manually completed and further improved by the crys-
tallographic simulated annealing routine followed by individual B-factor 
refinement in PHENIX52. The CD1-TSA structure was finalized by alternating 
rounds of rebuilding in COOT53 and refinement in PHENIX using individual 
anisotropic B-factor refinement as this lowered Rfree by more than 1% com-
pared to isotropic ADP treatment.
The CD2-TSA structure was finalized by several rounds of manual rebuild-
ing in COOT and refinement in BUSTER54 using TLS and individual isotropic 
B-factor methods. Structures of CD1-CD2 (cleaved linker) and CD1-CD2 
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(intact linker) in complex with NextA were solved by molecular replacement 
using high resolution CD1 and CD2 structures as search models. Both CD1-
CD2 structures were finalized by alternating rounds of rebuilding in COOT 
and refinement in BUSTER with and without TLS refinement, respectively. 
Map sharpening implemented in COOT was used to enhance details for mode-
ling the CD1-CD2 (intact linker) structure. The ZnF-UBP structure was solved 
by molecular replacement using PDB entry 3C5K as search model and the 
structure was completed by iterating rounds of manual rebuilding in COOT 
and refinement in BUSTER.
Metal ions were modeled considering crystallization conditions and peak 
heights in anomalous difference Fourier electron density maps. The metal ion 
bound to the CD1 active site in the CD1-CD2 NextA (intact linker) structure 
did not display any significant peak in the anomalous difference Fourier elec-
tron density map and metal ligand distances refined to values > 2.7 Å with 
notable rearrangement of metal position and ligand orientations owing to a 
crystal contact with the Lys57 side chain from a symmetry related molecule 
which is bound in the active site channel. Therefore, Zn2+ binding was very 
unlikely and a K+ ion was modeled at this position instead which refined well 
at 100% occupancy (no mFo − DFc electron density peak at ± 3 σ) matching 
B-factor values of the environment. Contrary, the active site in CD2 of this 
structure (complexed by NextA) displayed a large peak in the anomalous dif-
ference Fourier electron density map (14.9 σ) with much shorter metal ligand 
distances confirming binding of a Zn2+ ion.
Metal sites were validated using the CheckMyMetal server (http://csgid.org/
csgid/metal_sites) and ligand restraints were generated with the Grade web 
server (http://grade.globalphasing.org). Final structures were validated using 
COOT. Ramachandran-plot statistics: CD1-TSA: allowed 99.3%, outliers 0.7%; 
CD2-TSA: allowed 99.4%, outliers 0.6%, CD1-CD2 NextA (cleaved linker): 
allowed 99.7%, outliers 0.3%; CD1-CD2 NextA (intact linker): allowed 99.1%, 
outliers 0.9%; ZnF-UBP: allowed 99.0%, outliers 1.0%. Structural images for 
figures were prepared with PyMOL55.
Homology modeling of human HDAC6 CD1 and CD2 domains. HHPRED56 
was used to generate a large multiple sequence alignment of HDAC6 ortholo-
gous protein sequences. Aligned zebrafish and human HDAC6 sequences 
from this alignment were used as input to the modeler software57 together with 
high-resolution HDAC6 CD1 or CD2 structures from zebrafish as templates. 
TSA inhibitors and Zn2+ ions were included in the modeling calculations, and 
treated as rigid bodies. 100 models for each domain were generated and the 
best model was chosen according to lowest values for the modeler objective 
function and quality of the Ramachandran plot.
Deacetylase assays with HDAC6 knockout MEFs extracts. Microtubule 
deacetylation activity was measured with Hdac6 knockout cell23 extracts fol-
lowed by immunoblotting analysis. Extracts were prepared by lysing cells on ice 
for 30 min with CSK buffer (10 mM PIPES, pH6.8, 300 mM sucrose, 100 mM 
NaCl, 3 mM MgCl2, 1 mM EGTA, 0.1% Triton X-100) containing Complete 
protease inhibitor cocktail (Roche). The soluble supernatant containing most 
of tubulin was collected by centrifugation for 5 min at 13,200 r.p.m. at 4 °C and 
protein concentration was measured by Bradford assay.
30 μg knockout extracts were mixed with different amounts of purified 
HDAC6 catalytic domains, and incubated for 1 h at 37 °C. The reaction 
was stopped by adding SDS sample buffer and proteins were loaded onto 
4–12% NuPAGE gels (Invitrogen), transferred onto polyvinylidene fluo-
ride (PVDF) membranes (Millipore) and detected with specific antibodies 
(anti-AcK40 (BML-SA452-0100, Enzo, 1:3,000) and Mcm7 (47DC141(Ab2360), 
Abcam, 1:3,000).
HDAC activity assays and IC50 determinations of (R)-TSA and (S)-TSA on 
HDAC1−11. Enzymatic characterization (Km determinations, Supplementary 
Fig. 3C) of zebrafish HDAC6 proteins (CD1-CD2; CD1H193A-CD2; CD1-
CD2H574A; CD1H193A- CD2H574A) was done with 50 nM of purified protein and 
increasing amounts of Fluor de Lys substrate, using an HDAC assay kit from 
Enzo biochemicals and following the manufacturer’s instructions. Human 
HDAC6 protein (HsHDAC6 FL) was obtained from Reaction Biology 
Corporation. The fluorescence intensity was detected with a Spectromax 
Gemini plate reader (Molecular Devices). Curve fitting was done using 
GraphPad (GraphPad Software). The values expressed are the average of dupli-
cate independent trials ± s.d.
IC50 of (R)- and (S)-TSA on human HDACs as well as on zebrafish HDAC6 
were determined by Reaction Biology Corporation. Fluorogenic peptide from 
p53 residues 379-382 (RHKK(Ac)AMC) was used for HDAC1, 2, 3, 6 and 
zebrafish HDAC6. Fluorogenic HDAC class IIa substrate (trifluoroacetyl 
Lysine) was used for HDAC4, 5, 7, 9, and 11. Fluorogenic peptide from p53 
residues 379−382 (RHK(Ac)K(Ac)AMC) was used for HDAC8. The assay 
buffer contained Tris-HCL, pH 8.0, 127 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 
1 mg/mL BSA and 1% DMSO. Inhibitors were diluted in DMSO, preincubated 
with the enzyme for 10 min, after which substrate was added and the reaction 
allowed to proceed for 2 h at 30 °C. The reaction was terminated by addition of 
TSA and developer. Dose-response curves were generated by serial threefold 
dilution of compound to generate 10-dose plots; curve-fitting was done with 
GraphPad. IC50 values were derived from the plots and the values are expressed 
as the average of duplicate determinations ± s.d.
Cellular assays with (R)-TSA and (S)-TSA. MEFs were treated with the dif-
ferent inhibitors ((R)-TSA, (S)-TSA, TSA (Sigma) and NextA) for 12 h. The 
cells were washed with PBS and lysed in RIPA buffer (50 mM Tris–HCl, pH8.0, 
500 mM sodium chloride, 1 mM EDTA, 1.0% NP-40, 0.5% sodium deoxycho-
late, 0.1% SDS and Complete EDTA-free protease inhibitors (Roche)). After 
removal of the insoluble fraction by centrifugation, 20-30 μg protein extract 
was boiled for 10 min in LDS sample buffer (Invitrogen), and separated 
on 4–12% NuPAGE gels (Invitrogen). Proteins were transferred onto PVDF 
membranes (Immobilon-P, Millipore), probed overnight with specific primary 
antibodies (α-tubulin: DM1A, Sigma T9026, 1:2,500), ((K(Ac)40)-alpha-
tubulin: BML-SA452-0100, Enzo, 1:5,000), (histone H3: Abcam1791, 1:4,000), 
(acetyl-histone H3: Millipore 06-599, 1:4,000), followed by secondary antibod-
ies in 5% non-fat dry milk in TBS blocking buffer. Detection was done with 
Amersham ECL western blotting reagent (GE Healthcare).
(R)- and (S)-TSA synthesis and purification. Racemic TSA was obtained via 
synthetic methods described in58. Racemic TSA was purified using a Waters 
XBridge Prep C18 5 μm OBD column (19 × 50 mm) and water/acetonitrile 
gradient (15–80% ACN in water, pH = 7; 18 min run, flow rate = 20 ml/min; 
racemic TSA RT = 8.0 min). With analytically pure racemic TSA in hand, 
a method was developed for the chiral separation. Racemic TSA was deter-
mined to be separable using a Daicel ChiralPAK AD-H 5 μm column (amylose 
tris(3,5-dimethylphenylcarbamate-coated 5 μm silica gel, 4.6 × 250 mm) and 
heptane/isopropanol gradient (10–60% IPA in heptane, no additives; 23 min 
run, flow rate = 3 ml/min). (R)-TSA eluted at RT = 15.81 min. (S)-TSA eluted at 
14.41 min. These samples were collected and measured for their optical rotation. 
(R)-TSA [a]20D = + 80.5 (c = 0.2, MeOH). (S)-TSA [a]20D = –75.5 (c = 0.2, 
MeOH). 1H NMR and LCMS data conform to previously reported structural 
data in ref. 39.
Cloning, expression and purification of mouse α-TAT. For expression of the 
α-TAT protein, a cDNA encoding mouse α-TAT (amino acids 1–197) was 
cloned into pOPINF vector via Gibson assembly (NEB) and expressed in Sf9 
cells. Primers were constructed based on cDNA sequence (NP_001136216.1), 
mRNA was extracted from MEFs by using RNeasy mini kit (QIAGEN) as a 
template for cDNA. α-TAT was purified with the same procedures as described 
above for HDAC6 CD1. After first Ni-NTA IMAC agarose, His-tag was digested 
with 3C protease at 4 °C overnight. The cleaved α-TAT was further purified 
with second Ni-NTA agarose resin, then injected onto S200 gel filtration col-
umn (one step gel filtration). Purified α-TAT was assessed by in vitro acetyla-
tion assay with acetyl-CoA in the microtubules as previously described17–19.
Tubulin and microtubule deacetylation assays. Microtubules were recon-
stituted with purified porcine brain tubulin or bovine brain tubulin 
(Cytoskeleton T238P or TL238, respectively). Microtubule reconstitution was 
done as described59; briefly, 10 mg/mL purified tubulin was polymerized with 
2× Polymix (80 mM PIPES pH6.8, 1 mM EGTA, 1 mM MgCl2, 2 mM GTP, 
20% DMSO) for 40 min at 37 °C, then stabilized with pre-warmed BRB80-DT 
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anti-beta tubulin antibodies (Sigma-Aldrich, 1:400 dilution), then detected by 
staining with Alexa-488 goat anti-rabbit (Lifetechnologies, 1:1,000 dilution) 
and Alexa-568 goat anti-mouse secondary antibodies (Lifetechnologies, 1:500 
dilution). Microtubule images were captured with an Axioimager Z1 micro-
scope (Zeiss) using a 100x objective lens. The acetylated microtubule signal 
intensity was traced and quantified by ImageJ (NIH).
(80 mM PIPES pH6.8, 1 mM EGTA, 1 mM MgCl2, 5 mM DTT, 20 μM Taxol) 
buffer for 10 min. Taxol-stabilized microtubules were spun down 16,000g for 
30 min at room temperature. Subsequently, polymerized microtubules were 
treated at 37 °C for 1 h with 5 μM mouse TAT (α-TAT) in the presence of 
3H-acetyl-CoA (0.1mCi/mL). Fully-acetylated microtubules were spun down 
at 16,000g for 30 min at room temperature, and washed with BRB80-DT 
buffer three times to remove α-tubulin α-TAT and unincorporated radioac-
tivity of acetyl-CoA. Free tubulin dimers were generated from this material 
by cold treatment together with nocodazole: radiolabeled microtubules were 
spun down and dissolved in BRB80 buffer containing 5 mM DTT and 1 mM 
nocodazole. After incubation on ice for 1 h, residual MTs were spun down at 
maximum speed for 30 min. The supernatant was used as the free tubulin frac-
tion. The absence of contamination with residual microtubules was checked 
by microscopy. For experiments with polymerized microtubules, MTs were 
stabilized with Taxol in BRB80-DT buffer. For the assays, different amounts of 
purified HDAC6 proteins were incubated at 37 °C for 1 h with equal amounts 
of radiolabeled acetylated microtubules or free tubulin. The reaction was 
stopped by adding 5% TCA, and the precipitated material was collected by 
a filter binding assay. The amount of precipitable 3[H] tritium remaining in 
the tubulin or MTs was measured by liquid scintillation counting (Beckman). 
The level of tubulin deacetylase activity was determined by subtracting the 
counts obtained with HDAC6 treatment from those without HDAC6 treat-
ment (i.e., input radioactivity).
Single molecule assay by immunofluorescence microscopy for microtubule 
deacetylation. Microtubules were reconstituted in vitro as mentioned above, 
and fully acetylated with 5 μM α-TAT and 250 μM acetyl-CoA, because tubu-
lin from brain is not fully acetylated60. Deacetylation assays were performed 
with purified catalytic domains of zebrafish HDAC6 at 37 °C for different time 
point. Reactions were stopped by fixation with 1% glutaraldehyde, and dropped 
onto poly-Lys-coated coverslips for 10 min. Microtubules were stained with 
rabbit anti-AcK40 antibodies (BML-SA452-0100, Enzo, 1:400 dilution) and 
48. Kabsch, W. Xds. Acta Crystallogr. D Biol. Crystallogr. 66, 125–132 (2010).
49. Vonrhein, C. et al. Data processing and analysis with the autoPROC toolbox. 
Acta Crystallogr. D. Biol. Crystallogr. 67, 293–302 (2011).
50. McCoy, A.J. et al. Phaser crystallographic software. J. Appl. Crystallogr.  
40, 658–674 (2007).
51. Cowtan, K. The Buccaneer software for automated model building. 1. Tracing 
protein chains. Acta Crystallogr. D Biol. Crystallogr. 62, 1002–1011 (2006).
52. Afonine, P.V. et al. Towards automated crystallographic structure refinement 
with phenix.refine. Acta Crystallogr. D Biol. Crystallogr. 68, 352–367 (2012).
53. Emsley, P., Lohkamp, B., Scott, W.G. & Cowtan, K. Features and development 
of Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486–501 (2010).
54. Bricogne, G. et al. BUSTER version 2.11.4. (Global Phasing Ltd., Cambridge, 
UK, 2011).
55. Schrödinger, LLC. The PyMOL Molecular Graphics System Version 1.7.6 
(2010).
56. Söding, J., Biegert, A. & Lupas, A.N. The HHpred interactive server for 
protein homology detection and structure prediction. Nucleic Acids Res.  
33, W244–W248 (2005).
57. Martí-Renom, M.A. et al. Comparative protein structure modeling of genes 
and genomes. Annu. Rev. Biophys. Biomol. Struct. 29, 291–325 (2000).
58. Cosner, C.C. & Helquist, P. Concise, convergent syntheses of (±)-trichostatin 
A utilizing a Pd-catalyzed ketone enolate α-alkenylation reaction. Org. Lett. 
13, 3564–3567 (2011).
59. Ziółkowska, N.E. & Roll-Mecak, A. In vitro microtubule severing assays. 
Methods Mol. Biol. 1046, 323–334 (2013).
60. Carbajal, A., Chesta, M.E., Bisig, C.G. & Arce, C.A. A novel method for 
purification of polymerizable tubulin with a high content of the acetylated 
isotype. Biochem. J. 449, 643–648 (2013).
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 2.3 Appendix 
2.3.1 Functional importance of two α-helices for deacetylation of α-tubulin by HDAC6 in vivo 
Appendix 1 
The structure of HDAC6 solved by our work (2.2) indicates that catalytic domains contain unique α-
helices among HDAC family member proteins: Helix 6 and Helix 25 (in CD1 and in CD2 respectively). 
As only HDAC6 can deacetylate α-tubulin among HDAC family proteins, we hypothesized that these 
unique two α-helices are key molecular features for α-tubulin deacetylation. In the published work 
(2.2), the functional importance of these α-helices were tested in vitro using cellular lysate containing 
Ac-α-tubulin and purified HDAC6 catalytic domains, where Helix 6 and Helix 25 are replaced with a 
loop structure originating from HDAC8, respectively. In subsequent work, each α-helix was 
systematically replaced with the other α-helix or a HDAC8 loop, and the α-tubulin deacetylation 
activity was tested in HDAC6 rescuant MEFs. We found that it is necessary for CD2 to have an 
appropriate helix at the place where Helix 25 resides for α-tubulin deacetylation, and that Helix 6 is 
also important for deacetylation activities for α-tubulin, although this effect was not observed in vitro 
(2.2). 
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Figure legend: The functional importance of two helices for deacetylation of α-tubulin by HDAC6 
(mouse) in vivo. (A) Sequences of HDAC6 specific α-helices and the loop derived from corresponding 
region of HDAC8. (B) Each HDAC6 WT and helix-mutant construct in retroviral pMSCV-IRES-
EGFP vector was expressed in HDAC6 KO cells. EGFP-positive cell populations were sorted by FACS, 
and Ac-α-tubulin in each pooled population was tested by western blotting. Mcm7 was also tested as 
loading control. 
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 2.3.2 Functional importance of N-terminal domain for deacetylation of α-tubulin by HDAC6 in 
vivo 
Appendix 2 
The laboratory of our collaborator, Dr. Cyril Barinka (Institute of Biotechnology CAS, Prague), found 
that the clusters of lysine(K)-rich positively charged residues in N-terminal domain of HDAC6 are 
necessary and sufficient for its binding to microtubule in vitro. Furthermore, they assume that these 
regions are acetylated, and that this charge neutralization impairs the binding ability. According to this 
finding, we hypothesized that the regions are also important for α-tubulin deacetylation activity of 
HDAC6. In order to test this hypothesis, catalytic activity of each HDAC6 N-terminal domain mutant 
was tested in HDAC6 KO 293T cells, which I had previously established by CRISPR/Cas9 genome 
editing (see Fig. S7 in 2.1). We revealed that both K-rich regions (KR1 and KR2) are important for 
the catalytic activity on α-tubulin, and also confirmed that positively charged lysines are necessary for 
the KR2 function. 
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Figure legend: The functional importance of N-terminal domain for deacetylation of α-tubulin by 
HDAC6 (human) in vivo. (A) HDAC6 N-terminal domain deletion mutants used for the assay. HDAC6 
harbors two K-rich sequences (K-rich region 1 and 2: a.a.32-37 and a.a.51-58, respectively) in its N-
terminal domain (a.a. 1-86). Mutant 5 is acetyl-mimic mutant of KR2, while mutant 6 is acetyl-dead 
mutant. Mutants 8 and 9 are human constructs corresponding to zebrafish HDAC6 constructs, a.a. 25-
831 and a.a. 40-831, respectively. (B) Each HDAC6 WT and mutant construct in pcDNA3 vector was 
transiently expressed in HDAC6 KO 293T cells, and Ac-α-tubulin level was tested by immunoblotting. 
(C) Quantification of Ac-α-tubulin signal in (B). The result is normalized by expression levels of α-
tubulin and HDAC6. (*) P < 0.05, (**) P < 0.01, (***) P < 0.001 and (****) P < 0.0001 by one-way 
ANOVA. 
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 2.3.3 Previously reported HDAC6 substrates in the HDAC6-dependent acetylome 
Appendix 3 
HDAC6-dependent acetylome analysis identified 2029 acetylation peptides in total (2.1). To test the 
validity of the methodology, we determined which of the previously reported HDAC6 substrates 
(1.2.2) could be identified in our HDAC6-specific acetylome.   
A) 
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 B) 
 
Reported substrates Gene names Position Tubacin Bufexamac HDAC6_KO VSL2 VL3-BA
00. DDX3X Ddx3x;D1Pas1 118 2.78 2.95 2.87 D D
01. alpha-tubulin Tuba1b;Tuba4a;Tuba1a;Tuba1c;Tuba3a;Tuba8 96 0.25 0.01 -0.42 D -
01. alpha-tubulin Tuba1b;Tuba1a;Tuba1c;Tuba3a 326 0.01 -0.15 -0.19 - -
01. alpha-tubulin Tuba1b;Tuba4a;Tuba1a;Tuba1c;Tuba3a;Tuba8 370 0.38 -0.02 -0.49 - -
01. alpha-tubulin Tuba1b;Tuba4a;Tuba1a;Tuba1c;Tuba3a;Tuba8;Tubal3 394 0.01 0.23 -0.17 - -
01. alpha-tubulin Tuba1b;Tuba4a;Tuba1a;Tuba1c;Tuba3a;Tuba8 401 -0.08 N.D. -0.61 - -
02. beta-tubulin Tubb2a 58 N.D. -0.02 0.38 - -
02. beta-tubulin Tubb4b 58 0.27 -0.09 0.30 - -
02. beta-tubulin Tubb5 58 0.02 0.12 -0.02 - -
02. beta-tubulin Tubb3 58 -0.38 N.D. -0.06 - -
04. Cortactin Cttn 87 3.00 3.98 4.68 D D
04. Cortactin Cttn 124 N.D. 3.52 4.06 D D
04. Cortactin Cttn 144 N.D. 2.25 2.97 D D
04. Cortactin Cttn 161 N.D. 3.55 4.37 D D
04. Cortactin Cttn 198 3.25 3.39 4.27 D D
04. Cortactin Cttn 235 N.D. 3.33 4.15 D D
04. Cortactin Cttn 272 N.D. 3.72 4.67 D D
04. Cortactin Cttn 309 2.79 3.65 4.60 D D
05. MHC9 Myh9 8 1.29 0.74 1.19 - -
05. MHC9 Myh9 74 -0.04 -0.24 -0.70 D D
05. MHC9 Myh9 102 0.23 -0.13 -0.31 - -
05. MHC9 Myh9 299 -0.18 -0.13 -0.35 - -
05. MHC9 Myh9 355 0.03 0.06 -0.50 - -
05. MHC9 Myh9 435 -0.08 N.D. -0.37 - -
05. MHC9 Myh9 439 N.D. -2.78 -3.08 D -
05. MHC9 Myh9 545 0.54 -0.13 -0.28 D -
05. MHC9 Myh9 555 0.10 -0.25 -0.21 D -
05. MHC9 Myh9 613 0.17 -0.21 2.32 - -
05. MHC9 Myh9 856 -0.79 -0.29 -0.18 D D
05. MHC9 Myh9 972 N.D. -0.19 -0.28 D D
05. MHC9 Myh9 1048 0.09 -0.51 -0.35 D D
05. MHC9 Myh9 1181 -0.03 -0.01 -0.44 D D
05. MHC9 Myh9 1209 0.23 0.56 -0.12 D D
05. MHC9 Myh9 1249 0.07 N.D. 0.10 D D
05. MHC9 Myh9 1330 0.57 N.D. -0.27 D D
05. MHC9 Myh9 1392 0.56 -0.07 -0.13 D D
05. MHC9 Myh9 1404 0.01 N.D. -0.07 D D
05. MHC9 Myh9 1410 -0.13 N.D. -0.02 D D
05. MHC9 Myh9 1445 N.D. -0.74 -0.89 D D
05. MHC9 Myh9 1454 -0.10 -0.41 -0.59 D D
05. MHC9 Myh9 1459 -0.98 -0.57 -0.31 D D
05. MHC9 Myh11;Myh10;Myh9 1477 -0.73 -0.17 -0.77 D D
05. MHC9 Myh9 1492 -0.16 0.02 -0.12 D D
05. MHC9 Myh9 1513 N.D. 0.05 0.32 D D
05. MHC9 Myh9 1525 -0.32 -0.17 -0.54 D D
05. MHC9 Myh9 1614 0.04 -0.34 -0.26 D D
05. MHC9 Myh9 1638 -0.14 -0.44 -0.34 D D
05. MHC9 Myh9 1648 -0.65 0.04 -0.38 D D
05. MHC9 Myh9 1669 0.11 -0.41 -0.28 D D
05. MHC9 Myh9 1724 N.D. -0.26 -0.56 D D
05. MHC9 Myh9 1775 N.D. -0.63 -0.58 D D
05. MHC9 Myh9 1793 -0.28 -0.48 -0.30 D D
05. MHC9 Myh9 1828 N.D. -0.36 -0.71 D D
05. MHC9 Myh9 1845 -0.24 N.D. -0.32 D D
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Figure legend: Previously reported HDAC6 substrates identified in the HDAC6-dependent acetylome. 
(A) The scatter plots show the correlation between acetylated sites quantified in HDAC6-specific 
inhibitor-treated MEFs vs acetylated sites quantified in HDAC6 KO MEFs. X-axis: log2 SILAC ratio 
of Tubacin-treated MEFs vs control-treated MEFs (Tubacin, upper panel) or log2 SILAC ratio of 
Bufexamac-treated MEFs vs control-treated MEFs (Bufexamac, bottom panel). Y-axis, both panels: 
Reported substrates Gene names Position Tubacin Bufexamac HDAC6_KO VSL2 VL3-BA
06. Hsp90 Hsp90ab1 53 -0.66 N.D. -0.36 D -
06. Hsp90 Hsp90aa1;Hsp90ab1 275 0.06 0.62 0.83 D D
06. Hsp90 Hsp90aa1;Hsp90ab1 284 0.05 -0.01 -0.27 D D
06. Hsp90 Hsp90aa1;Hsp90ab1 399 N.D. 0.70 -0.17 - -
06. Hsp90 Hsp90ab1 435 0.30 -0.34 -0.23 D -
06. Hsp90 Hsp90aa1 444 -0.17 N.D. 0.09 - -
06. Hsp90 Hsp90ab1 481 N.D. -0.43 -0.34 D D
06. Hsp90 Hsp90aa1 490 N.D. -0.16 -0.32 - -
06. Hsp90 Hsp90ab1 531 0.11 -0.32 -0.24 D D
06. Hsp90 Hsp90ab1 538 N.D. -0.03 -0.17 D D
06. Hsp90 Hsp90ab1 550 -0.13 -0.20 -0.29 D D
06. Hsp90 Hsp90ab1 559 N.D. -0.56 -0.27 D D
06. Hsp90 Hsp90aa1 559 -0.13 -0.20 -0.29 D D
06. Hsp90 Hsp90ab1 565 -0.47 -0.19 -0.50 D D
06. Hsp90 Hsp90ab1 568 -0.42 -1.02 -0.55 D D
06. Hsp90 Hsp90aa1 577 -0.33 -0.11 0.17 D -
06. Hsp90 Hsp90b1 597 0.91 -0.24 0.17 D D
07. Hsp70 Hspa4 194 N.D. -0.57 -1.27 - -
07. Hsp70 Hspa4 272 N.D. 0.33 0.05 D D
07. Hsp70 Hspa4 559 N.D. 2.15 3.32 D D
07. Hsp70 Hspa4 681 N.D. -0.58 0.40 D D
08. Hsc70 Hspa8 56 -0.15 -0.03 0.06 - -
08. Hsc70 Hspa8 71 N.D. 0.12 -0.16 - -
08. Hsc70 Hspa8 108 N.D. -0.46 -0.16 D -
08. Hsc70 Hspa2;Hspa8 187 0.30 0.07 0.35 - -
08. Hsc70 Hspa8 246 -0.49 0.00 -0.10 D D
08. Hsc70 Hspa8 319 -0.02 0.29 2.27 - -
08. Hsc70 Hspa2;Hspa8 348 0.00 N.D. -0.28 - -
08. Hsc70 Hspa2;Hspa8 451 N.D. -0.10 -0.12 - -
08. Hsc70 Hspa8 512 -0.38 -0.01 0.25 D D
08. Hsc70 Hspa8 524 0.03 -0.08 0.22 D D
08. Hsc70 Hspa8;Hspa8 589 N.D. -0.22 -0.14 D D
08. Hsc70 Hspa8;Hspa8 597 -0.25 0.03 -0.14 D D
08. Hsc70 Hspa8 601 -0.27 0.02 -0.11 D D
09. DNAJA1 Dnaja1;Dnaja4;Dnajc5 32 -0.17 0.05 -0.10 D D
10. GRP78 Hspa5 548 N.D. 0.08 0.47 D D
11. Peroxiredoxins Prdx1 27 0.91 0.09 -0.59 - -
11. Peroxiredoxins Prdx1 35 N.D. 0.16 -0.88 - -
11. Peroxiredoxins Prdx5 79 0.07 N.D. 1.78 - D
11. Peroxiredoxins Prdx1 136 0.65 N.D. -0.25 - -
11. Peroxiredoxins Prdx6 209 -0.11 -0.66 -0.45 D D
14. RIG-I Ddx58 852 1.77 -0.94 1.83 D -
22. 14-3-3zeta Ywhaz 3 N.D. -0.35 -0.41 D D
22. 14-3-3zeta Ywhaz 68 0.05 -0.12 -0.11 D D
22. 14-3-3zeta Ywhaz 115 0.07 N.D. -0.10 - -
22. 14-3-3zeta Ywhaz 120 0.15 -0.36 -0.10 - -
22. 14-3-3zeta Ywhaz 157 0.39 N.D. 0.11 D -
25. RelA/p65 Rela 310 0.21 -0.18 0.44 D D
27. HMGN2 Hmgn2;Gm6724;Gm16494 73 0.84 0.97 0.17 D D
27. HMGN2 Hmgn2 86 0.17 0.19 0.36 D D
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 log2 SILAC ratio of HDAC6 KO MEFs vs WT MEFs (HDAC6_KO, both panels). In each plot, the 
colored dots show the peptides originated from reported HDAC6 substrates (numbering of each 
substrate is based on the definition in 1.2.2). As mentioned in 2.1, DDX3X is the substrate identified 
by our study. (B) The log2 SILAC ratio of identified acetylation sites originated from the 14 indicated 
proteins are listed. Positions written in red demonstrate acetylation sites previously reported as 
HDAC6 target sites. The columns, “VSL2” and “VL3-BA” show the disorder status of the identified 
site, which is defined by the VSL2 or VL3-BA programs of the PONDR suite (Prediction Of Naturally 
Disordered Regions). “D” indicates that the site is in IDRs while “-” indicates that the site is not in 
IDRs. N.D., not detected. 
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 2.3.4 Quality check of commercial acetylated lysine antibodies 
Appendix 4 
First of all, evaluation of DDX3X acetylation in immunoblotting was required to further analyze its 
biological functions. Agarose conjugated acetyl-lysine antibody supplied from Immunechem 
(ICP0388) had been used for acetylome analysis, however it is not suitable for immunoblotting. Thus, 
in order to detect acetylation of DDX3X and other high-confidence HDAC6 target sites by 
immunoblotting, six commercial pan-acetyl-lysine antibodies were compared in parallel. We found 
that the CST (#9441) antibody exhibits a broad range of reactivity, and it was used in subsequent 
experiments (2.1). 
 
A) 
Name and supplier Source Immunogen 
Immunechem, ICP0380, 
Anti Acetyl Lysine 
Rabbit polyclonal Acetylated KLH conjugates 
Cell Signaling Technology #9441, 
Acetylated-Lysine 
Rabbit polyclonal A synthetic acetylated lysine-containing 
peptide 
Cell Signaling Technology #9681, 
Acetylated-Lysine (Ac-K-103) 
Mouse IgG2a A synthetic acetylated lysine-containing 
peptide 
Cell Signaling Technology #9814, 
Acetylated-Lysine (Ac-K2-100) 
Rabbit IgG 
(mixture of 2 clones) 
A synthetic acetyl-lysine peptide library 
Millipore 05-515, 
Anti-Acetyl-Lysine Antibody (4G12) 
Mouse IgG Mixture of chemically acetylated antigens 
Thermo Scientific, MA1-2021 
Acetyl Lysine Antibody (1C6) 
Mouse IgG Synthetic peptide sequence surrounding 
H3K9Ac 
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 B)
 
 
Figure legend: Quality check of commercial acetylated lysine antibodies. (A) Information about 
sources and immunogens of the antibodies used in (B). (B) WT and HDAC6 KO MEFs were treated 
with 2 μM TSA for overnight, so that the acetylation level of the proteins in these cells is upregulated. 
Then, lysates of these cells were immunoblotted with six types of acetylated lysine antibodies 
(ICP0380, CST#9441, CST#9681, CST#9814, Millipore (4G12) and Thermo Fischer Scientific (TFS) 
1C6). 
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 2.3.5 Pex5 is a novel HDAC6 substrate 
Appendix 5 
Among high-confidence HDAC6 target sites, the biological role of DDX3X acetylation was mainly 
studied as mentioned above (2.1). Another candidate, Pex5 (acetylation site: K28) is the peroxisomal 
import receptor, which binds to its cargos in the cytosol and brings them to translocation machinery at 
the peroxisomal membrane. Given that HDAC6 regulates cellular redox status through deacetylation 
of peroxiredoxins (1.2.2), it may also control the function of peroxisomes, which play important roles 
in regulating redox signaling pathways, through Pex5 deacetylation. To further explore this possibility, 
the Pex5 acetylation level under Tubacin was tested, and it was confirmed that Pex5 is a novel HDAC6 
substrate. 
 
Figure legend: Pex5 is a novel HDAC6 substrate. (A) Acetylation of exogenous Pex5 by CBP and 
p300. Tagged versions of PCAF, Tip60, CBP and p300 were transiently transfected into 293T cells 
with FLAG-Pex5 (mouse). The acetylation status of exogenous Pex5 under Tubacin was analyzed by 
immunoblotting with a pan-acetyl-lysine antibody (AcK), following FLAG immunoprecipitation (IP). 
Cell lysate from parental 293T cells without Tubacin treatment was also loaded on the gel as a control 
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 (lane 1). Red arrowhead indicates FLAG-Pex5 while blue one indicates FLAG-PCAF. (B) Acetylation 
of exogenous Pex5 is increased by Tubacin treatment. 293T cells were transiently transfected with 
FLAG-Pex5 together with CBP or GFP (control, -), and were treated overnight with 10 μM Tubacin, 
as indicated. Cell lysates were used to examine the acetylation status of FLAG-Pex5 by 
immunoblotting with a pan-acetyl-lysine antibody after immunoprecipitation. Red arrowhead indicates 
FLAG-Pex5. 
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 2.3.6 SG formation ability of DDX3X catalytic activity mutants 
Appendix 6 
In this thesis, it was shown that DDX3X contributes to SG formation through its IDR1 and helicase 
core domain (Fig. S16 in 2.1). As mentioned above, IDR1 undergoes LLPS, and thus leads to SG 
formation. On the other hand, the exact role of the DDX3X helicase core in SG formation was still 
under discussion. Its RNA binding ability contributes to SG formation, as also observed in other RNPs. 
At the same time, it appears that such ATP-dependent remodeling complexes including helicases and 
chaperones also support RNP granules disassembly (Protter and Parker, 2016). Thus, a systematic 
study to examine all three activities of the helicase core (RNA-binding, ATPase and RNA-unwinding) 
in SG formation is required. The molecular mechanisms coupling these three properties are still 
unknown, which makes it difficult to separately assess the contribution of each function in SG 
formation. However, a study about crystal structure of another DEAD-box helicase, Vasa (DDX4 
ortholog of D. melanogaster), has provided some clues to uncouple these entangled functions 
(Sengoku et al., 2006). As DEAD-box helicase cores are well conserved between DDX3X and Vasa, 
functional key residues originally identified in Vasa were mutated in DDX3X, and SG formation ability 
of the DDX3X mutants were tested. We found that all six mutants formed smaller SGs, confirming 
that the helicase core is important for normal SG formation. Given that all mutants exhibit impaired 
RNA-unwinding ability, this primary helicase function may give a good explanation for these results.  
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 Figure legend: SG formation ability of DDX3X catalytic activity mutants. (A) Localization of 
DDX3X WT and its catalytic activity mutants transiently expressed in HeLa cells. Cells were treated 
with 1 mM arsenite for 30 min, localization of mCherry-DDX3X was assessed by microscopy after 
fixation. (B) Left: mCherry-DDX3X SG number (left panel) and size (middle panel) per cell were 
quantified (n = 50 cells in total, from biologically independent experiments) in (A), and displayed in 
violin plot; the thin line at the center represents the 95% confidence interval, and the bottom and top 
of the box represent the 25th and 75th percentile of the data, with the median value represented by a 
horizontal bold line. On each side of the thin line is a kernel density estimation showing the distribution 
shape of the data points from minima to maxima. Right: P values were determined by one-way 
ANOVA; (*) P < 0.05, (**) P <0.01, (***) P < 0.001 and (****) P < 0.0001. (C) Functional status of 
Vasa mutants corresponding to DDX3X Q477A, R480A, T498A and R503A mutants used in (A) (cited 
from (Sengoku et al., 2006)). RNA Xlink (%) indicates the relative RNA-binding ability compared to 
that of WT. It is important to note that the functional status of both DQAD and AAA mutants was not 
assessed in their work. (D) Alignment of Drosophila Vasa and Mouse DDX3X. Conserved motifs in 
the DEAD-box and residues mutated in this experiment are highlighted (cyan: ATP binding, magenta: 
RNA binding, light green: Link ATP and RNA binding, and yellow: mutated residues). 
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 2.3.7 LLPS efficiency of DDX3X-IDR1 with cancer-related mutations 
Appendix 7 
DDX3X can undergo LLPS, which is linked to its SG formation ability (2.1). DDX3X is recurrently 
mutated in some specific types of tumors, and the mutations are extensively mapped to its helicase 
core domain. These cancer-associated mutations in the helicase core domain drive SG formation and 
impair global translation (Valentin-Vega et al., 2016). Assuming from that certain oncogenes such as 
K-Ras enhance cell fitness through upregulated SG formation under stresses, this effect on DDX3X 
also contributes to tumor cell fitness. Furthermore, a few cancer-associated mutations in DDX3X-
IDR1 have been registered in the COSMIC database (although there are fewer than the helicase core 
mutations). As I have shown that acetylation of a single lysine residue affects LLPS and SG formation 
(Fig. 4 in 2.1), it is possible that these cancer-associated point mutations in IDR1 also may affect these 
properties. To test this hypothesis, IDR1 harboring individual cancer-associated mutation were purified 
and their LLPS propensity was tested by droplet formation assay in vitro. As is visible, several of the 
cancer associated mutations, such as D67Y or R113G among others, show an altered LLPS propensity. 
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Figure legend: LLPS efficiency of DDX3X-IDR1 with cancer related mutations. (A) Mutations 
located in DDX3X-IDR1 found in cancer samples (registered in COSMIC 
https://cancer.sanger.ac.uk/cosmic, and cited in (Sharma and Jankowsky, 2014)). (B) A Coomassie 
Brilliant Blue stained SDS-PAGE gel showing the purified WT and mutants of DDX3X-IDR1 (red 
arrowhead). (C) Percent of turbidity (OD600) of DDX3X-IDR1 mutants normalized to WT (mean ± 
SD, n = 3). (*) P < 0.05, (**) P < 0.01, (***) P < 0.001 and (****) P < 0.0001 by Student’s two-tailed 
t-test. 
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 2.3.8 SG formation ability of Serbp1 acetyl-mimic/dead mutants 
Appendix 8 
HDAC6-dependent acetylome analysis revealed that a large part of high-confidence HDAC6 target 
sites map to IDRs (Fig. 1 and S2 in 2.1), suggesting that HDAC6 globally regulates LLPS propensity 
of its target proteins through their IDR deacetylation. In addition to DDX3X, another SG component 
protein Serbp1 (Lee et al., 2014b) is in the list of high-confidence HDAC6 target sites (K122 of Serbp1, 
Fig. 1 and S2 in 2.1). Thus, we hypothesized that HDAC6 also regulates SG formation of Serbp1 
through its deacetylation. Serbp1, a RNA binding protein, harbors a long IDR containing two 
RGG/RG-rich sequences (RGG box1 and 2) (discussed in 1.3.2), and also has an isoform missing 6 
amino acids in the IDR. Thus, to test the importance of Serbp1 acetylation in SG formation, acetyl-
mimic/dead mutant, RGG box deletion mutants as well as isoform-specific 6 amino acids deletion 
mutant were constructed and their SG formation ability was tested in HeLa cells. We confirmed that 
RGG box, which is often associated LLPS propensity, is also important for Serbp1 to localize on SGs. 
Moreover, isoform-specific short 6 amino acids also contribute to SG formation ability. As observed 
in DDX3X, acetyl-mimic mutation (K122Q) in Serbp1 IDR also affected SG formation; numerous 
smaller SGs were induced, and this effect was not observed with K122R mutant. Thus, HDAC6 may 
regulate the acetylation status of IDRs in a set of SG components. 
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Figure legend: SG formation ability of Serbp1 acetyl-mimic/dead mutants. (A) Serbp1 (mouse) 
domain deletion mutants and acetyl-mimic/dead mutants used for the assay. Serbp1 harbors two 
RGG/RG-rich sequences (RGG box1 and 2, orange), and the short insertion (a.a. 203-208: SFSHYS, 
green) is removed from isoform2 by alternative splicing. Residue K122 in its IDR is identified as one 
of high-confidence HDAC6 target sites (see Fig. 1 and S2 in 2.1). (B) Each FLAG-Serbp1 WT and 
mutant construct in pcDNA3 vector was transiently expressed in HeLa cells, and localization of 
FLAG-Serbp1 after arsenite treatment (1 mM, 30 min) was tested by IF. (C) The number of cells 
having Serbp1-positive SGs in (B) were counted, and percentage of all transfected cells are shown. 
(D) Quantification of Serbp1-positive SG number (left panel) or size (middle panel) per cell (n = 50 
cells in total, from biologically independent experiments), and displayed in violin plot; the thin line at 
the center represents the 95% confidence interval, and the bottom and top of the box represent the 25th 
and 75th percentile of the data, with the median value represented by a horizontal bold line. On each 
side of the thin line is a kernel density estimation showing the distribution shape of the data points 
from minima to maxima. The five construct which induced over 50% SG positive cells in (B) were 
specifically tested. P values were determined by one-way ANOVA (right panel); (*) P < 0.05, (**) P 
<0.01 and (***) P < 0.001. 
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 3.1 Novel mechanical insights for HDAC6-mediated deacetylation 
3.1.1 Deacetylation mechanism by HDAC6 
The crystal structure of HDAC6 catalytic domains was recently solved by two groups 
including our group (Hai and Christianson, 2016; Miyake et al., 2016) (see 2.2). A prevalent model 
about the mechanism of HDAC6-mediated deacetylation suggested that only CD2 deacetylates its 
substrates including α-tubulin and cortactin in vivo. Our work successfully refined the model with 
providing important insights about both newly discovered HDAC6 specific α-helices and CD1. 
Two α-helices for α-tubulin recognition 
HDAC6 catalytic domains contain unique α-helices among HDAC family member proteins: 
Helix 6 and Helix 25 (in CD1 and in CD2 respectively). Replacement of CD2 Helix 25 by a loop 
structure coming from HDAC8 impairs its catalytic activity on α-tubulin, but not on acetylated lysine 
containing peptide in vitro. By contrast, replacement of CD1 Helix 6 by a loop structure originating 
from HDAC8 does not affect on its catalytic activity on α-tubulin in vitro. This suggests that Helix 25 
is important to recognize α-tubulin for its deacetylation even in vitro context. Subsequent analysis with 
corresponding mouse HDAC6 α-helices mutants (2.3.1 Appendix 1) in MEF cells provided further 
insight about α-tubulin deacetylation. In agreement with in vitro α-tubulin deacetylation, replacement 
of CD2 Helix 25 by a loop structure impaired its α-tubulin deacetylation (2.3.1 Apx. 1B; lanes 3, 6 
and 9). Interestingly, replacement of Helix 25 by Helix 6 did not impair its deacetylation activity (2.3.1 
Apx. 1B; lanes 1, 4 and 7), suggesting that it is necessary for CD2 to have an appropriate helix at the 
place where Helix 25 resides for α-tubulin deacetylation. At the same time, it clearly demonstrated that 
HDAC6 constructs lacking Helix 6 (2.3.1 Apx. 1B; lanes 5, 6, 8 and 9) have impaired deacetylation 
activities for α-tubulin, although this effect was not observed in vitro. As far as we know, this is the 
first evidence to show the importance of CD1 domain for α-tubulin deacetylation; it seems that CD1 
helps the process through this Helix 6, which fits well with previous observations from our laboratory 
(Zhang et al., 2006). We would like to propose a two-step deacetylation model for HDAC6-mediated 
α-tubulin deacetylation. First, Helix 6 in CD1 may recognize and bind to the α-tubulin or β-tubulin in 
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 tubulin dimers. Second, catalytic pocket of the CD2 may contact with α-tubulin, where deacetylase 
activity of CD2 requires Helix 25 (or similar helix structure). The structure of HDAC6 binding to 
unpolymerized tubulin dimers by the X-ray crystallography or cryo-EM should be clarified in future 
to delineate the process completely. 
In parallel, we also clarified that HDAC6 prefers to deacetylate unpolymerized tubulin, 
suggesting that it is acting as a resetting factor for acetylation status of tubulins once microtubule 
catastrophe takes place. By contrast, the initial work demonstrated purified HDAC6 potently 
deacetylated α-tubulin in assembled microtubules in vitro (Hubbert et al., 2002). This discrepancy may 
be due to the difference in assay system, HDAC6 protein species etc. and further investigations are 
required to determine the exact mechanism for α-tubulin K40 deacetylation by HDAC6 in vivo. 
CD1 as a deacetylase for intrinsically disordered regions? 
During the process to solve HDAC6 structure, we have also realized that the CD1 domain 
itself has catalytic activity, and deacetylates peptide substrates, but not α-tubulin in vitro. This 
observation has encouraged us to test CD1 catalytic activity for acetylated lysines located in IDRs, as 
we considered that IDRs may be regarded as long unstructured peptide in vivo. Expectedly, we 
observed that two of the high-confidence substrates whose acetylation site is in an IDR, DDX3X and 
cortactin, can be robustly deacetylated by CD1, as well as by CD2 (see Fig. S8 in 2.1). This is in 
contrast to deacetylation of α-tubulin, which strictly depends on CD2. These observations suggest that 
CD1 may be generally active on acetylated lysines in IDRs. It would be interesting to test whether or 
not mutation in Helix 6 and 25 affect HDAC6 catalytic activity on IDRs in future. This finding has 
important implications for the generation of HDAC6-specific inhibitors, which so far have been 
developed on the assumption that only CD2 is active, and inhibition of CD1 was usually not tested. 
N-terminal domain for α-tubulin recognition 
As mentioned so far, the molecular mechanism of α-tubulin deacetylation by HDAC6 is still 
under extensive investigation. Needless to say, its unique tandem deacetylase domains are central part 
of the study. In contrast, the N-terminal and C-terminal extensions including ZnF-UBP have not been 
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 widely accepted as regulatory domains for α-tubulin deacetylation. The laboratory of our collaborator, 
Dr. Cyril Barinka, found that two clusters of lysine (K)-rich positively charged residues (KR1: a.a. 32-
37 and KR2: a.a. 51-58) in N-terminal domain of human HDAC6 are necessary and sufficient for 
binding to microtubule in vitro. They also assumed that these regions are subjected to acetylation, and 
that the neutralization of positive charge impairs the binding ability. This hypothesis was partially 
supported by our observation that either KR1 or KR2 deletion impairs the catalytic activity on α-
tubulin (2.3.2 Apx. 2B; lanes 4 and 5, and 2C). KR2 is likely to have more significant contribution 
to the activity, and furthermore, KR2 acetyl-mimic mutant (KR2-6Q) shows decreased activity on the 
same level with its deletion (2.3.2 Apx. 2B; lanes 5 and 6, and 2C). On the other hand, KR2 acetyl-
dead mutant (KR2-6R) still has catalytic activity, which is comparable with that of WT (2.3.2 Apx. 
2B; lanes 2 and 7, and 2C). Accordingly, it seems that the positive charge of KR2 (a.a. 51-58) may 
play an important role for α-tubulin deacetylation in cells (2.3.2 Apx. 2). Two N-terminal domain 
deletion mutants, which are the human version of the zebrafish constructs used for crystallization (2.2), 
also exhibit less activity, which perfectly fits with the observations presented here (2.3.2 Apx. 2B; 
lanes 9 and 10, and 2C). A few studies reported the importance of N-terminal region of HDAC6; this 
region contains a nuclear localization signal (NLS, a.a. 14-58) and a nuclear export signal (NES, a.a. 
67-76) (Bertos et al., 2004). Given that the NLS including KR2 is important for HDAC6 to localize in 
the nucleus, KR2 mutant would prefer to stay in cytosol and actively deacetylate α-tubulin; however, 
KR2 could not deacetylate it efficiently. This discrepancy indicates that the effect of KR2 on α-tubulin 
deacetylation observed here is separate from its localization; obviously further studies are required to 
clarify the interactions between N-terminal region and tandem deacetylase domains of HDAC6.  
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 3.2 HDAC6 regulates stress granule formation through DDX3X deacetylation 
3.2.1 Identification of novel substrates of HATs/HDACs by acetylome analysis 
 In order to grasp a comprehensive picture of HDAC6 substrates, we utilized acetylome 
analysis combined with genetic and pharmacologic inhibition of HDAC6 (see Fig. 1 and S1 in 2.1). 
In total, approximately 2000 peptides were identified, and 1% of them were defined as high-confidence 
HDAC6 target sites that showed a more than 2-fold increase in acetylation in all tested conditions. 
Our acetylome covers 103 acetylation sites from 14 reported substrates, including cortactin, 
a well-known substrate (2.3.3 Apx. 3). Most strikingly, eight cortactin acetylation sites were detected 
in three independent acetylomes (Tubastatin, Bufexamac, and HDAC6 KO), confirming all the four 
sites previously reported. Additionally, four novel acetylation sites were revealed. Conversely, the 
canonical HDAC6 target site α-tubulin K40 peptide was not detected, although five acetylated peptides 
from α-tubulin were identified. This may be due to lack of lysines and arginines, which are targeted by 
two digestion enzymes (Lys-C and trypsin) used in acetylome analysis in the AcK40 neighborhood. 
Consequently, the associated peptides, including AcK40, are too large to be detected by mass 
spectrometry. In addition to the identification of the four cortactin sites, the identification of β-tubulin 
K58, Hsp90 K284, and 14-3-3ζ K120 were consistent with the findings of previous studies. However, 
their acetylation levels do not seem to be upregulated neither by HDAC6 inhibitors nor in the KO 
condition (log2 SILAC ratio < 0.5). Acetylation sites of other substrates, such as MHC9 and Hsp70, 
have not been identified previously. Moreover, none of the acetylation sites from MHC9 and Hsp70 
exhibit significant differences. The high-confidence HDAC6 target sites consist of an entirely new set 
of substrates, except cortactin. Differences in acetylation levels of the reported substrates have been 
determined using immunoblotting in previous studies. Considering that mass spectrometry is more 
sensitive compared to immunoblotting, it is tempting to think that acetylome could efficiently confirm 
significant changes in the acetylation status of previously reported substrates. To the best of our 
knowledge, this is the first study to revisit HDAC6 substrates utilizing acetylome analysis. Future 
studies are anticipated to resolve this discrepancy, with several possibilities (Fig. 15). 
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Figure 15.   Comparison between acetylome and immunoblotting to confirm HDAC6 substrates. Five 
potential reasons to explain the discrepancy between previous work about HDAC6 substrates identification and 
our acetylome are presented. Acetylation status of HDAC6 substrate may depend on cell type (1. Cell 
specificity). Several commercial pan-acetyl-lysine (AcK) antibodies, and also site-specific antibodies are 
available, but there is no consensus about their quality in the field (2. Antibody specificity). The experimental 
condition for antibody-antigen reaction is different; digested peptides are immunoenriched with AcK antibodies 
in the acetylome analysis while undigested denatured proteins are reacted with antibodies on the immunoblot 
membrane (3. Condition of epitope). Relatively large peptides are not detected by mass spectrometry (4. Bias 
from MS). Acetylome analysis measures acetylation status of each lysine residue individually, whereas 
immunoblotting detects the acetylation status of the whole protein (5. Output). 
 
Firstly, the repertoire of HDAC6 substrates may be greatly influenced by cell type specificity. We 
reported a HDAC6-dependent acetylome in MEFs, whereas previous studies employed different cells, 
including HeLa and other cancer cell lines to define HDAC6 substrates. Even if HDAC6 and other 
major substrates are ubiquitously expressed in almost all tissues, the regulatory system and how 
HDAC6 targets its substrates may be specific in every cell type. Secondly, the detection of protein 
acetylation in immunoblotting and acetylome analysis entirely depends on the affinity of antibodies, 
which could be another source of diverse contentious results. In some well-known acetylated proteins, 
-179-
 including histones and α-tubulin, highly site-specific antibodies are available. However, generating 
such antibodies is often time-consuming and uneconomical. Therefore, “pan”-acetyl-lysine antibodies 
are routinely applied in analyses. Moreover, to increase protein coverage, using a pan-acetyl-lysine 
antibody is more appropriate for acetylome analysis than a site-specific antibody for a specific protein. 
However, there is no consensus on “pan”-acetyl-lysine antibodies in acetylation research and their 
quality and specificity may vary (2.3.4 Apx. 4). Consequently, results vary substantially across studies. 
Further, even if the exact same antibody was to be utilized, the affinity would be altered based on the 
condition of its epitope. The antibody binds to its epitope on denatured protein in immunoblotting, 
whereas it binds to digested peptides in acetylome analysis. This makes it more challenging to compare 
results from two different experimental setups. Developing alternative universal approaches for 
detection (e.g. chemical probes directly recognizing acetyl-lysine residues without being affected by 
diverse physicochemical conditions) could benefit acetylation research in the future. Thirdly, bottom-
up strategies currently utilized in acetylome analysis effectively provide information on each 
individual acetylation “site” in target proteins, which is not easily integrated into their whole 
acetylation “status” derived from co-occurrence of acetylation as detected by immunoblotting. There 
are often several acetylation sites as clearly observed in the reported substrates in our acetylome. Even 
if each acetylation site were weakly regulated by HDAC6, an assumption based on the minor changes 
in their SILAC ratios, the overall effects of several acetylations on one protein species could be 
robustly detected using immunoblotting with pan-acetyl-lysine antibodies. Although top-down 
strategies analyzing undigested proteins may resolve this problem and provide information about the 
co-occurrence of acetylation on the same protein, they are not yet suitable for proteome-scale analyses. 
This gap should be addressed to facilitate the understanding of the biology of acetylation (or other 
PTMs), because it seems that several acetylations often collectively alter biological function in target 
proteins, which is the case in IDR acetylation in cortactin and DDX3X. Finally, the interpretation of 
the acetylome data is influenced by the intrinsic bias associated with mass spectrometry analysis. As 
exemplified above by α-tubulin K40, the use of trypsin and Lys-C in an analysis limits acetylation site 
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 identification based on their digestion capacities. To provide further protein coverage, additional 
alternative proteases, such as AspN and GluC, should be applied, although they are usually less specific 
and economical. Thus, it remains a major challenge to identify novel substrates of target PTM 
enzyme(s) utilizing conditional proteomes, where the PTM enzymes are inhibited or knocked out, and 
clarify their biological implications. Nevertheless, our study revealed important novel insights in the 
fields of protein acetylation, IDPs, and phase separation, beyond the biology of HDAC6 itself. 
Analysis of these high-confidence HDAC6 target sites defined a HDAC6 target motif where 
several positions show an enrichment, in particular the two residues immediately before the acetylated 
lysine -GGK(Ac)-. Of note, this is reminiscent of the so-called GK motif associated with histone 
acetylation by CBP and p300 (Bannister et al., 2000). The well-established HDAC6 substrate, cortactin, 
also has this GK motif in its repeat region (-GXGGK(Ac)XG-) (Zhang et al., 2007). As mentioned in 
1.2.2, K58 on β-tubulin is often regarded as the equivalent site to K40 on α-tubulin because these sites 
are characteristically exposed to the luminal face of microtubules (Janke and Bulinski, 2011), and K58 
is indeed deacetylated by HDAC6 (Liu et al., 2015). Surprisingly, K58 on β-tubulin fits well to this -
GGK(Ac)- motif often observed in histone acetylation sites, while K40 on α-tubulin does not. This 
GK motif on β-tubulin seems to bridge between two functionally unrelated proteins, histones and 
tubulins, and thus it may be key to explain in future why HDAC6 deacetylates tubulins apart from 
histones as destined substrates of the HDAC family proteins. Remarkably, the very large majority of 
the high-confidence HDAC6 target sites map to IDRs, suggesting the possibility that IDR acetylation 
and its regulation by HDAC6 may generally be implicated in controlling LLPS. Notably, previous 
work reported that acetylated lysines are frequently located in regions with ordered secondary structure 
and, compared with all lysines, acetylated lysines are significantly enriched in structured regions and 
depleted in unstructured regions (Choudhary et al., 2009). Thus, the HDAC6 acetylome defines a 
skewed subset of the acetylated lysines, which may identify a new function for lysine acetylation. We 
focused on the HDAC6 target site in DDX3X among the high-confidence sites in IDRs. It is worth 
mentioning that, in addition to our study, an independent study also showed that DDX3X is acetylated 
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 in mouse liver (Zhang et al., 2015b), indicating that the regulation of DDX3X by acetylation is 
observed not only in cell lines, but also in the whole organism. 
One remaining question is what is the biological meaning of other high-confidence HDAC6 
target sites? We realized that one of these is in the IDR of Serbp1, another SG component (Lee et al., 
2014b), and thus the effect of acetylation/deacetylation was tested in a similar way as utilized for 
DDX3X. As expected, acetylation impaired localization of Serbp1 on SGs (2.3.8 Apx. 8, discussed in 
3.2.5), thus confirming the validity of our observations. Moreover, Ranbp2, which is part of the nuclear 
pore complex (nucleoporin) (Strambio-De-Castillia et al., 2010), may be also an attractive candidate 
for further analysis. As mentioned below, purified FG repeats of nucleoporins including Ranbp2 (also 
known as Nup358) were reported to form hydrogels through liquid-solid phase transition in vitro (Frey 
et al., 2006; Labokha et al., 2013), which is associated with sieve-like meshwork structure of the 
nuclear pore complex for selective shuttling of nuclear transport cargos in cells (discussed in 3.3.1). 
Thus, in this case, HDAC6 may alter the material properties of the meshwork structure composed of 
Nups to control nuclear transport. Pex5 is the peroxisomal import receptor, which binds to its cargos 
in the cytosol and brings them to the translocation machinery at the peroxisomal membrane (Platta et 
al., 2007). Its deacetylation by HDAC6 was confirmed (2.3.5 Apx. 5). Synrg interacts with the AP1 
clathrin-adaptor complex at the trans-Golgi network for trafficking of clathrin-coated vesicles (Page 
et al., 1999). Apart from the involvement of IDRs in phase separation, it has been also reported that 
IDRs contribute to trafficking; for example, IDPs drive membrane curvature to form clathrin-coated 
structures (Busch et al., 2015). Thus, Pex5 and Synrg, both proteins involved in the interaction between 
membranes and cargos may also play similar roles in the trafficking process with their IDRs, which 
would be modified by HDAC6. Clearly, further studies are required for each candidate identified here 
and another acetylome analysis with much higher resolution may be required in the future. However, 
the current list of novel HDAC6 substrate candidates presented here encourages us to imagine that 
HDAC6 globally deacetylates IDR, and controls the biological functions where IDRs play an 
important role, such as granule formation, establishment of sieve-like nuclear pore structure through 
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 phase transitions and membrane curvature in the trafficking process. 
 
3.2.2 DDX3X, as a component of stress granules and novel HDAC6 substrate 
Our acetylome analysis revealed that DDX3X is a novel substrate of HDAC6 (see Fig. 1 in 
2.1). DDX3X is a member of DEAD-box ATP-dependent RNA helicase family (Linder and Jankowsky, 
2011). All DEAD-box helicases contain a structurally conserved helicase core with two RecA-like 
domains containing the characteristic Asp-Glu-Ala-Asp (DEAD) motif, whereas both N- and C-
termini of the helicases are variable. DEAD-box helicases comprise the largest helicase family, with 
37 members in humans and 26 in yeast. They are central players in essentially all aspects of eukaryotic 
RNA metabolism. 
Ded1/DDX3 helicases form a defined subfamily, and the proteins are highly conserved from 
yeast to human (Sharma and Jankowsky, 2014; Soto-Rifo and Ohlmann, 2013). The human genome 
codes for two related DDX3 genes, DDX3X and DDX3Y. DDX3X was first identified as one of the X 
chromosome-linked genes (Park et al., 1998), and its functional homolog DDX3Y was found in the Y 
chromosome. DDX3Y is specifically expressed in testis and has an important function in 
spermatogenesis (Foresta et al., 2000). The helicase core harbors all signature helicase motifs (Fig. 16). 
Motif II (or Walker B motif) has the DEAD sequence, together with motif I (or Walker A motif), the 
Q-motif and VI, is required for ATP binding and hydrolysis. On the other hand, motifs Ia to Ic, III, IV, 
V and Va have been characterized less well but may be involved in interaction with RNA (Linder, 
2006). In addition to this central helicase core, they have both characteristic N- and C-terminal domains, 
which are predicted as IDRs (Kim and Myong, 2016). These regions also provide potential sites for 
PTMs, most prominently the RG sequence in N-terminal IDR1 for methylation and the SR sequence 
in C-terminal IDR2 for phosphorylation (Gustafson and Wessel, 2010). However, there has been no 
report yet about DDX3X acetylation. While other DEAD box helicases, DDX5 and DDX17, are 
substrates of p300 (Mooney et al., 2010), no HATs were known for DDX3X acetylation.   
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Figure 16.   Functional domain organization of DEAD-box RNA helicase. Schematic representation 
showing domains and motifs common to the DEAD-box family. The catalytic helicase core is composed of two 
RecA-like domains, which contain conserved motifs involved in ATP binding (blue), RNA binding (brown), 
and linking of ATP and RNA binding (green). The variable N- and the C-terminus regions are also indicated. 
Adapted from (Soto-Rifo and Ohlmann, 2013). 
 
Our results show that DDX3X-K118 is robustly acetylated by CBP and slightly by p300. 
DDX3X is ubiquitously expressed in multiple tissue types, and implicated in various processes of 
cellular RNA metabolism; it includes transcription regulation, pre-mRNA splicing, mRNA export, 
translation and cellular signaling. As expected from its versatile roles, DDX3X is also involved in 
human physiology such as viral infection, and its mutations are recurrently observed in some tumors. 
These characteristics of DDX3X are summarized schematically (Fig. 17) below, and discussed in more 
detail in the following section. Most importantly, LLPS propensity of DDX3X contributes to 
membrane-less organelle formation; this ability is the main focus of our study and discussed separately 
below (discussed in 3.2.5). 
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Figure 17.   Diverse functions of DDX3X. The major biological processes regulated by DDX3X are presented: Transcription, RNA splicing, RNA export, 
Translation, Stress granule formation, Viral response and Wnt/β-catenin pathway. 
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 RNA metabolism (transcription, processing and translation) 
DDX3X is involved in transcription regulation for specific genes including p21, interferon-β 
(Inf-β), and E-cadherin, although it mainly localizes to the cytosol (Botlagunta et al., 2008; Chao et 
al., 2006; Soulat et al., 2008). DDX3X interacts with the transcription factor Sp1, and enhances 
transcription of p21 (Chao et al., 2006). Further studies directly indicated the association of DDX3X 
to the Inf-β promoter (Soulat et al., 2008), and DDX3X represses the expression from E-cadherin 
promoter in luciferase assay (Botlagunta et al., 2008). It still remains unknown how exactly DDX3X 
functions to regulate transcription of these selected genes. 
In the process of RNA splicing, DDX3X associates with the exon junction complex (EJC) 
(Merz et al., 2007). The EJC binds to spliced mRNAs approximately 20 nucleotides upstream of 
splicing junctions in a sequence-independent manner, and plays important roles in mRNA quality 
control (Le Hir and Andersen, 2008). As the EJC is a highly dynamic, consisting of several core 
proteins and transient interactors, it is still unclear whether DDX3X functions with all or only selected 
EJCs. DDX3X is implicated in mRNPs (messenger ribonucleoproteins) export in three ways. First, 
DDX3X is implicated in CRM1-mediated export of intron-containing RNA from HIV (Yedavalli et al., 
2004). The RNAs are bound by the HIV protein Rev, and DDX3X directly interacts with both the Rev 
and CRM1 to export RNA. Another study indicated that translation of the viral RNA is stimulated, 
suggesting the role of DDX3X in translation (Soto-Rifo et al., 2012). Second, DDX3X is involved in 
eIF4E/CRM1-dependent export mRNPs. A subset of mRNAs coding cell cycle regulators, such as 
cyclins, contain a characteristic RNA structure in their 3’UTR to efficiently bind to eIF4E. DDX3X 
associates with these mRNPs through protein-protein interactions (Topisirovic et al., 2009). Third, 
DDX3X also interacts with the mRNA export receptor TAP (NXF1) through its SR-rich IDR2 (Lai et 
al., 2008). DDX3X co-localizes with TAP in the nucleus and also in the cytosol. Thus, it is also 
implicated in TAP-dependent RNA export, which is distinct from the CRM1-mediated pathway. 
DDX3X has been linked to some translation initiation factors, especially components of eIF4 
(Shih et al., 2008; Soto-Rifo et al., 2012). DDX3X associates with eIF4E through consensus YxxxxLϕ 
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 motif at its IDR1, and partially through IDR2. The direct interaction between eIF4G is also observed 
for yeast homolog Ded1p. As expected from its binding to translation initiation factors, DDX3X indeed 
regulates translation. Knockdown of DDX3X decreases production of β-globin from a reporter 
construct, without any alterations in mRNA processing events upstream of translation (Lee et al., 2008). 
DDX3X also promotes translation of a subset of mRNAs, notably the cyclin mRNAs, and viral RNAs 
with a stem-loop in their 5’UTR in whose export DDX3X is thought to be involved (Lai et al., 2008; 
Soto-Rifo et al., 2012). DDX3X is involved in cap-dependent translation (Geissler et al., 2012; Shih 
et al., 2008), and it promotes or inhibits translation depending on the context, as has been suggested 
for its yeast homolog Ded1p (Hilliker et al., 2011). A recent study proposed a model where Ded1p and 
its orthologues engage RNAs during the initiation of translation. Ded1p associates with the translation 
pre-initiation complex at the mRNA entry channel and affects translation initiation by controlling the 
use of near-cognate initiation codons that are proximal to mRNA structure in 5’ untranslated regions 
(Guenther et al., 2018). A Ded1p mutant (with lower RNA binding ability, and impaired RNA 
unwinding ability) accumulates in 5’ untranslated regions, resulting in the initiation of translation from 
near-cognate start codons there, and subsequent decrease in protein synthesis from the corresponding 
main open reading frames. This regulatory system may have a role in meiosis, where a marked decrease 
in the levels of Ded1p is accompanied by the activation of the alternative translation initiation sites 
that are observed with Ded1p mutant. 
 
Cellular signaling 
 Apart from its main function as a regulator of RNA metabolism, DDX3X regulate cellular 
signaling, especially in two contexts: induction of IFN-α/β upon virus infection and the Wnt/β-catenin 
signaling pathway.  
 The IKKε/TBK1 complex is activated by upstream signaling cascade originating from pattern 
recognition receptors such as Toll-like receptors upon viral infection and leads activation of IRF3 and 
production of IFN-α/β (Kawasaki and Kawai, 2014). DDX3X interacts with IKKε and promotes its 
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 autophosphorylation and activation (Gu et al., 2013). IKKε phosphorylates several serine residues in 
DDX3X IDR1, and these phosphorylation promotes IRF3 to bind DDX3X, suggesting that DDX3X 
functions as adaptor that enhances activation of IRF3 by IKKε. Another study demonstrated that 
DDX3X also interacts with TBK1 and that its helicase core is phosphorylated (Soulat et al., 2008). 
This phosphorylation is important for DDX3X on the IFN-β promoter to mediate its transcription, 
although the involvement of IRF3 in this process was not tested. DDX3X also regulates the 
mitochondrial protein IPS-1, and functions as a regulator of IKKε/TBK1 complex, in order to activate 
IRF3 (Oshiumi et al., 2010). 
 In the Wnt/β-catenin signaling pathway, DDX3X acts as regulatory subunit of casein kinase 
1 (CK1) (Cruciat et al., 2013). CK1 phosphorylates and activates the scaffold protein dishevelled (Dvl), 
which binds components of Wnt receptor and the β-catenin destruction complex (Wallingford and 
Habas, 2005). Upon activation of Wnt receptors, DDX3X binds to and allosterically activates CK1. 
The helicase activities of DDX3X, including ATP hydrolysis and RNA unwinding, are not required for 
its ability to bind CK1, but its C-terminal region including IDR2 is required. DDX3X knockdown 
impairs the developmental process also in X. tropicalis and C. elegans, suggesting that the function of 
DDX3X in Wnt/β -catenin signaling is evolutionary conserved. 
 
Roles in human physiology 
DDX3X expression is deregulated in various types of tumors, and its recurrent mutations are 
associated with some specific types of tumors. Cancer promoting and suppressing roles of DDX3X 
are dependent on tumor cell types. DDX3X mRNA is overexpressed in hepatocellular carcinoma 
(HCC) tissues and, overexpression of DDX3X induces anchorage-independent growth of cells (Huang 
et al., 2004). However, another study demonstrated downregulation of DDX3X in HCC tissues (Chang 
et al., 2006a). Although the mechanism is unclear, DDX3X supports the interaction between p53 and 
Sp1 to promote the expression of p53-target genes such as p21, which is deregulated in lung tumors 
(Wu et al., 2011). The most persuasive evidence that DDX3X is important for tumor initiation and/or 
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 progression is coming from recent whole-exome sequencing studies of different cancer samples. 
Mutations are recurrently observed at catalytically important amino acids located in the DDX3X 
helicase core in a spectrum of cancers: chronic lymphocytic leukemia (Wang et al., 2011), head and 
neck squamous cell carcinoma (Stransky et al., 2011), medulloblastoma (Pugh et al., 2012; Robinson 
et al., 2012), and natural killer/T-cell lymphoma (Jiang et al., 2015). In some case of medulloblastoma, 
DDX3X and β-catenin mutations simultaneously occur. Expression of DDX3X mutant and β-catenin 
mutant indeed enhances the Wnt signaling activity defined by a reporter assay (Pugh et al., 2012). 
Given that DDX3X regulates β-catenin through CK1 activation, it may be possible that cancer-related 
mutations affect their interaction. The exact molecular mechanisms by which DDX3X mutants activate 
Wnt/β-catenin signaling pathway remain to be clarified in future, and moreover it should also be 
revealed whether these recurrent DDX3X mutations are driver mutations for the oncogenesis, or just 
support tumor progression. 
Diverse viruses utilize DDX3X as cellular co-factor for their replication. DDX3X binds to 
HIV Rev proteins, and is involved in export and translation of HIV RNAs, as mentioned above. And 
the helicase activity of DDX3X is required for HIV replication (Yedavalli et al., 2004). This was further 
confirmed that knockdown of DDX3X inhibits the export of HIV RNAs and viral replication without 
affecting cell viability (Ishaq et al., 2008), suggesting the possibility of DDX3X as a drug target. 
DDX3X is also involved in the replication of Hepatitis C virus (HCV); two genome-wide screens 
identified DDX3X as a cellular co-factor of HCV replication. DDX3X interacts and co-localizes with 
the Hepatitis C Virus (HCV) core protein, which forms part of the viral nucleocapsid, and it is required 
for HCV replication (Ariumi et al., 2007; Owsianka and Patel, 1999). It is still unknown how the 
interaction between HCV core protein and DDX3X supports viral replication. One possibility is that 
sequestering of DDX3X by the HCV core protein might disrupt other cellular functions of DDX3X, 
such as IFN-β production as mentioned above. This was observed in the case of another hepatotropic 
virus, Hepatitis B Virus (HBV); HBV polymerase binds to DDX3X, and blocks the function of 
DDX3X in innate immune signaling pathways (Wang and Ryu, 2010). In the case of vaccinia virus 
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 (VACV), the viral protein K7 binds to DDX3X, and inhibits the same pathways (Schroder et al., 2008). 
DDX3X levels were found to be reduced in HBV-positive HCC samples, while no reduction was 
observed in HCV-positive samples (Chang et al., 2006a), indicating that manipulation of DDX3X by 
these two viruses is different. Recent studies demonstrated that DDX3X also positively regulates 
Norovirus and West Nile virus replication (Chahar et al., 2013; Vashist et al., 2012), indicating that 
interactions between DDX3X and viral proteins for replication is a more general feature of RNA 
viruses. 
DDX3X is also related to a kind of intellectual disability (ID), which is called as “DDX3X 
syndrome” (Snijders Blok et al., 2015). Whole exome sequencing revealed that mutations in DDX3X 
helicase core are observed in female ID patients who also show various other features including 
hypotonia, movement disorders, behavior problems, corpus callosum hypoplasia, and epilepsy. These 
DDX3X mutation may account for 1-3% of unexplained ID in females. As mentioned above, DDX3X 
activates Wnt/β-catenin signaling pathway through the interaction with CK1. It was known that 
exogenous Wnt expression results in ventralization of zebrafish embryos, and this effect is enhanced 
by overactivation of Wnt due to DDX3X co-expression. The ID-related mutants were tested in this 
assay, and indeed exhibit a consistent loss-of-function effect on the Wnt/β-catenin pathway, suggesting 
that the mutations in DDX3X helicase core don’t efficiently activate the pathway, and that impaired 
Wnt/β-catenin pathway may cause ID. 
 
3.2.3 Acetylation in stress response 
We discovered that CBP autoacetylation occurs immediately after cells are treated with stress 
inducers (for oxidative stress, puromycin and sorbitol), resulting in global protein acetylation including 
DDX3X (see Fig. 2 in 2.1). A few studies have suggested a role for lysine acetylation on granule 
formation under stress, although without mechanistic insight. An RNAi screen in human cells 
identified the HAT p300 as an important factor for SG formation, although the outcome whether SG 
formation is inhibited or enhanced was not mentioned clearly (Ohn et al., 2008). Another study 
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 described the deacetylase SIRT6 as a critical factor for the process in C. elegans, and also in 
mammalian cells; SIRT6 knockout MEFs form less large SGs compared to WT under heat shock 
condition (Jedrusik-Bode et al., 2013). They demonstrated that the deacetylase activity of SIRT6 
regulates G3BP dephosphorylation at S149 by unknown mechanism. As G3BP phosphorylated at S149 
shows impaired self-association activity (Tourriere et al., 2003), they proposed that this would lead a 
defect in SG formation. Their result – knockout of a specific HDAC disrupts large stress granule 
formation – is fully compatible with our observations here and in the past (Kwon et al., 2007). It may 
be possible that knockout of SIRT6 also increases the acetylation in IDR-containing proteins, and 
controls their LLPS for SG formation besides the effect on G3BP. A recent study in S. cerevisiae 
demonstrated that the KAT complex NuA4 enhances SG formation upon glucose deprivation but not 
heat stress, and furthermore that pharmacological inhibition of Tip60, the human homolog of NuA4, 
decreases SGs in human cell lines (Rollins et al., 2017). The authors did not mention any effector 
molecules acetylated by NuA4/Tip60, but instead they showed that NuA4 is important for the full-
activity of Ac-CoA carboxylase Acc1. As Acc1 converts Ac-CoA to malonyl-CoA, NuA4 inhibition 
induces the accumulation of Ac-CoA in cells. They proposed that elevated Ac-CoA levels suppress SG 
formation, whereas decreased Ac-CoA levels enhance it upon glucose deprivation by an unknown 
mechanism. At first glance, the positive effect of a KAT NuA4 on SG formation seems to contradict 
the model that acetylation inhibits LLPS/SG formation. However, their work showed that Ac-CoA 
level increases under NuA4 inhibition, suggesting that increased Ac-CoA in this context may further 
be used for acetylation of IDR-containing proteins by other KATs. Although the studies mentioned 
above claimed the importance of catalytic activities of KATs/KDACs for SG formation, molecular 
mechanisms including their substrates were not described. A study showed that doxorubicin-mediated 
oxidative stress increased p300 expression in cardiac myocytes through its autoacetylation (Jain et al., 
2012). The increase in acetylated p300 is likely due to p300 autoacetylation, as it is decreased by 
inhibitors of p300 KAT activity, which is consistent with the observation that acetylated p300 enhances 
resistance to proteasomal degradation. In parallel, p300 mRNA decreased significantly over the time-
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 course, indicating that transcriptional induction is unlikely to account for the robust increase in p300 
during stress. This finding raises an important physiological mechanism to control p300 activity in the 
response to acute oxidative stress, and is a good match with our observations about CBP. Acetylation 
regulates RNP granule formation not only through altering net charge of IDR, but also through 
changing other protein properties. For example, acetylation in the RNA binding domain of TDP-43 
impairs its RNA binding ability and enhances aggregate formation, showing another critical role of 
acetylation in RNP granule formation (Cohen et al., 2015). In this case, acetylation sites are not in the 
IDR of TDP-43, but in its RNA binding domain and may affect the protein stability of TDP-43 or its 
association with RNA (discussed in 1.2.2). There are multiple open questions in this physiological 
system to control RNP granule formation through stress-regulated acetylation. Our study revealed that 
DDX3X acetylation by CBP is increased in early phase after stress-inducer treatment, while 
deacetylation by HDAC6 in SGs occurs in later phase. Along the same line, the kinetics of each 
KAT/KDAC under several types of stress should be examined in the future, and how specific stresses 
lead to their activation with concomitant acetylation of multiple targets should also be investigated. 
Moreover, it still remains unknown if/how the granule formation ability of other RNA binding proteins 
and RNA helicases are regulated by acetylation. Most importantly, it is currently unknown whether or 
not this global acetylation provides any benefits to cellular fitness. Nevertheless, lysine acetylation and 
deacetylation, as a regulator of RNP granule formation, may offer a novel therapeutic rationale for 
targeting HDACs or HATs in diverse neurodegenerative diseases. 
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 3.2.4 Roles of posttranslational modifications in phase separation 
Membrane-less organelle formation can also be regulated by modulating the phase separation 
threshold by changing the degree of valency and intrinsic solubility of components; PTMs appear to 
be an important factor to control these properties. We found that DDX3X-IDR1 can undergo LLPS, 
and lysine acetylation in the IDR1 disrupts it (see Fig. 3 in 2.1). Positively charged lysine residues in 
an IDR contribute to cation-anion or cation-π interactions, which are driving forces of LLPS. Lysine 
acetylation weakens these interactions due to neutralization, and as a result, LLPS of the IDR is 
attenuated. Our data also demonstrate that spatiotemporal modifications of DDX3X-IDR1 are 
regulated by CBP and HDAC6 in vivo, and that (de)acetylation-modulated DDX3X LLPS contributes 
to SG formation. As far as we know, DDX3X is the first example where acetylation regulates LLPS; 
(de)acetylation-modulated LLPS may become a general mechanism to control the formation of 
membrane-less organelles. Several examples of the phase separation controlled by PTMs have been 
recently revealed; they comprise phosphorylation, methylation, sumoylation, non-covalent 
interactions between ubiquitin/polyubiquitin and their receptor proteins, and Poly(ADP-Ribose), as 
well as acetylation first revealed by our study (Table 5). 
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 PTMs Targets Molecular 
Determinants 
Effect on phase 
separation 
Reference 
Phosphorylation N-WASP 
signaling 
MD Enhanced (Li et al., 2012) 
Phosphorylation LAT signaling MD Enhanced (Su et al., 2016) 
Phosphorylation HP1α IDR Enhanced (Larson et al., 2017) 
Phosphorylation PGL-1 N.A. Enhanced (Zhang et al., 
2018a) 
Phosphorylation Synapsin1 IDR/MD Attenuated (Milovanovic et al., 
2018) 
Phosphorylation FUS LCS Attenuated (Monahan et al., 
2017) 
Phosphorylation TDP-43 α-helix Attenuated (Wang et al., 2018a) 
Phosphorylation DYRK 
substrates 
N.A. Attenuated (Rai et al., 2018) 
Phosphorylation RNA Pol II 
CTD 
LCS Enhanced/ 
Attenuated 
(Kwon et al., 2013; 
Lu et al., 2018) 
Methylation  DDX4 RGG/RG motif Attenuated (Nott et al., 2015) 
Methylation hnRNPA2 RGG/RG motif Attenuated (Ryan et al., 2018) 
Methylation FUS RGG/RG motif Attenuated (Hofweber et al., 
2018; Qamar et al., 
2018) 
Methylation PGL-1, PGL-3 RGG/RG motif Attenuated (Zhang et al., 
2018a) 
Sumoylation PML body 
components 
MD Enhanced (Banani et al., 2016) 
Ubiquitin chain UBQLN2 IDR Attenuated (Dao et al., 2018) 
Ubiquitin chain p62/SQSTM1 MD Enhanced (Sun et al., 2018) 
Poly(ADP-
ribose) 
TDP-43 N.A. Enhanced (McGurk et al., 
2018) 
Acetylation DDX3X LCS Attenuated (Saito et al., 2019) 
Table 5.   Summary of phase separation regulated by PTMs. Molecular determinants indicate expected 
driving force for phase separation, that is affected by PTMs. MD: modular interaction domains; N.A.: not 
assessed. 
 
Phosphorylation 
Phosphorylation functions as ligand for binding modules of multivalent proteins, and thus 
promotes LLPS. Actin-regulatory signaling pathway, composed of nephrin, Nck and neural Wiskott-
Aldrich syndrome protein (N-WASP), is regarded as the first example that phosphorylation plays an 
important role in LLPS (Li et al., 2012) (discussed in 1.3.2); these components form oligomers through 
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 SH2 domains and phosphotyrosine residues (ligands of SH2 domains). LAT signaling assembly is also 
controlled mainly by interaction between SH2-containing proteins (GRB2, GADS and SLP76) and 
phosphortyrosine residues on the components (LAT and SLP76) (Su et al., 2016) (discussed in 1.3.2). 
Phosphorylation also alters the electrostatic and/or oligomerization abilities of IDRs, and affects phase 
separation. The N-terminal IDR of HP1α is phosphorylated, which induces its conformational change 
and subsequent higher-order oligomerization, and results in enhanced LLPS (Larson et al., 2017). 
Similarly, mTORC1-mediated phosphorylation of PGL-1 and PGL-3 is important for these proteins to 
phase separate and form PGL granules, which confer heat-stress resistance on C. elegans embryos, 
although the molecular mechanisms of their LLPS remain to be solved (Zhang et al., 2018a). It was 
also shown that phosphorylation can also negatively regulate phase separation. The C-terminal IDR of 
synapsin1 is phosphorylated by CaMKII, and this phosphorylation disrupts LLPS of synapsin1 to 
release lipid vesicles, mimicking the process observed at presynaptic sites (Milovanovic et al., 2018). 
Phase separation of neurodegenerative diseases-associated proteins is also regulated by 
phosphorylation, showing therapeutic possibilities to target kinases and phosphatases for the treatment. 
The N-terminal LCS of FUS is enriched with serine and threonine residues, which are phosphorylated 
by DNA-PK, and resulting negative charges at S/T sites in the LCS inhibit phase separation (Monahan 
et al., 2017). TDP-43 has a single serine phosphorylation site in the N-terminal globular domain for its 
oligomerization. Phosphorylation impairs the oligomerization and LLPS propensities, and increases 
fluidity of its nuclear assembly (Wang et al., 2018a). Although these examples clearly demonstrate the 
importance of phosphorylation in phase separation, a limited number of studies have focused on the 
interactome of a certain kinase or phosphatase in the context of membrane-less organelle formation. 
An exemplary study explained the molecular mechanism that membrane-less organelles disappear 
upon nuclear-envelope breakdown and reappear when mitosis is completed, and demonstrated that 
dual-specificity kinase DYRK3 acts as a central “dissolvase” for this process (Rai et al., 2018). The 
DYRK3 interactome was obtained by SILAC, which revealed that the majority of proteins identified 
were known to bind RNA, and also include well-known components of biomolecular condensates such 
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 as SGs, splicing speckles and the centrosome or pericentriolar matrix. Pharmacological inhibition of 
DYRK3 kinase activity causes aberrant mitotic hybrid phase-separated components, indicating that 
DYRK3 is important to prevent the unmixing of the mitotic cytoplasm. The other well-known example 
to show phosphorylation-mediated phase separation is a subunit of RNA polymerase II (Pol II) 
(discussed in 3.3.2). 
 
Methylation 
Positively charged arginine residues in an IDR contribute to cation-anion or cation-π 
interactions for phase separation. Unlike lysine acetylation, arginine methylation does not affect the 
positive net charge, but it alters hydrogen bonding and local hydrophobicity of arginines (Fuhrmann 
et al., 2015), and thus influences cation-π interactions that drive phase separation. The N-terminal IDR 
of DDX4 alone is sufficient for LLPS, and it contains several RGG/RG motifs where arginine 
methylation possibly occurs (Nott et al., 2015). Arginine methylation is regulated by protein arginine 
methyltransferases (PRMTs) in vivo. Several independent proteomic analyses identified arginines in 
LCS of hnRNPA2 that are methylated by PRMT1; two studies found demethylation and 
monomethylation at several modified RGG sites (Friend et al., 2013; Geoghegan et al., 2015), while 
another study further suggested that PRMT1 can methylate arginines at non-RGG sites, including RGF, 
which is also observed in the hnRNPA2 LCS (Wooderchak et al., 2008). Methylation of hnRNPA2 
LCS by PRMT1 in vitro induces asymmetric dimethylation of the several RGG sites there, and indeed 
decreases LLPS (Ryan et al., 2018). This RGG/RG motif is often found in RNA-binding proteins; 
another ALS-related protein, FUS, also has RGG/RG-rich domains at its C-terminus (CTD) in addition 
to the N-terminal LCS. Arginine methylation of RGG/RG motifs reduces phase separation of FUS and 
increases droplet dynamics. Moreover, hypomethylation of FUS caused by adenosine-2,3-dialdehyde 
(AdOx), an inhibitor of PRMT, is accompanied with enhanced cellular FUS granules formation in an 
AdOx dose-dependent manner (Qamar et al., 2018). It has also been revealed that TNPO1 (also known 
as importinβ2) functions as a chaperone protein for FUS (Guo et al., 2018a; Yoshizawa et al., 2018). 
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 The chaperone activity of TNPO1 is not impaired when FUS is hypomethylated, and TNPO1 has an 
even higher affinity for hypomethylated FUS (Hofweber et al., 2018), suggesting that TNPO1 
efficiently prevents FUS from phase separation when the methylation level of FUS is decreased. As 
mentioned above (discussed in 1.3.2), repetitive -G/S-Y- motifs in FUS N-terminal LCS are prominent 
drivers of its LLPS. FUS phase separation is impeded by either replacement of tyrosines in N-terminal 
LCS with alanines or arginines in CTD by alanines (Qamar et al., 2018). This strongly suggests that 
aromatic π of tyrosine residues in the LCS of FUS interact with cationic arginines in its CTD inter- 
and intra-molecularly, and thus that these cation-π pairings contribute to phase separation of FUS. This 
regulatory mechanism of hnRNPA2 and FUS by methylation will perhaps encourage the development 
of drugs that specifically activate PRMTs in ALS patients. Furthermore, methylation-mediated LLPS 
plays a physiological role in C. elegans embryos apart from pathological context; methylation of PGL-
1 and PGL-3 attenuates LLPS of PGL granules (Zhang et al., 2018a). This methylation simultaneously 
enhances their selective autophagic degradation to restrict germline P granules to germ blastomeres 
during embryogenesis (Li et al., 2013; Zhang et al., 2009). 
 
Ubiquitin-like modification 
Promyelocytic leukemia (PML) body is a membrane-less organelle that has been implicated 
in the regulation of various cellular functions, such as the induction of apoptosis and cellular 
senescence, inhibition of proliferation, maintenance of genomic stability and antiviral responses 
(Bernardi and Pandolfi, 2007). A large part of PML bodies components, including its prominent 
component PML, are sumoylated, and SUMO-SIM interactions among these components are 
considered as a driving force for the formation of PML bodies. Although a reconstituted system 
composed of synthetic SUMO and SIM proteins provided the evidence that valency of these two 
components defines the composition of PML body in vitro (Banani et al., 2016), the role and dynamics 
of each PML body component in vivo still remain unknown. It is also unknown whether or not 
ubiquitination affects LLPS, but there is some evidence showing that ubiquitin or polyubiquitin chains 
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 affect LLPS. Proteasomal shuttle factor UBQLN2, which mediates autophagy-independent protein 
aggregate clearance by the proteasome, is a component of SGs. UBQLN2 has an IDR at its C-terminus 
including oligomerization domain, and it exhibits LLPS in vitro (Dao et al., 2018). The oligomerization 
ability is connected to LLPS ability and its localization in SGs. Ubiquitin or polyubiquitin binding to 
UBA domain of UBQLN2 attenuates its LLPS, thus serving as a switch between condensed and 
dispersed phases. Hence, UBQLN2 may be recruited to SGs through its intrinsic LLPS ability without 
any ubiquitin binding, where its interactions with ubiquitinated substrates may reverse their LLPS to 
enable shuttling of clients out of SGs. LLPS mediated by ubiquitin is also important in protein 
aggregate clearance by autophagy. An autophagy receptor p62/SQSTM1 interacts with both ubiquitin 
and LC3/GABARAP on the autophagosome, thereby promoting autophagy of ubiquitinated 
aggregated proteins (Kirkin et al., 2009) (discussed in 1.2.3). The current concept is that ubiquitin-
tagged misfolded proteins are assembled into aggregates by the scaffold protein p62, and these 
aggregates are then engulfed and degraded by autophagosomes. One study revealed that p62 forms 
liquid-like droplets in vivo (Herhaus and Dikic, 2018; Sun et al., 2018). Purified p62 itself doesn’t 
undergo LLPS in vitro, but adding a K63 polyubiquitin chain to p62 induces its LLPS, indicating that 
the p62 LLPS is mechanistically dependent on its polymerization through the interaction between p62 
and ubiquitin/polyubiquitin. p62 is mutated in Paget’s disease, and disease-related mutations impaired 
its LLPS. These examples clearly demonstrate that the LLPS propensities of proteasome shuttle factors 
or autophagy receptors are mediated by ubiquitin/polyubiquitin binding, and that their LLPS plays an 
important role for aggregate clearance. 
 
Poly(ADP-ribose) 
Poly(ADP-ribose) (PAR) is a negatively charged biopolymer, which is covalently attached to 
target proteins by PAR polymerases (PARPs); it is recognized by specific ‘‘reader’’ proteins, and thus, 
PAR drives the assembly of protein complexes. SG and aggregate formations of TDP-43 are regulated 
by PAR; TDP-43 binds to PAR through its nuclear localization sequence, and this binding promotes 
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 its LLPS (McGurk et al., 2018). As PAR localizes in SGs, it functions as a homing signal for TDP-43, 
directing it to SGs. In Drosophila models of neurodegenerative diseases, reduction of a representative 
PARP called tankyrase, mitigates the disease phenotype associated with TDP-43 overexpression. 
Consistently, tankyrase inhibitors, which have been developed as cancer therapeutics, can reduce SG 
accumulation of TDP-43 in mammalian cells, likely by inhibiting PARylation of SG components and 
allowing TDP-43 to shuttle back to the nucleus; this suggests that tankyrase inhibition could be 
developed as a therapeutic modality for TDP-43 associated ALS/FTD.  
 
Acetylation 
Acetylation can be now added to the list of PTMs that regulate phase separation and 
membrane-less organelle formation on the basis of our work (see 2.1). We observed that DDX3X-
IDR1 can undergo LLPS, and that lysine to glutamine (KQ and allQ) mutants exhibited reduced LLPS 
propensity. Positively charged lysine residues in an IDR contribute to cation-anion or cation-π 
interactions, which are driving forces of LLPS. Lysine acetylation weakens these interactions due to 
neutralization, and as a result, LLPS of the IDR may be attenuated. We also examined systematic K to 
Q mutagenesis at multiple lysines in DDX3X-IDR1 to test its LLPS propensity, and found interesting 
positional effects of lysines there. Mutation on seven residues (K35, 50, 55, 64, 66, 81, and 118) 
impaired LLPS, while three residues (K130, 138 and 162) did not (Fig. 18). One study redefining the 
DDX3X catalytic core may explain these positional effects of K to Q mutations on LLPS (Floor et al., 
2016). The DDX3X subfamily has a conserved N-terminal extension (NTE, a.a. 132-167 in human 
and mouse), which harbors a predicted short α-helix at the C-terminal end of the region (a.a. 1-167) 
that is predicted to be an IDR by several established algorithms. Although secondary structures such 
as α-helix were also reported to trigger LLPS (Conicella et al., 2016), our observation indicates that in 
the case of DDX3X lysine acetylations in a “genuine” IDR (K35, 50, 55, 64, 66, 81, and 118) impair 
LLPS more effectively than acetylations in an α-helix. We also confirmed that cortactin, a well-
established substrate of HDAC6, also has an IDR in its N-terminus (Li et al., 2017), and undergoes 
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 LLPS. In this case as well, K to Q mutation, as an acetylation mimic, impairs LLPS. Thus, our 
observations with DDX3X hint to a general mechanism for LLPS regulation by acetylation. In addition 
to impaired droplet formation, we observed that acetylated DDX3X-IDR1 is not precipitated from 
cellular lysates by the b-isox chemical. It would be interesting to determine the structure of soluble, 
monomeric DDX3X-IDR1 by solution NMR spectroscopy (as done in (Monahan et al., 2017; Ryan et 
al., 2018)) and compare with the acetylated form. 
 
 
Figure 18.   Positional effect of acetylation on DDX3X-IDR1. Although the structure prediction program 
VL3-BA defines DDX3X a.a. 1-167 as an N-terminal IDR1 (bottom, PONDR score graph), a recent structural 
analysis study (Floor et al., 2016) defines only a.a. 1-131 as an IDR1 of DDX3X. The region (a.a.1-131) in red 
represents this genuine IDR1, while the region in green (a.a. 132-167) represents an α-helical extension of the 
helicase core. All 10 lysine residues in each region are numerated. 
 
3.2.5 DDX3X in stress granule formation 
DDX3X has been reported as a component of SGs and neuronal kinesin-associated granules 
(Kanai et al., 2004; Lai et al., 2008; Shih et al., 2012). Overexpressed DDX3X-GFP formed SGs (Lai 
et al., 2010), which reflects the SG formation observed in yeast upon overexpression of DDX3X 
homolog Ded1p (Beckham et al., 2008). This study reported that knockdown of DDX3 did not impair 
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 SG assembly under arsenite (Lai et al., 2010), while the other reported that knockdown of DDX3X 
interfered with SG formation under the same context (Shih et al., 2012). The difference between these 
two conditions may be due to knockdown efficiency of DDX3X and/or SG-quantification methodology. 
We established DDX3X KO MEFs and observed that the total SG area defined by G3BP 
immunofluorescence microscopy in cell is decreased in KO cells under specific stress conditions 
(oxidative stress, energy depletion and puromycin). As DDX3X can be divided into three functional 
domains, IDR1, helicase core and IDR2, it is important to dissect the contribution of each domain to 
SG formation. While the role of IDR1 was extensively studied in our work (2.1), several observations 
argue that RNA/DNA helicases including DDX3X, which utilize the energy of ATP hydrolysis to 
unwind DNA/RNA, play roles in controlling SG formation and disassembly. This supports a concept 
of SG as ‘active liquids’ where the energy of ATP-driven remodeling keeps the assembly in a dynamic 
state. Indeed, previous work has already tried to dissect the role of the helicase core for its SG 
localization and/or formation, but it is still unresolved; mutations in important residues for its helicase 
activity in DDX3X do not interfere with SG formation (Shih et al., 2012), while medulloblastoma-
associated mutations in its helicase core enhance SG formation (Valentin-Vega et al., 2016). These 
studies only provide qualitative data, that is, percentage of SG-positive population, and do not quantify 
SG parameters such as its number and average size inside each cell. Thus, we also tested the 
contribution of DDX3X helicase core domain to SG formation with our experimental setup with 
quantification (2.3.6 Apx. 6). DQAD (E348Q) mutant and AAA (S382A and T384A) mutant are 
commonly used in the field; a point mutation of the DEAD sequence (Motif II) to a DQAD severely 
impairs ATPase activity and helicase activity, while the conversion of the SAT motif (Motif III) into 
AAA impairs the RNA-unwinding activity, but retains the ATPase activity of the helicase (Soto-Rifo 
and Ohlmann, 2013). A study about the helicase core of another DEAD-box helicase, Vasa (DDX4 
ortholog of D. melanogaster), has revealed other key residues for its function (Sengoku et al., 2006). 
As DEAD-box helicase cores are well conserved between DDX3X and Vasa, the corresponding four 
residues of DDX3X: Q477A and R480A (Motif IVa), T498A (Motif V) and R503A (Motif Va) are 
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 mutated, and their SG formation ability was also tested (2.3.6 Apx. 6). All six mutants formed smaller 
SGs, confirming that the helicase core is important for normal SG formation. Increased SG number 
was also observed with DQAD and AAA mutants, and DQAD mutant showed the most significant 
difference compared to other constructs. Although four mutants (Q477A, R480A, T498A and R503A) 
lose RNA-binding ability (2.3.6 Apx. 6C), DQAD and AAA mutants are still fully capable to bind 
RNA (Pause and Sonenberg, 1992). Thus, the RNA-binding ability itself may not be the cause of 
impaired SG formation observed in this experiment. Given that all mutants exhibit impaired RNA-
unwinding ability, this primary helicase function seems to be connected to maintenance of SG rather 
than simple SG disassembly, and may give a good explanation for the observation here. Although both 
DQAD and AAA mutants lost RNA-unwinding ability, ATPase activity-deficient DQAD mutant 
formed much smaller SGs than ATPase activity-intact AAA mutant, implying that ATPase activity 
itself contributes to keep SG size. It is important to mention that DDX3X plays important roles in 
regulation of translatome as mentioned above, and other RNA-binding proteins, ribosomes and RNAs 
may be affected by DDX3X mutants, resulting in impaired SG formation. Obviously, further 
systematic studies to compare in parallel several biological function of DDX3X including three major 
properties of the helicase core (RNA-binding, ATPase and RNA-unwinding), global effect on 
translatome and SG formation would be required. 
On the other hand, the contribution of N-terminal IDR1 has been firmly confirmed 
independently by several groups (Shih et al., 2012; Valentin-Vega et al., 2016). Moreover LAF-1, a 
related C. elegans protein, has been shown to undergo LLPS, which depends on its N-terminal RGG 
region (Elbaum-Garfinkle et al., 2015). Here, we demonstrated that DDX3X-IDR1 undergoes LLPS, 
and that this propensity is important for both localization of DDX3X into SGs and their maturation. In 
addition to acetyl-mimic/dead mutations, cancer-related mutations in IDR1 also affected its LLPS 
(2.3.7 Apx. 7). Especially arginine mutations in RG or RXG sequences impaired its LLPS, suggesting 
that these motifs function as driving force for LLPS also in the case of DDX3X-IDR1. The biological 
relevance of these mutations and stress sensitivity in cancer cells should be tested in near future. 
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 Spatiotemporal modifications of DDX3X-IDR1 regulated by CBP and HDAC6 control SG maturation. 
Earlier work from our laboratory (Kwon et al., 2007) demonstrated that loss of HDAC6 reduces the 
number of large SGs under arsenite treatment, which is likely related to the work presented here. It is 
important to note that other SG components harboring IDRs also would possibly be regulated by 
HDAC6. We realized that one of our HDAC6 high-confidence target sites is in IDR of Serbp1, another 
SG component (Lee et al., 2014b). Serbp1, a RNA binding protein, harbors a long IDR containing two 
RGG/RG-rich sequences (RGG box1 and 2). These RGG/RG-rich regions are also methylated by 
PRMT1 as mentioned above (discussed in 3.2.4), and hypomethylated Serbp1 prefers to localize in the 
nucleus (Lee et al., 2012). Along the same line, we observed that large part of Serbp1 SG formation 
ability is depending on these two RGG boxes, suggesting the importance of these regions for its SG 
formation (2.3.8 Apx. 8B). As observed in DDX3X, acetyl-mimic mutation (K122Q) in the Serbp1 
IDR also affected SG formation; numerous smaller SGs were induced (2.3.8 Apx. 8C). Thus, HDAC6 
may regulate the acetylation status of IDRs in a set of proteins contributing to SG formation. 
Several models have been proposed to explain the formation of SGs. A prevalent “Cores First” 
model (Jain et al., 2016; Protter and Parker, 2016; Wheeler et al., 2016) suggests that mRNPs first 
condense into stable core structures through strong specific interactions (initiation), and the high local 
concentration of IDRs on SG components then triggers a LLPS for shell components of SGs 
(maturation). Specific stresses induce autoacetylation and activation of CBP, and lead to global protein 
acetylation, including DDX3X. Another RNP component, TDP-43, also becomes acetylated by CBP 
under oxidative stress, and aggregated. This aggregation is resolved by counteraction of HDAC6 
(discussed in 1.2.2). Many open questions in this granules/aggregates formation mediated by stress-
induced acetylation still remain unanswered (discussed in 3.2.3). Nevertheless, active deacetylation by 
HDAC6 of some RNP components is essential for their normal dynamics and function in the stress 
response; deacetylation is necessary for some IDR-containing proteins including DDX3X to undergo 
LLPS and induce appropriate SGs formation. Our quantitative analysis and mathematical modeling of 
SG growth with a series of DDX3X mutants (see Fig. 5 in 2.1) provided additional evidence that 
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 regulation of LLPS by acetylation/deacetylation is critical not for the initiation of the SG formation, 
but for their maturation, which is consistent with the model mentioned above. The comparison of 
interactomes between DDX3X WT and acetyl-mimic allQ mutant revealed that the acetyl-mimic 
mutant does not interact with some IDR-containing proteins such as hnRNPA2/B1. This further shows 
that the recovery of DDX3X LLPS propensity by HDAC6 on SGs is important for localized 
recruitment of other proteins which themselves can undergo LLPS and contribute to the formation of 
SG shell together with DDX3X. Thus, our results demonstrate a novel physiological role for 
acetylation/deacetylation in LLPS during SGs maturation (Fig. 19), and may help to further refine the 
models for SG assembly. 
 
 
Figure 19.   HDAC6 regulates SG maturation through DDX3X deacetylation. Upon stress, CBP becomes 
activated and elicits acetylation of DDX3X-IDR1 among other proteins, thus impairing LLPS and leading to 
formation of small SGs. While CBP does not localize to SGs, HDAC6 is recruited to SGs where it deacetylates 
the IDR1. Positively charged lysine residues in the IDR1 contribute to cation-anion or cation-π interactions. 
This promotes LLPS of DDX3X and allows other IDR-containing proteins as interaction partners of DDX3X-
IDR1 to engage in the formation of large mature SGs. 
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 3.3 Future of acetylation-modulated LLPS 
3.3.1 HDAC6 at the crossroad between liquid-liquid and liquid-solid phase separation 
Liquid-solid phase transition in biology 
Membrane-less organelles generally possess liquid-like properties, but some have more solid-
like properties. Importantly, physical properties of phase-separated droplets can change over time in 
vitro and in vivo. Some IDR-containing proteins initially form fluid droplets, but become more 
viscoelastic over time, and eventually stop to exchange molecules with the surroundings and behave 
as solid (also known as “maturation” or “aging”) (Lin et al., 2015; Patel et al., 2015). The material 
properties of the mature solid state observed in vitro are currently unclear, but one possible type is gel. 
The ALS-related proteins such as FUS and hnRNPA1 can form hydrogels under high-concentration 
and low-temperature conditions (Kato et al., 2012; Molliex et al., 2015; Murakami et al., 2015) (Fig. 
20). 
 
 
Figure 20.   Hydrogels formed by the LCS of FUS. Purified N-terminal LCS of FUS linked to three different 
protein tags (GST, mCherry, and GFP) adopted a gel-like state when stored at low temperature. The hydrogels 
retained the cylindrical shape of the silicon tube and exhibit the respective colors of the tags (GST, clear; 
mCherry, red; GFP, green). Scale bar, 3 mm. Adapted from (Kato et al., 2012). 
 
There were several attempts to reveal the unique properties of such hydrogels; electron microscopy 
revealed that the FUS-LCS hydrogel contains fibrils, X-ray diffraction uncovered a cross-β pattern 
reminiscent of amyloids (Kato et al., 2012), and solid state NMR elucidated that 57 of the 214 residues 
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 of FUS LCS form an ordered core, with the remaining residues dynamically disordered (Murray et al., 
2017). However, such amyloid-like fibrils are sensitive to heat and SDS, while classical amyloid fibrils 
resist to boiling and SDS-denaturation. This relative labile character of the hydrogel had suggested that 
the structure inside is different from amyloids. The atomic structure of segments from several LCSs in 
hydrogel demonstrated that the short peptides consistently form kinked β-sheet structures. Although 
cross-β strand formations among side chains give amyloid fibrils their characteristic strength and 
irreversible nature, this kinked nature of the structure called LARKS (Low-complexity Aromatic-Rich 
Kinked Segments) prevents strong cross-β strand formation, and contributes to its reversible 
meshworks (Hughes et al., 2018). Moreover, computational 3D profiling to identify potential LARKS 
in the human proteome revealed hundreds of human proteins with the sequence propensity to form 
LARKS. They comprise prominent components of each membrane-less organelle (e.g. DDX3X in SGs, 
LSM14 in P-bodies and Fibrillarin in nucleolus) and nucleoporins such as Nup54 and Nup98. Purified 
FG repeats originated from nucleoporins were first reported to form hydrogels in vitro, which evoke 
sieve-like meshwork structure of the nuclear pore complex to achieve selective shuttling of nuclear 
transport cargos (Frey et al., 2006; Schmidt and Gorlich, 2016). Thus, the affinity and kinetics defined 
by LARKS may impact on the process where liquid-droplets age and evolve into a solid-like state. It 
is important to note here that maturation is not observed in droplets formed by interactions among 
modular domains and their ligands such as SH2+phosphotyrosine and SIM+SUMO; dynamic 
behaviors remain constant and are determined by the affinity and kinetics of the domain-ligand 
interactions. 
Given that some membrane-less organelles exhibit solid-like properties, and that pathological 
mutations affect in vitro maturation process (Patel et al., 2015) to cause aggregates in vivo 
(Kwiatkowski et al., 2009; Vance et al., 2009), maturation is also likely to occur in vivo and plays a 
key role for physiology and pathology. Balbiani bodies are solid-like membrane-less organelles in 
immature oocytes of all animals, and are thought to protect the quality of mitochondria and other 
organelles during long periods of oocyte dormancy (Boke et al., 2016). Purified Xvelo, a prominent 
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 component of Balbiani bodies, forms solid-like structures in vitro, which are distinct from liquid-like 
structures formed by FUS or hnRNPA1. However, whether Xvelo forms solid-like Balbiani bodies de 
novo or they mature from a more liquid-like state is not known, and there are still technical challenging 
points to monitor the material properties over time in vivo. On the other hand, it has become apparent 
that disease-related mutations can change the threshold for the proteins to form pathogenic solid-like 
aggregations. Clues regarding the transition from physiological liquids to pathological solids come 
from recent study on expanded polyQ tracts of huntingtin (HTT) relevant to pathogenic aggregations 
observed in Huntington's disease (Peskett et al., 2018). HTT exon1 with sub-toxic polyQ lengths (n = 
25) can form liquid-like droplets in cells, but does not form irreversible solid-like aggregates. The 
conversion occurs only when polyQ length extends beyond the threshold for HD (n ≥ 42 in human). 
However, sub-toxic polyQ droplets convert to irreversible solid-like structures in vitro, suggesting that 
other cellular components such as chaperones may prevent the liquid-solid phase transition in vivo. 
Nevertheless, this correlation between mutation degree and material property of polyQ indicates that 
their liquid state is a preliminary step before their “solid” state. Complicatedly, however, liquid state 
can also be regarded as a safe reservoir to prevent proteins from being aggregated. Phase separation of 
TDP-43 is triggered by its α-helix, and ALS-associated mutations in that region significantly disrupt 
LLPS, favoring the conversion to aggregates (Conicella et al., 2016). In sum, it still remains unknown 
which parameters govern the phase transition kinetics in vivo, and several experimental observations, 
including LLPS, hydrogels in vitro, amyloid-like fibers in vivo, and more general “aggregate” 
composed of misfolded proteins all may contribute partly. 
There are a few reports that delineated how the material properties of cellular granules are 
defined and how they are changed over time. In order to identify a sequence-encoded molecular 
“grammar” underlying the driving forces of phase separation, extensive mutagenesis was carried out 
for FUS and related proteins (Wang et al., 2018b). Multivalent interactions among tyrosine residues in 
prion-like domains and arginine residues in RNA-binding domains provide the primary driving force 
for LLPS. Material properties are modified by other characteristic amino acids; glycine residues 
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 enhance the fluidity, whereas glutamine and serine residues promote hardening. One recent study 
enabled to control phase transitions spatiotemporally in living cells by using optogenetic protein 
constructs fused to various IDRs, including FUS, DDX4, and hnRNPA1 (Shin et al., 2017). The 
constructs undergo light-activated phase separation and form cytoplasmic and nuclear “optoDroplets”. 
When the system is only moderately supersaturated above the threshold by light with low intensity, 
the optoDroplets are spherical and exhibit liquid-like behaviors, including fusion and efficient FRAP 
recovery. However, when sufficient high intensity light is used to drive the system, the resulting 
condensates become more solid-like, with irregular morphology and incomplete FRAP recovery. This 
platform could be utilized to understand maturation process of liquid droplets within living cells and 
describe the biological consequence when a cell harbors condensates with a given material property. 
The majority of these studies focused on kinetics of a single protein species in the experimental system, 
and no studies mimicked the real situation where membrane-less organelles are composed of many 
hundreds of proteins. Detailed experimental studies with “artificial organelles” composed of a set of 
purified proteins including IDR-containing proteins, RNA-binding proteins and chaperons in vitro will 
be required to understand material properties of cellular condensates in future. 
  
HDAC6 as a “double-barreled” protein quality regulator 
The most cryptic thing about HDAC6 biology could be the co-existence of two functionally 
unrelated domains, that is, deacetylase domains and ZnF-UBP in a single molecule. There are a few 
reports describing the interplay between these domains; for example, K63-linked C-terminal free 
unanchored ubiquitin chains bind to ZnF-UBP of HDAC6, resulting in increased HDAC6 deacetylase 
activity (Hao et al., 2013). Yet, we still do not have any rational explanation to connect this interesting 
domain organization of HDAC6 to its biological function. Considering our novel findings and the 
discussion so far, we would like to propose here a new concept that HDAC6 is a “double-barreled” 
protein quality regulator (Fig. 21).  
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 Figure 21.   HDAC6 is a “double-barreled” protein quality regulator. HDAC6 removes acetylation so that 
IDR-containing proteins can appropriately separate into “liquid” phase. In parallel, HDAC6 brings 
unpreventable aggregates to aggresome for autophagy-mediated clearance. 
 
Given that glutamines in IDRs promote hardening, acetylated lysines may also exhibit similar 
properties due to their similarity of charges and chemical structures. Thus, the deacetylase domains – 
the first barrel – support appropriate “liquid-liquid” phase separation by converting acetylated lysine 
to lysine in IDRs. Enhanced LLPS by HDAC6 may be a way to keep proteins in a healthy “liquid” 
state after their phase separation, and prevent further droplet ageing and protein aggregation. Moreover, 
HDAC6 has a "contingency plan" to cope with protein aggregates; ZnF-UBP – the second barrel – 
binds to misfolded ubiquitinated proteins, and brings them to aggresome for autophagy-mediated 
clearance. Both functional domains of HDAC6 contribute to prevent aberrant protein aggregation at 
different scales in our novel concept. Several points should be experimentally tested to confirm this 
concept, for example: 
 
(1) Clarify the effect of acetylated lysines in liquid droplets 
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 Acetylation inhibits DDX3X LLPS in our study, suggesting that positively charged lysines in DDX3X-
IDR1 provide the driving force for its LLPS. Is this effect generalized for all IDRs? Or are there any 
examples that acetylated lysines contribute to LLPS as glutamine do? 
(2) Monitor the metastability from liquid-like SGs to solid-like aggresome over time 
Proteasome inhibitors including MG132 are often utilized to induce aggresome in cells (Kawaguchi et 
al., 2003), but SGs are also observed before aggresome form (Mazroui et al., 2007). How can we 
integrate mechanisms for these two types of membrane-less organelle formation? 
(3) Connect the acetylation status of the protein to its localization 
Some proteins such as TDP-43 (Arai et al., 2006; Dewey et al., 2011) and C9orf72 (Boeynaems et al., 
2017; Guo et al., 2018b) are components of both SGs and aggresome. With such proteins, can we link 
the acetylation status of their IDR to their localization? TDP-43 has been reported as an HDAC6 
substrate, and indeed deacetylation is required to prevent its aggregation (Cohen et al., 2015), although 
the acetylation site is not in its IDR.  
 
We hope that our daring concept could be confirmed and/or refined through such analyses, to better 
explain why HDAC6 has this unique domain organization. 
 
3.3.2 Phase separation in transcription control: beyond granule formation 
Our finding about membrane-less organelle formation regulated by (de)acetylation-
modulated LLPS is a fundamental mechanism that would explain various cellular processes. This 
would be a good match especially with emerging concept that transcription is regulated by LLPS (Fig. 
22). 
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Figure 22.   Phase Separation model for transcription. Some of the candidate transcriptional regulators 
forming the complex are highlighted. P-CTD indicates the phosphorylated CTD of RNA Pol II. PTMs of 
nucleosomes (acetylation, Ac; methylation, Me) are also highlighted. Divergent transcription at enhancers and 
promoters produces nascent RNAs. These components associate each other with weak interaction (dashed lines), 
contributing LLPS. Adapted from (Hnisz et al., 2017). 
 
Three longstanding observations propelled to describe transcription in terms of LLPS. First clue is the 
observation that labelled nascent transcripts are clustered in the nucleus, which indicates the existence 
of nuclear site with highly concentrated RNA polymerase II (Pol II) and related transcription machinery. 
Such a site is now well-known as a “transcription factory” (Iborra et al., 1996; Papantonis and Cook, 
2013), which is compatible with other membrane-less organelles observed by microscopy. The 
structure of transcription factors (TFs) provides us with a second clue. As the history of transcription 
study narrates it, TFs have been cloned usually based on their structured DNA-binding domains, and 
thus these domains have been at the center of transcription research. At the same time, however, TFs 
have a general feature in that they usually harbor IDRs in addition to their DNA-binding domains, and 
these often function as transcription activation domains in functional assays (Staby et al., 2017). 
Furthermore, the last clue to engage transcription in the LLPS concept is associated with the unique 
structure of Pol II. 
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 Transactivation domains (TADs) are functionally defined based on their capacity to activate 
transcription when tethered to the DNA, as monitored in a suitable assay. They are usually unstructured 
and form a scaffold harboring binding sites for other transcription coregulators. Because TADs lack 
sequence similarity and exhibit high degree of LCS, they have been classified according to their amino 
acid profile: for example, acidic, glutamine-rich, or proline-rich domains have been known from the 
early days of transcription study (Mitchell and Tjian, 1989) (Fig. 23). 
 
 
Figure 23.   Three major types of transactivation domains (TADs) found in transcription factors. This figure 
is adapted from the review article published ca. 30 years ago (Mitchell and Tjian, 1989), and this drawing style 
clearly shows that TADs were already regarded as IDR at that time, but this was not recognized as important 
then. Amino acid components that characterize the three domain types: acidic, glutamine-rich and proline-rich 
are written in bold. 
 
As discussed below, some TFs with LCS functioning as TAD have recently been shown to form 
biomolecular condensates at nuclear loci where target DNA array localizes, suggesting that TADs 
undergo LLPS to form transcriptional hubs. Thus, TAD-IDR can be regarded as LCS harboring LLPS 
propensity, but at the same time, it often contains the region functioning as short linear motif (SLiM) 
and molecular recognition feature (MoRF) (discussed in 1.3.2) to recruit transcriptional coregulators. 
This two-faced function is also observed with other IDRs of non-TF proteins such as synapsin1, which 
can undergo LLPS by itself and also binds to SH3 domain through its PRM domain for efficient LLPS 
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 (discussed in 1.3.2). Taken together, transcriptional hub formation may be mediated by LLPS in the 
following way: TFs bind to their target sequence with strong and specific interactions through their 
DNA binding domain (usually multiple TFs binding in close vicinity), resulting high local 
concentration of their TADs which can recruit other coregulators through SLiM and/or MoRF and 
trigger LLPS. It is worth mentioning that this working model is highly similar to the prevalent SG 
formation “Core first” model (Fig. 24), and that the sole unique point about transcription is how to 
recruit Pol II; this process is still wrapped in mystery and being extensively studied. 
 
 
Figure 24.   Analogy between formation processes of stress granules (SGs) and transcriptional hubs. RNP 
components often have both RNA-binding domain (RBD) and IDR. According to a prevalent “Core First” SG 
formation model, RNP components first form stable core structures through specific, strong interactions 
between RBD and RNA. Then, the high local concentration of IDRs on SG components would trigger a LLPS 
to mature SGs. Similarly, TFs are usually equipped with both DNA-binding domain (DBD) and intrinsically 
disordered TAD. Specific binding between DBD and target DNA sequence cause high local concentration of 
TADs, resulting in LLPS to establish transcriptional hub. It is still unknown when and how RNA pol II is 
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 recruited to this hub to initiate transcription. Double-headed black arrows indicate the dynamic interaction 
among IDRs. 
 
Extending from the Pol II catalytic core is a long IDR composed of tandem heptapeptide 
repeats (52 repeats in human) with consensus “YSPTSPS” sequence which forms the carboxy-terminal 
domain (CTD) of the largest subunit of RNA polymerase II (RPB1). Although the CTD is not required 
for the catalytic functions of Pol II, it is essential for several steps in the transcription cycle. The CTD 
is subjected to multiple PTMs, including phosphorylation, methylation and acetylation (Schroder et 
al., 2013; Serizawa et al., 1993; Zhao et al., 2016). Very recent studies have established that the CTD 
can be incorporated into phase-separated liquid droplets and hydrogels in vitro (Burke et al., 2015; 
Kwon et al., 2013; Lu et al., 2018). The LCSs of FUS and its related genes EWS and TAF15 (FET 
proteins) are translocated onto diverse different DNA-binding domains, which is observed in some 
cancers including Ewing’s sarcoma. These translocated LCSs function as transcriptional activation 
domains in the context of fusion proteins to regulate transcription for cancer cell survival (Boulay et 
al., 2017). The purified Pol II CTD directly bound to hydrogel formed by FET proteins, and the degree 
of binding correlated with the strength of transcriptional activation (Kwon et al., 2013). This binding 
depends on the length and phosphorylation state of the CTD: a shorter CTD (five heptapeptide repeats) 
is not binding to the hydrogel, whereas longer ones (ten or more repeats) are efficiently incorporated. 
In parallel, phosphorylation attenuates the CTD incorporation into the hydrogels, indicating that 
phosphorylation may inhibit phase separation of the CTD. At the same time, given that FUS has been 
shown to regulate CTD phosphorylation in vivo (Schwartz et al., 2012), it is possible that the CTD and 
other factors may undergo phase separation in a way that requires CTD phosphorylation. Actually, the 
CTD phosphorylation seems to either promote or prevent phase separation, depending on its 
interaction partners. Recent study proposed that CTD itself doen’t phase separate and phosphorylation 
is required for its phase separation. IDR of cyclin T1, a component of positive transcription elongation 
factor b (P-TEFb) complex known to stimulate Pol II through phosphorylation, undergoes LLPS driven 
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 by its histidine-rich sequence, and recruitment of Pol II into the cyclinT1-IDR droplets is enhanced by 
its CTD phosphorylation (Lu et al., 2018). DYRK1A, another kinase for CTD (Di Vona et al., 2015), 
also has histidine-rich sequence, indicating that these key initiation and elongation factors can phase 
separate to actively recruit Pol II through multivalent interactions to their droplets. Clearly, more 
studies are required to delineate whole molecular processes from transcription initiation to termination; 
nevertheless, these observations certainly demonstrate that the phase separation ability of CTD is 
important for transcription. 
The endeavor to clarify the mechanism of transcription with LLPS has just started with 
detailed analysis of its prominent component Pol II and its regulatory factors mentioned above. Various 
high-end imaging methods (e.g. lattice light-sheet microscope) in live cells have recently shed new 
insights into the nature of LCS interactions and their role in transcription (Chong et al., 2018). 
Transactivation domains form local high-concentration hubs of TFs through their dynamic LCS-LCS 
interactions. The hubs stabilize DNA binding, recruit Pol II, and activate transcription. LCS-LCS 
interactions are sequence specific; heterotypic-interactions between LCSs derived from same TF 
family proteins (e.g. FUS-EWS, both are FET proteins) are stronger than the interactions between 
different TF family proteins (e.g. FUS-Sp1). Both the composition of LCSs in hubs and their 
interaction specificity could influence their LLPS propensity and subsequent transcription. It was also 
shown that LCS-LCS interactions play a role in dysregulated gene expression by the EWS fusion 
protein associated with Ewing’s sarcoma, suggesting that LCS-LCS interactions may represent a new 
class of therapeutic targets. In addition to TFs, transcription is skillfully regulated by other components 
such as enhancers and mediators in case of eukaryotic cells (Levine et al., 2014). Enhancers are gene 
regulatory elements bound by the transcription apparatus and transcription factors, they control cell 
type-specific gene expression. Super-enhancer (SE) is defined as a cluster of enhancers, which is 
occupied by high densities of transcriptional machinery. This high density assembly at SEs show to 
exhibit sharp transitions of formation and dissolution, implying that the high concentrated 
biomolecules at SEs may be assembled through phase separation (Hnisz et al., 2017). Transcriptional 
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 coactivators BRD4 and MED1 are important components of SEs, and recent studies clarified their 
contribution to LLPS in detail (Cho et al., 2018; Sabari et al., 2018). BRD4 and MED1 form nuclear 
puncta, which are also positive for specific transcripts from SEs (Sabari et al., 2018). A companion 
work showed that Pol II clusters colocalize with this mediator puncta (Cho et al., 2018). These nuclear 
puncta show liquid-like properties, and are indeed dissolved by 1,6-hexanediol, a compound known to 
disrupt liquid-like condensates (Lin et al., 2016). This disruption is accompanied with the 
downregulation of the SE-driven gene expression. Both BRD4 and MED1 contain IDRs and they can 
phase separate in vitro. Droplets of MED1-IDR, which is enriched in conserved serine residues 
important for its LLPS, incorporate both BRD4 and subunit of RNA pol II (RPB1), suggesting that it 
can sequester key components of the transcription apparatus. These results strongly support a model 
(Hnisz et al., 2017) in which transcriptional coactivators form phase-separated compartments to 
concentrate the transcription apparatus at SEs. 
Transcriptional hubs are composed of multiple components, many of which carry PTMs, and 
interactions between them may provide the valency necessary for LLPS. Given that HDAC6 regulates 
SG formation by promoting LLPS, it is tempting to speculate that other HDACs in the nucleus may 
also regulate the formation of transcriptional hubs by modulating LLPS. Further functional analysis 
about TAD-IDR is awaited to delineate the role of IDR-acetylation in the concept of LLPS-mediated 
transcription. In particular, our understanding about the molecular grammar of IDRs is not yet 
sufficient to classify them into subgroups based on their traits so that we can explain the formation of 
a wide variety of transcriptional hubs enriched with a combination of diverse transcriptional regulators 
in a unified manner. In the case of DDX3X-IDR1, positively charged lysine residues contribute to 
LLPS by themselves or with other SG components mainly through cation-anion or cation-π 
interactions, and thus acetylation works as a negative regulator for LLPS. However, it may also be 
possible that polar acetylated lysines can promote LLPS, as is the case with polar glutamine in some 
TADs or prion-like domains. Accordingly, the effect of IDR-acetylation on LLPS would depend on the 
amino acid composition and sequence of IDR itself and its interaction partners. In order to assess such 
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 context-dependent physicochemical properties of acetylated lysines in LLPS, recombinant proteins 
with site-specific acetylations would be helpful (Neumann et al., 2008). At the same time, functional 
hierarchy of substructures within IDR (SLiM, MoRF and LCS) should be also defined in more in 
detail; this is especially important because it is necessary to consider that acetylated lysines in SLiM 
or MoRF may also provide a binding platform for acetyl-lysine “reader” domains including BRD 
mentioned above, and that their multivalent interactions may themselves promote LLPS. This could 
therefore also be another mechanism for acetylation-modulated LLPS, distinct from our findings that 
acetylation impairs LLPS through neutralization of IDRs. Given that acetyl-lysine reader proteins are 
more enriched in the nucleus than the cytosol (Filippakopoulos and Knapp, 2012), it may be possible 
that acetylation inhibits LLPS in cytosol and enhances it in nucleus (Fig. 25). 
 
 
Figure 25.   Acetylation-modulated LLPS. Acetylation of IDR impairs the interaction between anionic 
residues (red) and pi electrons on aromatic residues (purple) in other IDRs, and therefore inhibits LLPS (shown 
by blue arrows), as observed in DDX3X-IDR1. On the other hand, resulting acetylated lysine (orange) prefers 
to bind other types of amino acids including polar amino acids (G, Q, N and S; green) and may enhance LLPS. 
Apart from IDR-IDR interactions, acetylated lysines in SLiM or MoRF of IDRs work as ligands for acetyl-
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 lysine reader proteins (Acetyl-reader), and the resulting multivalent interactions between acetylated IDR and 
acetyl-readers would also enhance LLPS (shown by red arrows). This may regulate formation of nuclear 
biomolecular condensates including transcriptional hubs because acetyl-readers such as BRD family proteins 
are enriched in the nucleus. 
 
Taken together, functional hierarchy of IDR-substructures for LLPS may also depend on surrounding 
protein species in addition to their positioning within IDR. Screening with deeply mutated IDRs 
(Fowler and Fields, 2014) or synthetic IDR libraries of de novo amino acid sequences (Simon et al., 
2017), which should be supported by machine learning algorithms (Ravarani et al., 2018), would help 
to systematically delineate the molecular grammar of IDRs including TADs in LLPS. Collectively, we 
discovered that histone deacetylases regulate LLPS in membrane-less organelle formation, and 
anticipate that additional biological processes regulated by acetylation-modulated LLPS will be 
identified in the future. 
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 DNA constructs and antibodies 
DDX3X, Pex5 and Serbp1 cDNAs were cloned from WT MEF cells into expression vectors 
(pcDNA3.1 for transient expression or pMSCV for stable expression). Expression vectors for HATs 
(FLAG-PCAF, HA-CBP, Myc-Tip60 and HA-p300) were kindly supplied from Dr. Renate Voit 
(German Cancer Research Center, Heidelberg). To construct expression vectors for functional mutants 
of HDAC6, DDX3X and Serbp1, a plasmid of interest was amplified with appropriate sets of primers, 
then the PCR product was self-ligated to obtain a mutated plasmid. Primary antibodies were as follows: 
anti-α-tubulin (DM1A) (Sigma, T9026), anti-Acetylated Tubulin (6-11B-1) (Sigma, T7451), anti-
FLAG (M2) (Sigma, F1804), anti-HDAC6 (ab56926), anti-HA (16B12) (ab130275), anti-c-Myc 
(9E10) (ab32), anti-Phopho-eIF2α (Ser51) (D9G8) (Cell Signaling Technology (CST) #3398), anti-
Histone H3 (D1H2) (CST#4499), anti-Acetyl-CBP (Lys1535)/p300 (Lys1499) (CST#4771), anti-
eIF2α (D7D3) (CST#5324), anti-CBP (D6C5) (CST#7389), anti-HDAC6 (D21B10) (CST#7612), 
anti-DDX3 (D19B4) (CST#8192), anti-TIAR (D32D3) (CST#8509), anti-Acetylated-Lysine 
(CST#9441), anti-Acetylated-Lysine (Ac-K-103) (CST#9681), anti-Acetylated-Lysine (Ac-K2-100) 
(CST#9814), anti-PABP1 (clone 10E10) (Millipore#04-1467), anti-Acetylated-Lysine (4G12) 
(Millipore#05-515), anti-acetyl-Histone H3 (Millipore#06-599), anti-DDX3X (Millipore#09-860), 
anti-Cortactin(p80/85) (4F11) (Millipore#05-180), anti-Acetylated-Lysine (Immunechem, ICP0380), 
anti-Acetylated-Lysine (1C6) (Thermo Fisher Scientific, MA1-2021), anti-DDX3X (clone 15D1B11) 
(BioLegend#658602), anti-Ub (P4D1) (Santa Cruz, sc-8017), anti-[K(Ac)40]-α-tubulin (Enzo, BML-
SA452-0100) and anti-G3BP (Aviva Systems Biology, ARP37713_T100). Anti-mouse-HDAC6 was 
developed in Matthias laboratory, FMI (Banerjee et al., 2014). Secondary antibodies were as follows: 
Amersham ECL Mouse IgG, HRP-linked whole Ab from sheep (GE Healthcare, NA931V), Amersham 
ECL Rabbit IgG, HRP-linked whole Ab from donkey (GE Healthcare, NA934V), Alexa Fluor 488 
Goat anti-Mouse IgG (H+L) Secondary Antibody (Invitrogen, A11001), Alexa Fluor 568 Goat anti-
Mouse IgG (H+L) Secondary Antibody (Invitrogen, A11004), Alexa Fluor 488 Goat anti-Rabbit IgG 
(H+L) Secondary Antibody (Invitrogen, A11034) and Alexa Fluor 568 Goat anti-Rabbit IgG (H+L) 
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 Secondary Antibody (Invitrogen, A11036). 
  
Establishment and characterization of DDX3X-K118Ac-specific antibody 
The DDX3X-K118 acetylated peptide, CDRSGFGK(Ac)FERG (PSL Peptide Speciality Laboratories) 
was conjugated with mcKLH by Imject Maleimide Activated Carrier Protein Spin Kits (Thermo 
scientific) and the KLH conjugated peptide was used to immunize two rabbits (Pocono Rabbit Farm 
& Laboratory). Collected serum was passed over K118 acetylated peptide CDRSGFGK(Ac)FERG-
conjugated agarose column prepared by SulfoLink Immobilization Kit for Peptides (Thermo scientific) 
and eluted with 0.2 M glycine-HCl, pH 2.0 and neutralized. Then, the elution was passed over K118 
unacetylated peptide CDRSGFGKFERG-conjugated agarose column and the flow through was used 
as DDX3X-K118Ac-specific antibody. The specificity for K118Ac was assessed by ELISA using K118 
acetylated and unacetylated peptide-coated plates (TaKaRa) and 1-Step Slow TMB-ELISA (Thermo 
scientific). 
 
Cell culture 
MEF cells, HEK293T cells, HeLa cells and Plat-E packaging cells were cultured in DMEM 
supplemented with 10% heat-inactivated FBS, penicillin, and streptomycin at 37 °C and 5% CO2. 
 
Transfection 
HEK293T cells, HeLa cells and Plat-E packaging cells were transfected with Lipofectamine 2000 (Life 
Technologies) or FuGENE HD (Promega), and MEF cells were transfected with 4D-Nucleofector™ 
System (Lonza, Kit: P4 Primary Cell 4D-Nucleofector™ X, Pulse program: CZ-167), following 
manufacturer's protocol. 
 
Immunoblotting and immunoprecipitation 
Cells were washed by ice-cold PBS and lysed in Triton lysis buffer (50 mM Tris, pH 8.0, 150 mM 
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 NaCl, 1 mM EDTA, 0.1% TritonX-100 and Complete EDTA-free protease inhibitors (Roche)) for 
analysis. To detect protein acetylation, 0.2 μM Trichostatin A and 5 mM nicotinamide was added to 
PBS for wash, and 10 μM Trichostatin A, 10 mM nicotinamide, 50 mM sodium butyrate were added 
to Triton lysis buffer. To detect protein phosphorylation, Pierce Protease and Phosphatase Inhibitor 
Mini Tablets (Thermo scientific) were added to Triton lysis buffer instead of Complete EDTA-free 
protease inhibitors. Five hundred μg protein lysates were incubated with the specific antibody for 
overnight at 4 °C, and immunoprecipitated with Dynabeads ProteinG (invitrogen) for 1 h at 4 °C. 
Samples were boiled for 10 min in SDS-PAGE sample buffer, and separated with 4-12% NuPAGE gels 
(invitrogen). Proteins were transferred onto PVDF membranes (Immobilon-P, Millipore), proved with 
specific primary antibody for overnight and secondary antibody for 1 h under 5% non-fat dry milk in 
TBS or 5% BSA, 0.1% Tween20 in TBS blocking conditions and detected with Amersham ECL 
Western blotting reagent (GE Healthcare). For inhibition of HDACs in cells, concentration of each 
HDAC inhibitor was following: 20 mM Nicotinamide (Sigma), 5 μM MS275 (Sigma), 2 μM SAHA 
(Sigma), 2 μM TSA (MBL), 50 μM Bufexamac (Sigma, European Pharmacopoeia (EP) Reference 
Standard), 10 μM Tubacin (Sigma), 10 μM Tubastatin A (Sigma), and 5 mM Sodium butyrate (Sigma), 
respectively. Cells were harvested for lysis after 16 h treatment with these inhibitors. 
 
Identification of the DDX3X acetylation sites 
The protein pellets were reduced with 10 mM TCEP, alkylated with 20 mM iodoacetamide and cleaved 
first with 0.1 µg Lys-C (Wako) for 6 h and then with 0.1 µg porcine sequencing grade trypsin 
(Promega) for overnight. The extracted peptides were analyzed by capillary liquid chromatography 
tandem mass spectrometry with an EASY-nLC 1000 using the two-column set up (Thermo Scientific). 
The peptides were loaded in 0.1% formic acid, 2% acetonitrile in H2O onto a peptide trap (Acclaim 
PepMap 100, 75 µm x 2 cm, C18, 3 µm, 100 Å) at a constant pressure of 600 bar. Then they were 
separated, at a flow rate of 150 nl/min with a linear gradient of 2-6% buffer B in buffer A in 3 min 
followed by a linear increase from 6 to 22% in 40 min, 22-28% in 9 min, 28-36% in 8 min, 36-80% in 
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 1 min and 12 min at 80% buffer B in buffer A (buffer A: 0.1% formic acid, buffer B: 0.1% formic acid 
in acetonitrile) on a 50 µm x 15 cm ES801 C18, 2 µm, 100Å column mounted on a DPV ion source 
(New Objective) connected to a Orbitrap Fusion (Thermo Scientific). The data were acquired using 
120000 resolution for the peptide measurements in the Orbitrap and a top T (3 s) method with HCD 
fragmentation for each precursor and fragment measurement in the linear ion trap. MASCOT 2.5 was 
used in the Decoy mode to search the Swiss-Prot mouse version 2015_01 including common 
contaminants. The enzyme specificity was set to trypsin allowing for up to three incomplete cleavage 
sites.  Carbamidomethylation of cysteine (+57.0245 Da) was set as a fixed modification, oxidation of 
methionine (+15.9949 Da) and acetylation of lysines (+42.0106 Da) were set as variable modifications. 
Parent ion mass tolerance was set to 10 ppm and fragment ion mass tolerance to 0.6 Da. The results 
were validated with the program Scaffold (version: 4.4) and Scaffold PTM (version: 2.2) (Proteome 
Software, Portland, USA). Peptide identifications were accepted if they could be established at greater 
than 0.1% probability as calculated in Scaffold and acetylation sites were accepted if they had a greater 
than 80% site probability as calculated with Scaffold PTM. 
 
Interaction proteomics 
FLAG-DDX3X was immunoprecipitated with Anti-FLAG M2 Magnetic Beads (Sigma) from cellular 
lysate of each 293T sample expressing either DDX3X WT or mutants. Cellular lysate of parental 293T 
cells was used as a negative control. Precipitants were digested on beads by Lys-C (Wako) in digestion 
buffer (3 M GuHCl, 20 mM EPPS, pH 8.5, 10 mM CAA and 5 mM TCEP), further digested by trypsin 
(Promega), and analyzed by LC-MS/MS, essentially as described (Ostapcuk et al., 2018). In short, the 
peptides were separated with an EASY-nLC 1000 on a 50 μm × 15 cm ES801 C18, 2 μm, 100 Å 
column (Thermo Scientific) mounted on a DPV ion source (New Objective). They were measured with 
a Orbitrap Fusion (Thermo Scientific) using a top T (3 s) method as recommended by the manufacturer 
(Thermo Scientific). Andromeda implemented in MaxQuant (version: 1.5.3.8) (Cox et al., 2011) was 
used to search the mouse subset of the UniProt (version: 2017_04) combined with the contaminant 
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 database from MaxQuant and label-free quantification (LFQ (Cox et al., 2014)) was used with a protein 
and peptide FDR of 0.01. Statistical analysis was done in Perseus (version: 1.5.2.6) (Hubner et al., 
2010; Tyanova et al., 2016). Results were filtered to remove reverse hits, contaminants and peptides 
found in only one sample. Missing values were imputed and potential interactors were determined 
using Student’s two-tailed t-test and visualized by a volcano plot. Significance lines corresponding to 
a FDR of 0.03 and a S0 of 1.5 are shown in the corresponding figures. Results were exported from 
Perseus and visualized using statistical computing language R. 
 
Biotinylated isoxazole (b-isox) -mediated precipitation 
Cells were washed by ice-cold PBS and lysed in EE buffer (50 mM HEPES, pH 7.5, 150 mM NaCl, 
1 mM EDTA, 2.5 mM EGTA, 0.1% NP-40, 10% Glycerol, 1 μM DTT and Complete EDTA-free 
protease inhibitors (Roche)) To detect DDX3X acetylation, 10 μM Tubacin was added to EE buffer. 
Biotinylated isoxazole (Sigma) in DMSO was added to cell lysates at 100 μM final concentration. The 
reaction solutions were incubated for 4 h at 4 °C and then centrifuged at 13200 rpm for 10 min. 
Precipitates were washed five times in EE buffer before SDS solubilization, following analyzed by 
immunoblotting as mentioned above. 
 
Immunofluorescence microscopy and live-cell imaging 
Stress granules were induced by the following conditions: 1 mM sodium arsenite (Millipore) for 15 
min-1 h, 2 mM H2O2 (Sigma) for 1 h, 3 mM Diethyl maleate (Sigma) for 1 h, 20 μM CCCP (Sigma) 
in glucose-free DMEM (Gibco) with 10% FBS for 1 h, 40 μM clotrimazole (Sigma) in glucose-free 
DMEM with 10% FBS for 3 h, 20 μg/ml puromycin (Sigma) for 3 h, 10 μM thapsigargin (Invitrogen) 
for 1 h, 10 μM MG132 (Sigma) for 3 h, heat shock at 43 °C for 1 h and 0.5 M sorbitol (Sigma) for 1 
h. Catalytic activities of HDAC6 or CBP were inhibited by treatment of 10 μM Tubacin (Sigma) or 10 
μM A-485 (Lucerna-Chem) for 3 h, respectively. For knockdown of CBP, ON-TARGETplus 
SMARTpool siRNA mouse CBP (Dharmacon) were delivered via nucleofection (2 μM). Cells on a 
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 coverglass were washed with ice-cold PBS, then fixed with ice-cold methanol or 4% paraformaldehyde. 
After permeabilization with 0.5% TritonX-100 or 0.005% digitonin in PBS for 10 min, the cells were 
incubated with specific primary and secondary antibodies in 10% goat serum (Sigma) blocking buffer, 
then mounted with ProLong Gold Antifade Reagent with DAPI (Cell Signaling Technology #8961). 
Images were captured by Axioimager Z1 microscope (Zeiss). SGs in images were defined by a plugin 
of Fiji (SG counter). Volume of SG V = 4πR3/3, where R is SG radius, was calculated for each SG, and 
total volume of SGs in a cell was determined. In each violin plot, the thin line at the center represents 
the 95% confidence interval, and the bottom and top of the box represent the 25th and 75th percentile 
of the data, with the median value represented by a horizontal bold line. On each side of the thin line 
is a kernel density estimation showing the distribution shape of the data points from minima to maxima. 
For live-cell imaging, WT or DDX3X KO MEF cells were transfected with expression vectors 
encoding mCherry-DDX3X WT or mutants, cultured for a day on a glass bottom dish 35 mm (ibidi), 
and images were captured with a spinning-disk confocal microscope (Olympus IX81 + Yokogawa 
CSU-X1 scan head) with a 561 nm laser for mCherry signals.  
 
Mathematical modelling of SG growth 
Live-cell image stacks, captured as mentioned above, were subjected to maximum intensity projection, 
and SGs were defined by SG counter. The time point when cells are treated with arsenite was set as t 
= 0, and the initiation time of SGs (T) was defined as the time point when SG is observed for the first 
time. The obtained total SG area is regressed on Avrami equation: 
𝐴(𝑡)=AF(1 − 𝑒
−𝑘(𝑡−𝑇)) 
and two parameters AF and k were estimated from this fit. To simulate kinetics of each DDX3X 
construct, the effect of size scaling was adjusted: the initial area A0 was measured at t = 0 for each cell, 
and the scaling ratio r (= AF / A0) was obtained. The best estimate and associated error (SD) for k and 
r were calculated from the fit (n = 5 for each construct). To visualize the data, the mean value of r for 
WT is arbitrarily set as 100, and the curves obtained with the best estimates of T, k and r were shown. 
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 The areas where each curve exists with three parameters: T, k and r in the range of mean ± SD were 
also shown. 
 
Establishment of KO cell lines using CRISPR/Cas9 genome editing 
HDAC6 KO HEK293T cells were established by CRISPR/Cas9 genome editing. The guide sequence 
targeting human HDAC6 was designed by the CRISPR design tool at http://www.genome-
engineering.org/crispr/ and cloned into pX330-Cas9-T2A-mCherry vector (Addgene). The inserted 20 
nucleotides is following: 
5’-GGTGGAATCCTGGCCGGTTG-3’ 
The pX330 vector was transfected into HEK293T cells as mentioned above. Two days after 
transfection, the mCherry positive cells were collected by FACS. Then single cell clones were sorted 
again week after and expanded. Screening for HDAC6 knockout was done by immunoblotting. 
Genomic DNA was purified from the HDAC6 KO clone and the region surrounding PAM of the 
sgRNA was cloned into pGEM-T Easy vector (Promega) for sequencing after amplification with a pair 
of primers: 
5’-GGCAGAGAGGTGGGGTCCTC-3’ 
5’-CTCATCAGGGCGGGTCTAGG-3’ 
To determine the indels of individual alleles, the amplicons from 20 bacterial colonies were sequenced. 
Establishment of DDX3X KO MEFs followed the same procedure. The inserted nucleotides and a pair 
of primers for genotyping are followings: 
5’-TGGCAGTGGAAAATGCGCT -3’ (for guide RNA) 
5’-GAGGAGGGCACACGTCTTAC-3’ (for genotyping) 
5’-AACTTAAAGAGCTGCGCCAC-3’ (for genotyping) 
 
Protein expression and purification 
The DNA fragments of mouse DDX3X-IDR1 (a.a. 2-167) and DDX3X-full-length (a.a. 2-662) were 
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 inserted into the BamHI sites of the pET28 vector. All proteins were expressed in E. Coli BL21 (DE3) 
cells with 1.0 mM IPTG at 16 °C for overnight. Cells were lysed with a lysis buffer containing 20 mM 
Tris, pH 7.5, 500 mM NaCl, 2 mM DTT, Complete EDTA-free protease inhibitors (Roche) for 30 min 
on ice, followed by sonication. The lysate was centrifuged at 15000 rpm for 30 min. The supernatant 
was incubated with Ni-NTA resin (QIAGEN) for 1 h at 4 °C. The Ni-NTA resin was packed in a column 
and washed with a buffer containing 20 mM Tris, pH 7.5, 500 mM NaCl, 20 mM imidazole, 2 mM 
DTT. The bound proteins were eluted with a buffer containing 20 mM Tris, pH 7.5, 500 mM NaCl, 
500 mM imidazole, 2 mM DTT. The purified His-SUMO-tagged proteins were concentrated with 
Amicon Ultra centrifugal filters (Millipore), and digested by SUMO protease (MCLAB) for overnight 
at 4 °C. Then, the digested samples were passed over Ni-NTA resin and the flow through was collected 
and concentrated. They were subjected to size exclusion chromatography on a Superdex 200 Increase 
10/300 GL column (GE Healthcare) equilibrated in the Gel Filtration buffer, 20 mM Tris, pH 7.5, 250 
mM NaCl, and 2 mM DTT. The fractions were concentrated to 20 mg/ml and stored at -80 °C. For 
full-length protein, 1 M NaCl buffers were used through the whole purification process. The purities 
of the purified proteins were tested on SDS-PAGE gels, and the concentrations were determined by 
absorbance at UV at 280 nm. 
 
In vitro droplet formation assay 
For the phase separation of purified DDX3X, experiment was performed in 20 mM Tris, pH 7.5, 2 mM 
DTT. The concentrations of DDX3X and NaCl are 0-200 μM and 0-250 mM, respectively as indicated 
in the figure legends. As a molecular crowder, PEG4000 (Sigma) was added to samples at 10% (w/v). 
For acetylation of DDX3X-IDR1 in vitro, 40 μg of the IDR1 was incubated with 2.5 μg of human 
recombinant CBP catalytic domain (Enzo) and 10 mM acetyl-CoA (Sigma) for 3 h at 37 °C. For 
deacetylation of DDX3X-IDR1 in vitro, D. rerio HDAC6 CD1-CD2 (a.a.40-831) was expressed in Sf9 
insect cells, purified based on the method previously described (buffer and salt were adjusted to the 
droplet formation assay), and added into DDX3X-IDR1 acetylation reaction mixture. Alexa Fluor 488 
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 Protein Labeling Kit (Molecular Probes) was used for fluorescent labeling of the IDRs, followed by 
dialysis against Gel Filtration buffer using Slide-A-Lyzer™ MINI Dialysis Devices (Thermo 
scientific). The droplets were observed using an Axioimager Z1 microscope (Zeiss) and Spinning-Disk 
Confocal microscope, and turbidity of the samples (OD600) is quantified with NanoDrop (Thermo 
scientific). For temperature-dependent droplet dissolution and condensation experiments, samples 
were mounted inside small compartments sealed with a pegylated coverslip on a custom-built 
temperature-controlled stage (Mittasch et al., 2018). For imaging, the heating/cooling system was 
mounted on a Nikon TiE stand equipped with a Perfect Focus System. Image stacks were captured 
every 10 s using a 40x air objective (0.95NA) combined with a spinning-disk confocal unit CSU-X1 
(Yokogawa) and an EMCCD camera IXON+ (Andor). Image data was analyzed with MATLAB. In 
brief, image stacks were subjected to maximum intensity projection, the background was subtracted, 
and they were binarized after further filtering. In the binarized image-series, particle number was 
analyzed. 
 
Computational prediction of disordered regions 
Computational prediction of disordered regions was done with the PONDR VSL2 and VL3-BA 
programs. As queries for the prediction, protein sequences from the UniProt database released in 
March 2017 were used. Missing protein entries in this version were cited from the one released in 
February 2012.  
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